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Abstract 
The Baby Bio Bank (BBB) is a UK based pregnancy complications cohort, with clinical 
data and biological samples from over 2500 mother, father, and infant trios. Within this 
large cohort, a significant number of infants were born preterm (<37 weeks gestation). 
The experimental work outlined in this thesis focused on these participants, alongside 
a selection of full term pregnancies for comparison.  
All investigations were based on the hypothesis that many preterm births, particularly 
those precipitated by spontaneous events, have an underlying infectious aetiology. 
Total bacterial load in samples of placental DNA from 225 term and 141 preterm 
pregnancies was quantified, using quantitative PCR. An increase in total bacterial load 
was observed in placenta from spontaneous preterm births, compared to all other 
outcome groups.  
A subsection of these samples were then taken forward for next generation sequencing 
of the 16S gene. We hypothesised that bacterial DNA found in the placenta would differ 
qualitatively, as well as quantitatively, between preterm and term pregnancies. An 
enrichment of genera previously associated with adverse outcomes, such as 
Mycoplasma spp., was observed in spontaneous preterm placenta. Other, less 
established oral species were also associated with this outcome, such as 
Capnocytophaga spp. Evidence for the existence of a normal, healthy placental 
microbiome was less clear, and these analyses were complicated by a significant impact 
of delivery contaminants on sequencing results. 
The concentrations of 27 cytokines were also quantified in 149 maternal sera samples. 
These samples were from pregnancies that resulted in either term or spontaneous 
preterm births, and were taken within six weeks of delivery. Associations between 
cytokine concentrations and outcomes of interest were investigated. An upregulation of 
CC-type chemokines, as well as a number of other cytokines, was observed in 
spontaneous preterm pregnancies, implicating inflammatory events in the aetiology of 
spontaneous preterm birth. 
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: General Introduction Chapter 1
This thesis began as an exploration of a new clinical and biological resource for 
research into pregnancy complications within the UK: the Baby Bio Bank (BBB) (Abu-
Amero et al., 2014, Leon et al., 2016). The BBB offers opportunities to explore four of 
the most common complications: preeclampsia (PE), preterm birth (PTB), fetal growth 
restriction (FGR), and recurrent miscarriage (RM), from many different molecular and 
clinical perspectives. After consideration of the practical possibilities of this resource 
and gaps in knowledge of pregnancy complications, I chose to focus my investigations 
on the molecular and microbiological aetiology of PTB within the BBB population. 
As a student with a background in molecular genetics and fetal growth, and a personal 
interest in infectious disease, a chance to explore the nascent field of the maternal 
microbiome during pregnancy was both exciting and novel. Specifically, I chose to 
study whether the so-called ‘placental microbiome’, which can be defined as all of the 
microorganisms inhabiting this particular tissue, is altered in pregnancies that 
terminate in a PTB. In addition, were there identifiable signals of maternal immune 
disruption in PTBs from the BBB when compared to healthy, term births?  
Clinical and molecular research into PTB has a long and broad history. The following 
general introduction will outline some of the key epidemiological, clinical, molecular, 
and technological developments that have contributed to our thorough, yet still 
incomplete, picture of the PTB phenotype. It will also touch on the tools currently 
available to clinicians for its prediction and prevention.  On account of its known 
importance to PTB risk, and moreover the focus of this PhD, this introduction will pay 
particular attention to the role of intra-uterine infection in PTB. A more detailed 
exploration of specific developments and challenges concerning the maternal 
microbiome, and immunology and parturition, will be provided within the relevant 
individual chapters. A comprehensive review of all the multiple causes and 
consequences of PTB, is beyond the scope of this thesis. Furthermore, several excellent 
reviews already exist in the literature (Goldenberg et al., 2008, Blencowe et al., 2013, 
Romero et al., 2006, Iams et al., 2008). 
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1.1 Preterm birth (PTB) 
PTB, defined as any delivery before 37 completed weeks of gestation, is the leading 
cause of neonatal morbidity and mortality worldwide, and inflicts substantial physical, 
psychological and economic costs upon society. It is best conceptualised as a syndrome 
rather than one homogenous disease phenotype. The clinical manifestations of PTB are 
varied, and much of its underlying aetiology remains incompletely understood 
(Romero et al., 2014a).  
PTB can be split into two broad categories: spontaneous and indicated/non-
spontaneous. Spontaneous PTB (sPTB) includes two further sub-types: spontaneous 
preterm labour (sPTL) with intact membranes and preterm premature rupture of 
membranes (PPROM) resulting in preterm delivery, either vaginal or by caesarean 
section (CS). In either case, the initiation of labour or membrane rupture is a 
spontaneous event, elicited by maternal and/or fetal biochemical changes. By contrast, 
indicated/non-spontaneous PTB (nsPTB) is the result of a clinical intervention on 
account of fetal distress or maternal conditions, such as preeclampsia. Such cases 
culminate in delivery by CS or, rarely, preterm induction of labour.  sPTL accounts for 
around 40-45% of all PTBs, PPROM for 30-35%, with nsPTBs making up 25-30% of the 
burden (Goldenberg et al., 2008).  
PTB can be further divided according to gestational age (GA) at the time of occurrence. 
This division is associated with changing incidence, as well as mortality and morbidity 
rates. ‘Very early PTB’ is often defined as any birth before 33 weeks gestation and 
includes a high proportion of infants of very low birthweight (<1500 grams (gm)). This 
group represents 1-2% of all births. A higher number of these early births is 
spontaneous rather than indicated. The majority of serious illness and mortality is 
concentrated amongst these early deliveries (Goldenberg et al., 2000). In England and 
Wales, where some of the most advanced neonatal facilities are available for preterm 
infants, around 85% of infants born under 24 weeks die within the first year of life 
(Office for National Statistics, 2015). This percentage rapidly declines to 24% under 26 
weeks and under 10% by 28 weeks gestation. By 34 weeks over 99% of infants survive. 
This significant relationship between GA at birth and survival highlights the 
importance of research identifying causal factors that precipitate the very earliest 
births.  
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1.1.1 Epidemiology of preterm birth 
PTB affects between 5-18% of births worldwide. In the majority of countries with 
reliable data, PTB rates rose globally in the decades following the 1980s (Blencowe et 
al., 2013). This trend was especially marked in the United States of America (USA) 
where there was a 30% rise in the PTB rate between 1981 and 2006, reaching a peak of 
12.8% (Martin and Osterman, 2013). Interestingly, although the USA remains one of 
the countries with the highest PTB rates, the latest figures indicate that since this peak, 
the rate has been declining and in 2013 was 11.4% (Martin et al., 2014). In terms of 
absolute numbers, less economically developed countries bear by far the largest 
burden of PTB incidence, morbidity and mortality. It is reported that approximately 
85% of PTBs occur in Africa and Asia (Beck et al., 2010). The PTB rate in England and 
Wales is at the lower end of the global scale at around 7%, and has been steady over the 
past decade (Office for National Statistics, 2014, Office for National Statistics, 2015). 
In industrialised countries, PTB incidence is strongly associated with maternal 
ethnicity (Khalil et al., 2013). In the UK, mothers of Caribbean and African origin have 
the highest rates of PTB, followed by Asian women, whilst white women have the 
lowest rates (Moser et al., 2008). In the USA, black women have almost twice as many 
PTBs as white women (Muglia and Katz, 2010). The above associations remain when 
data on potential confounding variables, such as income and education are taken into 
account (Goldenberg et al., 1996). PTB is a complex phenotype with a wide range of 
underlying, and often interacting causes. Table 1.1 outlines a selection of additional 
environmental, maternal, and physiological factors thought to contribute to the risk of 
PTB.  
Table 1.1 – Previously identified risk factors for PTB.  
Risk factor for PTB Example reference(s) 
Smoking  
Maternal BMI  
Maternal ethnicity  
Maternal stress  
Intra-uterine infection  
Variation in vaginal flora  
Pre-eclampsia  
Inter-pregnancy interval  
Pregnancy history  
Maternal age  
Maternal diabetes  
Genetic variation 
Parity  
Goldenberg et al. (2008) 
Shaw et al. (2014), Torloni et al. (2009), Girsen et al. (2016) 
Schaaf et al. (2013) 
Petraglia et al. (2010) 
Goncalves et al. (2002) 
Leitich et al. (2003) 
Meis et al. (1995) 
Conde-Agudelo et al. (2006) 
Boyd et al. (2009), Carr-Hill and Hall (1985) 
Restrepo-Mendez et al. (2015) 
Kock et al. (2010) 
Plunkett and Muglia (2008) 
Kozuki et al. (2013) 
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1.1.2 Impact of preterm birth 
An estimated 2.761 million neonatal deaths occurred globally in 2013, comprising 44% 
of all deaths under five (Liu et al., 2015). PTB is the largest contributor to these figures, 
accounting for around 29% of the total (Liu et al., 2015, Lawn et al., 2010), although 
survival rates following a PTB show substantial inter-country variation (Blencowe et 
al., 2013). Unlike other contributors to neonatal mortality such as tetanus, limited, if 
any, progress has been made in reducing the global mortality burden of PTB (Lawn et 
al., 2010). Furthermore, it is customary to record deaths among preterm infants that 
ultimately die from infection as infectious related deaths, rather than preterm 
complications. Since many of these neonates will have succumbed to the infectious 
insult as a direct result of their prematurity, the total contribution of PTB to neonatal 
mortality is likely to be underestimated in these figures. 
Preterm infants who survive beyond the neonatal period often face a lifetime of 
increased health risk and complex morbidities (Saigal and Doyle, 2008). Compared 
with children born at term, premature infants have higher rates of infection, 
neurodevelopmental disorders, sensory deficits, respiratory and gastro-intestinal 
problems, and cerebral palsy. Even those infants born at later, ‘safer’ GAs (32-36 
weeks), who do not generally require neonatal intensive care, face higher short and 
long term morbidity compared to their term peers (Blencowe et al., 2013). 
Beyond the emotional and physical costs to the infant and their family of being born too 
early, there are substantial economic costs associated with PTB related care. In a recent 
study, Mangham et al. (2009) estimated that the total cost of a year’s worth of PTBs 
within England and Wales, from birth to adulthood (18 years), was £2.946 billion. One 
third of these costs were borne during the neonatal period. Unsurprisingly, the cost of 
treating a neonatal infant was found to be inversely proportional to GA at birth. The 
model estimated that delaying PTB by one week, across all gestational categories, could 
save around one billion pounds in healthcare expenditure. This finding highlights the 
value of treatments that delay the onset of labour and keep the fetus in-utero for as long 
as is safely possible.  
1.1.3 Predicting preterm birth 
Identifying women at risk of PTB enables the implementation of appropriate 
observational, surgical or pharmacological strategies to minimise risks to the mother 
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and baby. In general, these serve to either prevent or delay labour/delivery, or reduce 
the neonatal risks associated with prematurity, such as immature organ development. 
However, identifying which pregnancies will result in a preterm delivery, and may 
benefit from the available therapies, remains a significant challenge. This is the case 
even amongst women showing symptoms of preterm labour. For example, in a study 
following women from 20-34 weeks gestation, who presented with uterine 
contractions and minimal cervical dilation, only 7% delivered before 34 weeks and 
24% before 37 weeks. Therefore, 69% of women who threatened labour before 34 
weeks ultimately delivered at term (Guinn et al., 1997).  
One of the strongest predictors of PTB, and one of the only pre-pregnancy indicators, is 
a history of previous PTB (Mercer et al., 1999, Carr-Hill and Hall, 1985, Iams et al., 
1998). Mercer et al. (1999) found that if a woman had previously experienced a sPTB 
they were 2.5 times more likely to experience another in the current pregnancy, when 
compared to women with no prior sPTB history. The size of this effect was inversely 
proportional to the GA of the previous sPTB. Furthermore, the type of sPTB (sPTL or 
PPROM) in the previous pregnancy correlated with outcome (sPTL or PPROM) in the 
current pregnancy. This relationship implied a preservation of pathological 
mechanisms between pregnancies, which were specific to sub-types of the syndrome.   
Although difficult to assess accurately, estimates of heritability of the PTB phenotype 
range from 25% to 40% (Allen and Founds, 2013). In a large Norwegian cohort, 
mothers born preterm had a 55% increased chance of having a preterm delivery 
themselves. This risk increased when the mothers had been born at the more extreme 
end of prematurity (Wilcox et al., 2008). Interestingly, little or no evidence was 
observed in this study for the effect that preterm fathers had on the GA at birth of their 
children, implicating the maternal genotype rather than the paternal genotype in these 
repetitive events. Increased risks associated with individual pregnancy history, in 
addition to inter-generational effects, indicate an important role for specific genetic 
factors in PTB risk. A number of genes and single nucleotide polymorphisms (SNPs) 
have indeed been associated with PTB risk, many of which are associated with 
immunological pathways (Crider et al., 2005, Allen and Founds, 2013). It is also 
possible that the repetition of preterm labour within individuals could reflect the 
persistence of non-heritable risk factors such as chronic, potentially subclinical, 
infection. This latter hypothesis is rarely explored in the literature. 
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Among the most powerful predictive tests currently available to clinicians during 
pregnancy is the fetal fibronectin (fFN) test, which was first described in 1991 
(Lockwood et al., 1991). The test measures the presence of the fFN protein in cervico-
vaginal secretions. fFN is a placental glycoprotein present in amniotic fluid, fetal 
connective tissues, and placenta, that functions as an adhesion molecule, ‘gluing’ the 
placental tissue and membranes to the maternal decidua (Matsuura et al., 1988). 
Goldenberg et al. (1998) showed that a positive fFN test was the single strongest 
available indicator for PTB risk in asymptomatic women, and that this value was 
increased in earlier gestations. Following a positive fFN test, a relative risk of 14.1 (9.3-
21.4 95% confidence interval (CI)) was calculated for preterm births before 32 weeks 
gestation and 6.7 (4.9-9.2 95% CI) for delivery before 35 weeks (Goldenberg et al., 
1998). The study also reported that among asymptomatic women, risk of delivery 
before 37 weeks was highest amongst women with a history of PTB, a positive fFN 
result, and a shortened cervix.  
Trans-vaginal ultrasound measurement of cervical length has been used as a method to 
predict PTB since the 1980s (Grimes-Dennis and Berghella, 2007). Many studies have 
shown that women with a shortened cervix, often defined as <25mm, in the mid-
trimester of a singleton pregnancy, who may or may not have been threatening labour, 
are at a higher risk of delivering preterm (Grimes-Dennis and Berghella, 2007, Hassan 
et al., 2006, Botsis et al., 2005, Iams et al., 1996). However, the reported predictive 
value of this test varies considerably between studies and populations. Evidence 
suggests that cervical screening has greatest specificity in high-risk women, e.g. those 
with a history of a PTB (Grimes-Dennis and Berghella, 2007). It is generally 
hypothesised that these associations are the result of structural inadequacy of the 
shortened cervix. However, a reduced distance between the uterus and the bacterial 
rich vagina could also increase the chances of ascending infections reaching the intra-
uterine cavity. The relative contribution of either hypothesis is under-explored. 
Correlations between intra-uterine infection and/or inflammation and shortened 
cervices have been reported. However, the direction of causality here remains unclear 
(Guzman et al., 1999, Goldenberg et al., 2000).  
1.1.4 Preventing preterm birth 
Cervical cerclage and, less commonly, the administration of progesterone can be used 
to delay or prevent premature labour in at-risk groups. Corticosteroids and tocolytics 
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can be offered to women threatening preterm delivery to delay labour and reduce 
prematurity associated risks to the fetus, such as respiratory distress and necrotizing 
enterocolitis. Despite their availability, evidence for the efficacy of these strategies is 
mixed, and clear consensus regarding the appropriate indications for their use is 
lacking. 
Cervical cerclage, in which a stitch is placed around the cervix to keep it closed, was a 
technique first performed in 1902 (RCOG, 2011). It is now a commonly used 
prophylactic intervention in modern obstetrics for women with shortened and/or 
prematurely dilated cervices. A recent Cochrane review showed an appreciable 
reduction in PTB rates, but no impact on associated neonatal morbidities, when 
cerclage was performed (Alfirevic et al., 2012). Recent National Institute for Health and 
Clinical Excellence (NICE) accredited guidelines state that, dependent upon clinical 
examination, women with a history of multiple PTBs, or those with an ultrasound 
identified shortened cervix and PTB history, should be considered for this therapy 
(RCOG, 2011). 
Progesterone is a critical hormone throughout pregnancy and its functional or systemic 
withdrawal towards the end of gestation has been hypothesised to play a central role in 
the initiation of labour in mammals (Golightly et al., 2011). These observations have 
highlighted progesterone as a potential treatment for women at risk of PTB. Although 
many trials showed positive effects, the overall evidence remained mixed (Meis and 
Aleman, 2004).  The publication in 2003 of positive results from two large randomised 
controlled trials of its mid-gestational use in high-risk women, served to renew interest 
in its use (Meis et al., 2003, da Fonseca et al., 2003). Meis et al (2003) found that in 
women with a prior PTB, administration of the progestational compound 17α-
hydroxyprogesterone caproate reduced the incidence of PTB by up to one third. A 
recent Cochrane review has provided further evidence for its reductive effect on PTB 
rates in at risk (short cervix or PTB history), singleton pregnancies. However, 
consensus over its use, dosage, and long-term effects, is yet to be reached (Dodd et al., 
2013).  Trials of progesterone as a tocolytic drug to delay labour have shown little, if 
any, efficacy (Meis and Aleman, 2004). 
Given the strong evidence for a link between PTB and a variety of infections, there has 
been substantial interest in the use of antibiotics to prevent or delay early delivery. 
However, the use of antibiotic therapy in women showing signs of infection during 
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gestation, or threatening preterm delivery, has shown mixed success (Hutzal et al., 
2008, Kenyon et al., 2013). A large body of clinical research has investigated their 
impact on pregnancy and neonatal outcomes, using both broad range and targeted 
drugs at a variety of GAs. Decisions regarding which drugs to use, in which situations, 
remain complex and controversial (Subramaniam et al., 2012). 
Despite decades of research, and the widespread use of clinical strategies to prevent or 
delay PTB, there is little evidence that its incidence has shown any appreciable decline. 
Indeed, in many countries, rates appear to be rising (Blencowe et al., 2013). 
Furthermore, whilst neonatal survival, particularly in areas with access to modern 
medical techniques has improved considerably, reductions in associated morbidities 
have not been as significant (Stoll et al., 2015). Although this reduction in PTB-
associated mortality is, of course, to be celebrated, these concomitant morbidity trends 
imply an absolute increase in PTB associated complications. New clinical and ethical 
challenges are arising in this context as the so-called ‘limit of viability’ continues to 
decline (Seri and Evans, 2008). Taken together, these data continue to highlight the 
importance of identifying clinical strategies that will improve neonatal outcomes by 
extending gestation for as long as is safely possible. 
If prediction and prevention of PTB is to improve, we need a better understanding of 
the underlying pathology of this syndrome, including the molecular mechanisms that 
result in a woman embarking on the path to parturition too early. Some of the most 
promising mechanistic research of recent decades, and the focus of the experimental 
work for this thesis, has involved associations between PTB, and maternal infection 
and inflammation in pregnancy.  
1.1.5 Pregnancy, infection and PTB 
The danger of acute and chronic maternal infection during pregnancy is well known. 
Public health initiatives such as the provision of the flu vaccine to pregnant mothers, or 
development of specific food hygiene guidelines for pregnancy to avoid maternal 
ingestion of hazardous bacteria such as Listeria monocytogenes or the Toxoplasma 
gondii parasite, serve to mitigate the risks associated with certain infections in 
pregnancy (Plotkin, 2006, Steinhoff et al., 2012, Delorme-Axford et al., 2014). Maternal 
HIV and Hepatitis B infections have been associated with increased odds of PTB (Slyker 
et al., 2014, Reddick et al., 2011). Malaria has also been associated with shorter 
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gestations, particularly in the latter part of pregnancy (De Beaudrap et al., 2013, Uneke, 
2007). A number of emerging infections, most recently in the case of the Zika virus, 
have continued to keep infection and pregnancy central to the global public health 
agenda, with particular emphasis on associated developmental pathologies such as 
microcephaly (Johansson et al., 2016). The following section will focus on bacterial 
infection in pregnancy, specifically of the female reproductive and intra-uterine tissues, 
and their associations with PTB.  Whilst viral, parasitic, and fungal infections also 
contribute to fetal morbidity and pregnancy complications, the varied clinical and 
molecular pathology of all these diverse groups of organisms is beyond the scope of 
this thesis.  
Identification of bacteria from within the normally ‘sterile’ amniotic cavity were 
reported as early as the 1920s (Harris, 1927). However, molecular evidence causally 
linking such colonisation to PTB was not published until the 1970s (Bobitt and Ledger, 
1977). In the decades since, functional and observational evidence has continued to 
grow in support of the hypothesis that bacterial infection during pregnancy, 
particularly of the maternal reproductive tissues, is a significant contributor to PTB 
incidence. It is estimated that somewhere between 25% and 40% of sPTB cases may be 
mediated by intrauterine infection (Goldenberg et al., 2008). This proportion increases 
steadily as GA at birth decreases. Infection may be a mediator in as many as 79% of 
births at 23 weeks gestation (Onderdonk et al., 2008a).  
Evidence for the involvement of bacteria in preterm delivery comes from the 
identification of organisms within pregnancy related tissues using a variety of 
techniques including histopathology, immunohistochemistry, protein-assays, bacterial 
culture, and polymerase chain reaction (PCR) based methods. Such techniques have 
helped demonstrate an association between sPTB and the presence or profile of 
bacteria in amniotic fluid (Han et al., 2009, Hatanaka et al., 2014, Wang et al., 2013), 
placental parenchyma (Aagaard et al., 2014, Onderdonk et al., 2008b), fetal membranes 
(Fortner et al., 2014, Jones et al., 2009), the placental basal plate (Stout et al., 2013), 
cord blood (Wang et al., 2013), cervical fluid (Musilova et al., 2014), and maternal 
vaginal flora (de Andrade Ramos et al., 2014). The association between bacterial 
vaginosis (BV), in which a disruption in maternal vaginal flora leads to a loss of 
Lactobacilli species (spp.) and overgrowth of facultative anaerobe species, and PTB has 
been acknowledged for some time (Hillier et al., 1995). A meta-analysis of 18 studies 
including over 20,000 women, estimated that women with BV in early pregnancy had a 
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2 fold higher odds of PTB than asymptomatic women (Leitich et al., 2003). Although 
these observations provide support for the contribution of the maternal reproductive 
microbiome to PTB risk, BV is a fairly common pathology and its predictive power is 
limited, most women with BV will deliver at term (Romero et al., 2014a).  
Typically, organisms found in the intra-uterine tissues are hypothesised to originate in 
the vagina, ascend the genital tract, breaking the cervical barrier and colonising all or 
some of the amniochorionic membranes, the amniotic fluid, the parenchyma and villous 
tissue below the placental membranes, the umbilical cord and, rarely, the fetus itself 
(Figure 1.1). However, some recent evidence has pointed to alternative routes of 
infection, such as via haematogenous transport of bacterial species originating from 
non-reproductive tissues such as the oral cavity (Aagaard et al., 2014, Han and Wang, 
2013, Offenbacher et al., 2006). Infection of reproductive tissues in pregnancy may also 
be the result of invasive clinical procedures such as amniocentesis, chorionic villus 
sampling (CVS), and perhaps even cervical cerclage. Recent experimental work has also 
raised the possibility that in some (or all) women, bacteria may even be present in non-
pregnant uterine tissues prior to implantation (Verstraelen et al., 2016).  
All women harbour significant numbers of microorganisms within their reproductive 
tracts, with reproducible shifts in community composition noted before, during, and 
after pregnancy (MacIntyre et al., 2015). In the majority of cases these organisms will 
never reach the amniotic cavity, or its surrounding tissues. Even fewer will elicit a 
pathogenic response to their presence that may result in PTB. Many adaptations exist 
that serve to protect women from ascending infection. The mucus plug that 
accumulates at the cervix during pregnancy acts as a key physical and functional 
barrier to ascending infection. The release of anti-microbial, and pro-inflammatory 
peptides by vaginal epithelial cells additionally helps to create an environment hostile 
to overgrowth of non-commensal bacterial species (Witkin, 2014). However, in the rare 
cases in which these defences are compromised, or indeed bacteria and/or their 
products reach the uterus via the maternal bloodstream, a number of mechanisms have 
been postulated by which this bacterial infection may act to initiate or increase the risk 
of PTB. Most hypotheses about the mechanisms involved in infectious mediated PTB, 
regardless of where the organisms are thought to originate, propose a central role for 
inflammation-related pathways. 
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Figure 1.1 – Potential route of infection and reported sites of intra-amniotic 
infection. Image used with permission from Suzanne Ghuzzi-Silva, MPS North America 
(sghuzzi@gmail.com). 
 
1.1.6 Inflammation and chorioamnionitis 
The role of inflammation in infectious mediated PTB is strongly implied by the widely 
reported association between sPTB and intrauterine inflammation, most commonly in 
the form of clinical or subclinical (histologic) chorioamnionitis (Guzick and Winn, 1985, 
Mueller-Heubach et al., 1990, Kim et al., 2015). This condition is usually defined as 
inflammation of the fetal membranes (the outer chorion and inner amnion), which is 
mainly in the form of maternal neutrophilic infiltration (Figure 1.2). The majority of 
cases are histologic chorioamnionitis (HCA) with no observable clinical phenotype. 
Some are also associated with uterine tenderness, leucocytosis, fever and tachycardia 
and are known as clinical chorioamnionitis, but this proportion may be as low as 8% of 
the total (Guzick and Winn, 1985).  Less commonly, inflammation may also affect the 
villous tree, known as villitis. Funisitis, in which inflammation of the umbilical cord is 
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Figure 1.2 - Acute chorioamnionitis of the extraplacental chorioamniotic 
membranes: A, Normal chorioamniotic membranes shows the absence of 
neutrophils. B, Acute chorionitis is stage 1 acute inflammation of the chorioamniotic 
membranes, in which neutrophilic infiltration is limited to the chorion. C, Acute 
chorioamnionitis is stage 2 acute inflammation of the chorioamniotic membranes; 
neutrophilic migration into the amniotic connective tissue is shown 
(asterisk). D, Necrotizing chorioamnionitis is stage 3 acute inflammation of the 
chorioamniotic membranes, whose characteristic is the amnion epithelial necrosis (arrows). 
Image and legend reprinted from (Kim et al., 2015) with permission from Elsevier. 
observed, tends to be the result of fetal, rather than maternal, inflammatory responses 
(Kim et al., 2015).  
Incidence of chorioamnionitis is negatively correlated with GA at birth. Some studies 
report HCA incidence of over 90% in the earliest (21-24 weeks) deliveries (Kim et al., 
2015). Chorioamnionitis is often, but not exclusively, accompanied by positive results 
from bacterial cultures or PCR tests (Hillier et al., 1988, Redline, 2004, Galinsky et al., 
2013). The observed associations between chorioamnionitis, bacterial presence, and 
GA at birth, provide a plausible mechanistic link between intra-uterine bacterial 
infection and PTB. These associations implicate the maternal, or fetal, inflammatory 
responses to infection as possible triggers for labour and/or membrane rupture.  
Intrauterine infection is rarely accompanied by clinical symptoms; at least until 
membranes break or labour begins. This makes accurate estimation of the burden of 
PTB attributable to infection difficult. Furthermore, until recently, diagnosis of intra-
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amniotic infection relied either on histological evidence of chorioamnionitis or 
microbiological cultures. The reliance on these two strategies may have led to an 
underestimation of the infectious mediated PTB burden. Firstly, chorioamnionitis does 
not occur in all cases of infectious mediated PTB (Goncalves et al., 2002). Secondly, 
culturing techniques are only able to identify the presence of a limited proportion of 
microorganisms. This means that certain intra-amniotic infections, particularly novel 
ones, may be overlooked.   
Evidence for causality in the observed association between bacterial infection, 
inflammation, and PTB has come in large part from animal studies (Elovitz and 
Mrinalini, 2004). Many experimental models have shown that exposure to both live 
bacterial cells, as well as bacterial products, such as the endotoxin lipopolysaccharide 
(LPS), can induce host immune responses. These immune responses serve to trigger 
preterm labour, in species as diverse as rhesus monkeys (Gravett et al., 1994), sheep 
(Schlafer et al., 1994) and mice (Mussalli et al., 1999, Elovitz et al., 2003). Figure 1.3 
shows the likely physiological sequence of events linking bacterial infection to PTB in 
humans. The immunology of normal and pathological labour will be considered in more 
detail in Chapter 7. 
The precise mechanism by which infection results in PTB will depend on many factors. 
The origin of bacteria, e.g. oral or vaginal, will implicate what species infect the intra-
uterine space, and therefore what virulence factors elicit maternal or fetal responses 
(Fichorova et al., 2011, Menon et al., 2009). Where organisms originate will also impact 
which intra-uterine tissues become colonised in the first place. The maternal and fetal 
immune responses to the infectious insult are likely to vary on account of individual 
genetic factors, as well as variations in bacterial virulence factors. This variation may 
trigger different physiological pathways that result in labour, and may also impact 
neonatal outcomes differently. Additionally, at what stage of pregnancy the infection 
takes hold will be an important variable in the determination of both maternal and fetal 
responses to the insult, as well as maternal and fetal health.  
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Figure 1.3 - Hypothesised physiology of infectious mediated PTB, adapted from 
Goldenberg et al. (2000). 
 
1.1.7 Infection and the placenta 
Throughout pregnancy, the placenta is the organ through which all necessary 
exchanges of gases, nutrients and waste products take place. In addition, the placenta 
serves as a functional and immunological barrier from the hematogenous spread of 
microorganisms from mother to fetus, as well as from maternal immune system attacks 
(Delorme-Axford et al., 2014, Nelissen et al., 2011). The placenta consists of both fetal 
and maternally derived tissues that fuse together in early pregnancy to facilitate 
diffusion of substances between the maternal and fetal circulatory systems. The organ 
develops into three major structures: the umbilical cord, the chorioamniotic 
membranes, and the placental disc itself, which consists of parenchyma tissue on the 
fetal side and villous tissue at the maternal edge. The placenta’s functional capacity is a 
critical determinant of proper fetal growth and development. 
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Although evidence exists for the presence of bacteria in all intra-uterine tissues, the 
majority of studies have focused on identifying bacterial colonisation of the fetal 
membranes and amniotic fluid. The prevailing view has been that ‘bacterial infection 
within the placenta (villitis) is rare’ (Goldenberg et al., 2000). Nevertheless, evidence 
exists for the association between colonisation of placental tissue and adverse 
pregnancy outcomes (Onderdonk et al., 2008a, Onderdonk et al., 2008b, Prince et al., 
2016, Rours et al., 2011). Estimating the incidence and precise nature of pathogenic 
placental infection is difficult. Histopathological investigations of placental tissue can 
necessarily only identify infection after the event. Furthermore, evidence suggests that 
bacteria may be present in the uterus without causing a clinically observable 
inflammatory response (Steel et al., 2005). The organ cannot be studied at any time 
other than after birth, other than in extenuating clinical cases, such as when CVS is 
offered to mothers at risk of chromosomal abnormalities. By the time a placenta is 
delivered, the infection may have been proliferating, shrinking, and interacting with the 
maternal and /or fetal immune systems for up to 9 months. At present, the vast 
majority of research documenting such infections can only be carried out 
retrospectively. Furthermore, tissue samples collected after birth can easily be 
contaminated with allochtonous organisms at delivery, precluding the identification of 
only those species actually present in the placental tissue in-utero.  
Following the identification of bacteria in placental tissue from uncomplicated 
pregnancies (Stout et al., 2013) and the recent description of a so-called ‘placental 
microbiome’ (Aagaard et al., 2014), the dogma of placental sterility in normal 
pregnancy is being challenged. These observations have raised the possibility that the 
presence of bacteria in placental tissue may not always be damaging. Some have 
suggested it could represent an adaptive mechanism to prime the fetal immune system 
before birth (Satokari et al., 2009, Romano-Keeler and Weitkamp, 2014). The presence 
of bacteria in the meconium of newborn infants (Hansen et al., 2015) does indeed imply 
fetal exposure to certain organisms pre-delivery. However, the molecular detail of how 
placental colonisation could contribute to healthy fetal development remains sparse. 
The above hypotheses have not gone unchallenged (Kliman, 2014). In the nascent 
world of microbiome research it is becoming increasingly clear that the distinction 
between noise, whether technological error or sampling contamination, and signal, is a 
challenge that has not always been appropriately addressed. This issue is a particular 
concern when investigating samples of low biomass such as the placenta. Indeed, a 
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recent paper has challenged the idea of a placental microbiome entirely, attributing all 
bacterial reads within their samples to background contamination (Lauder et al., 2016). 
In addition, it is impossible to distinguish competent, living bacterial cells, from dead 
cells or translocated, cell-free bacterial DNA, when using sequencing based techniques. 
These are critical and often poorly documented aspects of microbiome studies that will 
be considered within the context of my own research in the forthcoming chapters.  
1.1.8 Characterising intra-uterine infection 
An inherent challenge in PTB research is identifying pre-clinical signs of bacterial 
infection that will ultimately provoke a pathological pregnancy outcome. Procedures, 
such as amniocentesis, which give rare access to the intra-amniotic environment 
during pregnancy, are risky and unethical to conduct without good clinical reason. 
Post-natal investigations of fetal and maternal tissues are no longer relevant for clinical 
management to delay or prevent PTB, but have been useful for research.  It is 
encouraging that new molecular techniques are helping to broaden our understanding 
of infectious mediated PTB. These are uncovering which specific strains of bacteria are 
implicated in these syndromes, and where such organisms tend to originate, thus giving 
clues to where eventual effective treatments could be targeted. However, almost all 
feasible study designs still rely on retrospectively collected samples to infer the 
existence of infection during pregnancy. 
Traditionally, identification and characterisation of prokaryotic organisms have relied 
on the ability of the microbiologist to isolate and grow cells of interest under laboratory 
conditions.  With the advent of molecular approaches in microbiological research, it 
soon became clear that culturing techniques had only been able to describe a fraction of 
global microbial diversity (Hugenholtz, 2002). This phenomenon is known as ‘the great 
plate count anomaly’ (Staley and Konopka, 1985). The use of PCR based molecular 
techniques in PTB research has confirmed such an underestimation of diversity. 
Studies have consistently shown that when the presence of bacteria in intra-uterine 
tissues is assessed using PCR and culture, culture-based methods are less sensitive and 
less able to identify mixed microbial infections (Han et al., 2006, Han et al., 2009, Harris 
and Hartley, 2003, Wang et al., 2013). 
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1.1.9 The 16S ribosomal RNA locus 
Since Leuwenhoek’s 17th century revolutionary developments of microscopy, 
identification and classification of microorganisms have largely been processes based 
on morphological and metabolic characteristics.  However, in recent decades, this 
taxonomy has been augmented, and in certain cases superseded, by molecular genetic 
techniques. The use of marker genes, particularly the 16S locus, for microbiological 
classification has become widespread in the decades following Woese and Fox’s 
seminal paper (Woese and Fox, 1977). Such molecular techniques have become the 
gold standard for clinical and academic assessments of intra-uterine infection. From 
end-point and real-time PCR, to Sanger and next-generation sequencing (NGS) assays, 
our perspective on intra-uterine infection is sharpening. Much of these developments 
are down to the ‘renaissance [of] the pioneering 16S gene’ (Tringe and Hugenholtz, 
2008). 
The transcribed 16S ribosomal ribonucleic acid (16S rRNA) gene, usually about 1500 
base pairs (bp) in length, forms a structural scaffold for the messenger RNA reading, 
small subunit (30S) of all prokaryotic ribosomes. The gene is present in all bacterial 
and archaeal genomes. The eukaryotic equivalent subunit, 18S rRNA, has no sequence 
overlap. As well as being critical to all prokaryotic life, the 16S rRNA gene has become a 
principle component of the microbiologist’s toolkit, owing to its well-characterised 
structure of conserved and variable genomic regions (Figure 1.4), making it an ideal 
target for phylogenetic, PCR-based analyses. 
 
Figure 1.4 - Approximately 1.5 kb of the E. coli 16S rRNA gene with its nine variable 
regions (purple) interspersed between highly conserved sequence. 
In genetic studies, primers can be designed with binding sites within either conserved 
or hypervariable regions, depending on whether species specific or broad-range 
amplification is required.  The design of ‘universal’ 16S primers that bind to conserved, 
but span hypervariable regions, enables investigators to describe the full 
microbiological diversity of a sample in a single experiment. Following amplification, 
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genetic sequencing of the target region enables characterisation of the microbiological 
composition of any sample of interest.   
The application of targeted 16S amplification translates across a range of molecular 
biology techniques. End-point 16S PCR describes the presence or absence of specific or 
broad-range prokaryotic targets, whilst qPCR is used for the quantification of bacterial 
load within a sample. More recently, the 16S region has been targeted in NGS assays, 
producing qualitative descriptions of microbial communities.  Given the specificity of 
the locus to prokaryotic genomes, these techniques can be used to investigate bacterial 
presence in mixed samples, for example investigating bacterial infection within human 
tissue.  However, depending on the region targeted, non-specific binding to 
phylogenetically related sites on mitochondrial and chloroplast genomes can be an 
issue. 
16S rDNA analysis has been an important component of research into infectious 
mediated PTB. The work has highlighted the sensitivity of the technique to the very low 
concentrations of bacterial DNA often present in intra-uterine samples, but also its 
ability to identify the presence of species not readily cultivable by traditional methods.  
1.1.9.1 Limits to the 16S approach 
In recent years, the dominance of 16S rDNA PCR in both conventional and NGS 
microbiological research has been challenged by the advent of whole genome shotgun 
(WGS) sequencing of entire microbial communities. Metagenomic experiments 
sequence a random sample of all genes that inhabit a particular niche of interest. This 
enables an investigator to consider the functional and metabolic properties of a 
microbial community, rather than just its taxonomic and phylogenetic composition. 
This provides powerful information when considering the functional impact of 
microbial communities on specific sample types of interest. Furthermore, the reliance 
on one amplicon in 16S sequencing analyses can lead to amplification biases, and the 
sequencing technologies used are often limited to relatively short read-lengths. This 
can lead to issues in the disambiguation of similar organisms, particularly at the species 
level. Furthermore, results between studies are only reliably comparable if the same 
variable region is used. 
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An additional limitation to the use of 16S amplicon sequencing is its reliance on so 
called ‘universal’ primers. No primer pair is truly universal in the sense that it will bind 
with equal efficiency to every prokaryotic 16S sequence in existence. It may in some 
cases miss out some evolutionary branches entirely, particularly for organisms whose 
genome has not been yet sequenced (Rosselli et al., 2016). However, in-silico tools as the 
Ribosomal Database Project’s (RDP) probe-match algorithm can be used to quantify 
how ‘universal’ such sequences are by estimating how many known sequences such 
pairs will anneal to (Cole et al., 2014). This enables the design of studies that capture as 
much bacterial variation as possible.  
Despite the above criticisms, the ‘pioneering’ 16S gene remains an essential tool in 
microbiome research. A broad and highly developed suite of analytical tools is available 
for the interpretation of 16S specific datasets and it remains the most cost-effective 
way to carry out microbiome studies. Additionally, read-depths and sequencing lengths 
are continuing to increase with developments in NGS technologies, increasing the 
power of these techniques to accurately describe the microbial communities in samples 
of interest.   
1.1.9.2 Using Next Generation Sequencing to infer taxonomy 
An incredible increase in sequencing power has been enabled by NGS technological 
advancements. As a result, high-throughput 16S sequencing has become a commonly 
used method in microbiological research. Chemical and technological developments in 
molecular genetics have enabled the production of datasets of tens, if not hundreds, of 
millions of bacterial amplicons in a single run. The development of specific analysis 
pipelines and statistical techniques to organise and analyse these data, have run in 
parallel to such technological progress.  
16S sequences must be clustered into smaller groupings in order to be used to calculate 
diversity estimates or compare taxonomy between outcomes under investigation. 
There are a number of approaches to classifying and characterising high-throughput 
16S amplicon data into a form that can be used to draw meaningful biological 
conclusions about the sample under study. These are mainly focused on clustering 
similar sequences into groups known generically as Operational Taxonomic Units 
(OTUs). Certain OTU-based approaches rely on sequence alignment algorithms such as 
Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990). Individual or 
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clustered reads are matched to sequences that have been deposited in taxonomic 
databases such as GREENGENES, SILVA, or RDP, and are within a specified percentage 
identity threshold of each other. Alternatively, reads are clustered together, using a 
variety of different algorithms, again based on percentage similarity but with no 
reference to an external database. Some techniques combine aspects of the two. In all 
cases, the intention is to divide sequences into groups defined by some fixed degree of 
genetic similarity. Such divisions are often interpreted as approximations of widely 
used taxonomic distinctions. For example, 97% genetic similarity is considered to 
approximate a species level classification. However, such approximations assume 
uniform rates of evolution across one locus, such as 16S, which is a scenario that is 
unlikely to hold in reality. For slowly evolving lineages this uniform threshold may be 
too relaxed and for those that undergo rapid evolution it will be too stringent (Mahé et 
al., 2014). 
1.1.9.2.1 De novo OTU-picking 
De novo OTU picking algorithms cluster reads against each other, without reference to 
an external database. One of the key benefits to de novo OTU clustering is that all reads 
are clustered, since they do not have to align to a known sequence. By the same 
reasoning, de novo OTU strategies enable analysis of samples from the rare or 
unexplored biosphere, which may include novel, as yet undocumented taxa. This 
feature of de novo OTU picking can also be problematic if sequencing data has a high 
error rate or is highly chimeric. In such cases, novel OTUs will be defined by erroneous 
reads, leading to inflation of measures of diversity within a sample. One of the major 
limitations of de novo OTU picking is in its speed. The nature of de novo clustering 
algorithms means that processes cannot be conducted in parallel, making the strategy 
prohibitively slow for large databases.  
1.1.9.2.2 Closed-reference OTU-picking 
In closed-reference OTU picking, reads are grouped together based on their similarity 
to pre-defined cluster centroids from an external reference database. This database 
may be a public resource such as RDP or SILVA (Pruesse et al., 2007), or an individually 
curated database of organisms of interest and their appropriate genetic sequence 
representative. If an input sequence matches nothing in the reference database, within 
the defined similarity threshold, the sequence is discarded and not used in subsequent 
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analyses. Clearly this is not appropriate for studies in which samples are taken from 
poorly characterized niches that may contain novel organisms. The primary advantage 
of this type of OTU picking is that each read is aligned to a database centroid 
independently. This process is therefore easily parallelizable, so issues of speed that 
limit the practicality of de novo strategies are avoided. Furthermore, the quality of 
sequences in curated databases tends to be high, thereby creating relatively robust 
OTU clusters. 
1.1.9.2.3 Open-reference OTU picking 
Open-reference protocols combine the two preceding strategies. First, a closed-
reference algorithm is run and all sequences that cluster to a reference database are 
assigned to a closed-reference OTU. Following this any sequences that failed to cluster 
via this original route are clustered de novo, with cluster centroids defined internally, 
rather than with reference to an external database. The computational power, and 
therefore time, for this process to run lies in between closed and de novo OTU picking, 
because it consists of aspects that are run both in parallel and serially. This was the 
strategy used in the sequencing analyses carried out in this PhD. 
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1.2 Hypothesis and aims 
The overarching hypothesis of this thesis was that a significant proportion of sPTB 
cases within the BBB would be due to bacterial presence in the intra-uterine cavity. 
Specifically, it was hypothesised that bacterial presence in the placenta would associate 
with delivery at earlier gestational ages. Differences between preterm and term 
placental colonisation patterns would be both quantitative and qualitative in nature. 
Additionally, it was hypothesised that sPTB occurrence would be associated with an 
up-regulation of pro-inflammatory cytokines within maternal blood, representing 
aberrant maternal immune responses during pregnancy to insults such as infection. 
To investigate these hypotheses, this research project encompassed the following four 
principle aims: 
1) Collate, clean up, and characterise the Baby Bio Bank clinical dataset with a 
particular focus on the establishment and investigation of the, as yet unstudied, BBB 
preterm birth cohort (Chapter 4). 
2) Test whether there are observable differences in the quantity and type of bacterial 
species observed within placental tissues according to pregnancy outcome, specifically 
preterm versus term birth (Chapter 5). 
3) Investigate the existence of a so-called ‘placental microbiome’ across placental tissue 
from healthy and complicated pregnancies, and examine how any diversions from the 
norm associate with GA at delivery phenotypes (Chapter 6). 
4) Characterise maternal systemic immune profiles in the run up to delivery in both 
spontaneous preterm and term births, as a potential proxy for an underlying intra-
uterine infection (Chapter 7). 
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: General Materials and Chapter 2
Methods 
All experimental work within this project was conducted on nested case-control 
cohorts within the larger BBB collection. The BBB study design, participant 
recruitment, ethical approval, procurement and access to clinical data, are outlined in 
Chapter 4. 
2.1 Placental sampling and DNA extraction 
2.1.1 Equipment and reagents 
 RNAlater® Stabilization Solution (AMBION) 
 DNeasy Blood & Tissue Kit (QIAGEN) 
 80% ethanol (HAYMAN) 
 TissueLyser LT (QIAGEN) 
 FastPrep® Lysing Matrix B Bacteria (Gram +/-) (MPBio) 
2.1.2 Sample collection and storage 
All placental samples were collected by the hospital’s maternity team and dissected by 
a BBB recruiter, usually within an hour of delivery. For each placenta, 1 cm3 specimens 
were excised from four points below the membrane on the chorionic plate (placental 
parenchyma), close to the umbilical cord entrance. Villous tissue pooled from 6 sites on 
the maternal side, the basal plate, of the placenta was also collected from a subset of 
participants, providing opportunity for comparison between tissue at the fetal and 
maternal side of the uterine cavity. All samples were rinsed in phosphate-buffered 
saline (PBS) to remove excess maternal blood, placed in barcoded cryogenic tubes 
along with 5 ml of RNAlater, and stored at -80°C.  
2.1.3 Dissection of placental tissue for extraction 
Placental tissue was located and thawed prior to excision of a subsample that was 
taken forward for experimental analysis. All dissections were carried out in a sterile 
lamina flow tissue culture hood using sterile scalpels, petri dishes, and appropriate 
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protective clothing. 20-50 mg of placental tissue was excised from each sample and cut 
into small pieces to aid tissue and cell lysis during DNA extraction. 
2.1.4 DNA extraction from tissue 
DNA was extracted from 20-50 mg of placental tissue using the Qiagen DNeasy Blood 
and Tissue Kit, with an additional bead-beating step following chemical lysis. 
Considerable debate exists around appropriate extraction procedures for microbiome 
studies that, by definition, require representative extraction of all bacterial species 
present. Many studies have noted a consistent under-representation of gram-positive 
bacteria using standard extraction techniques (Rantakokko-Jalava and Jalava, 2002, 
Harris and Hartley, 2003). Improved protocols aim to more effectively lyse the tough, 
peptidoglycan rich cell walls of gram-positive species such as Streptococci, or the 
robust and waxy ones of Mycobacterium spp., whilst not being too harsh as to degrade 
those nucleic acids extracted in the process.  
Extraction techniques have been shown to impact the relative abundances of species 
observed, as well as the proportions of eukaryotic to bacterial DNA recovered (Yuan et 
al., 2012, Sergeant et al., 2012, Willner et al., 2012, Wesolowska-Andersen et al., 2014). 
A number of strategies using heat, chemical lysis, enzymatic lysis, physical lysis, and, 
enrichment procedures (Feehery et al., 2013), in combination with standard DNA 
extraction kits, have been proposed to reduce bias and maximise yield in the extraction 
of DNA from mixed communities. Optimal conditions will likely vary depending on the 
types of organisms present, and the types of tissue being analysed. However, physical 
disruption using silicone beads and agitation has been consistently shown to be an 
effective method to minimise gram-negative extraction bias (Yuan et al., 2012, de Boer 
et al., 2010).  
In this study, 20-50 mg of tissue was added to 180 µl DNeasy Buffer ATL and 20 µl 
proteinase K in a 2 ml sterile screw cap tube and vortexed for 10 seconds. Tubes were 
then incubated at 56°C for 1-3 hours, vortexing 2 to 3 times an hour, until tissue 
appeared fully homogenized. Contents were then incubated at 95°C for 5 minutes, and 
spun at 8000 revolutions per minute (rpm) for 1 minute. 200 µl Buffer AL was next 
added to each vial and pulse vortexed for 15 seconds, followed by incubation for 10 
minutes at 70°C. 1/6th of a vial of MPBio Lysing Matrix B tubes containing 0.1 mm silica 
spheres were added to each tube and agitated at 50 Hz for 1 minute, followed by 
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addition of 200 µl of 100% ethanol. All samples were then centrifuged at 8000 rpm for 
1 minute and the lysed contents added to individual QIAmp Mini columns and spun 
again at 8000 rpm for 1 minute. A fresh collection tube was then placed below the spin 
column and 500 µl of Buffer AW1 added to the column, followed by further 
centrifugation at 8000 rpm for 1 minute and replacement of the collection tube again. 
500 µl Buffer AW2 was then added to the spin column and spun at 14000 rpm for 3 
minutes. 200 µl Buffer AE was then added to the column and incubated for 5 minutes to 
maximise yield, before spinning at 8000 rpm for 1 minute into a sterile, labelled 1.5 ml 
flip-top tube. All DNA was stored at -20°C until required.  
A negative extraction control, in which no tissue was added to extraction reagents and 
the normal protocol carried out, was produced for every round of extractions. 16S 
transcripts were subsequently quantified and sequenced to assess bacterial 
contamination of extraction reagents, the existence of which has been shown by 
numerous studies to be a significant analytical challenge for microbiome research (Cuiv 
et al., 2011, Kennedy et al., 2014b, Salter et al., 2014), particularly in samples of low 
biomass, such as the lungs (Jervis-Bardy et al., 2015) and the placenta (Lauder et al., 
2016). 
2.2 Quantitative Polymerase Chain Reaction 
2.2.1 Equipment and reagents 
 NanoDrop ND-1000 Spectrophotometer  
 MicroAmp® Fast Optical 96-Well Reaction Plate and Optical Adhesive Covers 
(Applied Biosystems) 
 StepOne PlusTM Real-Time PCR Systems with StepOne Software v2.1 
 Custom DNA Oligonucleotides (Sigma-Aldrich) 
 Power SYBR® Green PCR Master Mix (Applied Biosystems) 
 UltraPureTM Diethylpyrocarbonate (DEPC) treated water (Invitrogen)  
 Qubit® 2.0 Fluorometer with Qubit dsDNA Broad Range Assay Kit 
(ThermoFisher Scientific) 
2.2.2 Primer design and optimisation 
Ultra-pure barcoded primers had already been purchased for amplicon sequencing of 
the V5-V7 region of the bacterial 16S gene by a collaborating laboratory in the Institute 
of Child Health department of Infection, Immunity, Inflammation, and Physiological 
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Medicine. Although it would have been desirable to use the same primers for both 
quantitative and qualitative analyses, the sequencing target amplicon binds to a 390 bp 
region of the E. coli genome, which is relatively large for use in qPCR. Therefore, a 
number of primer pairs, most spanning a smaller region of the same V5-V7 region, 
were compared for use in quantitative experiments. Using the RDP Probe Match 
resource, an estimate of the number of target species to which the primers would 
anneal was produced. PCR efficiencies of E. coli standard curves (see section 2.2.4), at a 
variety of primer concentrations, were also recorded. These two factors were used as 
quantifiable outcomes for comparison and selection of optimal primer pairs (Appendix 
Table A 1, page 248). All primer pair sequences were also compared to the reference 
human genome (hg38, December 2013) using the UCSC Genome Browser (Kent et al., 
2002) in-silico PCR tool to check for non-specific binding. No pair had any known match 
to the human genome. 
Based on these comparisons, primer pair 785F-939R 
(GGATTAGATACCCBRGTAGTC/CTTGTGCGGGYCCCCGTCAAT), which produces an 
amplicon around half the size of the sequencing amplicon and showed much greater 
reaction efficiency, was chosen for use in qPCR experiments. Optimal annealing 
temperatures were assessed using end-point PCR. 61C produced the best results. 
Primer concentrations were compared using qPCR and 0.6 pmol/µl was chosen for use 
in experimental analyses.  
2.2.3 Reaction set-up 
qPCR was used to assess and quantify the presence of total bacterial DNA within 
samples extracted from preterm and term delivered placentas. Experiments were 
conducted using the Life Technologies StepOne PlusTM Real-Time PCR Systems machine. 
The absolute quantification method is used to analyse the quantity of bacterial 
template in a sample, with reference to a standard curve of five serially diluted (1:10) 
E. coli DNA samples, with each sample run in triplicate.  In addition to placental DNA 
samples, standards, and extraction negatives, 3 water blanks were included on each 
plate to check for PCR reagent contamination. Table 2.1 outlines reaction volumes and 
cycling parameters used in the assay. 
 
 49 
Table 2.1- PCR reaction mix and cycling parameters used to amplify 16S bacterial 
sequences. 
 
PCR cycling parameters: 
Step Temperature Time Number of Cycles 
Initial denaturation 95°C 10 min 1 
Denaturation 95°C 15 sec 40 
Annealing and extension, 
fluorescence reading 
61°C 1 min 
 
Followed by melt curve analysis conducted in increasing increments of 0.5°C 
 
2.2.4 qPCR analysis 
qPCR measures the emission of fluorescence from SYBR® Green molecules. SYBR® 
Green binds to double stranded DNA molecules as they are exponentially multiplied 
across successive PCR reaction cycles, producing a characteristic qPCR fluorescence 
curve (Figure 2.1). These data are used to infer RNA or DNA starting concentrations in 
samples of interest.  The concentration of PCR product in the sample initially increases 
at an exponential rate between cycles, but as reagents become depleted the process 
slows to a linear increase and eventually plateaus with very few new DNA molecules 
being synthesised. It is at the exponential phase of template amplification that a 
threshold level is chosen, and kept constant between plates. This is the most consistent 
phase of amplification. Cycle threshold (CT) values for each sample are calculated as 
the point at which their individual fluorescence curves pass this threshold.  All 
placental DNA samples were run in duplicate and the mean CT was taken for each 
sample. Duplicate CTs that were over 0.5 CT cycles apart were discarded. qPCR for such 
samples were repeated. If samples were again over 0.5 CT cycles apart, qPCR data for 
these samples were discarded altogether.  
 
 
 
 
Reaction component Final Concentration µl / reaction 
PCR grade water (Bioline) - 1.5 
Power SYBR Green Master Mix (Life) - 12.5 
Forward primer (785F) 0.6 pmol/µl 0.75 
Reverse primer (939R) 0.6 pmol/µl 0.75 
25 ng of 2.5 ng/µl template DNA 1 ng/µl 10 
Total - 25 
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Figure 2.1 - Amplification plot showing the characteristic increase in fluorescence by 
cycle number that is proportional to the amount dsDNA product in the reaction well. 
At the end of each experiment, a melt curve analysis was run to confirm the fidelity of 
amplification. The presence of one single peak implied the absence of non-specific or 
primer-dimer amplification, indicating that fluorescence values were representative of 
only the intended 16S target sequence (Figure 2.2). Results were quality control 
assessed and analysis conducted using the StepOne Software 2.1 program.  
The absolute quantification method of qPCR measures fluorescence from samples of 
known concentration in order to calculate the amount of DNA in samples of unknown 
concentration. By plotting the CT value of standards, in this case E. coli, against the log10 
of their known concentrations, a ‘standard curve’ is produced. The mean CT values of 
each experimental sample can be plotted onto this and their estimated quantity read off 
(Figure 2.3).  Vials with standard concentrations of E. coli DNA were kindly provided by 
the Microbiology, Virology & Infection Control Department at Great Ormond Street 
Hospital for Children. The first dilution on the curve represents DNA from an estimated 
40,000 E. coli colony forming units (CFUs). In order to ensure the most accurate 
quantification, E. coli DNA standards were also quantified using a Qubit® 2.0 
Fluorometer Broad Range reagent kit each time a new stock was used. Variations in 
concentrations were recorded and were used to calculate 16S copy number/µl of each 
E. coli standard. 16S copy number for E. coli standards were estimated using the 
relevant E. coli genome size (5,231,428 bp), average bp molecular weight (660 
gm/mol), Avogadro’s constant (6.022E+23 mol-1), and the knowledge that the E. coli 
genome has seven copies of the 16S gene.  
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A standard curve dilution series was run on each plate to minimise the impact of inter-
plate variation on sample quantification. The efficiency of each PCR reaction is a metric 
that describes how closely the reaction is adhering to the expectation of a doubling of 
PCR product per cycle. Efficiency (E) is calculated by plotting the log of the starting 
quantity of each standard curve point by their CT value and then inputting the slope of 
the curve into the equation:  
E = 10–1/slope 
Experiments with efficiencies between 90 and 110% are generally considered to be 
highly reliable. The mean efficiency for all 35 plates run for this project was 93.9% 
(standard deviation (SD) = 5.5). Pipetting accuracy is represented by the R2 value 
between points. 
Figure 2.2 – Representative melt-curve peak at around 84°C for two technical 
replicates indicating fidelity of observed signal to single 16S target sequence. 
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Figure 2.3 – Example of standard curve using 5 (1:10) serially diluted samples of E. 
coli DNA using primers 939R-785F. Efficiency = 100.8%, R2=0.99, slope =-3.3. 
 
2.3 16S rDNA amplicon high-throughput sequencing 
A subset of DNA samples with available qPCR data was taken forward for targeted 16S 
amplicon sequencing, using a multiplex design, on the Illumina MiSeq platform. 
2.3.1 Equipment and reagents 
 Veriti® 96-Well Thermal Cycler (ThermoFisher Scientific) 
 Thermo-Fast® 96 Non-Skirted (ThermoFisher Scientific)  
 MicroAmp® Fast Optical 96-Well Reaction Plate and Optical Adhesive Covers 
(Applied Biosystems) 
 StepOne PlusTM Real-Time PCR Systems with StepOne Software v2.1 
 Qubit® 2.0 Fluorometer with Qubit dsDNA High Sensitivity Assay Kit 
(ThermoFisher Scientific) 
 DynaMagTM-96 Side Skirted Magnet and DynaMagT M-2 Magnet 
(ThermoFisher Scientific) 
 Agilent 2200 TapeStation, D1000 ScreenTape and TapeStation Analysis 
Software A.01.05 (Agilent Technologies) 
 MiSeqTM Next-Generation Sequencer System and MiSeqTM Reagent Kit V2 (500 
cycles) (Illumina) 
 Moltaq 16S Bacterial DNA-free thermostable DNA polymerase (Molzym) 
 Moltaq DNA-free water, PCR-grade (Molzym) 
 Moltaq 16S PCR Buffer (Molzym) 
 Deoxyribonucleotides (dNTPs) (10mM) (Promega) 
 Agencourt AMPure® XP PCR Purification Beads (Beckman CoUlter) 
 80% ethanol (HAYMAN)  
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 Buffer EB (QIAGEN) 
 KAPA Library Quantification Kit for Illumina® platforms (Kapa Biosystems) 
 PhiX Control V2 (Illumina) 
 Sodium hydroxide (NaOH) 
2.3.2 Primer design 
Sequencing primers were kindly donated by Dr Ronan Doyle (Department of Infection, 
Immunity, and Inflammation, Institute of Child Health, UCL). The primers were 
designed to target the V5-V7 regions of the 16S rRNA gene, 785F: 5′-
GGATTAGATACCCBRGTAGTC-3′, 1175R: 5′-ACGTCRTCCCCDCCTTCCTC-3′ (Doyle et al., 
2014). The primers were adapted for high-throughput sequencing with the addition of 
Illumina P5 or P7 adapter sequences, and barcoded dual-index forward and reverse 
sequences as outlined in a previous publication (Caporaso et al., 2012). The addition of 
barcode sequences enabled multiplexing of up to 384 samples per run.  
2.3.3 Library preparation 
Preparation of samples for sequencing of the 16S V5-V7 region involved a 32-cycle end-
point PCR reaction. Ultra-pure Taq DNA polymerase (Molzym) was used to minimise 
the chance of contamination of the sequencing library from bacteria present in PCR 
reagents. Reaction components and cycling parameters were as shown in Table 2.2. 
Table 2.2 – Reaction components and cycling parameters for preparation of library 
for 16S amplicon sequencing of placental samples. 
 
Reaction component Final Concentration µl / reaction 
Moltaq PCR grade water - 13.575 
Moltaq PCR Buffer 1X 2.5 
dNTPs 180 µM 1.8 
Forward primer (785F) 0.4 µM 1 
Reverse primer (1175R) 0.4 µM 1 
Moltaq DNA polymerase 25mM 0.125 
Template DNA - 5 
Total - 25 µl 
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PCR cycling parameters: 
 
Step Temperature Time Number of Cycles 
Initial denaturation 94°C 3 min 1 
Denaturation 94°C 30 sec 32 
Primer annealing 60°C 40 sec  
Extension 72 90 sec  
Extension 72 10 min 1 
 
2.3.4 Library clean up and quantification 
PCR products were double cleaned to remove any primer-dimer and small, non-specific 
amplicons, using 0.8X Ampure XP beads, according to manufacturer’s instructions, and 
eluted into 20 µl of Buffer EB.  Samples were then quantified using the Qubit® 2.0 
Fluorometer and dsDNA HS Assay Kit reagents, and pooled in equimolar amounts to 
the highest possible concentration. 
Specificity of the final amplicon pool was assessed using the Agilent 2200 TapeStation 
and High Sensitivity assay kit, and libraries were re-cleaned using Ampure XP again if 
necessary (Figure 2.4). Apart from the library for the first run, in which concentration 
was quantified using the Qubit® and was overestimated, pools were quantified using 
the KAPA Library Quantification Kit for Illumina®. The latter quantifies only those 
amplicons that are able to hybridise to the flowcell by using Illumina adaptor specific 
primers and standards. Each qPCR quantified pool was normalised to 2 nM. Finally, up 
to four PCR plates (386 samples) were pooled into one final pool in preparation for 
sequencing. 
2.3.5 MiSeq set-up 
Following library preparation, clean-up and quantification, the pooled library was 
loaded onto the MiSeq according to Table 2.3. 
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Table 2.3 – Reaction components, volumes and final concentrations for MiSeq set-up 
Reaction component Final Concentration µl / reaction 
Final 2 nM pooled library 4.5-10 pM 2.25-5 
2 M NaOH - 2.25-5 
HT1 MiSeq buffer - 990-995.5 
Denatured PhiX stock 12 pM 100 
Index Sequencing Primer (100 µM) - 3.4 
Read 1 Sequencing Primer (100 µM) - 3.4 
Read 2 Sequencing Primer (100 µM) - 3.4 
 
 
 
A)	
B)	
Figure 2.4 - Agilent 2200 TapeStation High Sensitivity trace. Final 16S pooled library 
of target amplicon at ~502 bp (green box) A) before and B) after final clean-up using 
Ampure XP beads. A) hows non-specific smaller peaks (red box) no longer present in B) 
following clean-up 
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2.25-5 µl of the 2 nM library was combined with an equal amount of 0.2 M NaOH, 
vortexed briefly and left at room temperature for 5 minutes to denature. Depending on 
the desired loading concentration, 990-995.5 µl of HT1 buffer from the MiSeq reagent 
kit was added to the denatured library and mixed well. 100 µl of denatured and thawed 
12 pM PhiX stock was then added to 900 µl of this diluted, denatured library. 
Index 1 (GAGGAAGGHGGGGAYGACGTTAAAACGTGTT), custom Read 1 
(TACCGGGACTTAGGATTAGATACCCBRGTAGTC), and Read 2 
(TACCGGGACTTAGGATTAGATACCCBRGTAGTC) sequencing primers were loaded into 
the cartridge into wells 13, 12, and 14 respectively, and mixed thoroughly. The diluted 
library was added to well 17. The cartridge was loaded into the MiSeq machine as per 
manufacturer’s protocol for a 500 cycle V2 kit run. 
2.3.6 Bioinformatics analyses 
Paired-end 250 bp sequenced reads were merged, demultiplexed, quality filtered and 
assigned to OTUs with taxonomic labels. The UCLUST algorithm (Edgar, 2010) within 
Quantitative Insights Into Microbial Ecology (QIIME) pipeline was used to pick OTUs at 
97% similarity against the Greengenes core reference database version 12.10 
(McDonald et al., 2012). Any sequences that failed to match at 97% were clustered de 
novo using UCLUST. A representative sequence was then chosen for each OTU and this 
sequence was then aligned to the Greengenes ‘Core Set’ taxonomic alignment (DeSantis 
et al., 2006) using PyNAST (Caporaso et al., 2010a). These aligned sequences were used 
to build a phylogenetic tree using FastTree 2.1.3 (Price et al., 2010). Taxonomy was 
assigned using the RDP Classifier 2.2 (Wang et al., 2007) and the Greengenes taxonomy 
reference database, from which an OTU table was constructed. The specific error 
checking, filtering, and analysis pipeline devised for my samples will be discussed in 
further detail in 0.  
2.4 Multiplex ELISA assay in maternal serum 
In order to characterise a selection of the systemic inflammatory responses of BBB 
mothers in the run-up to delivery, the Bio-Rad 27-plex human cytokine assay was used. 
This kit assays the concentrations of 27 cytokines simultaneously in each individual 
biological sample of interest (Table 2.4). The assay is a sandwich enzyme-linked 
immunosorbent assay (ELISA) protocol in which each of the cytokines, if present in a 
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sample, will bind to one of the 27 specific capture antibodies provided in the kit that 
are covalently bound to magnetic beads. These solutions are then subjected to a 
number of washes to remove any unbound protein, and then combined with a 
biotinylated detection antibody forming the sandwich complex (Figure 2.5). Finally, 
streptavidin-phycoerythrin (SA-PE) conjugate is added, which binds to the biotinylated 
antibodies and serves as the fluorescence indicator when the assay is run. 
Table 2.4 – Names and abbreviations of 27 cytokines in the Bio-Rad 27-plex human 
cytokine kit used to assay maternal serum immunity in Chapter 7. 
Cytokine (alternate names in brackets) 
CCL2 (MCP-1) Chemokine (C-C motif) ligand 2/  monocyte chemoattractant protein 1  
CCL3 (MIP-1α) Chemokine (C-C motif) ligand 3/ macrophage inflammatory protein 1-alpha 
CCL4 (MIP-1β) Chemokine (C-C motif) ligand 4/ macrophage inflammatory protein 1-beta 
CCL11 C-C motif chemokine 1/ eosinophil chemotactic protein/ exotaxin-1 
CXCL10 (IP-10) C-X-C motif chemokine 10/  Interferon gamma-induced protein 10 
FGF basic Basic fibroblast growth factor 
G-CSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
IFN-γ Interferon gamma  
IL1ra interleukin-1 receptor antagonist 
IL1β Interleukin 1 beta 
IL2 Interleukin 2 
IL4 Interleukin 4 
IL5 Interleukin 5 
IL6 Interleukin 6 
IL7 Interleukin  7 
IL8 Interleukin 8 
IL9 Interleukin 9 
IL10 Interleukin 10 
IL12 Interleukin 12  
IL13 Interleukin 13 
IL15 Interleukin 15 
IL17 Interleukin 17 
PDGF-BB Platelet-Derived Growth Factor-BB 
RANTES (CCL5) 
Regulated on Activation, Normal T cell Expressed and Secreted/ Chemokine 
(C-C motif) ligand 5 
TNF-α Tumor necrosis factor alpha 
VEGF Vascular endothelial growth factor 
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Figure 2.5 – ELISA sandwich complex used in Bio-Rad assay, which results in 
fluorescence if cytokine of interest is present in sample. 
 
2.4.1 Equipment and reagents 
 Bio-Plex® MAGPIX™ Multiplex Reader (Bio-Rad) 
 Bio-Plex Pro™ Wash Station (Bio-Rad) 
 Microtiter plate shaker 
 Standard or sample diluent (Bio-Rad) 
 Assay buffer (Bio-Rad) 
 Wash buffer (10X) (Bio-Rad) 
 Detection antibodies (10X) 
 Detection antibody diluent (Bio-Rad) 
 SA-PE (100X) (Bio-Rad) 
 Coupled magnetic beads (10X) (Bio-Rad) 
 Sample or standard  
 Sealing tape (Bio-rad) 
 96 well flat bottom plate (Bio-Rad) 
 
2.4.2 Collection and processing of blood for serum 
For ease of collection and to encourage participation by minimising the number of 
blood draws/ hospital visits for mothers, maternal blood samples were collected once 
during pregnancy, at a time that was convenient to the mother. These were not 
restricted to a certain time point in gestation. This usually coincided with hospital 
appointments when blood draws were being taken for clinical purposes. 10 ml of 
maternal blood was collected according to BBB protocols in clotting tubes (red top) for 
collection of serum. The appropriate Vacutainers containing the blood samples were 
spun for 10 minutes at 1200 g and the upper aqueous layer then aliquoted into at least 
2 x 2 ml labelled cryovials. Aliquots were stored at -80°C. 
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2.4.3 Reaction set-up for cytokine experiment 
In light of a series of optimisation analyses, outlined in section 3.4, the following 
protocol was used for the quantification of cytokines in the sera samples of interest. 
Coupled beads, detection antibodies, and SA-PE were diluted with appropriate 
quantities of provided diluent. Standards were first suspended in 781 µl of standard 
diluent, vortexed and left on ice for 30 minutes, and then serially diluted (1:3) to 
produce a 9-point standard curve. Serum samples were thawed on ice, vortexed and 
spun down at 10,000 rpm for 10 minutes at 4°C and diluted 1:4 in standard diluent. For 
each run, along with standards and samples, a duplicate ‘blank’ sample consisting of 
50 µl of standard diluent was also run. This was in order to characterize any 
background fluorescence that would later be deducted from values observed in 
experimental samples. The assay was run following the Bio-Rad workflow (Figure 2.6). 
 
Figure 2.6 – Set-up of Bio-Rad cytokine panel for maternal serum profiling. 
 
 
Load into calibrated Bio-Plex MAGPIX  reader and set up software 
Resuspend in 125 µl assay buffer; shake at 850 rpm for 30 seconds 
Wash 3 x 100 µl 
Add 50 ul 1X streptavidin-PE; incubate on shaker at 850 rpm for 10 minutes RT 
Wash 3 x 100 µl 
Add 25 µl 1X detection antibody; incubate on shaker at 850 rpm for 30 minutes RT 
Wash 3 x 100 µl 
Incubate on shaker at 850 rpm for 1 hour at room temperature (RT) 
Add 50 µl standards, samples, controls 
Wash 2 X 100 µl 
Add 50 µl 1X beads to wells 
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2.4.4 Cytokine data analysis 
Raw fluorescence values were compared to each plate specific standard curve created 
by the Bio-Plex Manager™ V6.1 software, to calculate estimated concentrations (pg/ml) 
for each of the 27 cytokines. Data points above or below the reliable range of the 
standard curve, or below the background blank value, were flagged as out of range 
(OOR) by the software. How these missing values were dealt with prior to final 
analyses is discussed further in Chapter 3. 
2.5 Statistical analyses 
All statistical analyses were conducted within RStudio (version 0.99.484) 
(RStudioTeam, 2015) using the R (version 3.3.1 2016-06-21) statistical programming 
environment (R Core Team 2014). All graphs were created using the package ggplot2 
(version 2.1.0) (Wickham, 2009). A significance threshold of 5% (P<0.05) was used to 
define statistical significance, unless otherwise stated. Normality was defined using the 
Shapiro-Wilk test (Royston, 1982) in R. 
In a number of instances throughout this thesis, correlations between technical and 
biological replicates were quantified using the intra-class correlation coefficient (ICC) 
calculated within R, using the package ‘ICC’ (Wolak et al., 2012). The ICC is a value 
between 0 and 1 that describes how strongly observations within groups, in this case 
replicates, resemble each other. 
Univariate and multiple linear and logistic regression models were constructed using 
the in-built glm function in R. For certain analyses, a mixed effects model was deemed 
more appropriate. In such instances, the nlme (version 3.1.128) or lme4 (version 
1.1.12) packages were used. Availability of clinical data, interrogation of relevant 
literature, statistical analyses of my own dataset, and an awareness of the risks of 
overfitting (Babyak, 2004), formed the basis for my choice of study specific, a-priori 
identified covariates used in my final multiple regression models (Table 2.5).  For each 
study, covariates were combined to form multiple regression models in a single step, 
forced entry model.  
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Table 2.5 - Potential confounding variables/ covariates used in multiple regressions 
for each of the three experimental studies conducted 
Study 
qPCR Sequencing Cytokines 
Delivery method 
Maternal ethnicity 
Batch  
Smoking 
Maternal BMI* 
Recruiting  hospital 
Tissue type** 
Delivery method 
Maternal ethnicity 
Batch  
Smoking 
Maternal BMI* 
Recruiting  hospital 
Tissue type** 
Maternal ethnicity 
Batch (fixed or mixed) 
Smoking 
Maternal BMI* 
Maternal age 
Parity 
Days before birth at sampling 
* Categorical: underweight, obese, normal       ** Where relevant 
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: Development and Chapter 3
Optimisation of Methods 
Three core techniques form the basis of the experimental chapters in this PhD: qPCR, 
NGS, and ELISA. Despite being established techniques, they presented novel challenges 
for this specific cohort, which required refinement of existing protocols and analytical 
techniques. Chapters 5 and 6 describe quantitative and qualitative microbial variation 
within placental samples respectively. DNA extracts from this tissue contain mostly 
human DNA and, potentially, a very low abundance of bacterial DNA. The majority of 
microbiome work to date has focused on bacteria rich sites, such as the gut (Wu and 
Lewis, 2013), in which the ratio between human and prokaryotic DNA is less extreme. 
Microbiome analyses of sites invariably described as ‘sterile’, such as the lower 
respiratory tract (Bassis et al., 2015) and placenta (Aagaard et al., 2014), are rare. It is 
only recently that methodological and analytical developments specific to these sample 
types have started to be published (Jervis-Bardy et al., 2015, Glassing et al., 2016, 
Glassing et al., 2015). Challenges encountered in this project as a result of these sample 
specific issues were two-fold. The first involved the competing and inhibitory effect of 
endogenous human DNA on the ability to observe low-level bacteria present in the 
samples of interest. This impacted both PCR efficiency and sequencing optics. Secondly, 
it was critical to minimise the impact of contaminating OTUs on study results and 
interpretation. The influence of such OTUs on the interpretation of qPCR and 
sequencing outputs has been shown to be larger in low versus rich biomass tissues 
(Salter et al., 2014).  
The third section of this chapter documents the optimisation of the multiplex ELISA 
assay, the results of which are described in Chapter 7. The sensitivity of cytokine 
concentrations to sample handling and storage procedures has been reported 
previously (de Jager et al., 2009). In an attempt to characterise these potential biases, a 
number of variables were investigated in a preliminary cohort before carrying out 
analyses on the clinical samples. These investigations were used to establish optimal 
conditions and analytical models for final experiments.  
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3.1 Aims 
1) Define optimal conditions for quantification of total bacterial DNA from low-biomass 
placental samples, using V5-V7 16S universal primers. 
2) Estimate reproducibility of qPCR assay.  
3) Optimise loading concentration of placental DNA samples with low nucleotide 
diversity for sequencing of 16S amplicons using the Illumina MiSeq platform. 
4) Develop a sequencing analysis pipeline to use in conjunction with already available 
resources, such as QIIME, to account for assay specific error rates and contamination 
issues in low-biomass samples. 
5) Design and conduct an optimisation experiment to investigate impact of freeze-thaw 
cycling, sample dilution, and batch effect on cytokine profiles in maternal blood 
samples. 
6) Define a protocol for handling the substantial number of missing values produced by 
the Bio-Rad multiplex ELISA assay. 
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3.2 qPCR for quantitative analysis of placental infection 
The inhibitory effect of too much DNA in a PCR reaction is well known (Schrader et al., 
2012). However, this relationship is complicated when working with mixed (e.g. 
bacterial and human) samples of very low biomass, such as the placenta. In such 
instances, it is important to minimise the inhibitory effects of background human DNA 
on the assay, often via dilution of starting template. However, excessive dilution may 
reduce microbial DNA concentrations below the limit of detection (LOD) of the assay. 
The following section documents the optimisation of template concentration for use in 
downstream qPCR experiments. Secondly, reproducibility of the qPCR assay is reported 
using data from technical replicates. 
3.2.1 Methods 
See sections 2.1 and 2.2. 
3.2.2 Results 
3.2.2.1 Optimisation of template concentration for use in qPCR 
An inhibitory effect of background human DNA was observed in the placental samples 
when using V5-V7 16S primers, designed to target only bacterial content. Optimisation 
analyses were therefore performed in which 3-point standard curves were produced 
for human DNA samples, spiked with known quantities of E. coli DNA. These standard 
curves were then compared to those produced following amplification of the same 
concentration of E. coli DNA suspended in water. When the total starting amount of 
either sample type was increased from 1 µl to 2.5 µl in 0.5 µl increments, CT values 
increased in the mixed samples but reduced, as would be expected, in the pure E. coli 
samples. This observation indicates that although there was more bacterial DNA in 
either sample type, the effect of more human DNA in the spiked samples was to inhibit 
the reaction. This effect is demonstrated in Figure 3.1, and a trend was observed for 
multiple samples of varying starting concentrations.  
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To test whether this was just a general effect of too much overall DNA in the sample, 
regardless of target of interest, the same experiment was conducted using primers to 
target the human specific GAPDH locus. This did not detect the same inhibitory effect 
(data not shown). Indeed, there was only a small reduction in CT as the amount of 
starting template increased, which is to be expected given the increase in starting DNA.  
Melt curve analyses of placental DNA samples targeted with 16S primers also indicated 
that dilution of the starting template increased specificity of target amplification 
(Figure 3.2). It was next sought to establish the optimum starting amount of total DNA 
for use in the 16S qPCR experiments. In order to do this, a number of identical samples 
were run at three different starting concentrations (12.5 ng, 25 ng, and 50 ng). It was 
clearly visible that the sensitivity of the assay was reduced (i.e. higher CT values were 
recorded) if templates were diluted too much (12.5 ng) or not enough (50 ng) (Figure 
3.3). The 25 ng concentration was therefore chosen as the optimal starting template 
amount because the lowest median CT values were observed in these samples.  
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Figure 3.1 – Effect of different amounts of background human DNA on the sensitivity 
of detection of E. coli DNA 
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3.2.2.2 Reproducibility between technical replicates is high 
In total, 26 technical replicates were run across all qPCR plates. These were used to 
assess the reproducibility of the assay. The correlation between these technical 
replicates was high (ICC=0.89) (Figure 3.4). Only 39 samples could be run on any one 
plate, totalling 35 batches. When new E. coli stocks were used, concentrations of the 
estimated 10,000 CFU dilutions were assessed using the Qubit®. This meant any 
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Figure 3.3  – Comparison of assay sensitivity by total DNA starting amount (ng). P-
values from Mann-Whitney U test comparison of medians. 
 
Figure 3.2 – Melt curve analysis of 16S qPCR amplification in 4 serially diluted (1:10) 
placental DNA samples shows greater specificity with each of the four dilutions (far 
left = 10-1, far right = 10-4) 
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variation in starting concentration that could affect accuracy of assay quantification 
was taken into account appropriately (see Appendix Table A 2, page 249 for summary 
of plate statistics). Despite the potential impact that combining many batches and a 
variety of standard stocks may have on assay variability, this preliminary analysis 
provides evidence that the assay was highly reproducible across batches, as long as 
changes in standards were accounted for. 
 
 
 
 
 
 
 
 
 
 
3.2.3 Discussion 
Based on the above investigations, all placental DNA samples were diluted to a uniform 
concentration such that 25 ng of total starting material was present in each qPCR 
reaction. This was done in an attempt to maximise assay sensitivity. In addition, each 
time a new vial of 10,000 CFU E. coli standard DNA was collected it was quantified by 
Qubit®. This value, rather than the estimated CFU count, was used to draw up standard 
curves for each plate. 
Figure 3.4 - Reproducibility between experimental replicates when 16S 
quantification takes into account changes in E. coli batch concentration. ICC and 
unadjusted linear regression line with 95% CI show strong relationship between technical 
replicates. 
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3.3 Development of a 16S sequencing protocol and filtering 
parameters 
The low concentration of bacterial DNA in our placental tissue was also a pertinent 
consideration when conducting the qualitative microbiome analyses reported in 
Chapter 6. The following section documents the challenges encountered in producing 
high quality raw data from these particular samples. These were again addressed by 
adjustment of starting material concentration, generally at the expense of total sample 
size. In addition, this section will outline the customisation of available computational 
and analytical tools for analysis of high-throughput microbiome data. These study 
specific approaches were developed in an attempt to deal with the substantial issue of 
contamination in the cohort. They were also aimed at increasing statistical power to 
detect associations between bacterial abundance and outcomes of interest. 
3.3.1 Methods 
See sections 2.1 and 2.3.  
3.3.2 Results 
3.3.2.1 Optimisation of loading concentration 
Producing high quality sequences from targeted small amplicon libraries can be 
challenging. This is particularly true of 16S libraries, which have lower per cycle 
nucleotide diversity in comparison with random shotgun or multi-gene panel libraries. 
Low diversity libraries are problematic for sequencing by synthesis platforms such as 
the Illumina MiSeq because the two optical channels struggle to find distinct clusters on 
the images in cycles of limited diversity. For this reason, it is often suggested low-
diversity libraries be spiked with a percentage (10-15%) of the highly diverse PhiX 
genome provided by Illumina. However, even with a 12% spike, my placental libraries 
were still characterised by very low diversity. In genome libraries prepared using a 
random fragmentation step, each base would be present at approximately 25%. This 
would be reflected in a relatively constant, straight line of blue, red, green and black 
across the percentage base call chart created by Illumina BaseSpace software. By 
contrast, the base-call percentages of my 16S libraries fluctuated extensively across 
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cycles (Figure 3.5). This was a clear sign of low nucleotide diversity in the samples and 
proved problematic for the generation of high quality sequencing data. 
Figure 3.5 - Run 1 percent base calls per cycle. A screen shot from the Illumina 
sequencing analysis viewer in which percentage base calls (red=A, green=C, blue=G, 
black=T) are plotted by cycle number. 
For reduced diversity libraries, it is generally suggested to aim for a cluster density 
below the optimum suggested by Illumina for normal libraries (1000-1200 thousand 
clusters (k)/mm2) at around 800 k/mm2. This serves to use the flow cell to a high 
capacity without compromising on read quality, which deteriorates when the flow cell 
is overloaded. It proved challenging to identify the optimum loading concentration to 
achieve this density. The relationship between cluster density and loading library 
concentration is not strictly linear. It took a number of attempts to identify a 
reasonable loading concentration to use across runs.  
Table 3.1 documents how variation in loading concentration was adjusted across runs 
in an attempt to improve quality and yield. The first run was of high quality but 
significantly under-clustered. The second was over-clustered and of much lower 
quality. Sequence quality is very important for 16S bioinformatics analysis. Therefore, 
it was decided to concentrate on producing more high quality reads per sample, rather 
than settling for lower quality data from more samples. Therefore, the final three runs 
were repeats from the same 386-sample pool. It was not possible to sequence the 
whole qPCR cohort as had originally been planned. Reads that passed filter (PF) were 
pooled together before read-merging, quality control and taxonomic/phylogenetic 
analyses were conducted.    
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Table 3.1 – MiSeq platform loading concentration affects cluster density and read 
quality across 4 different runs. % >Q30 is a commonly used threshold that refers to the 
% total bases on a run with less than 1/1000 chance of being an erroneous call. 
Run 
Loading 
concentration 
Quantification % >= Q30 
Cluster density  
(% PF) 
Target reads 
PF (M) 
Run 1 10 pM  Qubit* 78.8 224 ± 40 (78.4) 2.65 
Run 2 12 pM qPCR 61.5 1367 ± 70 (23.6) 4.96 
Run 3 8 pM qPCR 70.7 1015 ± 69 (46.6) 8.47 
Run 4 4.5 pM qPCR 71.1 785 ± 97 (63.4) 9.13 
* Run 1 was quantified by Qubit, which severely overestimated total concentration. 
 
3.3.2.2 From FastQ to OTU table 
Paired-end 250 bp sequenced reads from the four MiSeq runs were merged using Fast 
Length Adjustment of SHort reads (FLASH) v1.2.11.  A minimum overlap of 110 bp and 
maximum of 160 bp produced reads spanning 342-392 bp, with a median of 370 bp. 
Before OTU clustering, reads were demultiplexed using their 24 bp Golay barcode and 
the default options of the QIIME 1.9.1 (Caporaso et al., 2010b) split_library.py 
command within Python 2.7.11. This command has an option to filter out any reads 
that fail to meet a user specified Phred quality score (Q score) (Ewing et al., 1998) 
threshold.  Q scores are the most common metric used to assess the accuracy of base-
calls from a sequencer, and are used by Illumina to summarise per-cycle accuracy on 
their MiSeq platform. Q scores are logarithmically related to error probabilities, such 
that a Q score of 30 (Q30) represents a 0.001 probability of an erroneous base-call.  
Analyses from 16S rRNA microbial profiling are highly dependent on the pre-
processing steps applied to sequencing output. Removing sequences of poor quality via 
error-checking algorithms is one such tool that can be used to minimise the presence of 
erroneous OTUs in the final dataset. Failure to account for reads with high error rates 
can lead to spurious clustering, inflating diversity estimates. This risks leading to 
inaccurate biological inferences (Edgar and Flyvbjerg, 2015).  
The standard approach for error checking in microbiome pipelines, including QIIME, is 
to remove reads with an average Q score below a predefined minimum (e.g. 25), 
and/or truncate and discard reads at the point at which the per nucleotide Q score falls 
below a certain threshold (e.g. 20) (Bokulich et al., 2013). However, a different strategy 
has also been proposed that sums the per read Q scores to estimate the expected 
number of errors in a read, known as Maximum Expected Error (MEE) checking. In this 
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case a high score indicates low quality. A threshold can then be chosen, normally 1, 
above which reads are discarded. This approach has been shown to be a more stringent 
and accurate method of error reduction than traditional average Phred score strategies 
(Edgar and Flyvbjerg, 2015). Both methods work on the assumption that machine 
specific error calls are accurate. In the case of Illumina runs, this is normally based on 
output from those reads mapping to the PhiX genome, which are spiked into the library 
prior to loading. 
Given the issues that were encountered regarding low quality sequencing output, it was 
important to consider such error checking decisions carefully. Truncation on average 
read and/or per nucleotide Q scores, or filtering with MEE counts were tested via the 
QIIME split_library.py and VSEARCH fastq_filter commands respectively. Table 3.2 
shows that for two different approaches using QIIME, the first being the default <Q25 
filtering protocol and the second that discarded reads based on a minimum acceptable 
Q score of 19, kept a large proportion of reads. However, the number of OTUs was 
excessively high for such a low biomass library, with almost 30,000 OTUs for both 
outputs. By contrast, the more conservative MEE approach retained significantly less 
reads. However, given that a larger proportion of these were high quality, less than a 
third of the number of OTUs were clustered. This latter approach also better 
represented the mock communities that were sequenced (data not shown). 
Table 3.2 – Reads retained and clustered, and OTUs created following three different 
error checking strategies. 
On the basis of these comparisons, the VSEARCH MEE filtering approach was used. 
High quality reads from all four runs were then pooled. OTU picking, reference 
alignment, and taxonomic assignment were carried out as outlined in section 2.3.6 
using the default QIIME pick_open_reference_otus.py command. Singleton OTUs were 
removed and chimeric sequences identified and discarded using the uchime_ref 
command in VSEARCH. The final processed dataset of experimental samples, negative 
controls, and mocks, thus consisted of 6405 OTUs from 6,440,948 reads. See Figure 3.6 
for further details of this process.  
 
Default QIIME Q19 QIIME 
Default QIIME and 
VSEARCH MEE 
Total reads retained 14,294,890 11,277,801 7,103,877 
Total OTUs clustered 27074 26507 8644 
Total reads clustered (%) 11,235,523 (78.6) 11,161,537 (99.0) 7,099,603 (99.9) 
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Figure 3.6 – Flow diagram summarising key descriptive statistics of 4 MiSeq runs carried out, and the processes of read merging, initial filtering, 
pooling and OTU clustering of all resultant 16S sequencing reads that were amplified from placental DNA. 
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3.3.2.3 Using mock samples to approximate error rate 
It is unlikely that initial error checking will successfully identify all reads containing 
either PCR or sequencing error. In cases such as 16S amplicon sequencing, this 
contributes to the formation of spurious, low-abundance OTUs that would ideally be 
removed prior to diversity and taxonomic analyses. However, there are no universally 
agreed thresholds for at what abundance an OTU should be considered low confidence. 
Indeed, such thresholds are largely study specific. Stringency will depend on how much 
rare diversity one expects from a sample and the type of analyses that are planned. A 
common approach is to remove OTUs populated by fewer than 1% of reads (Jervis-
Bardy et al., 2015). However, error rates vary considerably across samples and runs. 
Such arbitrary thresholds do not account for such variability. Furthermore, cut-offs that 
use average OTU abundance thresholds, result in the removal of rare taxa that may be 
present at high abundance in only one or two samples. Very low prevalence and/or 
abundance does not necessarily discount an organism’s clinical relevance (Silva et al., 
2015).  
In this project, study specific error rates were approximated using data from 
sequenced mock community samples, as an alternative to arbitrary filtering. The 
intention was to use a filtering threshold to facilitate inclusion of all expected taxa, and 
maximal exclusion of OTUs that were experimental artefacts. Two independent mock 
communities were sequenced in the experiments. Mock 1   was obtained through BEI 
Resources (USA National Institutes of Health (NIH)) as part of the Human Microbiome 
Project (HMP) (Genomic DNA from Microbial Mock Community B Staggered, Low 
Concentration, v5.2L, for 16S rRNA Gene Sequencing, HM-783D). This was run on the 
first plate, with species composition listed in Table 3.3. Mock 2 consisted of genomic 
DNA samples from 10 species manually combined in units of equal volume, also 
purchased from BEI Resources (Table 3.4). This mock was run on plates 2, 3, and 4.  
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Table 3.3 – Species composition of Mock 1 used on sequencing run 1 and OTUs 
observed matching each expected organism to genus level following initial filtering 
at 0.002%.  
 
Table 3.4 - Species composition of Mock 2 used on sequencing runs 2, 3, and 4 and 
number of OTUs observed matching each expected organism to genus level following 
filtering at 0.002%. 
Organism OTUs identified to genus rank (N) 
Staphylococcus aureus, strain TCH1516 
53 
Staphylococcus epidermidis, FDA strain PCI 1200 
Escherichia coli, strain K12, substrain MG 1655 26 
Streptococcus agalactiae, strain 2603 V/R 
16 Streptococcus mutans, strain UA159 
Streptococcus pneumoniae, strain TIGR4 
Bacillus cereus, strain NRS 248 7 
Clostirdium beijerinckii, strain NCIMB 8052 5 
Pseudomonas aeruginosa, strain PAO1-LAC 4 
Bacteroides vulgatus, strain ATCC 8482 2 
Acinetobacter baumannii, strain 5377 1 
Actinomyces odontolyticus, strain 1A.21 1 
Deinococcus radiodurans, strain R1 (smooth) 1 
Enterococcus faecalis, strain OG1RF 1 
Helicobacter pylori, strain 26695 1 
Lactobacillus gasseri, strain 63AM 1 
Listeria monocytogenes, strain EGDe 1 
Neisseria meningitidis, strain MC58 1 
Propionibacterium acnes, strain KPA171202 1 
Rhodobacter sphaeroides, strain ATH 2.4.1 1 
Unassigned 1 
Other 0 
Total 124 
Organism OTUs identified to genus rank (N) 
Streptococcus anginosus, strain F0211 
78 Streptococcus mitis bv2, strain F0392 
Streptococcus pneumonia, strain TCH8431 
Staphylococcus aureus MRSA, strain TCH70 29 
Enterococcus facecalis, strain TX1322 16 
Peptostreptococcus anaerobius, strain UPII 653-L 12 
Lactobacillus crispatus, strain EX849587VC01 10 
Escherichia coli, strain  MS 110-3 6 
Fusobacterium nucleatum polymorphum, strain F0401 4 
Treponema denticola, strain F0402 2 
Unassigned 12 
Other 2 
Total 171 
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Mock samples were subset from the total cohort. The representative sequence of any 
OTU not identified to the rank of genus, using the QIIME OTU picking pipeline, was 
compared to the GenBank database using the NCBI Nucleotide BLAST tool (Altschul et 
al., 1990). Matches with a genus label and at least 97% similarity to the sequence were 
relabelled in the dataset. Any sequences that failed to match these criteria were 
recorded as genus ‘Unassigned’.  Observed OTU taxonomic classifications were 
compared to the known mock compositions provided by the manufacturers (Table 3.3 
and Table 3.4). An error threshold was defined from these data that struck a balance 
between the maintenance of false negative and false positive calls. Table 3.5 shows how 
filtering based on the relative abundance of the third encountered erroneous OTU 
(0.002%), enabled the inclusion of all correct genera across both mocks, along with 
three, very low abundance, erroneous OTUs. Experimental samples were then filtered 
based on the results from these analyses. Any OTU not present at a minimum relative 
abundance of 0.002%, in at least two experimental samples, was removed.  
Table 3.5 – Impact of filtering criteria on number of correct and incorrect OTUs 
identified in mock samples. Depending on the mean abundance chosen for filtering, 
which was based on abundance at which 1st, 2nd or 3rd erroneous OTU was encountered, 
accuracy of sequencing results changed. 
 
The expected make-up of the mock community samples, along with the number of 
OTUs matching these expectations to the level of genus, following filtering of OTUs 
below 0.002%, are shown in Tables 3.3 and 3.4. In Mock 1, all 17 expected organisms 
were identified to the rank of genus by a total of 124 OTUs, including one OTU that was 
‘Unassigned’ at the genus level. In Mock 2 171 OTUs were retained with at least one 
OTU mapping to all expected genera, in addition to one erroneous OTU mapping to 
Rummelibacillus; one to Carnobacterium; and 12 ‘Unassigned’ OTUs. Figure 3.7 and 
Error! Reference source not found. clearly show that certain genera were present at 
much higher abundances than others, following filtering. This is, in part, explained by 
the fact that certain genera (e.g. Streptococcus), mapped to more than one species in the 
Filter criteria 
Mean 
abundance 
Mock 1 Mock 2 
N/N correct 
genera 
N incorrect 
genera 
N/N correct 
genera 
N incorrect 
genera 
1st erroneous OTU 2.9 E-04 14 in 17 0 8 in 8 1 
2nd erroneous OTU 1.1 E-04 16 in 17 1 8 in 8 2 
3rd erroneous OTU 2.2 E-05 17 in 17 1 8 in 8 3 
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original community. However, such differences could also be the result of stochastic or 
biased variations in PCR amplification, due to discrepancies in primer annealing 
efficiencies between different 16S target sequences (Kennedy et al., 2014a). 
Additionally, 16S copy number can vary between organisms. This may account for 
some of the variation in total and relative abundances between genera. These observed 
biases highlight the fact that directly quantitative inferences from sequencing data 
should be reported with caution. Nevertheless, it is also clear from Figure 3.7 and 
Figure 3.8 that these differences in abundance were highly reproducible across mock 
replicates.  
 
Figure 3.7 – Relative abundances of OTUs remaining in Mock 1 following filtering, 
which were identified up to level of genus.  
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Figure 3.8 – Relative abundances of OTUS remaining in Mock 2 following filtering, 
which were identified up to level of genus. Red boxes identify genera not present in 
original community 
 
3.3.2.4 Identification and removal of likely contaminants 
Following error checking, negative extractions and PCR blanks were examined for 
presence of contaminants. Only negatives with >=500 reads were kept (N=16 for 
extraction negatives, N=3 for PCR negatives). 764 total OTUs were present in the 
extraction negatives, which decreased to 570 following the removal of singletons. Any 
OTUs with at least two reads in at least two of the negative extraction samples were 
considered potential reagent contaminants. A total of 134 OTUs were flagged using 
these definitions. Although this represented only 2% of the total OTUs identified across 
all samples, if all these OTUs were removed from experimental samples 50% of reads 
would have been lost. 
In an attempt to mitigate the loss of such a high proportion of reads, a pipeline was 
devised to ensure that those OTUs that were to be removed were most likely to be true 
contaminants. One strategy explored the possibility that some of the contaminating 
OTUs were not reagent contaminants, but instead represented sample-to-control 
crossover following false index pairings during PCR. This phenomenon has been 
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reported previously (Rinke et al., 2016, Kircher et al., 2011). To investigate this, the 
mean relative abundances of OTUs from the ‘potentially contaminating’ subset were 
compared between negative extractions and samples. From this it was clear that some 
of the ‘contaminating’ genera were in all likelihood originating from experimental 
samples themselves, rather than extraction kits. For example, whilst 33% of potentially 
contaminating reads in experimental samples mapped to Lactobacilli spp., only 0.34% 
of negative extraction reads mapped to this genus. Lactobacilli are also crucial vaginal 
organisms. Therefore, it is reasonable to hypothesise that those negative extraction 
reads mapping to Lactobacilli OTUs originated from highly abundant transcripts in 
experimental samples, rather than from reagent kits. By contrast, most genera 
previously reported as contaminants, were present at higher or equal abundances in 
negative extraction, compared to experimental, samples (see Figure 3.9 for such a 
comparison). Using this rationale, OTUs mapping to Lactobacilli spp., Veillonella spp., 
and Mycoplasma spp., were considered erroneously flagged contaminants and were not 
removed from samples.  55% of potentially contaminating reads from experimental 
samples mapped to these three genera.  
The remaining ‘potentially contaminating’ OTUs were then manually examined for 
known data on their ecology, and previous evidence for their presence in extraction 
kits (see Appendix Table A 3 page 250 for details of all genera investigated). Of the 43 
genera that the OTUs mapped to, 33 (72%) had been previously reported as reagent 
contaminants (Glassing et al., 2016). OTUs mapping to genera considered highly likely 
to be pure contaminants, e.g. Ralstonia, a pathogenic plant bacterium, were flagged 
across all samples. All OTUs mapping to these genera were removed from all 
experimental samples. Such highly likely contaminants were so defined if they had 
been previously reported as being present in extraction reagent kits in a recent review 
by Glassing et al. (2016), and/or they were highly unlikely to be a truly human 
associated bacteria e.g. Aureimonas, a genus of marine bacteria. For other genera the 
situation was less clear-cut. For example, Streptococci spp. are members of the normal 
human flora, but they have also previously been found in reagent kits. In such 
instances, only those specific OTUs present in negative extractions were removed from 
downstream analyses. This retained OTUs in the same genera as these potential 
contaminants that may have been of clinical relevance, whilst removing OTUs present 
in extraction negatives. These approaches lead to a substantial reduction in the size of 
the sample dataset, losing 22% (929,713) of reads. 
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The same process was repeated for PCR water blanks, which in general had far fewer 
reads than negative extractions (negative extractions median=2637, range=0-37410; 
PCR negatives median=1012, range=268-2712). Of the three PCR negatives with over 
500 reads, only 7 OTUs were present at a minimum depth of 2 reads in at least 2 
samples. Using manual inspection and comparison with abundances across samples, it 
was decided to remove all these OTUs from experimental samples. Additionally, all 15 
OTUs that mapped to the Hymenobacter genus, an environmental bacterium isolated 
from various river water and arctic marine sediment samples, were removed (Lee et al., 
2017, Kim et al., 2016). After filtering both extraction and PCR negatives according to 
these steps, a further 3436 reads were removed.  
Sample data was thus filtered by contaminant genera, and by OTU abundance, to 
produce the final filtered dataset. Filtering by OTU abundance removed 3256 low 
abundant OTUs but lost only 58,152 reads. Conversely, pruning only 291 contaminant 
OTUs from 40 genera (Table 3.6), removed almost 1 million reads. This highlights the 
significant sequencing effort that was directed at contaminating OTUs in the dataset. 
Any sample with under 500 reads was then discarded, because such low sequencing 
depth is unlikely to be representative of the true diversity of that sample. After all 
filtering steps were carried out, 272 samples from 189 pregnancies remained, with 
Figure 3.9 - Comparison of mean relative abundances of two potentially 
contaminating genera between negative extraction (N) and placental DNA samples 
(S). Substantial differences in abundances likely implicate experimental samples as the 
original source of OTUs mapping to Lactobacillus, and extraction reagents as the source for 
Massilia. 
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2862 OTUs, and 3,162,905 reads. Sample depth ranged substantially from 501 to 
239500 reads, with a median of 2160 reads per samples (IQR =1053-7392).  
Table 3.6 – Genera matching those OTUs identified in more than one read in at least 2 
extraction negatives, and subsequent treatment in experimental samples. 
Genera removed entirely Only contaminant OTUs removed Not contaminants 
Acidovorax Acinetobacter Lactobacillus 
Aeromonas Corynebacterium Mycoplasma 
Afipia Delftia Veillonella 
Arabidopsis Dermacoccus 
 
Aureimonas Enterococcus 
 
Brevibacterium Escherichia 
 
Chryseobacterium Finegoldia 
 
Cloacibacterium Granulicatella 
 
Enhydrobacter Haemophilus 
 
Hymenobacter Kocuria 
 
Janibacter Lactococcus 
 
Klebsiella Micrococcus 
 
Massilia Mycoplana 
 
Paracoccus Neisseria 
 
Polynucleobacter Peptoniphilus 
 
Ralstonia Peptostreptococcus 
 
Rheinheimera Propionibacterium 
 
Variovorax Pseudomonas 
 
 
Rothia 
 
 
Sphingomonas 
 
 
Staphylococcus 
 
 
Streptococcus 
 
 
3.3.2.5 Technical replicates cluster better following filtering 
20 technical replicates of sequenced placental samples remained following filtering as 
described above. Figure 3.10 shows a heatmap of log10 transformed OTU abundances 
for all these samples. The columns in the image (sample identifier) are clustered based 
on the ordination-based PCoA method. The majority of technical replicates clustered 
next to, or very close-by, each other using this visualisation method. This indicates 
substantial reproducibility of the technique across runs. Ideally, all amplifications 
originating from the same DNA extract should cluster side by side within this 
ordination. Remaining PCR and sequencing bias likely contributes to the small number 
of replicate amplifications that did not cluster together here. It has been observed that 
lower template concentrations contribute to greater heterogeneity in sample profiles, 
which may explain why not all of the technical replicates clustered together (Kennedy 
et al., 2014a). Reproducibility between replicates, as inferred from their heat-map 
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clustering tendencies, is substantially improved following filtering, when compared to 
the same analysis carried out on raw unfiltered reads (data not shown). For all 
proceeding analyses, OTUs from technical replicates were merged into one larger 
sample. 
 
Figure 3.10 – Heatmap of log10 transformed abundances for technical replicates, 
following filtering procedures. Sample identifiers tend to cluster together, indicating 
reproducibility of the assay. White = 0 reads present. 
 
3.3.3 Discussion 
In this section the development of a study specific filtering pipeline for 16S amplicon 
sequencing data from placental samples was described. The outlined strategies were 
aimed at differentiating clinically relevant sequences, amplified from original, 
endogenous bacterial cells, from contaminating reads. The presence of non-
endogenous transcripts in sequencing output may be the result of true bacterial 
contamination picked up during sample collection and experimental preparation 
processes. Or such ‘contamination’ may be a function of PCR and sequencing artefacts. 
The presence of contaminant OTUs in final datasets will not necessarily impact 
differential abundance testing, assuming that all samples are equally vulnerable to 
contamination. However, they will inflate diversity statistics and lead to erroneous 
biological conclusions when summarising the dataset as a whole. For samples in which 
little, if any, bacterial DNA was truly present in-utero, it is likely that contaminants will 
form a higher percentage of reads, thus biasing estimates further. This has been 
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documented in previous studies (Jervis-Bardy et al., 2015). It was critical to remove as 
many contaminants as possible before conducting experimental tests, whilst also 
mitigating unnecessary loss of OTUs that in fact originated from endogenous 
transcripts. To do this a manual filtering process, in which each genus of interest was 
considered individually, was employed. The development of more specific tools to deal 
with contamination are needed to improve, simplify, and automate this significant 
challenge of microbiome research. 
The removal of low confidence, low abundance OTUs via error checking and abundance 
filtering improves the power to detect meaningful biological associations with 
outcomes of interest. This is because given the size of the dataset, every extra 
erroneous OTU included in tests will reduce power when associations are adjusted for 
multiple testing. Strategies to tackle this issue are discussed further in Chapter 6.  
 
 
 
 
 
 
 
 
 
 
 
 83 
3.4 Optimisation of the cytokine assay protocol 
During the second year of my PhD I travelled to Virginia Commonwealth University 
(VCU) in the USA to spend 10 weeks in Gregory Buck’s laboratory in the Center for the 
Study of Biological Complexity. Professor Buck’s group specialises in women’s health, 
immunity and urogenital microbiology. In 2014, the team received a prestigious grant 
as part of the NIH HMP for the establishment of the Multi-Omic Microbiome Study-
Pregnancy Initiative (MOMS-PI), a multi-centre collaboration at the forefront of 
microbiome pregnancy research. The VCU group leads the Vaginal Microbiome 
Consortium (VMC) as part of MOMS-PI, which incorporates expertise from women’s 
health, pathogenic microbiology, human genetics, epidemiology, and biostatistics.  
As part of MOMS-PI, the group at VCU planned to conduct cytokine analyses of cervical 
swab and maternal plasma samples from their on-going collection of preterm and term 
pregnancies. Similarly, I planned to investigate maternal immunity and pregnancy 
outcome using maternal serum samples available from the BBB. During my trip, I 
designed, conducted and analysed optimisation experiments that would serve to 
inform both my project and MOMS-PI. The outcome of these optimisation experiments 
is outlined below. 
3.4.1 Methods 
See section 2.4.  
3.4.1.1 Study design 
One blood draw from three independent MOMS-PI participants was diverted from the 
main study pipeline. Sera and plasma were extracted from each in order to cover the 
different sample types available in the BBB and MOMS-PI respectively. Samples were 
assayed using the Bio-Plex Pro Human Cytokine 27-plex Assay from Bio-Rad. The 
effects on cytokine concentration and assay replicability of the following experimental 
and sampling variables were considered: 
1. Freeze-thaw cycles: each sample was subjected to between one and a total of 
three instances. 
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2. Sample dilution: bloods were either diluted 1:2 or 1:4, using standard sample 
diluent provided by the manufacturer. A previous experiment had shown that 
running samples neat produced very poor results, so this option was not included. 
3. Experimental batch effect: identical samples were run on two separate plates, on 
consecutive days, by the same investigator. Samples were assigned random 
positions on either plate, ensuring that any difference between results on these 
days would represent genuine experimental/stochastic batch effects. 
Each combination of the first two variables were assayed in duplicate using blood from 
three separate participants, such that 36 different experimental samples were assayed 
(18 plasma and 18 sera) alongside 9 standard dilutions and one assay blank.  
3.4.1.2 Statistical analyses 
In addition to the general methods outlined in section 2.5, non-parametric, two-sample 
Wilcoxon rank sum tests were used for comparison of medians. P-values were adjusted 
for multiple testing by controlling the family-wise error rate using the Benjamini-
Hochberg method (Benjamini and Hochberg, 1995) with the p.adjust function in R. 
Adjusted P-values less than 5% were considered significant. Dendograms were drawn 
from the output of the hclust hierarchical clustering algorithm within the rafalib R 
package.  
3.4.2 Results 
3.4.2.1 Dealing with missing values 
Raw fluorescence values from the assay were automatically converted into estimations 
of concentration (pg/ml), with reference to a 9-point standard curve created for each 
cytokine, on each plate. Observed standard curve values were considered reliable if 
they fell within 80-120% of expected values provided by the manufacturer. For certain 
cytokines, e.g. 1L-17A, not all 9 standard dilutions fulfilled this criteria. Thus, any 
experimental value that fell outside of this range was deemed to be OOR, either above 
or below the reliable range of the standard curve. Two other forms of missingness were 
encountered in the dataset. In the first, observed fluorescence for a sample fell outside 
of a standard curve in which all points were within the reliable expected range. In this 
case, the experimental software provided extrapolated values beyond the reliable 
curve. This extrapolation was considered reliable enough to include in the final dataset. 
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The final form of missingness occurred when fluorescence values fell below the 
background control value. These data points were recoded as zero. Any values which 
fell outside of any standard curves that were unreliable at the extremities were 
recoded as either half the minimum reliable value, or the maximum reliable value 
recorded for the cytokine in question. 
The numbers of missing values for each of the three categories showed substantial 
variation between cytokines, and at times, between batches (see Appendix Table A 4, 
page 252). The pattern of missingness observed between cytokines reflects both the 
sensitivity of the assay, with respect to the cytokine in question, as well as the 
reliability of the standard curve on a given plate. For example, across both 
experimental batches, over 80% of GM-CSF observations were below the background 
value. This observation either indicates a true absence of GM-CSF within the samples, 
or insufficient sensitivity of the assay to pick up molecules that were present at very 
low concentrations. In the latter case, the concentrations are said to fall below the LOD 
of the assay. By contrast, RANTES showed complete discordance between missingness 
on plates 1 and 2. The numbers of values that fell above the reliable range of the 
standard curve were 31 and 0 respectively. This reflects that the top two points in the 
standard curve from plate 1 fell outside of the acceptable range of the expected value 
(58% and 130% respectively), whereas only the highest point on plate 2 was out of 
range for RANTES. As a result of such variation in the types of missingness, the 
inclusion of cytokines in downstream analyses in experimental assays was considered 
on a case-by-case basis. Following the handling of missing values, standard curve 
observations and the assay blank were removed from the dataset. Effects of freeze-
thaw, dilution, and experimental batch on assay outcome were then explored. 
3.4.2.2 Freeze-thaw 
It has been reported that freeze-thaw cycles can have a substantial effect on cytokine 
concentrations, across a range of different sample types (de Jager et al., 2009). Contrary 
to expectations, in our cohort samples did not obviously cluster together (Figure 3.11), 
nor did concentrations appear to change (Figure 3.12), across freeze-thaw cycles. 
Previous studies have shown that certain cytokines are more susceptible to the effect of 
freeze-thaw cycles than others. However, in this study no cytokine on the panel showed 
a statistically significant difference in overall distribution across the three exposures 
using a one-way analysis of variance (ANOVA) test to compare means (data not 
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shown).  In the majority of cases, cytokine concentrations remained stable across 
freeze-thaw cycles for identical samples. In cases in which fluctuations were observed 
(e.g. VEGF), no clear pattern of change was identified using regression models (data not 
shown).  
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Figure 3.11 – Dendogram produced from samples ordered by hierarchal clustering, 
using he rafalib package in R. Each leaf represents a sample assayed in optimisation 
experiments and is coloured according to number of freeze-thaw cycles it was subjected to. 
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Figure 3.12 - Variation in cytokine 
concentrations (pg/ml) for each of the 24 
samples assayed, across one, two, or three 
freeze-thaw cycles. 
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 Figure 3.13 –   
Plot showing 
relationship 
between 
concentrations 
of technical 
replicates run 
on two 
different 
batches for 
each of the 27 
assayed 
cytokines. Blue 
line is linear 
regression line 
with 95% CI of 
the estimate 
shaded either 
side. 
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3.4.2.3 Dilution 
The Bio-Plex Pro Human Cytokine assay had not been carried out on serum or plasma 
samples in the VCU lab, so optimal dilution ratios of sample to diluent were 
investigated, to ensure best downstream results. Cytokine concentrations in identical 
samples were compared when a 1:4 dilution and 1:2 dilution ratio was used (see 
Appendix Table A 5, page 252 for full comparison of results). Results supported the use 
of a 1:4 dilution for both blood types. When a more dilute sample was used, 
distributions tended to span wider ranges and have higher median and mean values. 5 
cytokines had identical means across the two dilutions. In the remaining 22 cytokines, 
all except IL10 and IL15 had a higher median in the 1:4 group. For 14 out of the 27 
cytokines, this difference was significant at the 5% level. This difference remained 
significant for 9 cytokines after adjustment for multiple testing using FDR. 
Furthermore, except for IL13, the 1:4 dilution produced results with a larger range.  
These results indicate increased sensitivity of the assay with a more dilute starting 
material. 
3.4.2.4 Batch effects 
Experimental batch effects can be powerful confounders, if not properly accounted for, 
when analysing experiments run on different days, machines, or by different handling 
personnel. In order to test their impact, two identical batches were run on the same 
apparatus, by the same handler, on consecutive days. Batch 1 and Batch 2 contained 
identical samples with randomly assigned positions within either plate to avoid any 
bias introduced by plate positioning. An exploration of the effects of batch on 
experimental outcome demonstrated the robustness of the assay to batch effect for 
most cytokines, and the reproducibility of results between days (Figure 3.13). In 18 out 
of 27 an ICC value above 0.7 was observed. 
Despite generally high correlations between most cytokines, a number showed 
unacceptably low reproducibility between batches, e.g. IFN-γ and RANTES. The reasons 
for this poor reproducibility may not be uniform between cytokines. For example, with 
RANTES, the first plate produced a variable distribution of concentrations, whereas the 
second plate was almost entirely made up of dummy maximum values. This was also 
the case for IFN-γ, in which the ICC value is essentially zero, since all the values in batch 
2 were identical dummy maximums. This lack of reproducibility is clearly an issue of 
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inter-plate standard curve variability. By contrast, for cytokines such as IL7 and IL15, 
in which correlations were very low, an explanation for the discordance is less clear. It 
may be that this assay is not well optimised for the reproducible quantification of these 
two cytokines in blood samples.  In downstream analyses, data from these cytokines 
will be considered cautiously within the context of poor reproducibility in this 
optimisation assay. 
Although there were generally high correlations between replicates, substantial 
variation was still introduced into the dataset across batches. This is clearly 
demonstrated by hierarchical clustering of the sample data, in which the tips of the 
dendogram are almost perfectly distinguished when coloured by batch (Figure 3.14). 
This observation highlights the critical importance of accounting for batch in 
experimental analyses. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 - Dendogram produced from samples ordered by hierarchal 
clustering, using he rafalib package in R. Each leaf represents a sample assayed 
in optimisation experiments and is coloured according to batch. 
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3.4.3 Discussion 
The sensitivity of ELISA assays to experimental and storage variables such as dilution 
ratios, batch effects, and freeze-thaw cycle exposure have been previously reported (de 
Jager et al., 2009). These variables may significantly impact either the true 
concentration of molecules in a sample, or the ability of the instrument to accurately 
detect concentrations within a reliable range. These three key variables of interest 
were tested on a small optimisation cohort. From these data, an optimal protocol using 
1:4 diluted samples was established for use with the experimental cohorts from MOMS-
PI and the BBB. 
Despite the substantial amount of missingness observed in the assay, 19 out of the 27 
tested cytokines were reliably quantified, with less than 50% of values missing. This 
served as a proof of principle for the use of the assay with our experimental samples. 
Despite substantial impacts of batch on the dataset, correlations were generally high 
between sampling replicates.  
Of particular interest was the marginal impact of freeze-thaw cycles on cytokine 
concentration. From the results it was reasonable to conclude that any fluctuations 
across freeze-thaw cycles observed in this assay represented stochastic fluctuations in 
instrumental measurement, rather than reproducible impacts of the freeze-thaw 
cycling on cytokine concentration. These observations provided reassurance in cases in 
which freeze-thaw data has perhaps not been recorded properly. Additionally, this 
supported the use of technical replicates across different plates that must be refrozen 
and thawed from one run to another.  
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: The Baby Bio Bank Chapter 4
All experimental and statistical analyses reported in this thesis were conducted on a 
subset of clinical data and biological samples taken from the recently completed Baby 
Bio Bank (BBB). The following chapter summarises the original study design, and 
clinical and biological sample composition for the entire BBB dataset, including 
samples not analysed in proceeding experimental chapters. This work formed the 
initial exploratory component of my PhD, which has been further documented in a 
recent publication (Leon et al., 2016). All figures taken from Leon et al. (2016), were 
printed with permission from Elsevier.   
4.1 Introduction 
Common complications in pregnancy affect tens of thousands of women and infants 
annually. Despite decades of research, and substantial financial investment, the precise 
molecular aetiology of adverse pregnancy outcomes requires further study. 
Reproducibility and power in pregnancy research is often limited by the inherent 
challenges in obtaining biological samples from participants, already heavily burdened 
with hospital tests and medical visits. The BBB is a large, UK based biobank. It was set 
up to remove the obstacle of recruitment in research into pregnancy. It is primarily 
aimed at facilitating research into the environmental and genetic mechanisms 
underlying common complications of pregnancy. Recruitment to the project began in 
2009 and ended in 2015. Pregnant mothers undergoing antenatal care in any of three 
hospitals across London were invited to participate by trained recruiters. The bank has 
now finished its sample collection phase. It has amassed over 54,000 biological samples 
from the mothers, fathers, and infants, relating to 2,515 pregnancies.  
Recruitment and sample collection occurred at Queen Charlotte and Chelsea (QC), 
Chelsea and Westminster (CW), and St Mary’s (SM) hospitals. Around 13,000 infants 
are delivered annually by staff at these centres. Ethical approval for recruitment and 
collection at these sites was given by the Trent Derby Research Ethics Committee (. 
Biological sample collection and clinical record retrieval was dependent on the 
procurement of ethical consent from mothers and, where relevant, fathers, in advance 
of delivery.  Samples are stored at the UCL Institute of Child Health. Duplicates are 
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stored at SM, Imperial College London. Semi-anonymised patient data were 
downloaded from clinical records and supplemented by data gathered by the BBB 
recruitment team. Data are currently stored in a secure database that can be matched 
to available biological samples.  
The four most common complications in pregnancy in the UK are fetal growth 
restriction (FGR), pre-eclampsia (PE), preterm birth (PTB), and miscarriage. BBB 
recruitment focused on women with these clinical indications, as well as recurrent 
miscarriage (RM). A group of healthy women with none of the above complications 
were recruited as a control comparison group. The underlying aetiologies of these 
disorders are multifactorial. They involve the interacting and additive impacts of the 
maternal and fetal genotype; maternal and intra-uterine environmental influences; and 
clinical interventions. These four common disorders range across a physiological 
spectrum, covering abnormal implantation to preterm membrane rupture and delivery. 
It is likely that they share overlapping molecular and physiological mechanisms and 
pathways. 
4.2 Recruitment design 
The BBB was principally conceptualised as a genetic and epigenetic resource, with an 
aim to collect DNA and RNA samples from mothers, infants, and fathers. Plasma, serum, 
and urine samples were also collected, providing additional opportunities for 
biomarker research. Recruitment for the BBB followed a targeted prospective cohort 
design (Figure 4.1). This generally took place either at antenatal or follow-up 
appointments, often when maternal conditions first presented. Some recruitment also 
occurred on antenatal and labour wards. Women were only approached prior to 
delivery.  Any consenting mother at any one of the participating units could take part in 
the project. 
A number of strategies were employed to ensure that recruitment to each complication 
was as high as possible. Women clinically defined as at-risk of particular complications, 
and flagged to the recruitment team, were particularly targeted. For example, women 
with a pre-existing hypertensive disorder or history of prior preterm birth, were 
approached by a recruiter. Nurses and clinicians would also notify recruiters when 
women threatened complications, such as at the onset of pre-eclampsia, or following 
preterm membrane rupture. In addition, many women who had normal, uncomplicated 
 94 
Women approached in hospital setting at booking, 
ante-natal clinic, follow-up appointment, or 
antenatal wards. 
Recruitment by trained member of BBB team 
following counselling and ethical discussions and 
completion of standard questionnaire by recruiter 
during discussion with mother/father. 
Maternal (and paternal) blood and urine (mother 
only) collected in hospital, at a time convenient for 
the mother, prior to delivery. 
Plasma and serum extracted from maternal, paternal 
(and cord) blood immediately after whole blood 
collection. All samples aliquoted, barcoded and 
stored at -80°C until required. 
At delivery, placenta, membranes, cord blood and 
umbilical cord were put aside by clinical team and 
collected by trained recruiters, normally within 1 
hour, at which point recruiters dissected and 
prepared samples for storage following BBB 
standard operating procedures. 
pregnancies were asked to participate in order to establish a BBB healthy control 
cohort.  
 
 
 
 
 
 
 
 
 
 
 
 
The BBB recruitment team consisted of three full-time recruiters who were responsible 
for counselling and obtaining consent. They also collected and prepared samples 
around the clock. Recruitment rates were highest at SM (44%), where the project was 
initiated, 35% were collected at CW, and 21% at QC (Table 4.1). 
 
Figure 4.1- Flow-diagram outlining BBB recruitment and sample collection process 
carried out by trained recruiting staff at 3 London hospitals 
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Table 4.1 – Percentage of participants recruited at each BBB hospital. 
The BBB contains data and paired biological samples from 236 FGR, 133 PE, 373 PTB, 
and 232 RM pregnancies. Over 1,500 ‘normal’ pregnancies with none of the above 
complications were also collected as a control group. 636 of these were classified as 
‘perfect’ controls with no recorded problems associated with the mothers’ health, 
pregnancy, or delivery. 68% of participating pregnancies also have data and samples 
from fathers. This is a unique and valuable aspect of the BBB, which, in combination 
with fetal and maternal tissue, gives it substantial power as a genetic resource. 
4.3 Sample collection and storage  
The variety of samples that were intended for collection from each pregnancy are 
presented in Table 4.2. Recruiters focused on securing the collection of ‘Trio’ sample 
sets in which tissue, DNA, and RNA were available from mother, father, and baby. This 
aim was achieved for 1328 pregnancies in total.  Each recruitment centre took 
responsibility for sample receipt and storage. Samples received were matched with 
clinical phenotype data and barcoded at point of entry.  All tissue and blood samples 
are stored at -80°C until requested, with tissue stored in RNAlater. DNA and RNA are 
stored at -80°C. These are available for all individuals in which the relevant primary 
tissue has been collected.  
 Table 4.2 - Variety of samples collected from participating trios in the BBB. 
 
  
 
 
 
 
Hospital BBB recruitment N (%) 
St Mary’s 1107 (44) 
Chelsea and Westminster 880 (35) 
Queen Charlotte’s and Chelsea 528 (21) 
Sample type 
Maternal whole blood/serum/plasma 
Paternal whole blood/serum/plasma 
Maternal urine 
Maternal DNA and RNA (from blood/buccal swab) 
Paternal DNA and RNA (from blood/buccal swab) 
Placental parenchyma, villous and membrane 
Cord blood 
Umbilical cord tissue 
Baby DNA and RNA (from placenta/buccal swab) 
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Collecting multiple samples from each placenta increased the total amount of tissue 
available, as well as facilitating investigations into variation in gene/protein expression 
in different parts of placenta. . In addition to sampling from the chorionic plate, villous 
tissue from the maternal side of the placenta, as well as umbilical cord, cord blood, and 
fetal membrane tissue were also collected, where possible.  All tissue was immediately 
transferred to a vile containing RNAlater to minimise degradation of nucleic acids. 
Occasionally the placenta, cord, or cord blood, were not available, for example, when a 
baby was delivered at home, in an emergency, or another hospital. In such instances a 
buccal swab from the baby was requested and DNA extracted from this specimen. 
Buccal swabs for DNA extraction were also taken from fathers, where blood was 
unavailable. Maternal blood and urine samples were collected once during pregnancy.  
Maternal blood collection ranged from 7 weeks gestation until delivery, with the mean 
gestational age for collection being 25 weeks. Bloods are available for points collected 
throughout pregnancy, with peaks at certain times, such as week 12 which coincides 
with a key antenatal hospital visit for mothers in the UK (Figure 4.2). 
 
 
Figure 4.2 - Graph showing distribution of gestational ages at maternal blood sampling 
within the BBB 
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4.4 Clinical and demographic characteristics 
The BBB clinical database consists of full downloads of electronic maternity records 
from each hospital, augmented by data collected by recruiters using standardised 
questionnaires.  All entries are available to BBB users on request. Manual surveys via 
the recruiters, enabled the collection of additional data, which were not available from 
clinical downloads. This included occupation and information relating to fathers. 
Furthermore, this enabled the identification of discrepancies in the dataset via 
comparisons of duplicate categories. Table 4.3 lists a selection of the clinical categories 
available to users, and their provenance.  
Table 4.3- Selection of clinical information available within the BBB clinical database. 
1    Information volunteered from patient to recruitment staff 
2     Information gathered from clinical records 
3     Measured by recruiting staff 
Originally, the BBB study design stipulated the collection of pregnancies from white 
European mothers only. This remains the largest ethnic group within the bank. 
However, given the nature of the underlying multi-ethnic population in London, clinics 
were also attended by a significant number of mothers of Asian and African origin. 
Many of these women expressed an interest in participating in the BBB. The BBB team 
were aware of the significantly enhanced value to the Bank of inclusion of women of all 
Maternal Paternal Fetal 
Age1/2 
BMI2 
Height 2/3 
Weight 2/3 
Ethnicity2 
Pre-Pregnancy Weight1 
Parity1/2 
Diabetes1/2 
Hypertension1/2 
Smoking1/2 
Medication1/2 
Occupation1/2 
Pregnancy history1/2 
Age at menarche1/2 
Marital status1/2 
Infectious disease2 
Age1 
Height1/3 
Weight1/3 
BMI3 
Ethnicity1 
Diabetes1 
Hypertension1 
Smoking1 
Medication1 
Occupation1 
Gender2 
Gestation2 
Birthweight2 
Placental Weight3 
Head Circumference2 
Birth Length2 
Apgar Score2 
Mode Of Delivery2 
Congenital abnormalities2 
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ethnic backgrounds. As a result, it was decided to recruit from all women, regardless of 
ethnicity. 
Maternal and infant clinical characteristics within the BBB are outlined in Table 4.4. 
Consensus regarding the definition and groupings used to categorise ethnicity is often 
lacking amongst researchers. Within the BBB there are two separate columns of data 
on maternal ethnicity. These are based on two distinct NHS categories, matching those 
used in the national census.  
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Table 4.4 - Selection of demographic and clinical characteristics of the BBB cohort. 
Variable Category Distribution N (%) Range (SD) Mean 
 
Maternal Ethnicity 
 
White 1565 (68.2) 
  
Black 229 (10.0) 
Asian 99 (4.3) 
Other** 401 (17.5) 
Maternal Smoking 
Non-smoker 2074 (87.7) 
  Smoker 100 (4.2) 
Quit within last 12 months 190 (8.1) 
Maternal age at 
booking 
<20 25 (1.3) 
14 - 55 (5.48) 32.83 
20-25 187 (9.6) 
26-30 372 (19.1) 
31-35 741 (38.0) 
36-40 478 (24.5) 
41-45 140 (7.2) 
>46 6 (0.3) 
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Maternal BMI at 
booking 
<18.5 (Underweight) 71 (3.0) 
14 - 66 (5.27) 24.87 
18.5-24.9 (Normal weight) 1304 (55.3) 
25.0-29.9 (Pre-obesity) 630 (26.7) 
30.0-34.9 (Obesity Class 1) 217 (9.2) 
35-39.9 (Obesity Class 2) 94 (4.0) 
Above 40 (Obesity Class 3) 42 (1.8) 
Maternal Parity 
Nulliparous 1324 (53.5) 
0 - 12 (0.95) 0.67 Primiparous 797 (32.2) 
Multiparous 354 (14.3) 
Neonate gender 
Male 1182 (52.0) 
  Female 1092 (48.0) 
Number of infants 
Singletons 2445 (97.2) 
  Twins 70 (2.7) 
Delivery method 
CS 716 (42.2) 
  Vaginal 980 (57.8) 
Birthweight (g) 
 
 295 - 5470 (728.92) 3164 
GA at birth 
(weeks) *  
 20 - 43 (2.81) 38.32 
* Assessed from ultra-sound scanning 
** Chinese, other Asian, other black, other, and all mixed groups. 
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4.5 Definitions and verification of outcome data 
4.5.1 Preterm birth 
373 women were recruited to the BBB who went on to have a preterm pregnancy. 122 
were collected as full trios. The statistical work in Chapter 5 was an analysis of the 
clinical data from all of these preterm pregnancies, whereas the experimental work 
utilised available placental and maternal serum samples from a subset. Recruiters 
targeted mothers with a history of preterm birth. In addition, they recruited women 
presenting at clinics who were threatening preterm delivery, either due to preterm 
membrane rupture, shortened cervices, preterm contractions, or positive fFN test 
results. ‘Very early preterm’ cases, generally classified as below 33 weeks gestation, are 
a powerful sub-group for research into preterm birth aetiology. However, these are the 
deliveries that are often most complicated and are therefore the most challenging from 
which to obtain samples. 96 such valuable cases were recruited for the BBB. 
The mean GA at birth for the preterm group was 33 weeks (Table 4.5). The youngest 
delivery was at just 20 weeks gestation, 3 weeks below the currently defined ‘limit of 
viability’ (Seri and Evans, 2008). The distribution of cases across the commonly used 
sub-phenotypes of PTB are listed in Table 4.5. These categories were defined using data 
from clinical records relating to membrane, labour, and delivery information. For births 
in which delivery data were available, 38% were vaginally delivered and 62% were 
delivered via CS.  
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 Table 4.5 - Number of preterm pregnancies according to GA and mode of delivery within the BBB. Not all fields had complete data. 
 
* Spontaneous labour and/or membrane rupture and delivery before 37 weeks 
** Labour is spontaneous and delivery occurs before 37 weeks 
*** Membrane rupture is spontaneous and resultant delivery occurs before 37 weeks 
****Emergency and elective 
Preterm birth data (cumulative N) 
GA at birth 
(weeks) 
Total sPTB* sPTL** PPROM*** Indicated PTB 
Missing data 
on labour/ 
membrane 
CS delivery**** 
Vaginal 
delivery 
20 1 1 0 1 0 0 0 0 
21 1 0 0 1 0 1 0 0 
22 2 0 0 1 0 2 0 0 
23 4 0 3 4 0 4 0 3 
24 6 0 4 5 1 5 0 5 
25 16 8 6 8 2 6 2 7 
26 15 11 9 10 4 0 6 8 
27 30 17 16 15 6 7 9 12 
28 33 22 19 20 11 0 17 14 
29 41 24 21 21 17 0 24 15 
30 61 30 27 25 21 10 31 17 
31 80 37 33 31 32 11 40 20 
32 96 44 39 36 40 12 49 25 
33 132 58 51 47 60 14 73 32 
34 186 80 70 64 86 20 94 43 
35 252 102 87 85 124 26 121 68 
36 373 145 113 123 186 42 172 105 
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4.5.2 Pre-eclampsia 
PE affects around 2-8% of global pregnancies (WHO, 1988, Roberts et al., 2011, WHO, 
2011). It is a dangerous, multi-system disorder. The condition tends to present in later 
pregnancy. It is estimated to account for 10-15% of all global maternal mortality. 
Women in developing countries bear the vast majority of this burden (Duley, 2009). PE 
is also associated with FGR and PTB, thereby impacting fetal morbidity and mortality. It 
is generally considered to be a pathology linked to poor placentation, with a number of 
genetic, immunological and lifestyle factors identified as risk factors. However, much of 
the underlying physiology is still poorly understood.  It remains the case that the only 
treatment for pre-eclampsia is delivery of the placenta: a clinical decision that often 
results in delivery of premature infants. 
Pre-eclampsia in the BBB was diagnosed by obstetricians as new hypertension, i.e. at 
least two consecutive blood pressure (BP) readings above 140/90 mmHg, or an 
increase in systolic BP of at least 30 mmHg or diastolic BP of at least 15 mmHg above 
booking, combined with new proteinuria defined as a protein creatinine ratio of greater 
than 50, or 24 hour quantitation with a level of greater than 300.  Recruitment of PE 
pregnancies focused on women with a medical history of the complication, or those 
being monitored or treated for the disorder already. The BBB contains over 700 
biological samples from 133 women who developed PE, of which 41 were trios, and 45 
delivered preterm. The BBB also contains a number of women with PE associated 
phenotypes such as pregnancy induced hypertension (PIH) or renal complications 
(Table 4.6).  
Table 4.6 - Number of pregnancies associated with a pre-eclamptic phenotype. 
Pre-eclampsia phenotype BBB N 
Pre-eclampsia  133 
PIH 57 
PIH in previous pregnancy/ies 76 
Essential hypertension 98 
Cardiac complications 15 
Renal complications 16 
Thrombosis 8 
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4.5.3 Fetal growth restriction 
FGR describes the condition of a fetus unable to reach its growth potential (ACOG, 
2001b, Hillman et al., 2015). Such cases are often recorded as small for gestational age 
(SGA) at delivery. FGR is associated with perinatal morbidity and mortality and 
complicates about 5-6% of pregnancies in high-income countries (Brodsky and 
Christou, 2004, Demetriou et al., 2014, Moore et al., 2015, Harding and Bocking, 2001). 
FGR is also associated with adult-onset diseases, such as type 2 diabetes, obesity and 
cardiovascular disease (Forsen et al., 2000, Simmons, 2009, Barker, 1992, Barker et al., 
1993).  
Fetal growth relies on successful nutrient exchange between mother and baby via the 
placenta, and is influenced both by environmental and genetic factors. A number of risk 
factors have been associated with low birthweight: smoking during pregnancy, pre-
eclampsia, multiple gestation, and a medical history of low birthweight babies. Other 
maternal, placental, and fetal factors that correlate with FGR are shown in Table 4.7 
(ACOG, 2001a, Harding and Bocking, 2001, Wilkins-Haug et al., 2006, Pollack and 
Divon, 1992).  
Table 4.7 - Maternal, placental and fetal factors that are correlated with FGR. 
Maternal factors* Placental factors* Fetal factors* 
Malnutrition  
Alcohol and substance abuse 
Medication use  
Uterine size  
Diminished uterine blood 
flow 
Placental size 
Placenta previa 
Primary placental disease 
(e.g. chorioangioma) 
Confined placental 
mosaicism 
Utilization and production of 
nutrients 
Diminished umbilical blood 
flow 
Hormonal factors 
Genetic disorders 
Epigenetic disorders 
Nutrient production 
Infections 
Hormonal factors growth 
factors 
*Some factors can affect the mother, placenta and fetus 
Within the BBB, SGA infants were used as a proxy for FGR during pregnancy. 
Birthweight for age centiles were defined with reference to the 1996 gender specific 
four-in-one growth charts produced by the Child Growth Foundation in London. Infants 
in the BBB below the 10th centile were placed in the FGR group. The BBB recruited 234 
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such pregnancies, 82 of which were trio sample sets. 112 babies were below the 5th 
birthweight centile and 50% delivered preterm. The distribution of birthweight for age 
centiles within the BBB, alongside the mean birthweight for each centile grouping are 
summarized in Table 4.8. The mean birthweight for this SGA cohort was 1880g. 
Table 4.8 - Distribution of centiles and mean birthweights across the BBB. 
There is growing interest in pregnancies in which neonates are large for GA 
(macrosomia). These infants pose particular risks to mothers during delivery. 
Macrosomia is therefore an important phenotype to study in attempts to minimize 
maternal morbidity and mortality related to childbirth. Over 300 BBB deliveries were 
above the 90th birthweight for age centile, and over 200 were above the 95th centile.  
4.5.4 Recurrent miscarriage 
Miscarriage is defined as the spontaneous loss of a fetus before it has reached viability. 
This includes losses from conception up to the 24th week of gestation. It is the 
commonest complication of pregnancy. About 1.5% of couples trying to conceive 
experience RM (Stirrat, 1990). RM in the BBB was defined as any mother that had 
experienced three or more consecutive pregnancy losses.  Previous studies have shown 
that the risk of miscarriage increases after each successive pregnancy loss. It can reach 
45% after three consecutive losses (Regan et al., 1989).  
232 women in the BBB had a clinical diagnosis of RM, of whom 97 were collected as a 
trio. 538 women within the BBB experienced one or two prior pregnancy losses (Table 
4.9). Many of these cases had been attending the internationally renowned centre for 
Centile BBB N Mean birthweight (gm) 
<5th  112 1555 
5th-<10thth  122 2179 
10th -< 25th  576 2614 
25th-<50th  410 2876 
50th-<75th 401 3273 
75th-<90th 273 3590 
90th-<95th 143 3913 
>95th 206 4122 
Data not available 272 NA 
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RM based at SM hospital. 770 women in the BBB had had at least one previous 
miscarriage prior to recruitment, totalling over 1500 miscarriage events.  
Table 4.9 - Distribution of number of previous miscarriages within BBB. 
 
 
 
 
 
RM has many underlying causes. For example, chromosomal abnormalities 
(Giorlandino et al., 1998), anatomical uterine defects (Grimbizis et al., 2001), endocrine 
disorders (Glueck et al., 2000), abnormalities in the immune system, e.g. 
antiphospholipid syndrome (Rai and Regan, 2006), and thrombophilic disorders, such 
as those caused by the Factor V Leiden mutation (Bertina et al., 1994).  
4.5.5 Other complications 
The size of the BBB allowed for the recording of a substantial number of other maternal 
complications, apart from the four main phenotypes targeted, as detailed in Table 4.10. 
Table 4.10 - Summary of extra clinical categories of interest within the BBB. 
Maternal clinical category BBB N 
Diabetes 23 
Gestational Diabetes 31 
Pregnancy from In vitro Fertilization 22 
Placenta previa 11 
Placental abruption 26 
Urinary tract infection 36 
Thyroid complications 27 
Cardiac complications 29 
Epilepsy 48 
 
Number previous miscarriages BBB N 
0 1666 
1 399 
2 139 
3 121 
4 55 
5 32 
6 11 
7 7 
8 2 
9 3 
10 1 
Data not available 79 
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4.5.6 The BBB and my PhD 
The work outlined in this chapter, carried out at the start of my PhD, characterised the 
biological and clinical composition of the whole BBB dataset, as a resource for future 
research into complications in pregnancy. I next went on to explore in further detail the 
pregnancies resulting in the delivery of preterm infants, using a healthy control group 
as a comparison. This work consisted of explorations of the clinical data at hand, as well 
as the main experimental work carried out during this thesis: using BBB preterm 
placental samples to investigate the role of intra-uterine infection in normal and 
complicated pregnancies. The statistical and experimental results from these 
investigations are outlined in the following chapters. 
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: Quantitative Analysis of Chapter 5
Placental Bacteria 
5.1 Introduction 
There exists substantial clinical, molecular, and microbiological evidence that the 
presence of bacteria in the intra-uterine environment during pregnancy is a risk factor 
for sPTB. This study was designed to explore this association using placental samples 
from both term and preterm deliveries collected as part of the BBB. The majority of 
previous work in this field has focused on infection within the fetal membranes and 
amniotic fluid (Gravett et al., 1986, Doyle et al., 2014). Therefore, this study contributes 
novel data from a tissue that is central to pregnancy and fetal outcome, but whose 
involvement in infectious mediated sPTB remains relatively underexplored. Samples of 
parenchyma tissue, biopsied from below the membranes on the fetal side of the 
placental disk, and villous tissue, from the basal plate at the maternal side, were 
available for analysis. Using the directly quantitative approach of qPCR, total bacterial 
load within placental samples from a subset of BBB participants was estimated. With 
these data it was possible to address whether total bacterial load, rather than simply 
presence or absence of organisms, may be a quantifiable risk factor for sPTB. The 
availability of these two placental tissue types also enabled the investigation of how 
bacterial colonisation may vary by placental localisation. 
This study also contributes to the growing debate about the existence of a healthy 
‘placental microbiome’ (Aagaard et al., 2014, Aagaard, 2014, Kliman, 2014, Lauder et 
al., 2016). The placenta has until recently been regarded as sterile, in all but the most 
extreme cases. However, in the wake of novel research it has been suggested that 
bacterial colonisation of the placenta may in fact be a feature of normal pregnancy. If a 
commensal microbiome does inhabit the placenta, this raises novel questions. How do 
these organisms interact with the developing fetal immune system? Can we 
characterise any quantitative and/or qualitative transitions from a healthy to a 
pathological placental microbiome? Do such changes have a causal role in adverse 
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pregnancy outcomes, such as preterm birth? Some of these questions were addressed 
in this study, using data on bacterial load from DNA samples, extracted from both term 
and preterm placenta. In addition, negative extraction controls were sequenced. This 
allowed the critical issue of how to distinguish between true endogenous signal and 
contaminant noise, in tissues of low biomass such as the placenta, to be addressed.  
The first part of this chapter describes preliminary statistical analyses that were 
carried out on the BBB preterm and term clinical dataset (section 5.3.1). These analyses 
were aimed at characterising relationships between potential confounding covariates 
and gestational age at birth. In order to maximise power to identify any underlying 
associations between our exposure groups and other clinical characteristics, the whole 
BBB clinical database was utilised at this stage. Any clinical sample that adhered to the 
cohort inclusion criteria for experimental analyses (see section 5.2.1), whether or not 
placental tissue was also available, was included in these exploratory statistical 
analyses. Experimental results are documented in the latter part of the chapter (section 
5.3.6). 
The hypothesis for this study was that total bacterial load (16S copy number) would 
vary between preterm and term phenotypes. The transition of a placenta from a 
‘healthy’ to a ‘pathological’ state, as inferred from its association with adverse 
outcomes such as sPTB, would have a quantifiable component. Specifically, the highest 
load would be observed in sPTB placenta, as this sub-phenotype accounts for the 
largest proportion of infectious mediated preterm births (Goldenberg et al., 2008).  
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5.1.1 Aims 
1) Characterise statistical associations between potential clinical confounders and key 
exposures using the BBB clinical dataset. 
2) Explore whether mode of delivery of placenta accounts for any observed variation in 
bacterial load, within the subset of BBB samples taken forward for experimental 
analyses. 
3) Test the hypothesis that placental bacterial load varies by pregnancy outcome, with 
higher loads associated with sPTB. 
4) Examine the presence of bacterial DNA within extraction negative samples in order 
to investigate the impact of reagent contamination on assay results.  
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5.2 Materials and methods 
5.2.1 Cohort selection 
All samples were obtained from the BBB biological database with accompanying 
clinical data that were cleaned and collated as part of this thesis. All experimental work, 
including the studies described in chapters 6 and 7, followed a case-control study 
design. For the qPCR analyses discussed in this chapter, cases were defined as any 
pregnancy terminating in a delivery under 37 weeks, in which placental tissue was 
available. Control samples were selected from the BBB healthy control cohort, which 
consists of any term pregnancy without a recorded complication, i.e. no PE, no IUGR, 
and <42 weeks gestation. Initially, a random selection of 150 healthy term births 
delivered between 40-41 weeks and with available placental tissue, were chosen as the 
control group. However, it was retrospectively decided to include a further 100 
randomly selected 37-39 week deliveries to increase the overall cohort size. qPCR 
analyses were conducted on total DNA from between one and three placental samples 
per pregnancy. All samples with qPCR data that passed qPCR quality control (QC) were 
used in final analytical models. Figure 5.1 outlines the process of sample selection from 
the BBB cohort for use in qPCR experimental work. 
5.2.2 Sample collection and DNA extraction 
See section 2.1. 
5.2.3 Quantitative polymerase chain reaction 
See section 2.2. 
5.2.4 Optimisation of methodology and reproducibility of assay 
See section 3.2. 
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Total BBB cohort (N=2515)* 
 Delivery ≥ 37 weeks (N=1931) 
 Singletons (N=1882) 
 Uncomplicated**, singleton term deliveries with placenta (N=810)   
 Control pregnancies selected for qPCR (N=260) 
 Control pregnancies passing qPCR QC (N=225) 
 Total samples passing QC (N=435) 
 1 sample (N=61) 
 2 samples (N=118) 
 3 samples (N=24) 
 Delivery ≤ 36 weeks 6 days (N=373) 
 Singleton preterm deliveries (N=291) 
 Singleton preterm deliveries with placenta (N=158) 
 Preterm pregnancies passing qPCR QC (N=141) 
 Total samples passing QC (N=264) 
 1 sample (N=42) 
 2 samples (N=75) 
 3 samples (N=46) 
*GA at birth data not available for all deliveries  
**No PE, no IUGR, <42 weeks 
 
Figure 5.1 – Summary of qPCR experimental cohort construction 
using samples available within the BBB.  
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5.2.5 Statistical analyses 
The distribution of qPCR data was highly negatively skewed. Therefore, initial 
exploratory analyses used non-parametric two-sample Wilcoxon rank sum tests, using 
the wilcox.test function in R, for comparisons of medians. The Kendall rank correlation 
coefficient tau (τ), from the cor.test function in R, was used to quantify correlations. 
The dataset contained biological replicates from the same clinical participant. It was 
important to account for this non-independence of replicate samples in the final 
models. Generalised linear multi-level regression models were used for this purpose. 
They were constructed with bacterial load as the outcome, pregnancy outcome as the 
main predictor, and participant as a random intercept. Models, with and without this 
random intercept were compared to test whether such multi-level strategies were an 
improvement upon standard fixed effect approaches. The inclusion of participant 
number as a random intercept significantly improved the model fit. This is shown by a 
smaller Akaike Information Criterion (AIC) statistic for the multi-level versus fixed-
effect model, which is statistically significant using a one-way ANOVA test (Table 5.1). 
Therefore, for all regression analyses, participant identity was included as a random 
intercept. Any additional covariates were included as fixed effects.  
Table 5.1 – Comparison of fixed intercept versus multi-level regression model to 
account for variation in qPCR data. 
 
Model AIC ANOVA P 
Fixed intercept 1709.5 
<0.0001 
Random participant intercept 1685.5 
All regression models were checked for normality and homoscedasticity (equal 
variance) of residuals. Influential samples were identified as residuals with a Cook’s 
Distance >0.1. Such samples were removed and the models rerun and any resulting 
change in effect sizes and/or significance recorded. 
  114 
5.3 Results 
5.3.1 Clinical dataset 
Hospital records for all participating mothers and babies were available from the BBB 
database. Using these data, associations between our outcomes of interest and other 
clinical variables were investigated. Clinical characteristics that could confound the 
relationship between gestational age and bacterial load were identified via an extensive 
literature review, as documented in Chapter 1. Delivery method, maternal ethnicity, 
smoking, diabetes, and BMI were identified in this way and were extracted from the 
BBB clinical dataset. Associations between these potential confounders and preterm 
birth, or gestational age at birth, were then explored. Any such associations would 
inform downstream analysis and interpretation of experimental results.  In order to 
improve power to detect such associations, all BBB clinical data that matched the 
cohort inclusion criteria were used in these preliminary analyses, regardless of 
whether a placental sample was available for experimental analysis.  
The clinical and demographic characteristics of the clinical cohort and their 
relationships with pregnancy outcomes of interest are summarised in Table 5.2. The 
reliability of our clinical data was supported by the observation that the data reflected 
expectations. For example, boys in the dataset were significantly heavier than girls, and 
preterm infants had a significantly lower birthweight than those born at term. Sections 
5.3.1-5.3.3 explore in further detail the nature of associations between GA at birth, 
preterm/term delivery, and a-priori identified confounders that were considered for 
inclusion in the final models.  
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Table 5.2 – Clinical and demographic characteristics of whole BBB preterm and healthy term cohorts. 
 
Variable Category Sub-category N (%) 
Shapiro 
test (P)* 
Median (IQR) Mean Range 
Total 
(N) 
Missing 
Wilcox,  X2, 
or Fisher’s 
exact test 
GA at birth 
(weeks) 
All 
  
<2.2E-16 39 (38-40) 38.4 20-41 1961 0 
 
Male 
  
<2.2E-16 39 (38-40) 38.4 23-41 982 0 
W=469140 
P=0.50 
Female 
  
<2.2E-16 39 (38-40) 38.4 20-41 939 0 
Preterm 
  
<2.2E-16 35 (32-26) 33.2 20-36 291 0 
W=0 
P<2.2E-16 
Term 
  
<2.2E-16 39 (38-40) 39.3 37-41 1670 0 
Birthweight 
(grams) 
All 
  
<2.2E-16 3320 (2960-3650) 3230 295-5470 1923 38 
 
Male 
  
<2.2E-16 3010 (3010-3700) 3294 295-5470 977 5 
W=410220 
P=8.49E-5 
Female 
  
<2.2E-16 3260 (2928-3600) 3175 340-4858 937 2 
Preterm 
  
0.0078 2167 (1566-2568) 2059 295-3910 282 9 
W=25476 
P<2.2E-16 
Term 
  
7.58E-09 3400 (3120-3700) 3432 2008-5470 1641 29 
Maternal 
BMI 
(weight/ 
height2) 
All 
  
<2.2E-16 24 (21-27) 24.77 14-66 1889 72 
 
Preterm 
  
3.05E-13 24 (21-27) 24.98 15-53 279 12 
W=226790 
P=0.79 Term 
  
<2.2E-16 24 (21-27) 24.73 14-66 1610 60 
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Maternal 
age at 
booking 
All   4.30E-09 33 (30-37) 32.8 14-48 1511 450  
Preterm   0.046 33 (29-37) 32.7 17-48 257 34 
W=1594 
P=0.79 
Term   2.11E-08 33 (30-36) 32.9 14-46 1254 416 
Maternal 
diabetes 
All 
None 1417 (93.8)     
1511 450 
 
Essential 34 (2.3)      
Gestational 60 (3.9)      
Preterm 
None 226 (89.0)     
254 37 
X2= 12.1, 
P=0.0024 
Essential 10 (3.9)     
Gestational 18 (7.1)     
Term 
None 1191 (94.8)     
1257 413 Essential 24 (1.9)     
Gestational 42 (3.3)     
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Maternal 
parity 
All 
0 972 (50.8) 
    
1914 47 
 
1 648 (33.8) 
    
2 or 3 266 (13.9) 
    
4 or more 28 (1.5) 
    
Preterm 
0 151 (53.4) 
    
283 8 
Fisher’s P= 
0.19 
1 84 (29.7) 
    
2 or 3 41 (14.5) 
    
4 or more 7 (2.5) 
    
Term 
0 821 (50.3) 
    
1631 39 
1 564 (34.6) 
    
2 or 3 225 (13.8) 
    
4 or more 21 (1.3) 
    
Maternal 
smoking 
behaviour 
at booking 
All 
Non-smoker 1610 (88.2) 
    
1825 136 
 
Smoker 76 (4.2) 
    
Quit <12 months 139 (7.6) 
    
Preterm 
Non-smoker 240 (87.0) 
    
276 15 
X2=6.7 
P=0.035 
Smoker 19 (6.9) 
    
Quit <12 months 17 (6.1) 
    
Term 
Non-smoker 1370 (88.4) 
    
1549 121 Smoker 57 (3.7) 
    
Quit <12 months 122 (7.9) 
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5.3.1.1 Maternal Ethnicity 
Numerous studies have demonstrated a strong association between maternal ethnicity 
and sPTB incidence (Khalil et al., 2013, Moser et al., 2008, Muglia and Katz, 2010). 
There was a clear difference in the distribution of maternal ethnicities between the 
BBB preterm and term groups (Table 5.3). These observations are supported by 
previous data in which black women have higher rates of preterm birth than any other 
ethnic group (Muglia and Katz 2010).  Asian women also had a relatively high rate of 
preterm birth in our cohort, which replicates independent data from a UK cohort 
(Moser et al. 2008). 
Table 5.3 – Distribution of maternal ethnicities in whole cohort and 
preterm/term sub-groups. N (%). 
* Chinese, other Asian, other black, other, and all mixed groups 
The estimated effect of maternal ethnicity on GA at birth in the cohort is presented in 
Table 5.4. Both black and Asian mothers had significantly shorter gestations than white 
mothers (Table 5.4). These groups also had significantly lower odds of having a term 
rather than preterm birth (Table 5.5). Similarly, Asian and black mothers had babies 
with significantly lower birthweights compared to white mothers (data not shown). 
Table 5.4 – Linear regression for effect of maternal ethnicity on GA at birth 
 
 
 
 
Asian, Asian 
British 
Black, black 
British 
White, white 
British 
All others* Missing X2 
All 84 (4.6) 179 (9.9) 1226 (67.8) 318 (17.7) 154  
Preterm 19 (7.1) 47 (17.7) 146 (54.9) 54 (20.3) 25 
X2=32.2 
P=4.8E-7 
Term 65 (4.2) 132 (8.6) 1080 (70.1) 264 (17.1) 129 
Predictor β (95% CI) β SE P 
Intercept 38.69 (38.54-38.85) 0.078 <2E-16 
Maternal ethnicity (baseline = White, white British)   
 Asian, Asian British -1.37 (-1.29- -0.21) 0.31 1.03E-5 
 Black, black British -1.26 (-1.24- -0.59) 0.22 1.03E-8 
 All others -0.57 (-0.75- -0.068) 0.17 0.001 
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Table 5.5– Logistic regression for effect of maternal ethnicity on odds of having a 
term over preterm birth. 
 
 
 
5.3.1.2 Maternal BMI 
Maternal BMI has been reported as a risk factor for PTB. There is a higher prevalence of 
PTB in both underweight and obese mothers (Girsen et al., 2016, Shaw et al., 2014, 
Torloni et al., 2009). To best model the non-linear relationship between GA at birth and 
maternal BMI, data were split into three categories. Underweight was defined as a BMI 
below 18.5 kg/m2, normal weight as 18.5 to 19.9 kg/m2, and obese as over 30 kg/m2. In 
the BBB population there was no significant difference in the distribution of maternal 
BMI categories between preterm and term groups (Table 5.6). Lower GA at birth and 
reduced odds of having a term birth were observed for obese and underweight women, 
when linear and logistic models were run. However, these trends were neither 
statistically significant in unadjusted nor adjusted models (Appendix Table A 6 page 
253 and Appendix Table A 7 page 253).  
Table 5.6 – Distribution of maternal BMI categories in whole cohort and 
preterm/term sub-groups 
 
5.3.1.3 Maternal diabetes 
Maternal diabetes can increase the risk of preterm birth (Kock et al., 2010). Gestational 
or established maternal diabetes had a significantly reductive impact on GA at birth 
(gestational = -0.87 weeks, 95% CI= -1.62--0.12; established = -1.38 weeks, 95% CI = -
2.36--0.39) (Appendix Table A 8 page 254). The odds of having a preterm rather than 
Predictor OR (95% CI) β SE P 
Intercept 7.40 (6.25-8.27) 0.089 <2E-16 
Maternal Ethnicity (baseline = White, white British)   
 Asian, Asian British 0.46 (0.27-0.81) 0.31 0.0051 
 Black, black British 0.38 (0.26-0.56) 0.22 4.19E-7 
 All others 0.66 (0.47-0.93) 0.17 0.017 
BMI group N (%) Underweight Normal Obese X2 
All (N=1961) 57 (2.9) 1631 (83.2) 273 (13.9)  
Preterm (N=291) 11 (3.8) 232 (79.7) 48 (16.5) X2=3.01 
P=0.22 Term (N=1670) 46 (2.7) 1399 (83.8) 225 (13.5) 
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term birth were also higher for women with gestational (OR = 0.44, 95% CI = 0.25-0.8) 
and established (0.46, 95% CI = 0.22-1.01) diabetes in this cohort (Appendix Table A 9 
page 254). The inclusion of maternal ethnicity as a potential confounder in the above 
models, impacted effect sizes only marginally. However, the effect of gestational 
diabetes on GA at birth, and established diabetes on preterm versus term odds were no 
longer significant. Data on maternal diabetes status was relatively incomplete for our 
cohort. Its inclusion in downstream analyses would have significantly limited the 
sample size. Therefore, final models did not include diabetes, acknowledging that this 
may have limited the precision of the estimate. However, sensitivity analyses were run 
in which diabetes was included as a covariate in final models using the smaller sample 
set. Results were consistent whether or not maternal diabetes was included (data not 
shown). 
5.3.1.4 Maternal smoking 
Maternal smoking behaviour was associated with a significant reduction in GA at birth 
(Table 5.7), as well as birthweight (Table 5.8) in the cohort.  Initial analyses were 
conducted using a three-group model for maternal smoking behaviour: women given 
up within 12 months of booking, smokers, and non-smokers. Smokers also had 
significantly higher odds of having a preterm birth than non-smokers (OR=0.53, 95% 
CI=0.31-0.92, P=0.019). However, no significant relationship was observed for those 
smokers who quit within 12 months, when compared to non-smokers. 
Table 5.7 - Effect of maternal smoking behaviour on GA at birth using a linear 
regression model with categorical predictors to estimate effect size. 
Predictor β (95% CI) β SE P 
Intercept 38.4 (38.27-38.54) 0.068 <2E-16 
Maternal smoking (baseline=non-smoker) 
  
 
Smoker -0.76 (-1.4--0.12) 0.32 0.019 
Quit within last 12 
months 
0.13 (-0.35-0.61) 0.52 0.6 
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Table 5.8- Effect of maternal smoking behaviour on birthweight using a linear 
regression model with categorical predictors to estimate effect size. 
Predictor β (95% CI) β SE P 
Intercept 3241.75 (3207.37-3276.13) 17.53 <2E-16 
Maternal smoking (baseline=non-smoker) 
  
 
Smoker -326.76 (-487.87--165.66) 82.14 7.23E-05 
Quit within last 12 
months 
8.19 (-113.16-129.55) 61.88 0.9 
GA at birth and birthweight were very strongly correlated in the cohort (τ=0.46, 95% 
CI=0.44-0.49, P<2e-16). The relationships between smoking and birthweight, and 
numerous other pregnancy complications, are widely reported (Mund et al., 2013). 
Therefore, further analyses were conducted in which the prediction of GA at birth from 
smoking status was adjusted for birthweight and vice versa. This analysis clarified that 
the main effect of smoking on fetal outcome in our cohort was on birthweight. The 
relationship between smoking and GA in our cohort may be confounded by the fact that 
lower weight infants tend to be born earlier. When birthweight is included in the model 
predicting GA at birth, the negative relationship disappears (β=0.25, 95% CI=-0.14-
0.63) and is no longer significant. When the model predicting birthweight from 
smoking behaviour is adjusted for GA at birth, the effect of smoking is attenuated 
substantially, reducing the effect by almost 200 grams (β=-169.96, 95% CI=-267.66- -
72.26). However, the association remains highly significant (P=0.00066). 
A significant effect of smoking on birthweight is only observable for mothers who 
continued to smoke during pregnancy, not for those who gave up within the 12 months 
preceding booking. For this reason the two-group model of smokers and non-smokers 
was used in final models. This two-group effect on birthweight is clearly observed in 
Figure 5.2, which shows that smoking reduces birthweight, regardless of GA at birth. 
Previous evidence has described an association between smoking and GA at birth 
(Kyrklund-Blomberg and Cnattingius, 1998), as well as with microbiome profiles in 
sites such as the mouth (Wu et al., 2016). Therefore, although in the BBB data the 
majority of this association appears to be attributable to the confounding effects of 
birthweight, smoking was still considered an important covariate to retain in final 
models based on the strength of previous evidence.  
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Figure 5.2 – Association between GA and birthweight by maternal smoking status. 
Lines indicate linear regression line for association between two variables for non-smokers 
(red) and smokers (blue). 
 
5.3.2 Delivery method and gestational age at birth 
Delivery method was identified as a potentially important confounder in associations 
between GA at birth and placental microbial profiles. In our data there was a trend 
towards more vaginal deliveries as GA at birth increased. However, the eight earliest 
births in this cohort were vaginal (Figure 5.3). This mild, but highly significant, positive 
relationship between increasing GA at birth and odds of vaginal delviery was confirmed 
using regression analysis (OR = 1.2, 95% CI = 1.15-1.25 per week increase). The 
association persisted and remained statistically significant with the addition of possible 
confounding covariates into the model (Appendix Table A 10 page 255). 
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Figure 5.3 – Delivery method by GA at birth in the BBB preterm/healthy term cohort. 
A significantly higher proportion of preterm births in the cohort were delivered by CS 
when compared to term deliveries (Table 5.9). This trend may reflect the higher 
incidence of clinical indications, such as PE, which require swift delivery to protect the 
health of mother and/or baby, in preterm rather than term groups. The odds of having 
a CS section and a preterm birth were 2.76 (95% CI = 2.09-3.66, P=1.07e-12) times 
higher than amongst term deliveries. This relationship was essentially unchanged by 
the addition of the potential confounding effects of maternal parity, age, BMI, and 
diabetes status into the model (data not shown).  
 Table 5.9 – Distribution (N (%)) of CS and vaginal deliveries in the whole 
preterm/healthy term BBB cohort and X2 comparison of proportions. 
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Delivery method CS Vaginal Missing X2 
All 595 (40.2) 886 (59.8) 480  
Preterm 152 (60.8) 98 (39.2) 41 
X2=52.2 
P=5.01E-13 
Term 443 (36.0) 788 (64.0) 439 
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5.3.3 Labour onset and membrane rupture  
A central hypothesis of this thesis was that sPTBs would have a stronger bacterial 
signal than both nsPTB and term births. A sPTB is considered to be any delivery 
precipitated by spontaneous labour and/or spontaneous membrane rupture. Non-
spontaneous events are those precipitated by artificial or no membrane rupture, 
combined with induced or no labour. These are considered inter-changeable with the 
‘indicated’ PTB label. The proportion of non-spontaneous deliveries was significantly 
higher in the preterm than term group (Table 5.10), reflecting the fact that indicated 
preterm births make up the largest proportion of the BBB preterm cohort. Whilst a 
very small proportion of nsPTBs births occurred before 29 weeks (7%), 17% of sPTB 
events occurred in this very early period. This trend possibly reflects reluctance 
amongst obstetricians to facilitate delivery of very preterm infants, except in the most 
extreme cases. The very early births that do occur are more likely to be spontaneous, 
i.e. beyond medical control. Labour and membrane rupture data were not available for 
all BBB pregnancies. This limited the total sample size of certain final models that used 
sub-phenotype categorisations of preterm/term deliveries based on labour/membrane 
rupture data. 
Table 5.10 – Number (%) of term and preterm births precipitated by 
spontaneous/non-spontaneous events in BBB preterm/healthy term cohort and X2 
comparison of proportions. 
 
Figure 5.4 and Figure 5.5 show the distribution of spontaneous/non-spontaneous 
labour and membrane rupture events by GA at birth in the clinical cohort. The figures 
are remarkably similar, reflecting the strong relationship between labour onset and 
membrane rupture method. The odds of having spontaneous labour occurring 
alongside spontaneous membrane rupture are 13.05 (95% CI = 10.23-16.74, P<2E-16) 
times higher than spontaneous labour associated with non-spontaneous membrane 
rupture.  
Outcome Spontaneous Non-spontaneous Missing X2 
Preterm 123 (48.6) 130 (51.4) 38 
X2=22.2 
P=2.5E-6 Term 802 (35.4) 439 (64.6) 429 
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Logistic regression analysis also revealed relationships between membrane 
rupture/labour onset and mode of delivery.  The odds of having a vaginal birth 
following spontaneous rupture of membranes are 7.86 (95% CI: 6.21-10.01, P<2E-16) 
times higher than having a CS delivery following spontaneous rupture of membranes. 
In other words, spontaneous rupture of membranes (SROM) tended to be followed by a 
vaginal delivery.  Similarly, the odds of having a vaginal birth following spontaneous 
labour were 9.52 (95% CI: 7.46-12.22, p<2E-16) times higher than having a CS birth 
following spontaneous labour. Whilst vaginal births may seed the infant and placenta 
with vaginal flora, CS deliveries are more likely to be seeded with skin flora. It is also 
plausible that differences in delivery method contamination may also have a 
quantitative component. These relationships with delivery method were critical to 
consider when analysing variation in placental bacterial load, according to definitions 
that used labour or membrane rupture data. 
 
 
 
Figure 5.4 – Labour onset by GA at birth in the BBB preterm/healthy term cohort. 
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5.3.4 BBB clinical data and sample availability 
Placenta was not available for all BBB clinical data described above. It was important to 
establish whether any significant differences existed between the types of pregnancies 
for which placenta was, and was not, available. Delivery method, birthweight, GA at 
birth, labour onset, and membrane onset did not vary significantly between the BBB 
preterm samples with (N=146, 50.2%) and without (N=145, 49.8%) placental samples 
(see Appendix Table A 11, page 256). There were also no differences between these 
characteristics between term pregnancies with and without available placental 
samples. These observations imply that the reasons for which placentas were accrued 
were not biased by some clinically relevant outcome, such as delivery method or labour 
onset. All available preterm placenta were taken forward for qPCR analyses.  
5.3.5 Summary of experimental cohort 
This section will describe additional clinical data and sub-groupings for only those 
pregnancies within the experimental cohort, i.e. for samples with useable qPCR data. 
Preterm deliveries are routinely categorised into clinically relevant subgroups, for both 
clinical and research purposes. These divisions often include information regarding 
whether labour onset and/or membrane rupture method were spontaneous or not. In 
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Figure 5.5 - Membrane rupture method by GA at birth in the BBB 
preterm/healthy term cohort. 
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this study, associations between pregnancy outcome and bacterial load were 
investigated using both categorical and continuous exposure variables. These were GA 
at birth; the binary category of preterm/term delivery; a three-group division of sPTB, 
nsPTB, and term delivery; and a four-group model of sPTB, nsPTB, spontaneous term, 
and non-spontaneous term outcomes. The distributions of spontaneous outcomes by 
preterm/term grouping in this qPCR cohort are outlined in Table 5.11. Further detail of 
the labour and membrane rupture processes underlying these groupings are in Table 
5.12. It was also noted that 35 preterm membrane rupture events were prolonged 
(over 18 hours between rupture and delivery), and 8 term ruptures were prolonged.  
Table 5.11– Distribution of spontaneous/non-spontaneous outcomes by 
preterm/term delivery in the experimental cohort (N (%)) and X2 comparison of 
proportions. 
Sub-group Term (N=225) Preterm (N=141) X2 
Non spontaneous 73 (43.2) 70 (55.1) X2=3.7 
P=0.056 Spontaneous 96 (56.8) 57 (44.9) 
Missing 56 14 - 
 
 
Table 5.12– Detailed labour/membrane rupture groupings by preterm/term 
delivery in the experimental cohort (N (%)) and X2 comparison of proportions. 
33 (23%) preterm infants in the experimental cohort were born under 33 weeks 
gestation, and 108 (77%) at between 33-36 weeks. 8 women who delivered preterm 
were given a cervical suture compared with 4 term deliveries.  23 preterm births were 
associated with preeclampsia (15.8%), 4 had congenital abnormalities, 2 resulted in a 
neonatal death, and 1 term birth was stillborn. 30 women who delivered preterm 
received steroids (20.6%). Table 5.13 summarises available clinical information on 
maternal infection in our experimental cohort from the clinical database. As can be 
seen, this information is relatively sparse and the vast majority of women had no 
recorded, clinically identifiable infection during pregnancy. 
Labour/membrane detailed Term (N=225) Preterm (N=141) X2 
No labour/no membrane rupture 73 (43.2) 70 (55.1) 
X2=5.3 
P=0.15 
Spontaneous labour intact 
membranes 
18 (10.7) 7 (5.5) 
Spontaneous labour/SROM 58 (34.3) 36 (28.4) 
SROM/no labour 20 (11.8) 14 (11.0) 
Missing 56 14 - 
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Table 5.13 – Maternal infections in experimental cohort by pregnancy outcome. 
 
Information regarding the level of neonatal care delivered to infants within the 
experimental cohort was available from the BBB clinical database. Over 50% of 
preterm infants, for whom data were available, ended up in special care (SCBU), or 
neonatal intensive care (NICU), units. By contrast, only 1.2% of term infants required 
this specialised attention (Table 5.14). 88% of infants with available data on their 
neonatal status who were born under 33 weeks were admitted to either NICU or SCBU, 
compared to 34% of ‘late preterm’ infants born between 33 and 37 weeks. These 
figures highlight the strong relationship between GA at birth and neonatal morbidity.  
Table 5.14 – Level of neonatal care by pregnancy outcome (N (%)) and comparison of 
proportions using X2 test. 
 
Neonatal care Term (N=225) Preterm (N=141) X2 
None 164 (98.8) 60 (48.8) X2=98.5 
P<2.2E-16 SCBU/NICU 2 (1.2) 63 (51.2) 
Missing 59 18 - 
The distribution of samples collected at each of the three recruiting hospitals differed 
by pregnancy outcome (Table 5.15). Given the potential impact of variations in 
infection patterns, sterilisation procedures, and recruiter biases at different sites, on 
study outcome, recruiting hospital was included as a covariate in final models. 
Table 5.15 – Distribution of preterm/term deliveries by study recruitment site (N 
(%)) and X2 comparison of proportions. 
Maternal infection status Term (N=225) Preterm (N=141) 
Asymptomatic bacteriuria 1 1 
Candida 4 1 
Chlamydia 1 0 
Cystitis 1 0 
Urinary tract infection 3 1 
Group B Streptococcus 0 0 
Other 1 2 
None 161 120 
Missing 53 16 
Hospital Term (N=225) Preterm (N=141) X2 
SMH 98 (43.6) 52 (36.9) 
X2=21.3 
P=2.4E-5 
CW 71 (31.5) 75 (53.2) 
QCCH 56 (24.9) 14 (9.9) 
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5.3.6 Bacterial load and pregnancy outcome 
Following exploration of the clinical dataset, summarised in preceding sections, 
experimental work to investigate associations between pregnancy outcome and 
placental bacterial load was carried out. Results from these tests are described and 
discussed in the remaining sections of this chapter.  
Table 5.16 provides a summary of qPCR data across all samples, as well as by 
preterm/term groupings. As can be seen by the distributional characteristics of these 
data, and highly significant Shapiro Test output, all three were highly negatively 
skewed. Therefore, it was decided to log transform the 16S copy number data for 
downstream plotting, regression, and non-parametric comparisons. These summary 
data show distributions with large ranges that overlap between term and preterm 
groupings. Evidence for bacterial presence was observed across all types of 
pregnancies, even those with no pathological outcome. Indeed, the sample with the 
highest bacterial load, more than double the highest preterm value, was from a term 
delivered placenta with no recorded complication.  
Table 5.16 – Summary of placental bacterial load data from qPCR experiments. 
Normality of distributions assessed using Shapiro test. 
 
 
 
5.3.6.1 Bacterial load does not vary by mode of delivery 
Placental load by delivery method was investigated in an attempt to explore whether 
bacterial load differed according to whether placenta were vaginally or abdominally 
delivered. Previous research has shown that vaginally delivered infants have a distinct 
structure of microbial colonisation compared to those delivered abdominally, via CS 
(Dominguez-Bello et al., 2010). However, whether this variation has a quantitative, as 
well as qualitative, component has not, to our knowledge, been explored. In our cohort, 
605 experimental samples had data on delivery method available. No difference in 
Group 
Placental bacterial load (16S copy number) 
Mean (SD) Median (IQR) Range Shapiro test 
All (N=701) 213.2 (714.0) 109.9 (70.8-179.9) 17.8-15860 
W=0.15 
P<2.2E-16 
Preterm (N=265) 202.5 (508.1) 116.3 (71.8-192.6) 24.5-7348 
W=0.22 
P<2.2E-16 
Term (N=436) 219.3 (814.5) 102.2 (70.8-167.7) 17.8-15860 
W=0.13 
P<2.2E-16 
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Figure 5.6 – Boxplot with individual points for log 16S copy number of placental DNA 
by delivery method. Boxes show median, 25th and 75th centiles with points beyond 
highest and lowest whiskers representing outliers (>1.5*IQR). P value for comparison of 
medians using Wilcoxon rank sum test. 
median bacterial load was observed between placentas delivered abdominally and 
those delivered vaginally (Figure 5.6). This was confirmed using both an unadjusted 
multilevel model, with participant number as a random intercept, and one in which 
batch and tissue type were also included as fixed level covariates (data not shown). 
 
  
 
 
 
 
 
 
 
5.3.6.2 Time between membrane rupture and delivery and bacterial load 
Data for time between membrane rupture and delivery were available for 201 samples 
from 111 pregnancies. The maximum time between membrane rupture and delivery in 
the experimental cohort was 1875 hours (78 days). The mean was 87.6 hours 
(SD=273.2), and the median 16.6 hours (IQR 3.1-38.2). There was no significant 
association between time between rupture and delivery, and bacterial load, in 
unadjusted and adjusted models (data not shown).  
5.3.6.3 Bacterial load and tissue type 
Endogenous bacteria found at the maternal or fetal side of the placenta may have 
reached either site by distinct means. Organisms at the fetal side may have ascended 
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from the vagina and across the uterine tissues. By contrast, bacteria may be more likely 
to reach the basal plate from sites such as the oral cavity, via the maternal circulatory 
system. It is plausible that infection of the fetal side may be a more frequent event, 
reflected in a higher average bacterial load in these tissue samples. However, any such 
differences could be obscured in our dataset on account of delivery effects. Whilst 
parenchyma tissue was excised from beneath the placental membrane, the villous 
tissue was potentially more exposed to delivery contaminants because it was not 
covered in a protective membrane during delivery.  
Running a univariate regression model, with participant number as a random effect, 
showed an increased load in parenchyma tissue, with an estimated reduction of -0.17 
log 16S copy numbers in parenchyma samples (95% CI -0.33 - -0.016, P=0.031).  
However, when the same model was adjusted for batch and delivery method, this 
difference disappeared completely to 0.06 log (95% CI -0.1- 0.23, P=0.45). This shows 
that the univariate associations were confounded by delivery method and/or batch. 
Following adjustment, the null hypothesis of no association between bacterial load and 
placental tissue type could not be rejected. 
5.3.6.4 Bacterial load does not vary by GA at birth or by preterm versus term 
outcome 
The principal aim of this study was to investigate whether pregnancy outcome was 
associated with quantifiable differences in placental bacterial load. To address this aim, 
any associations with categorical and continuous predictors, based solely on 
gestational age data, were first investigated. Bacterial load did not significantly differ 
between preterm and term deliveries in the experimental cohort (Figure 5.7). 
Univariate and multivariate multi-level regression models were subsequently run to 
explore this association further. The same models were then run with the inclusion of 
only samples of parenchyma or villous tissue. There was also no association between 
bacterial load and GA at birth for adjusted and unadjusted models run on all samples or 
samples of either tissue type investigated individually (data not shown).  
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Previous research has reported an increase in incidence of infectious mediated PTB 
with decreasing GA at birth. Intra-amniotic colonisation is particularly frequent in the 
earliest births (<33 weeks) (Onderdonk et al., 2008a). In this cohort, there was no 
observable increase in bacterial load in the earliest births. These results were 
consistent whether a two group model, comparing early births to all other births, or a 
three group model comparing early preterm, to late preterm, and term births was used 
(data not shown).  
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Figure 5.7 – Boxplot comparing log 16S copy number between preterm and term 
delivered placenta. Boxes show median, 25th and 75th centiles with points beyond highest 
and lowest whiskers representing outliers (>1.5*IQR). P value for comparison of medians 
using Wilcoxon rank sum test. 
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5.3.6.5 Bacterial load is highest in placenta from spontaneous preterm births 
An alternative approach to exploring associations between bacterial load and 
pregnancy outcome was to use predictor groups that took account of 
labour/membrane rupture information, in addition to GA data. Figure 5.8 summarises 
bacterial load using a four-group model of pregnancy outcome: sPTB, nsPTB, 
spontaneous term, and non-spontaneous term deliveries.  Using a Wilcox-test for 
comparison of medians, it is clear that sPTB placental samples had a significantly 
higher median bacterial load, than each of the three other groups. This provides 
support for the hypothesis that placental ‘infection’, characterised by increased 
bacterial load, may have been involved in the aetiology of a proportion of sPTB events 
in this cohort.  
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Figure 5.8 – Boxplot comparing log 16S bacterial load by pregnancy outcome (four 
group model). Boxes show median, 25th and 75th centiles with points beyond highest and 
lowest whiskers representing outliers (>1.5*IQR). P-value for comparison of medians 
using Wilcoxon rank sum test. 
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No difference was observed in bacterial load between the two term groups (W=11629, 
P=0.59). Multi-level regression analyses were conducted to further model any 
differences between the term outcomes and the null hypothesis of equal loads could 
again not be rejected. Therefore, it was decided to model associations between 
bacterial load and pregnancy outcome using a three-group, rather than four group 
model, in which both term groups were analysed together. When sPTB bacterial load 
was compared to data from all term births, power to detect the differences between the 
two groups was increased, as indicated by the smaller Wilcox Test P-value in Figure 
5.9. 
Figure 5.9 – Boxplots comparing bacterial load in placenta from sPTB and term 
pregnancies. Boxes show median, 25th and 75th centiles with points beyond highest and 
lowest whiskers representing outliers (>1.5*IQR). P-value for comparison of medians using 
Wilcoxon rank sum test. 
Unadjusted regression models confirmed that placenta from sPTB deliveries had a 
higher bacterial load in comparison to nsPTB and term births. This trend was observed 
when all samples were analysed together in a single model. It was also observed when 
parenchyma, and villous tissue were analysed separately (Table 5.17). These 
differences were signfiicant for the whole cohort comparsions, and the parenchyma 
only model. When only villous samples were included, the difference was only 
signficant for the comparison between sPTB and term placenta.  
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Table 5.17 - Univariate models of association between bacterial load (log 16S copy number) and three group model of pregnancy outcome in 
whole cohort and parenchyma and villous tissue separately. Whole cohort and parenchyma analyses included participant identifier as a random 
intercept. 
 
 
 
Predictors 
All N=668 
 
Parenchyma N=566 
 
Villous=102 
N β (95% CI) β SE P 
 
N β (95% CI) β SE P 
 
N β (95% CI) β SE P 
Intercept - 
5.03 
(4.85-5.20) 
0.089 <2.2e-16 
 
- 
5.04 
(4.85-5.22) 
0.095 <2.2e-16 
 
 
5.02 
(4.62--0.87) 
0.20 <2e-16 
Outcome  
(baseline= sPTB) 
100 - - - 
 
83 - - - 
 
17 - - - 
 
Preterm non 
spontaneous 
133 
-0.32  
(-0.55--0.09) 
0.12 0.0068 
 
116 
-0.34 
(-0.58--0.09) 
0.12 0.0071 
 
17 
-0.31 
(-0.87--0.9) 
0.28 0.27 
 Term 435 
-0.26  
(-0.45--0.06) 
0.099 0.0095 
 
367 
-0.23 
(-0.44--0.03) 
0.11 0.027 
 
68 
-0.46 
(-0.89- -0.02) 
0.22 0.041 
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To investigate these associations further, the same models were run with the addition 
of fixed covariates: delivery method, maternal ethnicity, batch, maternal smoking, 
maternal BMI, and recruiting hospital (Table 5.18). The whole cohort model was also 
adjusted for tissue type. In the adjusted model for the whole cohort (N=569 samples, 
308 participants), there was a significant reduction in placental bacterial load in nsPTB 
compared to sPTB placenta. The reduction in bacterial load in term births was 
attenuated in the adjusted model, and no longer significant. When two potential 
influential values from participants 2371 and 2081 were removed from the model, 
effect sizes were increased slightly, and significance for both comparisons increased. 
However, the comparison between sPTB and term load remained, marginally, non-
significant (β nsPTB=-0.34, 95% CI -0.54--0.15, P=0.00058; β term = -0.15, 95% CI -
0.31-0.0019 , P=0.053). 
Similar effect sizes and patterns of signfiicance were observed in the adjusted models 
looking only at parenchyma tissue (N=488 samples, 299 participants) and those 
including samples from both tissue types. One influential sample from participant 
2373, an nsPTB delivery, was identified via regression diagnostics. Its removal 
increased the strength of the associations for both groups (nsPTB = -0.36, 95% CI = -
0.56--0.16, P=0.00042; term=-0.15, 95% CI = -0.32--0.0029, P=0.054). 
The relationship between bacterial load and pregnancy outcome was investigated in 
villous tissue using an adjusted linear regression model. Again the trend was for sPTB 
placentas to have the highest bacterial load. However, in this relatively small sub-group 
analysis (N=81), these relationships were not significant. Removal of two potential 
influential values identified via diagnostic tests, lead to an increase in effect size and 
significance between nsPTB and sPTB samples (β =-0.72, 95% CI=-1.37--0.072), 
P=0.03). No change was observed with the comparison between sPTB and term 
placenta. 
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Table 5.18 – Summary of output from adjusted linear regression models predicting log 16S copy number from pregnancy outcome in full cohort, 
as well as parenchyma tissue, and villous tissue only. Full tables with data on all covariates included in models in Appendix Table A 12 and Table A 13, 
pages 257-258. 
Analysis Predictor β (95% CI) β SE P 
All samples 
(N=569) 
Intercept 4.67 (4.25-5.09) 0.21 <2.2e-16 
Pregnancy outcome (baseline=sPTB)    
 
nsPTB  -0.29 (-0.5--0.08) 0.11 0.0064 
Term -0.13 (-0.3-0.04) 0.09 0.13 
Parenchyma 
(N=488) 
Intercept   4.74 (4.32-5.16) 0.21 <2.2e-16 
Pregnancy outcome (baseline=sPTB)    
 
nsPTB -0.33 (-0.53--0.12) 0.11 0.0022 
Term -0.15 (-0.32-0.02) 0.09 0.076 
Villous 
(N=88) 
Intercept 5.25 (3.72-6.78) 0.76 7.04E-09 
Pregnancy outcome (baseline=sPTB)    
 
nsPTB -0.59 (-1.43-0.26) 0.42 0.17 
Term -0.32 (-1.01-0.36) 0.34 0.35 
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5.3.6.6 Bacterial load and cervical suture 
In some initial exploratory analyses an association was observed between whether or 
not a woman had a cervical suture during her pregnancy, and placental bacterial load 
(Figure 5.10). This was not a prior hypothesis. However, it was of interest to explore 
this further, given the clinical implications of any such association. 
 
 
This association was investigated further using unadjusted and adjusted multi-level 
linear regression models. 493 experimental samples from 273 pregnancies had 
associated information regarding whether or not a woman had a cervical suture during 
her pregnancy. Since only one of these samples was from villous tissue, it was decided 
to only conduct this analysis using the whole cohort, and not for each tissue 
individually. A reduction in bacterial load in placentas not associated with cervical 
sutures was observed using an unadjusted regression model, but this association was 
not significant (Table 5.19).  
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Figure 5.10 - Bacterial load appears to vary according to whether or not mothers 
have had a cervical suture in the current pregnancy. Boxes show median, 25th and 75th 
centiles with points beyond highest and lowest whiskers representing outliers (>1.5*IQR). 
P value for comparison of medians using Wilcoxon rank sum test. 
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Table 5.19  – Unadjusted regression model for association between placental 
bacterial load (log 16S copy number) and cervical suture in current pregnancy. 
 
Predictor β (95% CI) β SE P 
Intercept 5.12 (4.73-5.5) 0.20 <2.2e-16 
Cervical suture (baseline = yes)   
 
No -0.31 (-0.7-0.08) 0.20 0.12 
The model was subsequently adjusted for the potential confounding effects of batch, 
delivery method, tissue type, and pregnancy outcome (three-group model). The effect 
remained the same and reduced marginally in significance, but the P value was still 
above 5% (Appendix Table A 14 page 259).  
5.3.6.7 Bacterial load does not vary by level of neonatal care 
Neonatal infection is dangerous, particularly for preterm infants, and such infections 
may originate from maternal uterine tissues or seeding at delivery (Camacho-Gonzalez 
et al., 2013, Chan et al., 2015). It was therefore important to investigate any 
associations between placental bacterial load and neonatal outcomes. Available clinical 
data on the level of neonatal care for each pregnancy was used as a proxy for outcome. 
527 samples from 290 pregnancies were associated with information on neonatal care. 
No association was observed between whether or not a neonate received special care 
and bacterial load. This lack of association was confirmed using both unadjusted and 
adjusted multi-level regression models (data not shown). 
5.3.6.8 Correlation between biological replicates is low 
In this study, data on bacterial load from a substantial number of biological replicates, 
consisting of up to three samples from distinct sites on a single placenta, were 
available. By quantifying correlations between these replicates, the degree of similarity 
between bacterial profiles within individual pregnancies could be investigated. This 
provided a powerful opportunity to assess the extent to which placental ‘infection’ or 
overall microbiome load was a localised or diffuse phenomenon within placenta. 
Biological replicates could either both be from the fetal side of the placental disk 
(parenchyma 1 or parenchyma 2), or one from a parenchyma sample and the other 
from the maternal side of the placental disk (villous).  
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There was a significant and positive relationship between samples from the same 
participant, in which qPCR data from two parenchyma placental samples were 
available (Figure 5.11). However, this relationship was mild and appeared to be mainly 
driven by those samples with the highest bacterial load.  To investigate this further, 
data was log transformed so that the most extreme values would have less influence on 
the overall correlation (Figure 5.12). Following transformation, the ICC remained 
significant, but reduced to 0.21 (0.08-0.33). However, after removing only two samples 
with the highest mean load between parenchyma replicates, this relationship 
disappeared, whether or not the data was log transformed (non-transformed ICC = 
0.045, 95% CI = -0.084-0.17).  This clearly indicates that the initial relationship 
observed between these replicates was solely driven by correlation between the most 
highly infected samples. 
There was no observable relationship between bacterial load at the fetal side of the 
placenta (parenchyma tissue) and the maternal side of the placenta (villous tissue) 
(ICC=0.03, 95% CI=-0.17- 0.22). It was not possible to test correlations in bacterial load 
across the maternal side of the placenta because a maximum of one villous sample was 
ever run per participant.  
 
Figure 5.11– Relationship between bacterial load from biological replicates both 
taken from parenchyma samples from the fetal side of the placental disk. 
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Figure 5.12 - Relationship between log transformed bacterial load from biological 
replicates both taken from parenchyma samples from the fetal side of the placental 
disk. 
 
5.3.6.9 Negative extraction and PCR controls 
Three PCR negative controls were run on each plate to control for the presence of 
contaminants in PCR reagents. In addition, a total of 21 ‘negative extraction’ controls 
were run across the qPCR plates to explore the presence of bacteria in extraction kits. 
CT values from PCR negatives were consistently higher, indicating a lower load, than 
the experimental samples (W=11166, P<2.2E-16). In all but 8 of 699 total samples, 
sample CT values were over 1 CT cycle higher than the PCR negative controls on each 
respective plate. By contrast, there was substantial signal from the small number of 
extraction negatives. When compared with experimental samples, no significant 
difference in load was observed between the two (W=8622, P=0.17). This indicated the 
potentially significant impact of extraction procedures to bacterial signal in our study.  
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5.3.6.10 Summary of key results from qPCR analyses 
A summary of the main findings discussed in this chapter is presented in Table 5.20. 
Table 5.20 – Outline of key results from main statistical analyses conducted. 
 
Association with 
placental bacterial 
load investigated 
Significant 
difference using 
Wilcox test? 
Significant trend in 
unadjusted 
regression model? 
Significant trend in 
adjusted regression 
model? 
Mode of delivery No No No 
Time between 
membrane rupture 
and delivery 
No No No 
Tissue type Yes 
Higher in 
parenchyma 
No 
Term/preterm birth No No No 
GA at birth - No No 
sPTB vs nsPTB /term Yes 
Higher in sPTB vs 
nsPTB 
Higher in sPTB vs 
nsPTB 
Cervical suture Yes No No 
Neonatal care No No No 
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5.4 Discussion 
In this study it was demonstrated that placental bacterial load was higher in sPTB 
deliveries, when compared to term and nsPTB events. This trend was observed when 
all samples were considered together, as well as separately by tissue type. Comparisons 
between sPTB and nsPTB events, using all samples and those from parenchyma tissue, 
were statistically significant in final adjusted models. No difference was observed in 
total load between placenta that were delivered vaginally and those delivered by CS, or 
when tissue from the maternal side was compared to tissue from the fetal side of the 
placenta. Preterm birth has previously been associated with increased frequency of 
intra-uterine infection using microbiological cultures, as well as broad-range and 
species specific end-point PCR (Jones et al., 2009, Onderdonk et al., 2008a, Han et al., 
2006). This study is the first, to our knowledge, that demonstrates a quantitative 
association between total placental bacterial load and sPTB. 
Cervical cerclage is a common prophylactic treatment for women at risk of preterm 
birth. However, literature on the associated risks of intra-uterine infection is sparse. 
Such risk could be due to either the morphological characteristics of the women that 
indicate them for suture in the first place, or the invasive nature of the procedure itself. 
A recent publication described dysbiosis in the vaginal microbiome among women who 
received braided over monofilament sutures, providing compelling evidence for the 
procedure’s impact on maternal microbiome profiles (Kindinger et al., 2016). In the 
present study, there was an increase in median placental bacterial load associated with 
cerclage. However, potentially on account of the very small number of samples, 
regression models used to investigate this association were not significant. Replication 
of this comparison in a larger cohort is needed to confirm or refute this preliminary 
observation.  
The fact that evidence for a positive association between bacterial load and sPTB was 
stronger when comparisons were made with nsPTBs, rather than with term births, is 
interesting. Arguably, nsPTBs are a better-matched control for the sPTB placenta, given 
that the placental samples are matched for GA at delivery. The non-spontaneous group 
could be seen as a representation of the infection status of ‘normal’ placenta at this 
stage of gestation. This provides support for the hypothesis that women who undergo 
sPTB events tend to be those exposed to a more profound bacterial insult prior to 
delivery. If the risk of ascending infection is a function of time, then average bacterial 
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load in the placenta may increase across gestation. This could explain the reduced 
difference between bacterial load in sPTB placenta and all term births, when compared 
to sPTB and nsPTB differences. However, such a positive association with GA was not 
observed in our experimental data.  
From these data, as well as those from previous studies (Stout et al., 2013, Aagaard et 
al., 2014), it seems unlikely that all women who make it to term have sterile placenta. 
The similarity in signal between term and sPTB placental load may reflect a scenario in 
which those term delivered placenta with relatively high bacterial load were simply 
infected later in pregnancy. It is possible that a number of term births were 
precipitated by increased levels of bacterial placental colonisation that were causally 
involved in labour and/or membrane rupture. Because this challenge occurred later in 
gestation, it was not considered a pathological outcome. However, if this were the case 
we may expect to see an increased bacterial load in spontaneous term compared to 
non-spontaneous term events, which was not observed in this study.  
A number of SNPs, particularly those in genes involved in immune related pathways 
have been associated with preterm birth (Crider et al., 2005). It may be that the 
divergent outcomes in women with similar levels of bacteria in their placenta could 
reflect important differences in maternal and/or fetal genetics. Certain women may 
respond to bacterial presence with an inflammatory signal that results in membrane 
rupture or labour, and preterm delivery. Others may be more likely to tolerate the 
foreign invasion longer and carry their infant to term.  
In this study there was a measureable fluorescence signal, indicating the presence of 
bacterial DNA, across all placental samples. The interpretation of these signals will vary 
depending on the underlying assumptions of the nature of the ‘placental microbiome’. 
If, as has been recently hypothesised by Aagaard et al. (2014), the presence of bacteria 
within the placenta is a normal and non-pathological occurrence, then a general 
bacterial presence across the whole cohort is to be expected, regardless of outcome. By 
contrast, it has traditionally been hypothesised that bacteria are only rarely able to 
break through the cervix and fetal membranes, eventually reaching the placenta. Under 
this scenario, it is more reasonable to consider only those samples with the highest 
loads to represent instances of ‘true’ bacterial infection. Signal from the remaining 
samples with lower loads, may instead be a function of stochastic noise and 
environmental/delivery contamination. 
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The placenta is an organ of very low biomass that, by definition, must pass through the 
bacterial rich environments of either the skin or the vagina prior to collection. The 
combination of these factors means that a large part of studying the ‘true’ placental 
microbiome must be developing tools to differentiate endogenous signal from 
organisms present in the organ during gestation, from noise picked up via reagent, 
delivery, and environmental contamination. A growing body of work is being 
developed to address these issues (Jervis-Bardy et al., 2015), with investigations 
concerning the lungs being of particular note (Aho et al., 2015). However, there is still 
relatively little literature directly addressing this topic.  
In this study, bacterial load in negative extraction control samples was not significantly 
different to experimental samples. Clearly, this indicates that contaminating bacteria 
were present in extraction reagents, as has been noted in other publications (Salter et 
al., 2014, Weiss et al., 2014, Glassing et al., 2016). This observation also implies that 
much of the signal from the experimental samples may well be noise from 
contaminants picked up during sample preparation. However, it is important to 
consider, as discussed in section 3.2.2.1, the impact of background human DNA in this 
context. Competition with endogenous DNA was shown to affect the ability of the qPCR 
primers to pick up low biomass bacterial DNA in the mixed experimental samples. This 
makes it difficult to directly compare the quantitative results from negative extraction 
samples, in which no background contaminating DNA was present, with those in which 
the majority of nucleic acids present were non-target, human molecules, i.e. 
experimental placental samples. Therefore, despite the significance of the negative 
extraction qPCR signal, I propose that the comparisons within the experimental 
samples should be considered valid within the context of a potentially lower efficiency, 
mixed-sample qPCR assay. There also remains the likelihood that a number of samples 
in this dataset had very low, if any, true bacterial DNA present in-utero and that much 
of the signal is from organisms picked up at extraction or delivery. 
It has also been shown in this study that bacterial load was only correlated between 
distinct samples excised from the same placenta in samples with the very highest load. 
Furthermore, no correlation was observed between biological replicates from opposite 
sides of the organ. These observations imply that where bacteria were present in the 
placenta, they were not necessarily diffuse across the whole organ, which is perhaps to 
be expected, except for in the most extreme cases. However, given the negative 
extraction observations, it is also possible that much of the signal in this assay was a 
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function of low level, stochastic noise originating from contaminants. If this were the 
case, this could also explain the low reproducibility between biological replicates. 
Validating either hypothesis is challenging with only these quantitative data at hand 
and will be further investigated in Chapter 6. Using sequencing data, the qualitative 
nature of signals in all samples, both extraction negatives and placental extracts, will be 
explored. Part of the hypothesis for the proceeding work was that signal from 
extraction negatives would be of a different, non-clinically relevant make up when 
compared to those species identified in clinical samples of interest. Furthermore, 
although no difference in load between CS and vaginally delivered placentas were 
observed, qualitative differences by delivery group may be much clearer than 
quantitative ones. This is something that can only be explored through comparison of 
sequencing data. 
There are several strengths to this study. Often studies investigating the molecular 
aetiology of preterm birth do not have such a large number of sPTBs to work with. 
Furthermore, given the completeness and comprehensiveness of the matched clinical 
data, important phenotypic distinctions could be investigated. It was also possible to 
include potential confounders in final models. The fact that negative extractions were 
investigated for their bacterial signal is also a strength of the study. This remains a rare 
practice within the field. Furthermore, the inclusion of technical replicates enabled the 
estimation of the reproducibility of the assay, which was shown in Section 3.2.2.2 to be 
high, with substantial correlation between such repeats. The nature of bacterial spread 
across the tissue was theoretically observable using biological replicates, although this 
was a more difficult analysis to interpret.  
One of the main weaknesses of this study was that it used a discrete sample to make 
inferences about an entire organ. One, two, or three samples of less than 50 μg each 
were used to summarise the nature of bacterial colonisation across an organ that 
usually weighs about 500 gm. This relies on the assumption that bacterial presence will 
be relatively reproducible and diffuse across the organ, which is logically unlikely and 
not supported by our data. To overcome this limitation, taking a much larger number of 
samples, and mixing them together before DNA extraction, may enable a more reliable 
average estimate to be made. However, this then limits the chance to explore the nature 
of bacterial spread across the organ. 
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: The Placental Microbiome Chapter 6
and Pregnancy Outcome 
The principal objective of the work outlined in this chapter was to investigate whether 
the taxonomic bacterial composition of the placenta varied according to pregnancy 
outcome. It was shown in Chapter 5 that total bacterial load tended to be highest in 
placenta from sPTB placenta. The nature of this association was further explored using 
NGS techniques, and will be described in this chapter. Using 16S sequencing, the 
association between bacterial presence in the placenta and sPTB could be qualitatively 
explored. This served to elaborate in more detail, the quantitative associations 
reported in Chapter 5. The existence of a ‘normal’, shared placental microbiome, 
common across both healthy and complicated pregnancies, was also investigated. 
Dealing with issues of contamination in tissues of very low biomass, such as the 
placenta, were discussed in Chapter 3 and Chapter 5. These will be further considered 
in this chapter. Bacterial composition was addressed using a targeted 16S sequencing 
approach. The study cohort was a subset of samples from the quantitative 
characterization of placental bacteria and pregnancy outcome described in Chapter 5. 
6.1 Introduction 
As discussed in detail in Chapter 1, maternal infection is a well-known risk factor for 
sPTB.  The investigations described in this chapter were carried out to explore this 
relationship, with respect to qualitative differences in bacterial infection by pregnancy 
outcome. A large challenge in the analysis and interpretation of these data was the 
differentiation of true, endogenous signal, from exogenous contamination and 
experimental artefacts. Table 6.1 outlines some of the potential sources of variation in 
16S sequencing data. These alternative explanations must be kept in mind when 
analysing and interpreting results. 
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Table 6.1 – Potential endogenous and exogenous causes of observed variation in 
placental microbiome profiles assessed by 16S sequencing 
Biological variation Contamination Experimental artefacts 
Differences by ethnicity 
 
Lysis and extraction kit 
contaminants 
Primers chosen 
 
Differences by outcome 
group 
Delivery method 
 
16S region targeted 
 
Individual variation in 
microbiome profiles 
Hospital specific 
contaminants 
PCR error and bias 
 
 Sample excision process Sequencing error 
 Storage buffer 
contaminants 
Library quantification and 
normalisation techniques 
  Chimera formation 
  OTU picking strategies 
  Reference database used 
for taxonomic classification 
 
6.1.1 What we know about the placental microbiome 
Evidence of bacteria in placental tissues comes from a number of sources: 
microbiological culture, PCR, molecular cloning and sequencing, fluorescence in-situ 
hybridization (FISH), histological staining, and most recently, next generation 
sequencing (Pelzer et al., 2016). These observations have often, but not exclusively, 
been associated with pathological outcomes, most commonly, PTB. The case for 
bacterial presence in the placenta is strengthened because evidence has come from 
both cellular and molecular techniques. The growth in the use of molecular techniques 
enables the identification of intra-uterine infections that often consist of predominantly 
anaerobic species that can be difficult to culture. By contrast, some studies have used 
cell based techniques to demonstrate the presence of live bacterial cells within 
placental tissue (Stout et al., 2013). These cell based techniques address a common 
criticism of purely molecular microbiome studies (Kliman, 2014).  Specifically, that the 
presence of bacterial DNA does not prove that live, viable cells were present in tissue 
from which the DNA was extracted.  
The majority of studies reporting bacterial presence in intra-uterine and placental 
tissue have been designed to investigate the aetiology of adverse pregnancy outcomes. 
However, bacteria have also been observed in uterine tissues from healthy pregnancies 
(Stout et al., 2013, Jones et al., 2009). Recently, Aagaard et al. (2014) described a 
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‘unique placental microbiome’ that was observed across both term and preterm 
pregnancies. These data have been used as evidence that a low biomass, non-
pathogenic commensal community may be a functional component of normal human 
pregnancy. It has been suggested that such communities may train the fetal immune 
system prior to birth (Charbonneau et al., 2016). This has sparked considerable 
discussion in the literature regarding the meaning, reliability, and frequency of such 
non-pathogenic placental colonisation (Mysorekar and Cao, 2014, Wassenaar and 
Panigrahi, 2014, Payne and Bayatibojakhi, 2014, Charbonneau et al., 2016, Kliman, 
2014). A recent study has challenged Aagaard et al.’s observations, using data from an 
independent, but small (N=12), cohort (Lauder et al., 2016). Lauder et al. (2016) 
observed no difference in the microbial signatures from contamination controls 
collected at all stages of collection and sampling, and DNA extracted from placental 
samples. These results suggest that previously reported signals did not originate from 
true placental colonisation, but instead from poorly controlled for contamination. It is 
plausible that observations of bacterial DNA within healthy placental tissue may reflect 
one of three scenarios: 
1. An evolutionarily adaptation, facilitating beneficial exposure of the fetus to 
diverse microbes in-utero, during immune system development; 
2. Neutral, stochastic, and low-biomass presence of organisms that have little or 
no functional significance and may never reach the fetus; 
3. The result of a poorly controlled study in which most/all signal actually 
originates from exogenous contaminants. 
 
The paper by Aagaard et al. (2014) described a community that consisted of low 
numbers of a variety of organisms. These organisms were largely from the phyla: 
Bacteroidetes, Firmicutes, Fusobacteria, and Tenericutes. The study also compared their 
data with those from the HMP (Huttenhower et al., 2012). This was an attempt to 
identify any overlap in composition with their placental cohort, and therefore identify 
the body site from which their sequences were likely to have originated. Their results 
were somewhat unexpected. They showed that placental samples clustered with oral, 
rather than vaginal samples from the HMP dataset. This has been used to support the 
claim that their observations are unlikely to reflect contaminants picked up at delivery, 
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but rather the hematogenous spread of microorganisms from the maternal oral cavity 
to the placenta (Aagaard et al., 2014). There has been previous evidence of the recovery 
of oral species from placental tissue (Han et al., 2010). However, these observations 
challenge traditional dogma in which the majority of organisms recovered from uterine 
tissues have tended to resemble the vaginal microbiome (Goldenberg et al., 2000).  
The idea that the placenta may seed the developing fetus’ environment and train its 
immune system is of great interest, whether or not the placental microbiome is 
established from the vaginal or oral communities. From where, and at what point in 
development, the fetus is first exposed to microorganisms, remains undetermined. First 
pass meconium has been shown to contain microbes, implying that there may exist 
some seeding prior to delivery in infants (Gosalbes et al., 2013, Hansen et al., 2015, 
Moles et al., 2013). Aagaard et al. (2014) use their data to suggest that a ‘starter culture’ 
of bacteria is transferred from mother to baby via the placenta in-utero. The 
significance of such a placental microbiome to fetal development is an active and 
nascent topic of research.  
It is clear from studies examining infants delivered via the vagina or by CS that delivery 
method plays a large role in the primary seeding process of infants (Dominguez-Bello 
et al., 2010). This bacteria rich transition from the intra-uterine environment to the 
outside world also presented a methodological challenge in this study. Bacteria 
collected on tissues of interest during delivery may obscure signal from endogenous 
seeding that does occur. Experimental and computational methodologies for 
differentiating delivery contamination from endogenous signal require further 
attention. 
The involvement of placental infection in adverse pregnancy outcomes, particularly 
preterm birth, is a less controversial topic. A number of microorganisms have been 
repeatedly implicated in the pathogenesis of preterm labour (Goldenberg et al., 2000). 
Many of these are of low virulence in normal situations, and are associated with BV. It 
is generally hypothesised that an opportunistic pathogen will ascend to the placenta 
from the vagina, and initiate preterm labour via inflammatory mechanisms (see 
Chapter 7). However, as mentioned above, the descent of organisms from the oral 
cavity to the uterus is an additional route that is gaining increasing attention. Different 
types of organisms may be found in the placenta, depending on whether they originate 
in the vagina or the oral cavity. Therefore, identifying whether vaginal or oral 
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colonisation routes are most likely to be responsible for intra-uterine infection, will 
improve the capacity of clinicians to target treatment more effectively.  
The varying impact of different genera/species/serotypes upon obstetric outcomes has 
been noted in studies of both humans and animals (Oh et al., 2010, Migale et al., 2015). 
These varying responses highlight the importance of identifying which specific 
taxonomic groups are associated with adverse outcomes, rather than simply the 
identification of bacterial presence or absence. A detailed understanding of the types of 
microorganisms involved in sPTB will aid the development of more targeted clinical 
approaches. A summary of some of the key organisms that have been isolated from the 
intra-uterine environment, the majority using molecular techniques, and many of 
which have also been associated with sPTB, are listed in Table 6.2. This list is not 
exhaustive and is likely to grow as culture independent sequencing techniques 
continue to be employed. Given the potential influence of contaminants on low biomass 
tissues, such as the placenta, it is important to report associations with novel bacteria 
with caution. 
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Table 6.2 – Overview of most common organisms identified within uterine cavity tissues in normal and complicated pregnancies. AF=amniotic fluid; FM=fetal 
membrane; P=placenta 
Genus Example species Tissue  References 
Acinetobacter baumanii, lwooffii, junii AF and P Prince et al. (2016); Romero et al. (2014d)  
Atopobium vaginae AF, FM, and P Jones et al. (2009); DiGiulio et al. (2010) 
Bacteroides 
ureolyticus, fragilis, 
hemolyticus 
AF, FM, and P 
Aagaard et al. (2014); Combs et al. (2014); Hitti et al. (1997);Han et al. (2009) Jones et al (2009); 
Marconi et al. (2011); Wang et al. (2013); DiGiulio et al. (2010) 
Bergeyella zoohelecum AF, FM, and P 
Aagaard et al. (2014); Combs et al. (2014); Han et al. (2009); Hitti et al. (1997); Jones et al. (2009) 
Marconi et al. (2011); Wang et al. (2013) 
Clostridium hiranonis AF Combs et al. (2014); Han et al. (2009); Wang et al. (2013); DiGiulio et al. (2010) 
Enterococcus faecalis AF DiGiulio et al. (2010); Markenson et al. (1997) 
Escherichia coli AF, FM, and P Hitti et al. (1997); Jones et al. (2009) 
Fusobacterium nucleatum polymorphum AF, FM, and P 
Aagaard et al. (2014); Combs et al. (2014); DiGiulio et al. (2008); DiGiulio et al. (2010); Gardella et al. 
(2004) Hitti et al. (1997); Han et al. (2009); Jalava et al. (1996); Jones et al. (2009); Romero et al. 
(2014c); Wang et al. (2013) 
Gardnerella vaginalis AF, FM, and P 
Combs et al. (2014); DiGiulio et al. (2008); Hitti et al. (1997); Jones et al. (2007); Romero et al. 
(2014c)  
Haemophilus 
influenzae, 
haemoglobinophilus, 
parainfluenzae 
AF, FM, and P Combs et al (2014); DiGiulio et al. (2010); Jalava et al. (1996); Jones et al. (2009); Wang et al. (2013) 
Klebsiella pneumoniae AF and P Aagaard et al. (2014); Hitti et al. (1997)  
Lactobacillus 
crispatus, gasseri, 
delbrueckii 
AF, FM, and P DiGiulio et al. (2010); Jones et al. (2009); Onderdonk et al. (2008b); Prince et al. (2016) 
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Leptotrichia amnionii 
 
Combs et al. (2014); DiGiulio et al. (2010); Gardella et al. (2004); Han et al. (2009); Marconi et al. 
(2011) 
Listeria monocytogenes AF Combs et al. (2014); DiGiulio et al. (2010); Wang et al. (2013) 
Mycoplasma hominis AF, FM, and P 
DiGiulio et al. (2008); DiGiulio et al. (2010); Hitti et al. (1997); Han et al. (2009); Jones et al. (2009); 
Marconi et al. (2011); Onderdonk et al. (2008b); Onderdonk et al. (2008a); Wang et al. (2013); 
Romero et al. (2014c) 
Neisseria 
gonorrhoeae; cinerea; 
subflava; polysaccharea, 
lactamica 
AF and P Aagaard et al. (2014); DiGiulio et al. (2008); DiGiulio et al. (2010) 
Pantoea dispersa AF, FM, and P Jones et al. (2009); Romero et al. (2014c) 
Peptoniphilus 
lacrimalis, 
asaccharolyticus, harei 
AF, FM, and P Jones et al. (2009); Wang et al. (2013) 
Peptostreptococcus asaccharolyticus AF, FM, and P DiGiulio et al. (2010); Hitti et al. (1997); Han et al. (2009); Jones et al. (2009) 
Prevotella 
tannerae, oulora, bivia, 
copri, oris 
AF, FM, and P 
Aagaard et al. (2014); Han et al. (2009); DiGiulio et al. (2008); DiGiulio et al. (2010); Hitti et al. 
(1997); Marconi et al. (2011); Onderdonk et al. (2008b); Wang et al. (2013) 
Sneathia sanguinegens AF, FM, and P 
Combs et al. (2014); DiGiulio et al. (2008); DiGiulio et al. (2010); Han et al. (2009); Romero et al. 
(2014c); Wang et al. (2013) 
Staphylococcus 
equorum, pettenkoferi, 
aureus, hemolyticus 
AF and P Combs et al. (2014); DiGiulio et al. (2010); Onderdonk et al. (2008b); Romero et al. (2014c)  
Streptococcus 
agalactiae (Group B), 
thermophillus, oralis, 
mitis, anginosus, 
alivarius, pneumoniae 
AF, FM, and P 
Combs et al. (2014); DiGiulio et al. (2008); DiGiulio et al. (2010); Han et al. (2009); Hitti et al. (1997); 
Jones et al. (2009); Prince et al. (2016); Romero et al. (2014c); Wang et al. (2013) 
Ureaplasma urealyticum, parvum AF, FM, and P 
Combs et al. (2014); DiGiulio et al. (2008); DiGiulio et al. (2010); Han et al. (2009); Jalava et al. 
(1996); Jones et al. (2009); Onderdonk et al. (2008b); Romero et al. (2014c); Wang et al. (2013) 
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6.1.2 The vaginal microbiome 
The majority of intra-uterine infections are believed to be of vaginal origin. In order to 
colonise uterine tissues they must ascend from the lower genital tract, and break the 
functional and structural barrier of the cervix and mucous plug (Goldenberg et al., 
2000). Therefore, understanding the nature of the vaginal microbiome before, during, 
and after pregnancy, is an important part of understanding infectious mediated PTB. 
The vaginal microbiome can vary by factors including age, ethnicity, menses, and sexual 
practices (Huang et al., 2014, MacIntyre et al., 2015). Additionally, changing 
environmental conditions, such as those associated with pregnancy, antibiotics, or 
hormone therapy, may facilitate normally commensal species becoming opportunistic 
pathogens. These changes may also enable the colonization of non-endogenous species 
within the vagina. Such changes could lead to situations that are detrimental to the 
host, such as reproductive tract infections.  
A rich and complex ecosystem of microorganisms inhabits the vagina. Most members of 
this community are commensal species that are neutral to the host. Others are 
symbiotically beneficial mutualists, which are critical components of female 
reproductive health, most notably Lactobacilli spp. The dominance of Lactobacilli as the 
‘cornerstone of vaginal health’ has been appreciated for over a century (Huang et al., 
2014). This picture has been refined and developed using data from 16S and 
metagenome analyses of women, at various stages of their reproductive cycles and 
lives. One common framework describes five discrete and relatively stable vaginal 
‘community state types’ (CSTs), which were first described in a group of asymptomatic, 
non-pregnant women (Ravel et al., 2011). Four of these CSTs were classified according 
to the dominance of a single Lactobacillus species: L. crispatus (CST I), L. gasseri (CST 
II), L. iners (CST III), and L. jensenii (CST V). CST IV is considered the somewhat 
anomalous state, and is often seen as a proxy for BV. It is characterized by a 
Lactobacillus poor community, and a relatively diverse, predominantly anaerobic, 
remaining microbiome. CST IV associated organisms include: Prevotella spp., Dialisters 
spp., Atopobium vaginae, Gardnerella vaginalis, Megasphaera spp., Peptoniphilus spp., 
Sneathia spp., Finegoldia spp., and Mobiluncus spp. (MacIntyre et al., 2015).  
There is currently conflicting evidence regarding how variation in vaginal flora can 
impact pregnancy outcome (Romero et al., 2014b, Romero et al., 2014c, Hyman et al., 
2014, Witkin et al., 2007). Studies into the relationship between BV and preterm birth 
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have formed a major part of this area of research. BV was traditionally considered to be 
the function of overgrowth of Gardnerella vaginalis and a concomitant reduction in the 
prevalence of ‘healthy’ Lactobacilli spp. However, recent evidence supports a definition 
of BV that is more polymicrobial, including organisms associated with CST IV and 
others such as Ureaplasma spp. (Africa et al., 2014). These relatively low virulence, 
mainly anaerobic organisms also tend to be the most commonly recovered species 
from intra-uterine samples. Lactobacilli spp., by contrast, are much less commonly 
recovered (Charbonneau et al., 2016).  
Understanding why an environment rich in ‘healthy’ Lactobacilli spp. protects women 
from ascending infection could improve understanding of the link between infection 
and preterm birth. Figure 6.1 outlines a hypothesised mechanism behind Lactobacilli 
spp. dominance within the vagina (Zhou et al., 2007). During pregnancy, estrogen is 
produced by the placenta, which may further this dominance of Lactobacilli spp. and 
potentially encourage community stability. Indeed, the pregnant vaginal microbiome 
has been characterised as a period of relative stability, greater Lactobacilli dominance 
and reduced alpha, within sample, diversity (MacIntyre et al., 2015). Post-partum, 
estrogen levels fall dramatically, which may reflect some of the changes in microbiome 
dynamics observed in recent studies (MacIntyre et al., 2015).  
 
 
Figure 6.1 – Hypothesised link between estrogen, vaginal glycogen, Lactobacilli 
growth, and vaginal health (Zhou et al., 2007) 
 
Low pH precludes growth of many pathogenic organisms 
Results in low pH of vagina 
Glycogen metabolised by bacteria (primarily Lactobacilli) to produce organic (lactic) 
acids 
Glycogen deposits on vaginal epithelium 
High levels of estrogen in reproductive age women 
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6.1.3 The oral microbiome and pregnancy 
An association between maternal periodontal infection and PTB was first proposed two 
decades ago. Offenbacher et al. (1996) described a cohort in which periodontal disease 
was associated with low birthweight and PTB. Work that came out of this initial study 
indicated that this effect was likely due to hematogenous spread of oral microbes to the 
uterine cavity, independent of maternal vaginal and reproductive tract infection status 
(Offenbacher et al., 1996). An alternative explanation is that bacterial endotoxin or 
inflammatory cytokines originating at the oral site, rather than the organisms 
themselves, may have travelled to the uterine cavity and elicited an inflammatory 
response (Klebanoff and Searle, 2006). However, this explanation does not account for 
the genetic identity of specific bacteria recovered from both oral and placental sites in 
the same individual in more recent studies (Han et al., 2010).  
Evidence from epidemiological studies, as well as animal models, has supported the 
role of periodontal disease as an independent risk factor for preterm birth 
(Offenbacher et al., 2006, Goepfert et al., 2004, Offenbacher et al., 2001, Arce et al., 
2009, Boggess et al., 2005). The strength of association between periodontal infection 
and gestational length increases with disease severity, and reduces with gestational 
length. Crucially, these relationships persist following adjustment for other social risk 
factors that lead to poor oral hygiene and periodontal disease, such as smoking and 
access to care. Despite these associations, a relatively recent meta-analysis did not 
report an improvement in obstetric outcomes, following maternal periodontal disease 
treatment (Chambrone et al., 2011).  
The most widely studied oral species implicated in preterm birth, as well as other 
adverse pregnancy outcomes such as stillbirth, is the gram-negative anaerobe 
Fusobacterium nucleatum. This organism is one of the most abundant commensal oral 
species, and is rarely detected at other body sites under normal conditions. A case-
report provided the first direct evidence of translocation of the organism from a sub-
gingival plaque infection to the placenta and fetus, eventually leading to inflammation 
related fetal death at term (Offenbacher et al., 2001, Jeffcoat et al., 2001). Its presence 
has been detected independently in a variety of uterine tissues including amniotic fluid 
(Wang et al., 2013), and placental and fetal membranes (Jones et al., 2009). It has also 
been found in the fetal lung and stomach (Han et al., 2010). The highly invasive nature 
of F. nucleatum has been investigated in-vitro and in-vivo. Such research has provided 
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functional support for its involvement in PTB, and its capacity to overcome the 
placental barrier between the maternal and fetal compartments. This work has also 
highlighted the involvement of the highly conserved protein FadA, a surface adhesin 
expressed by oral Fusobacteria, in intra-uterine infection. FadA is expressed on the 
organisms’ cell surface. It has been shown to impact the ability of the bacteria to 
colonise and proliferate within the placenta in a mouse model (Han et al., 2010).  
F. nucleatum infections are often part of a larger multi-species infection (Ikegami et al., 
2009). It has been suggested that the binding of F. nucleatum to endothelial cells, via 
FadA, increases permeability of the endothelium to other organisms such as E. coli (Han 
et al., 2009). F. nucleatum may enable other microorganisms to spread in this way, 
facilitating mobile and mixed microbiological infections travelling to the intra-uterine 
cavity from distinct body sites. This is an interesting observation given that some 
estimates put poly-microbial invasion of the intra-uterine space at as high as 30% of 
cases (Fardini et al., 2011).  
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6.1.4 Hypotheses and objectives 
This study was designed under the hypothesis that the placental microbial community 
would be altered in sPTB pregnancies when compared to term pregnancies. This 
alteration could have taken two main forms. Firstly, specific changes in the abundances 
of individual taxonomic groups, both at the OTU level, approximately accounting for 
species groupings, and the genus level, could predispose individuals to certain clinical 
outcomes. Linear models of normalized OTU count data were used to explore such 
associations between specific organisms and sPTB. Secondly, changes in the overall 
diversity of organisms within a sample could be associated with pregnancy outcome. 
For example, a more diverse environment may be more protective of adverse 
outcomes. In order to investigate this, alpha diversity estimates were used to assess 
whether pathological pregnancy outcomes associated with any changes in community 
diversity and richness. Beta diversity metrics were also used to visualize and quantify 
any potential differentiation in community structures between outcomes of interest.  
The following questions address the main aims of this study: 
1) Can we define a ‘placental microbiome’? 
2) Are there differences in the types of species recovered from vaginal and CS delivered 
placenta? 
3) Are certain OTUs or genera enriched in sPTB, versus term and nsPTB delivered 
placenta?  
4) Can we define a ‘preterm placental microbiome’ using ecological diversity metrics? 
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6.2 Materials and methods 
6.2.1 Cohort selection 
Time and resources permitted the sequencing of at least one sample from 73% of the 
pregnancies from the qPCR dataset. We plan to complete the sequencing dataset in the 
future when more resources become available. Figure 6.2 outlines the process of cohort 
selection and sample retention across all stages of my PhD, from the clinical analyses in 
Chapter 5, to beta diversity comparisons within this chapter. The proportions of 
samples sequenced from the three outcome groups were very similar between the 
qPCR and sequencing datasets (X2=3.6, P=0.6), whilst fewer biological replicates were 
sequenced (Table 6.3). Given the smaller size of the sequencing cohort, both 
parenchyma (N=350) and villous (N=44) tissues were included together in final 
models, except for sections 6.3.4.2.2 and 6.3.4.2.3 where parenchyma samples were 
also analysed separately. An adjustment term was included in models to account for 
any potential confounding by tissue type, as well as a random intercept term to account 
for correlations between biological replicates. Alongside the experimental samples, 9 
mocks, 19 negative extractions, and 5 PCR blanks were also sequenced. .  
Table 6.3 – Distributions of samples by outcome group in sequencing and qPCR 
datasets.  
 *Includes preterm samples with no delivery data 
 
6.2.2 Sample collection and DNA extraction 
See section 2.1. 
Group 
Sequencing dataset  N (%) qPCR dataset N (%) 
Total 
pregnancies 
Total samples 
Total 
pregnancies 
Total samples 
sPTB 41 (16.5) 61 (15.5) 57 (15.6) 100 (14.3) 
nsPTB 50 (20.2) 77 (19.5) 70 (19.2) 133 (19.0) 
Term 145 (58.5) 237 (60.2) 225 (61.5) 435 (62.2) 
Total 248* 394* 366* 699* 
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Clinical dataset 
Term = 1670 
Preterm = 291 
qPCR dataset 
Term = 225 (436) 
Preterm = 141 (265) 
Sequencing dataset 
4,180,928 reads 
Term = 145 (237) 
Preterm = 91 (138) 
Summary of 
sequencing data  
3,744,216 reads 
Term = 128 (192) 
Preterm = 81 (129) 
Beta diversity and 
abundance 
comparisons 
3,471,436 reads 
Term = 128 (192) 
Preterm = 81 (129) 
Alpha diversity 
analyses 
269,000 reads 
Term = 117 (161) 
Preterm = 68 (108) 
No preterm placenta 
available (N=145) 
Healthy term pregnancies 
not randomly selected for 
qPCR (N=1445) 
Samples not sequenced due to resource 
limitations 
 Raw reads filtered based on 
mock error rates and negative 
contaminants. Samples with 
<500 reads then removed 
 OTUs with <10 reads removed 
prior to VST normalisation 
 Samples rarefied 
to 1000 reads, 
samples with 
smaller read 
depth lost 
Figure 6.2 – Flow diagram documenting use and loss of samples (and sequencing reads) through process of PhD from clinical to final sequencing 
analyses. N total pregnancies (N total samples). 
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6.2.3 Quantitative polymerase chain reaction 
See section 2.2. 
6.2.4 16S rDNA amplicon high-throughput sequencing 
See section 2.3. 
6.2.5 Bioinformatic and statistical analyses 
Following filtering, as described in sections 3.3.2.1-3.3.2.4, any sample with less than 
500 reads was removed from the dataset. Taxonomic labels were assigned to the 
highest possible level using the QIIME pipeline. 64% of OTUs were assigned up to the 
level of genus, which accounted for 93% of filtered reads. Where OTUs of interest were 
identified, the representative sequence for this OTU was compared to the NCBI 
reference database, aiming to assign species level taxonomy to the group. Where a 
match of >97% to species in the NCBI database was observed, this was listed as the 
representative species for the OTU. Where there was ambiguity, a description only up 
until the level of genus was used. The Phyloseq v1.16.2 package in R was used to 
produce summary statistics, such as mean abundance by phyla or genera (McMurdie 
and Holmes, 2013). 
6.2.5.1 Differential abundance testing: Limma 
Differential abundance testing in microbiome datasets is often complicated by high 
variability in sampling sizes, i.e. read depths, and large numbers of zero counts. A 
number of different analytical strategies have been proposed to mitigate these issues. 
The majority of these build upon those developed for microarray and RNA-seq data. 
Most strategies involve some form of normalisation of count data to account for large 
variations in sampling depths, such as relative abundance or log transformation. There 
remains considerable debate regarding whether normalisation or rarefaction to even-
sampling depth is the best strategy to deal with the statistical challenges of these 
datasets (see McMurdie and Holmes (2014) for discussion).  
In this analysis, raw abundance data was normalised using the Variance Stabilizing 
Transformation (VST) approach in DESeq2 v1.12.4 (Love et al., 2014) within Phyloseq. 
These normalised data were then transformed into a Limma v3.28.21 (Ritchie et al., 
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2015) object to take advantage of the multi-level functions available in this package. 
The package was first developed to model microarray data but has since been extended 
for use with other experimental designs. In order to improve the chances of identifying 
significant associations, and minimise the number of tests carried out, any OTUs 
unassigned at the level of genus and with 10 reads or less were removed. Models were 
corrected for the potential confounding influences of delivery method, maternal 
ethnicity, collection hospital, maternal BMI, tissue type, and maternal smoking. All 
models were run with a random intercept to account for correlations between 
biological replicates. P-values were corrected for multiple testing using the Benjamini-
Hochberg procedure to produce Q values (Benjamini and Hochberg, 1995). OTUs were 
also merged to the level of genus and then models were re-run, to investigate genus, 
rather than OTU level, associations. 
6.2.5.2 Calculating beta diversity 
Three common methods for assessing distance or dissimilarity between samples or 
groups of samples are weighted UniFrac (Lozupone et al., 2007), unweighted UniFrac 
(Lozupone and Knight, 2005), and the Bray-Curtis dissimilarity metric (Bray and Curtis, 
1957). Bray-Curtis is a quantitative, non-phylogenetic metric that falls between 0 and 1. 
It describes the degree of dissimilarity between the taxonomic structures of two 
communities, based on differences in absolute abundances. By contrast, UniFrac was a 
measure developed recently, which quantifies difference between two groups based on 
phylogenetic data. The measure counts the fraction of branch lengths in a phylogenetic 
tree leading to members of one group or other, but not to both. Weighted UniFrac also 
incorporates differences in relative abundances of taxonomic groups into the summary 
statistic. 
Many approaches to using these methods suggest rarefying to an even sampling depth 
prior to calculating beta diversity. However, some have questioned the use of this 
technique given its requirement to remove data (McMurdie and Holmes, 2014). For 
beta diversity calculations, the VST normalised matrix was used. VST matrices can 
include negative values, which represent zero or very small original counts, and are not 
permitted by certain distance metrics. To mitigate this, any negative value was replaced 
with a zero, under the assumption that these cases were of very low, near zero 
abundance, and thus of negligible importance to the hypotheses under investigation. 
Following the computation of the three metrics, differences between the outcome 
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groups of interest were visually explored using Principal Coordinates Analysis (PCoA), 
a multidimensional scaling technique. The adonis function in the Vegan v2.4.1 package 
(Dixon, 2003) was used to quantify differences in beta diversity between outcomes of 
interest. Adonis uses a model analogous to multivariate analysis of variance 
(MANOVA), to assess how much variance in the beta diversity matrix can be explained 
by groups of interest. Significance tests are performed using F-tests, from 999 
permutations of the raw data. 
6.2.5.3 Calculating alpha diversity 
Alpha diversity was calculated using the Shannon diversity index (Shannon, 1948), a 
summary statistic incorporating both overall diversity and evenness within samples. In 
order to account for any bias introduced by sequencing depth, whilst retaining absolute 
abundance counts, samples were rarefied to 1000 reads, over 100 iterations. The mean 
Richness and Shannon indices were then calculated. Associations between Shannon 
values, as well as raw richness calculations, with pregnancy outcomes were then 
investigated, using a mixed effects multivariate linear regression model, with 
participant identifier as a random intercept. All models were adjusted for the fixed 
effects of delivery, ethnicity, BMI, smoking behaviour, and tissue type.   
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6.3 Results 
Following read and sample processing and filtering, 3,744,216 reads were retained, 
mapping to 298 unique biological samples from 215 pregnancies. A significant number 
of samples (N=96) were rejected during filtering, on account of low read depth (<500-
fold). The mean read depth per sample following filtering was 11660-fold 
(sd=28137.4) and the median was 2977-fold (range=501-239500).  
6.3.1 Read number and bacterial load 
It was of interest to explore whether the sequencing and qPCR datasets were 
associated in any quantifiable way. When log bacterial load was used to predict log 
read depth in the cohort, there was a significant positive correlation between the two 
(Spearman’s rank correlation coefficient=0.33, 95% CI=0.23-0.43, P=1.35E-9) (Figure 
6.3). With each 1 log increase in read number there was a 0.5 log (95% CI=0.34-0.66) 
increase in 16S copy number (P=1.35E-9). This observation shows that there is a semi-
quantitative component to sequencing output. It also suggests that those samples 
identified as most ‘highly infected’ by qPCR data, had the most amount of sequencing 
information retrieved from them.  
6.3.2 Summarising the ‘placental microbiome’ 
99.98% of reads matched to a taxonomic classification at the level of Phyla. The most 
abundant phylum recovered from all placental tissues was the Firmicutes, accounting 
for 70% of filtered reads. The distributions of the top 5 phyla recovered from placental 
tissue, accounting for 99% of reads, are described in Table 6.4. Trends in total load did 
not always mirror those relating to average abundance. For example, the Tenericutes 
had the third largest number of reads overall, but the 5th largest mean relative 
abundance. Whilst some samples were almost entirely made up of Firmicutes, 
Proteobacteria and Tenericutes, by contrast, Bacteroidetes and Actinobacteria never 
made up more than 38 or 76% of any one sample, respectively. Variation in individual 
placental sample composition is demonstrated using examples from four pregnancies 
in Figure 6.4. These plots also demonstrate the similarity in phylum level compositions 
across placental biological replicates taken from the same pregnancy. 
  165 
  
Figure 6.3 – Bacterial load is positively associated with the total read number from 
16S sequencing analysis. Individual samples with regression line and 95% confidence 
interval around the estimate are shown. 
 
 
 
Table 6.4 – Total read and relative abundance distributions across the top 5 phyla in 
order of total abundance. 
Phylum 
Total reads  
(% total) 
Mean (SD) 
total reads 
Median 
(range) 
total reads 
Mean (SD) 
% relative 
abundance 
Median (range) 
% relative 
abundance 
Firmicutes 
2631043 
(70.3) 
8196 
(26741) 
1072 
(2-239400) 
46.3 
(28.3) 
42.4 
(0.035-99.96) 
Proteobacteria 
500476 
(13.4) 
1559 
(4354) 
576 
(1-46670) 
29.4 
(25.0) 
24.3 
(0.0009-99.46) 
Tenericutes 
249100 
(6.7) 
776 
(6698) 
0 
(0-86120) 
3.0 
(12.8) 
0 
(0-99.17) 
Actinobacteria 
245924 
(6.6) 
766 
(1596) 
335 
(4-15840) 
16.3 
(13.9) 
13.5 
(0.0058-76.04) 
Bacteroidetes 
79814 
(2.1) 
249 
(1041) 
33 
(0-13770) 
3.3 
(6.0) 
0.74 
(0-37.37) 
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V1081 P202 P751
Figure 6.4 – Phylum level composition of individual placental biological replicate 
samples, taken from four different participants. P = parenchyma, V= villous. 
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92.8% of reads mapped to a genus using the QIIME pipeline. The distribution of the 
read counts for the top 10 genera were slightly different when ordered by total reads 
(Table 6.5) or mean relative abundance (Table 6.6). Most notably, Veillonella is the 
third most abundant genus in terms of total reads, but its mean relative abundance is 
only 1.02%, 12th in total. Similarly, Mycoplasma does not appear in Table 6.6, although 
it is the fifth most abundant genus in Table 6.5. The genera in Table 6.5 account for 
78.4% of total reads in the dataset. Whilst the first three genera In Table 6.5 
(Streptococcus, Lactobacillus, and Veillonella) represent almost 60% of total reads, the 
remaining genera in this dataset were of relatively low total abundance. The median 
number of reads in any genus was 284, but the highly skewed nature of the dataset 
meant the mean was significantly larger at 9001. This number was further reduced 
when individual OTUs were considered. The median number of reads in a single OTU, 
post filtering, was just 34, and the mean was 1266. Theoretically, OTUs in this dataset 
should approximate species level assignments, given the 97% similarity threshold used 
in OTU clustering. However, it is likely that phenomena such as sequencing artefacts 
and PCR error, lead to some inaccurate and redundant divisions in this dataset. Indeed, 
when comparisons of interest were made to the NCBI database, many unique OTUs 
mapped to the same species classifications.  
Another way of describing the taxonomic make-up of the placental microbiome in this 
cohort was to use rank abundance. The top 20 OTUs in Figure 6.5 were all present in 
over 25% of samples, demonstrating that a substantial number of OTUs were shared 
across a substantial proportion of samples. OTU 1098473, mapping to 
Propionibacterium acnes was present in 75% of samples. The observation of many 
shared OTUs across the dataset could be interpreted as providing support for the 
existence of a shared, unique placental microbiome as suggested by previous groups 
(Aagaard et al., 2014). However, it is worth noting that many of these shared OTUs map 
to taxa that are skin and vaginal commensals. This raises the alternative possibility that 
this signature may largely reflect delivery contamination, rather than the actual 
endogenous placental microbiome.  
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 Table 6.5 – Top 10 most abundant genera in order of total abundance.            Table 6.6 – Top 10 genera in order of mean relative abundance 
  
Genus 
Total reads 
(% total) 
Mean (SD) 
reads 
Median (range) 
reads 
Streptococcus 1074952 (28.7) 3349 (19433.3) 86 (0-239000) 
Lactobacillus 762789 (20.4) 2376 (10915.6) 35 (0-122900) 
Veillonella 393271 (10.5) 1225 (15340.5) 0 (0-200800) 
Staphylococcus 155937 (4.2) 486 (1539.6) 129 (0-20290) 
Ureaplasma 152502 (4.1) 475 (4943.2) 0 (0-86120) 
Mycoplasma 95334 (2.5) 298 (4499.9) 0 (0-79190) 
Erwinia 88754 (2.4) 277 (2804.3) 0 (0-34350) 
Corynebacterium 79269 (2.1) 247 (529.7) 100 (0-4615) 
Pseudomonas 71448 (1.9) 226 (2170.4) 3 (0-37870) 
Propionibacterium 60537 (1.6) 189 (483.1) 65 (0-5443) 
Genus 
Mean % 
relative 
abundance (SD) 
Median % relative 
abundance (range) 
Lactobacillus 16.15 (27.2) 1.1 (0-99.2) 
Streptococcus 11.27 (20.9) 3.1 (0-99.8) 
Staphylococcus 10.53 (15.0) 4.9 (0-79.7) 
Corynebacterium 6.75 (7.8) 3.7 (0-43.2) 
Propionibacterium 5.33 (7.2) 2.7 (0-60.6) 
Escherichia 4.9 (14.0) 0 (0-99.1) 
Acinetobacter 4.2 (11.3) 0.7 (0-96.5) 
Sphingomonas 4.1 (9.9) 0 (0-59.0) 
Pseudomonas 3.54 (10.6) 0.04 (0-98.7) 
Ureaplasma 2.56 (11.7) 0 (0-89.7) 
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Figure 6.5 – Rank abundance curve of the 
top 20 most widely abundant OTUs. 
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6.3.3 Delivery method is very influential for certain key genera 
Around half of the placental samples in the cohort contained reads mapping to the 
vaginal commensal species Lactobacillus crispatus (Figure 6.3). Given that 47% of 
deliveries in this cohort were vaginal, this observation warranted further exploration. 
In order to investigate the potentially significant contribution of delivery contaminants 
to sequencing results, the taxonomic make-up of vaginal and CS deliveries were 
compared graphically and statistically. 
Figure 6.6 combines the ten genera with highest mean relative abundance from CS 
deliveries with the ten highest from vaginal deliveries. Most of these genera were 
shared between CS and vaginal groups. However, when the mean relative abundances 
were compared between the two groups, there were some significant differences, most 
notably in the Lactobacilli distribution. Whilst in vaginal samples, the mean relative 
abundance of Lactobacilli spp. was over 0.25, in CS delivered placenta it was under 
0.05. When the relative abundances of all these 11 genera are compared between the 
two groups, using an independent two-sided T-test, 6 are significantly differentially 
abundant (Table 6.7). Two common vaginal genera, Ureaplasma and Lactobacilli were 
significantly more abundant in vaginal deliveries. By contrast, the common skin flora, 
Streptococci, Staphylococcus, Propionibacterium, and Corynecbacterium, were present at 
significantly higher abundance in CS samples. These observations confirm that certain 
highly abundant genera likely reflect delivery method, rather than endogenous 
colonisation. Controlling for delivery method is therefore critical in order to tease out 
any potential signals from organisms that may be associated with pregnancy outcome. 
For example, Ureaplasma spp. were enriched with vaginal deliveries. However, this is 
also an organism that has been previously implicated in intra-uterine infection and 
adverse outcomes.  
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Table 6.7 – Difference in mean relative abundance of the 11 CS and vaginal genera 
with highest mean relative abundances. Student’s T-test and two-sided test for 
significance used for comparison of means (*<0.05).  
Genus 
Difference in % relative 
abundance (CS-vaginal) 
T P 
Streptococcus 10.38 3.67 3.24E-04* 
Staphylococcus 5.65 2.88 4.42E-03* 
Propionibacterium 3.15 4.05 7.45E-05* 
Pseudomonas 2.48 1.66 9.80E-02 
Corynebacterium 2.37 2.42 1.63E-02* 
Tepidimonas 1.01 1.52 1.30E-01 
Sphingomonas 0.67 0.58 5.64E-01 
Escherichia 0.47 0.37 7.14E-01 
Acinetobacter -0.69 -0.49 6.24E-01 
Ureaplasma -2.48 -2.47 1.45E-02* 
Lactobacillus -23.9 -8.59 3.57E-15* 
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Figure 6.6 – The top 10 genera from CS (red) and vaginal (blue) deliveries with 
highest mean relative abundance. Genera were combined to form 11 unique groups and 
the mean relative abundances between the two groups were compared. Error bars show 
95% CI around the mean. 
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6.3.4 Differential abundance analyses with outcomes of interest 
Following further filtering and transformation, as outlined in Section 6.2.5.1, OTUs 
from 249 identified genera were retained, and their relative abundances compared 
between the three pregnancy outcome groups. Multi-level models were first run 
unadjusted. Models were then run again with adjustment for fixed level potential 
confounders. 
6.3.4.1 Differentially abundant OTUs and delivery method 
When OTU abundances were compared between vaginally and CS delivered placenta, of 
the top 46 most differentially abundant OTUs (P<0.01), 30 mapped to Lactobacilli spp. 
(see Appendix Table A 16, page 261). These data provide further support for the 
observations discussed in section 6.3.3. 
6.3.4.2 Identification of taxa enriched in sPTB placental samples 
The primary hypothesis of this study was that certain organisms would be 
differentially abundant in placental tissue, according to pregnancy outcome. 
Specifically, it was hypothesised that an overgrowth or colonisation of particular 
organisms would lead to a pathogenic inflammatory response, followed by early birth. 
Therefore, it was important to identify organisms present at higher abundances in the 
placental tissue of sPTB pregnancies, compared to term or nsPTB pregnancies. It is 
possible that certain placental organisms are protective against sPTB and would 
therefore be less abundant in sPTB placenta, perhaps equivalent to the role of 
Lactobacilli in vaginal health. However, this hypothesis will not be explored here. In 
order to explore both higher and lower levels of taxonomic assignment, differential 
abundance testing was carried out at the OTU and genus level. Comparisons were made 
between sPTB placenta and nsPTB placenta, as well as sPTB and term placenta. 
6.3.4.2.1 Unadjusted models 
Table 6.8 lists those genera that were found to be at a greater abundance in sPTB 
placenta (P<0.01). As will be discussed below, a number of these genera, such as 
Ureaplasma and Mycoplasma, have been consistently associated with adverse 
pregnancy outcomes in previous studies. Others, such as Tepidimonas, have not. 
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Table 6.8 – Genera enriched in sPTB placenta using an unadjusted model, P<0.01. 
Genera enriched versus nsPTB Genera enriched versus term 
Ureaplasma Tepidimonas 
Mycoplasma Mycoplasma 
Salinicoccus Salinicoccus 
Prevotella Capnocytophaga 
Bilophila Erwinia 
 
Bilophila 
 
Finegoldia 
 
Neisseria 
 
Sneathia 
 
Coprobacillus 
 
Phenylobacterium 
 
Actinobaculum 
 
6.3.4.2.2 Enriched OTUs and genera in sPTB versus nsPTB placenta 
All OTUs with higher abundance in sPTB versus nsPTB placental tissue, and with a 
P<0.01 after adjustment for confounders, are listed in Table 6.9. When this comparison 
was repeated at the level of genus, Ureaplasma, Mycoplasma, and Capnocytophaga were 
found to be at a significantly higher abundance at a threshold of P<0.01 (Table 6.10). It 
is important to note that when P-values were adjusted using FDR, none of the 
comparisons fell below the widely used threshold of Q<0.1. This may to some extent 
reflect the large number of tests carried out in these comparisons. When only 
parenchyma tissue was considered, only Capnocytophaga was higher in sPTB versus 
nsPTB placenta and had a P<0.01 (data not shown).  
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Table 6.9 – OTUs enriched in sPTB vs nsPTB placenta with P<0.01 using an 
unadjusted Limma model. 
OTU Genus 
Species from 
NCBI BLAST 
Log2 fold change  
(95% CI) 
P Q 
884685 Finegoldia - 0.24 (0.06-0.43) 0.0093 0.41 
518865 Fusobacterium nucleatum 0.2 (0.06-0.34) 0.00469 0.34 
531206 Mogibacterium - 0.46 (0.12-0.8) 0.00791 0.41 
317108 Mycoplasma hominis 0.83 (0.31-1.35) 0.00197 0.27 
548556 Mycoplasma hominis 1.03 (0.35-1.7) 0.00326 0.33 
573950 Mycoplasma hominis 0.32 (0.08-0.55) 0.00779 0.41 
575236 Mycoplasma hominis 0.65 (0.23-1.06) 0.00253 0.31 
594001 Mycoplasma hominis 0.5 (0.2-0.79) 0.00102 0.27 
OTU4796 Mycoplasma hominis 0.2 (0.06-0.34) 0.00427 0.33 
OTU47 Mycoplasma hominis 0.56 (0.17-0.95) 0.00546 0.38 
NROTU83 Mycoplasma hominis 0.33 (0.08-0.58) 0.00886 0.41 
183158 Peptoniphilus - 0.25 (0.09-0.4) 0.00194 0.27 
4332287 Streptococcus sanguinis 0.35 (0.15-0.56) 0.0008 0.27 
15806 Ureaplasma 
parvum/ 
urealyticum 
1.99 (0.86-3.12) 0.00064 0.27 
 
Table 6.10 – Genera enriched in sPTB vs nsPTB placenta with P<0.01 using an 
unadjusted Limma model. 
 
6.3.4.2.3 Enriched OTUs and genera in sPTB versus term placenta  
When OTU abundance was compared between sPTB and term delivered placenta, 47 
OTUs were more abundant in the sPTB cohort with a P<0.01 (Table 6.11). As seen 
above, many of these OTUs had duplicate species assignments. For example, 5 OTUs 
mapping to Mycoplasma hominis assignments were significantly enriched in sPTB 
placenta. This repetition may reflect the presence of a number of different sub-species 
within the placenta, or redundancy in the OTU clustering method used. 
 
Genus 
Log2 fold change 
(95% CI) 
P Q 
Ureaplasma 2.4 (0.96-3.85) 0.0012 0.25 
Mycoplasma 1.58 (0.58-2.59) 0.0022 0.25 
Capnocytophaga 0.6 (0.2-0.99) 0.0031 0.25 
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Table 6.11 – OTUs enriched in sPTB versus term placenta following adjustment, 
P<0.01. 
OTU Genus 
Species 
from NCBI 
BLAST 
Log2 fold change 
(95% CI) 
P Q 
574249 Actinobaculum schaalii 0.32 (0.09-0.56) 0.00603 0.19 
1077793 Alloiococcus - 0.45 (0.19-0.7) 0.00065 0.12 
419366 Anaerococcus - 0.37 (0.09-0.65) 0.0097 0.24 
503387 Anaerococcus - 0.31 (0.1-0.52) 0.0036 0.15 
1002634 Anaerococcus - 0.2 (0.05-0.35) 0.00798 0.21 
276484 Bacteroides - 0.13 (0.04-0.23) 0.00427 0.16 
2066505 Bacteroides - 0.09 (0.03-0.15) 0.00285 0.13 
2283111 Bacteroides uniformis 0.1 (0.04-0.15) 0.0009 0.12 
360660 Blautia - 0.26 (0.12-0.4) 0.0003 0.12 
NCROTU4734 Blautia - 0.13 (0.04-0.22) 0.00648 0.19 
71957 Capnocytophaga - 0.21 (0.07-0.35) 0.00438 0.16 
1010329 Capnocytophaga gingivalis 0.45 (0.18-0.72) 0.00111 0.12 
4354247 Capnocytophaga - 0.15 (0.05-0.25) 0.00528 0.18 
NCROTU55 Capnocytophaga - 0.19 (0.06-0.32) 0.00432 0.16 
189459 Clostridium - 0.23 (0.11-0.36) 0.00036 0.12 
369763 Coprobacillus - 0.14 (0.05-0.23) 0.00222 0.12 
308983 Coprococcus - 0.15 (0.06-0.25) 0.00217 0.12 
977739 Corynebacterium - 0.15 (0.04-0.25) 0.00628 0.19 
1010113 Erwinia - 0.29 (0.1-0.48) 0.0025 0.12 
317108 Mycoplasma hominis 0.67 (0.25-1.08) 0.00189 0.12 
548556 Mycoplasma hominis 0.89 (0.35-1.44) 0.00133 0.12 
575236 Mycoplasma hominis 0.5 (0.17-0.83) 0.00336 0.15 
NCROTU4796 Mycoplasma hominis 0.15 (0.04-0.26) 0.00855 0.22 
NROTU47 Mycoplasma hominis 0.46 (0.15-0.77) 0.00427 0.16 
364341 Oscillospira - 0.16 (0.06-0.26) 0.00216 0.12 
548692 Oscillospira - 0.14 (0.05-0.22) 0.0022 0.12 
291090 Parabacteroides - 0.09 (0.03-0.15) 0.00244 0.12 
254401 Phenylobacterium - 0.08 (0.02-0.14) 0.00623 0.19 
262857 Salinicoccus - 0.32 (0.13-0.5) 0.00099 0.12 
931528 Sporobacterium - 0.11 (0.03-0.18) 0.00545 0.18 
526131 Streptococcus pneumonia 0.45 (0.18-0.72) 0.00101 0.12 
859700 Streptococcus - 0.5 (0.19-0.81) 0.0016 0.12 
942927 Streptococcus - 0.38 (0.19-0.58) 0.00016 0.12 
983335 Streptococcus - 0.52 (0.21-0.84) 0.00121 0.12 
986708 Streptococcus sanguinis 0.23 (0.09-0.38) 0.00207 0.12 
996434 Streptococcus - 0.51 (0.2-0.82) 0.00141 0.12 
1023716 Streptococcus oralis/mitis 0.3 (0.1-0.5) 0.00405 0.16 
1061897 Streptococcus - 0.57 (0.21-0.93) 0.00196 0.12 
1078207 Streptococcus - 0.37 (0.1-0.65) 0.00766 0.2 
4295788 Streptococcus sanguinis 0.19 (0.05-0.33) 0.00726 0.2 
4321400 Streptococcus pneumonia 0.52 (0.22-0.83) 0.00092 0.12 
4332287 Streptococcus sanguinis 0.28 (0.11-0.44) 0.001 0.12 
4433192 Streptococcus - 0.31 (0.09-0.53) 0.00545 0.18 
189076 Sutterella - 0.13 (0.05-0.22) 0.00278 0.13 
697479 Tepidimonas aquatica 1.73 (0.74-2.71) 0.00066 0.12 
15806 Ureaplasma 
parvum/ 
urealyticum 
1.24 (0.34-2.14) 0.0073 0.2 
676611 Ureaplasma 
parvum/ 
urealyticum 
0.23 (0.07-0.39) 0.00466 0.16 
 
 
  176 
Table 6.12 – Genera enriched in sPTB vs term placenta following adjustment, P<0.01. 
Genus Log2 fold change (95% CI) P Q 
Capnocytophaga* 0.67 (0.36-0.99) 3.73E-05 0.01 
Tepidimonas* 2.42 (1.26-3.58) 5.44E-05 0.01 
Salinicoccus* 0.36 (0.13-0.6) 2.40E-03 0.17 
Coprobacillus* 0.12 (0.04-0.2) 2.68E-03 0.17 
Mycoplasma 1.17 (0.37-1.98) 4.42E-03 0.22 
Bilophila* 0.15 (0.04-0.25) 5.92E-03 0.25 
Erwinia* 1.2 (0.32-2.08) 7.71E-03 0.25 
Actinobaculum* 0.34 (0.08-0.6) 9.99E-03 0.25 
*also <0.01 in parenchyma only analysis 
The majority of OTUs and genera groupings did not reach statistical significance, once 
adjusted for multiple testing. However, a number of the associations were with taxa 
that have previously been associated with sPTB, such as Mycoplasma spp. and 
Ureaplasma spp. The observation that certain associations replicated previous findings 
in the field served to support the reliability of our data, even if significance was lost 
following adjustment for multiple testing. Therefore, it was considered reasonable to 
further explore the nature of the organisms associated with sPTB across all the tests 
carried out. To do this, the characteristics of genera associated with sPTB via the OTU 
or genus level analyses at a significance of P<0.01 were investigated further. The core 
habitats of these 26 genera of interest, and relevant references for their involvement in 
adverse pregnancy outcomes, are summarised in Table 6.13.  
The associations identified via these analyses could reflect both widespread differences 
in abundance, which are largely consistent between groups, or less common ‘outlying’ 
cases of extreme and highly abundant infections. To explore the nature of these 
associations further, genus relative abundances were calculated for individual 
pregnancies, by pooling biological replicates into one sample. Plots were then 
constructed with relative abundance on the Y-axis and pregnancies on the X-axis. 
Separate plots for sPTB, term, and nsPTB cases were compared in order to visually 
explore if abundance patterns were largely consistent across groups, or associations 
were mainly driven by individual, influential cases (see Appendix Figure A 1 – A 3 
pages 262-264 for all plots).  
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Table 6.13 – Normal habitat and relevant references relating to PTB for all genera enriched in sPTB placenta in our cohort with P <0.01 in either 
OTU or genus level analyses.  
Phylum Genus Species isolated from human… Previous associations with preterm birth 
Actinobacteria 
 
Actinobaculum Blood, urine, oral cavity  
Corynebacterium Oral cavity, mucosa and skin Oh et al. (2010) 
Bacteroidetes 
 
Bacteroides Vagina, mouth, gastro-intestinal tract Jones et al. (2009), (Han et al., 2009) 
Capnocytophaga Oral cavity Ernest and Wasilauskas (1985), (Lopez et al., 2010a) 
Parabacteroides Faeces  
Firmicutes 
 
Alloiococcus  Vagina, oral cavity, auditory canal  
Anaerococcus Vagina, oral cavity, preterm gut, skin  
Blautia Gastro-intestinal, preterm gut  
Clostridium Vagina, gastro-intestinal  
Coprobacillus Gastro-intestinal DiGiulio et al. (2010) 
Coprococcus Gastro-intestinal  
Finegoldia Vagina, oral cavity, and skin  
Mogibacterium Oral cavity  
Oscillospira Gastro-intestinal  
Peptoniphilus Vagina, mouth, gastro-intestinal Jones et al. (2009), (Wang et al., 2013) 
Salinicoccus -  
Sporobacterium -  
Streptococcus Vagina, mouth, skin, gastro-intestinal (Jones et al., 2009, Oh et al., 2010) 
Fusobacteria Fusobacterium Oral cavity 
Combs et al. (2014); DiGiulio et al. (2010); Gardella et al. (2004); Han et al. (2009); Jones et 
al. (2009); Wang et al. (2013) 
 
Bilophila Faeces, oral cavity, vagina  
Erwinia Meconium  
Phenylobacterium -  
Sutterella Vagina, gastro-intestinal Ollberding et al. (2016) 
Tepidimonas -  
Tenericutes 
Mycoplasma Vagina, oral cavity 
DiGiulio et al. (2010); Hitti et al. (1997); Han et al. (2009); Jones et al. (2009); Marconi et al. 
(2011); Onderdonk et al. (2008a); Wang et al. (2013) 
Ureaplasma Vagina 
Combs et al. (2014); DiGiulio et al. (2010); Han et al. (2009); Jalava et al. (1996); Jones et al. 
(2009); Wang et al. (2013) 
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Figure 6.7 shows a selection of these individual pregnancy plots, demonstrating 
patterns of interest. Erwinia, Fusobacteria, and Mycoplasma were all consistently 
identified as being at higher abundance in sPTB cases compared to the other groups, 
using Limma regression models. It is clear from the plots that these associations were 
driven almost entirely by 5 pregnancies in which the majority of reads mapped to these 
three genera. This observation supports a scenario in which a single organism came to 
dominate the placenta of these specific pregnancies, potentially triggering the sPTB 
event. For these three organisms, little evidence of their presence in term or nsPTB 
placenta was found. This picture is not so clear for other genera, which tended to be 
more consistently present across samples, generally at lower abundances.  
Ureaplasma enrichment within sPTB placental tissue was more apparent in statistical 
comparisons with nsPTB, as opposed to term placenta. A substantial number of term 
placenta had a high abundance of Ureaplasma, as did a number of sPTB births. 
However, only one read from Ureaplasma mapped to nsPTB placenta. Since Ureaplasma 
is a common vaginal organism, and a lower proportion of nsPTB deliveries were 
vaginal, this may account for at least some of this observed pattern. The distributions of 
reads mapping to other genera that were at higher abundances in sPTB placenta, such 
as Peptoniphilus, Capnocytophaga, and Finegoldia, were also not as exclusively 
concentrated in those of the sPTB group, as the first three genera discussed. These 
genera were generally found at lower abundances (<10%), but in a larger number of 
individual placentas.  
6.3.4.3 Cervical suture 
Only 11 samples were available with cervical suture data, following filtering. Therefore, 
an investigation of the types of organisms present in placenta following cervical suture, 
was not carried out within the sequencing cohort. 
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Figure 6.7 – Abundance (%) of total reads in placentas from individual pregnancies for 6 genera of interest. A) sPTB placenta B) Term delivered placenta 
C) nsPTB placenta. 
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6.3.5 Between sample (beta) diversity 
Weighted UniFrac, unweighted UniFrac, and Bray-Curtis distance matrices were 
produced from the data to estimate beta diversity. Distances were then plotted using 
PCoA to visualise the first two axes. They were coloured by pregnancy outcome (Figure 
6.8). Samples did not clearly cluster by pregnancy outcome with any of the methods 
used. Therefore, in order to explore the distance matrices in a quantitative manner, 
which may be more sensitive to underlying patterns, beta diversity was compared 
between groups in both adjusted and unadjusted analyses using adonis.  
Adonis does not allow for the addition of a random intercept to make a multi-level 
model. As a result, using all samples at once would not account for likely correlations 
between biological replicates. Therefore, two analysis designs were used. The first used 
all samples with the knowledge that there might be a higher false positive rate. The 
second merged all biological replicates from individual pregnancies together, 
producing a more conservative estimate of associations. 
Results from all 12 adjusted and unadjusted tests produced very similar R2 values, all of 
which were significant at P=0.001 (Table 6.14). Despite this significance, it is clear that 
only a very small proportion of the variance between samples (~2%) is accounted for 
by the three outcome groups of interest: nsPTB, sPTB, and term delivery. It is 
reasonable to conclude that these very subtle differences in overall taxonomic 
composition are unlikely to be clinically relevant. Evidence from these analyses does 
not support the existence of a meaningful ‘preterm placental microbiome’.  
Table 6.14 – R2 values for comparisons of three diversity metrics between three 
groups of interest (sPTB, nsPTB, term) for adjusted and unadjusted models using all 
samples or data merged for individual pregnancies. 
*P=0.001 
Beta diversity 
metric 
All samples (R2) Participant level (R2) 
Unadjusted 3 
group model 
Adjusted 3 
group model 
Unadjusted 3 
group model 
Adjusted 3 
group model 
Weighted UniFrac 0.019* 0.017* 0.0021* 0.022* 
Unweighted 
UniFrac 
0.015* 0.017* 0.0016* 0.018* 
Bray-Curtis 0.018* 0.021* 0.0018* 0.020* 
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Figure 6.8 – PCoA plot of first two axes from A) weighted UniFrac; B) unweighted UniFrac; C) Bray-Curtis distances using VST normalised counts 
of all samples in the cohort.  
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6.3.6 Within sample (alpha) diversity 
Within sample, alpha diversity can be quantified using a number of indices. These tend 
to calculate a score based on the total number of species/OTUs present within a sample 
(richness), and, sometimes, evenness of read distributions between these groups. Table 
6.15 summarises estimates of Richness and Shannon indices across a subset of the 
whole cohort, rarefied to 1000 reads and averaged over 100 iterations. A total of 
269/321 samples were retained after rarefaction. The mean number of OTUs in any 
one sample was 48.5. As discussed above, this is likely to be an inflation of the true 
species richness within samples. This potential inflation is a result of errors in the 
experimental and computational processes that create these sequencing cohorts, which 
serve to introduce false variation into the nucleotide sequences. 
Table 6.15 – Summary of Shannon diversity and total richness estimates for whole 
cohort. 
Index Mean (SD) Median (IQR) Range 
Shannon index 2.3 (0.95) 2.5 (1.7-3.0) 0.05-4.5 
Total richness 48.5 (25.4) 43.6 (31.7-48.5) 5.1-169.2 
 
As demonstrated in Figure 6.7, placental infection within certain sPTB samples 
appeared to be driven by growth of a single organism. It follows that placenta with 
more significant infections, as reflected by higher bacterial loads, may then have lower 
alpha diversity measures. To explore this, total bacterial load (see Chapter 5), was 
plotted against the Shannon index for each individual sample. The Shannon index 
increases with the increasing evenness and richness of a community.  
Figure 6.9 shows that as 16S load increases, mean Shannon index decreases. This 
implies that a larger bacterial presence in placental tissue is associated with a 
reduction in alpha diversity. This reduction in diversity is both in terms of evenness 
and richness. This scenario could be interpreted as an expansion of one organism at the 
expense of many others. When a linear regression model is fitted to this relationship, 
for every 1 increase in 16S copy number, there is a -0.24 reduction in Shannon index 
(P=0.00017). A similar, significant observation was noted when Simpsons index was 
used instead of Shannon in this model (data not shown). No relationship was observed 
when mean richness was used instead of the Shannon value. 
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Figure 6.9 – The mean Shannon index reduces with increasing bacterial load in 
placental tissue from a rarefied cohort. 
 
6.3.6.1 Alpha diversity and pregnancy outcome 
To investigate associations between alpha diversity and pregnancy outcome, multi-
level regression models were run, with participant as a random intercept. If a 
significant proportion of infectious mediated preterm births within the cohort were 
driven by overgrowth of a single, or a small number of species, it would be reasonable 
to hypothesise that sPTB may be associated with a reduction in alpha diversity. 
However, no significant difference was observed in the mean Shannon diversity index 
between sPTB and nsPTB (P=0.53, adjusted model), or between sPTB and term 
(P=0.14, adjusted model) placenta, in univariate analyses, as well as those adjusted for 
the potential effects of delivery method, ethnicity, BMI, smoking, and tissue type. There 
was also no association observed when mean richness was the outcome (P=0.29, 
P=0.39, for adjusted comparisons between sPTB and nsPTB or term placenta, 
respectively). Delivery method was not associated with any difference in Shannon 
diversity (P=0.96, adjusted model) or total richness (P=0.1, adjusted model). 
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6.4 Discussion 
This study has shown that bacterial DNA from a wide variety of organisms was present 
in the placenta of both normal and complicated pregnancies. In order to understand the 
clinical significance of such observations, identifying where the sequenced DNA 
originates from is critical. This will facilitate the development of clinical interventions 
to mitigate the adverse impacts of infection during pregnancy. From the analyses 
conducted in this chapter, it is clear that delivery method contributed significantly to 
the taxonomic composition of the sequenced placental samples. Nevertheless, a 
number of organisms were clearly enriched within sPTB placental samples, 
independently of mode of delivery.  
Analyses focusing on diversity metrics also identified some associations of interest. 
Shannon diversity was negatively associated with bacterial load, implying that those 
placental samples that were most ‘infected’, were also less diverse and less evenly 
colonised. This perhaps represents overgrowth of a single or small number of species 
in a small number of extreme cases. Despite this, alpha diversity did not associate with 
pregnancy outcome specifically, and beta diversity measures differed minimally 
between groups. These observations together, imply that it is largely in the presence of 
single or small numbers of organisms of interest that risk of sPTB is increased. 
Evidence for the existence of a shared ‘preterm placental microbiome’ was less 
conclusive. A summary of the key findings from this chapter are as follows: 
1. The majority of organisms recovered from the placenta were assigned to five phyla: 
Firmicutes, Proteobacteria, Tenericutes, Bacteroidetes and Actinobacteria. 
2. Relative abundances of some of the most prevalent genera varied by delivery 
method. Vaginally delivered placenta were dominated by Lactobacilli spp. and CS 
deliveries by common skin commensals. 
3. A number of OTUs and genera were consistently enriched in sPTB placenta, some of 
which are well known organisms hypothesised to be involved in sPTB, although few 
reached statistical significance when adjusted for multiple testing.  
4. For some enriched organisms, the associations appear to be largely driven by highly 
infected, ‘outlying’ placental infections of single pregnancies. 
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5. Using three measures of beta diversity, the placental microbiome did not cluster by 
outcome group. Although statistical tests of difference were significant, the proportion 
of variance accounted for by the model was very low (<2%) and thus assumed to be of 
limited clinical significance. 
6. With increasing bacterial load, evenness and richness was reduced within samples, 
as quantified by the Shannon index. 
7. Alpha diversity did not associate with the pregnancy outcomes of interest. 
Aagaard et al (2014) described a somewhat similar high-level taxonomic community in 
their microbiome analysis of placental parenchyma samples as those found in this 
study. Three of the top four most abundant phyla in their study were in the top five 
most abundant in this cohort (Bacteroidetes, Firmicutes, and Tenericutes). The five most 
abundant phyla found in our cohort contain many well-known human commensals, 
from the gut, to the skin, oral, and vaginal microbiomes (Huttenhower et al., 2012).  
Many of the organisms recovered from our placental samples are also known vaginal 
and skin commensals, such as Lactobacilli and Corynebacterium spp. respectively. It 
was shown that some of these most abundant organisms did associate strongly with 
delivery method. These patterns were also observed in parenchyma tissue, which was 
collected from beneath the protective fetal membrane. Similar observations were 
drawn from villous samples that were analysed separately. Given the hypothesis that at 
least some intra-uterine colonisation will be the result of ascending vaginal infection, it 
would be overly conservative to label all vaginal species, or indeed all skin-associated 
organisms, as delivery contaminants. Indeed, none of the delivery-associated 
organisms were exclusive to one or other delivery type. However, these associations do 
make it difficult to describe conclusively a placental microbiome, which is distinct from 
the ‘delivery microbiome’. Further, the observation of a low-level, relatively diverse 
placental microbial signature is supported by other recent molecular studies working 
in the same tissues (Doyle et al., 2014, Jones et al., 2009, Aagaard et al., 2014). 
The most powerful observations from this cohort surround comparisons of normalised 
abundances of OTU and genus level counts, between sPTB and other pregnancy 
outcomes. The most significantly enriched genera and OTUs were, in large part, 
organisms previously associated with adverse pregnancy outcomes. Although few of 
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these associations survived conservative cut-offs following multiple correction. Some, 
such as Mycoplasma, Ureaplasma, and Fusobacteria spp., have been known as 
opportunistic intra-uterine pathogens for decades (Combs et al., 2014, DiGiulio, 2012, 
Jones et al., 2009, Hitti et al., 1997). Others, such as Capnocytophaga, are less well 
studied with respect to sPTB pathogenesis. Interestingly, the organisms that associated 
with sPTB in the Aagaard et al. (2014) study, such as Burkholderia spp., did not overlap 
with those found here. A smaller study describing the placental membrane microbiome 
from preterm and term pregnancies reported results that were much more similar to 
our own (Doyle et al., 2014). For example Fusobacteria, Mycoplasma, and Ureaplasma 
spp. were also enriched in their vaginally delivered sPTB samples, when compared to 
term placenta. 
There was a notable prevalence of oral bacteria in the organisms enriched in sPTB 
placenta within this cohort. These associations contribute to a growing body of 
research supporting a link between organisms isolated from the placental and the oral 
cavities. These associations are supported by both human and animal data. Han et al. 
(2004) injected F. nucleatum into the tail of pregnant mice, ultimately inducing preterm 
delivery and fetal loss. These live F. nucleatum cells were found to have proliferated 
within uterine tissues examined from these animals, but they did not persist in other 
organs such as the spleen or liver. As previously discussed, Aagaard et al. (2014) also 
reported a significant overlap of their data with the oral rather than vaginal HMP 
dataset. Indeed, from our data it was clear that at least one sPTB placenta was 
significantly infected with Fusobacterium spp. This was a relatively early, 29th week 
delivery by CS, in which the infant was admitted to intensive care. This type of single 
organism overgrowth, in which a very large proportion of reads mapped to a single 
genus, was also observed in at least two other instances for Mycoplasma hominis and, 
curiously, OTUs mapping to the Erwinia genus. Erwinia spp. were present in four 
placental samples from the same pregnancy (two technical replicates of parenchyma, 
one more parenchyma biological replicate, and one villous sample) at between 86 and 
89% abundance. The abundances were very similar between all four samples from the 
same pregnancy, demonstrating the robustness of this observation. Furthermore, the 
placenta was taken from a very early vaginal birth at 24 weeks: this infant also went to 
the NICU. Erwinia species have not been previously associated with sPTB. Indeed it is a 
genus of bacteria containing mostly plant pathogens, which makes this observation 
somewhat unexpected. However, it has previously been isolated and cultured from 
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meconium samples from a number of very preterm neonates (Moles et al., 2013). This 
unexpected but interesting association therefore requires further exploration.  
Capnocytophaga, was present across a number of samples at a relatively low total 
abundance, when compared to genera such as Mycoplasma. However, it was one of the 
two genera that remained significantly associated with sPTB placenta following 
adjustment for multiple testing. This anaerobic organism is usually isolated from the 
oral cavity, and rarely the genital tract. Capnocytophaga infections tend to be most 
commonly reported in immunocompromised children and are known to be involved in 
periodontitis (Campbell and Edwards, 1991). The genus has been previously associated 
with intra-uterine infection in a handful of publications (Douvier et al., 1999, Lopez et 
al., 2010b, Hill, 1998). In a recent review of the literature, Lopez et al. (2010b) 
identified a total of 19 reported cases of Capnocytophaga infection of the amniotic 
cavity and/or a preterm infant and concluded that: 
‘Infection with Capnocytophaga sp. is therefore probably an underestimated 
aetiology of occult chorioamnionitis and preterm delivery leading to neonatal 
infection.’ 
 
Capnocytophaga’s occasional, but independently reported, associations with adverse 
pregnancy outcomes, as well as its status as an oral opportunistic pathogen, provide 
support for its association with sPTB in our cohort. Furthermore, it is often in 
immunocompromised patients that infections of this organism take hold. This is 
interesting, considering the immuno-suppressed state of pregnancy. Taken together, 
this may well be a promising and underappreciated candidate for placental mediated 
sPTB pathogenesis. Capnocytophaga was also isolated from one nsPTB placenta in our 
cohort. The infant associated with this placenta was delivered by CS at 29 weeks. It was 
significantly growth restricted, with a birthweight of only 634g, and was admitted to 
intensive care. This mother had previously delivered another preterm infant. Whether 
this Capnocytophaga infection contributed in some way to the fetal growth of this 
infant is worthy of further exploration. 
The significant enrichment of Tepidimonas within sPTB versus term placenta, and its 
particularly high log2 fold change value, is perhaps the most enigmatic result from 
these analyses. Over 12,000 reads mapped to 5 Tepidimonas labelled OTUs. This was 
found across all outcome groups and many individual pregnancies. A literature search 
for publications relating to human infections and Tepidimonas spp. revealed only one 
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case, where there was a bone marrow infection in a leukemia patient (Ko et al., 2005). 
This lack of previous human associated evidence questions the validity of the 
widespread presence of this genus in our cohort. This genus was first described as an 
isolate from a hot spring in central Portugal (Moreira et al., 2000). Thus this 
observation may be a false positive association between outcome and a contaminating 
genus that is specific to our cohort.  
Bacteroides, Peptoniphilus, Streptococcus, and Suterella species were some of the most 
significantly enriched genera and OTUs within our sPTB cohort. These genera have also 
previously been associated with preterm birth (Combs et al., 2014, Wang et al., 2013, 
Hitti et al., 1997). In one sample with a particularly high Peptoniphilus abundance, 
reads mapping to Sneathia, another well-known sPTB associated organism, made up 
over 25% of total reads. Some genera, such as Mogibacterium and Finegoldia contain 
oral and vaginal species respectively, with the former notably associated with 
periodontitis and the latter with BV (Nakazawa et al., 2000, MacIntyre et al., 2015). 
These initial associations require further exploration for validation.  
These data support the notion that certain bacteria, when present in the placenta, may 
contribute to an inflammatory response and a subsequent preterm delivery. However, 
the data do not support the existence of a ‘unique preterm microbiome’ in terms of a 
structured community, which is shared amongst this particular obstetric group, and 
distinguishable from other outcome groups. This interpretation is supported both by 
the graphical ordination of the beta diversity data, and the quantitative statistical tests 
that were conducted. Although the P-value of all adonis tests could lead us to reject the 
null hypothesis of no difference in community structure between groups, only around 
2% of variation in the beta diversity matrices was ever accounted for by these 
groupings. This is a very small proportion and unlikely to be of clinical relevance. Given 
the data at hand, it is reasonable to assert that the high-level community structure of 
the placental microbiome in this cohort is not significantly associated with pregnancy 
outcome.  
There were a number of limitations to this study. The first was that we were unable to 
sequence the whole cohort for which qPCR data were available, necessarily limiting 
power to identify all associations of interest. This will hopefully be addressed in the 
future when more resources become available. Despite this, our study provides one of 
the largest cohorts of 16S sequenced placental tissue from sPTBs in the literature. 
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Furthermore, some of these cases were delivered at extremely low GAs, making this a 
particularly valuable and rare sample set.  
A further limitation of this study was that some clinical categories of interest, such as 
delivery method or maternal smoking status, were incomplete. This limited the size of 
some of the final adjusted models. It would also have been of interest to examine the 
association of microbiome profiles with the well-known clinical phenotype of 
chorioamnionitis, but this data was unavailable in the BBB clinical records. In the 
future it would also be of great interest to collect parallel samples from other maternal 
body sites. This could help to identify the origins of organisms of interest.  
Sequencing a tissue of low biomass is a challenge for reasons discussed throughout this 
PhD. Those microbiome studies focusing on tissues of high biomass, such as the vagina, 
oral cavity, or intestine, produce 16S sequencing outputs of even and high per-sample 
read depth. This was not the case for our placental cohort. Although for some samples 
very large numbers of reads were procured, the likely underlying variation in starting 
material within this tissue meant that normalisation of template amount was a 
particular challenge for this cohort. As a result, very few reads were produced for 
certain samples and there was a very wide range of sequencing depths across the 
cohort. This presented challenges for statistical interpretation of the data, which were 
met via normalisation methods originally designed for RNA-seq and micro-array data. 
Additionally, 73 samples (19%) were discarded during the filtering process, as their 
read depth, following filtering, was not considered sufficient to be representative of the 
entire diversity of the population sampled. The development of techniques, some of 
which are already starting to be used in which microbial DNA enrichment precedes 
sequencing, will be a powerful improvement in future studies.  
The dissection and extraction procedures for this study were carried out using 
rigorously controlled, sterile procedures. However, the samples were not originally 
collected with the intention to be used in microbial analyses. Placenta were not 
collected under strictly sterile conditions and it is acknowledged that this may limit the 
reliability of observations noted here. Similarly, the storage and cleaning reagents, 
RNAlater and PBS, which were used by the collection team were not available to use as 
comparative sequencing controls, in the same way that extraction reagents were. 
Perhaps this explains the unexpected associations with genera such as Tepidimonas. 
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However, adjustment in final models for hospital collection site, will have accounted for 
at least some site-specific contamination patterns.  
The specific study of the placental microbiome remains in its infancy. This research and 
other similar data suggest that there may be a low-level non-pathogenic placental 
microbiome present in many, if not all, placenta. However, differentiating this from 
organisms picked up at delivery, or during experimental handling is an on-going 
challenge. A recent publication examining placental tissue from healthy pregnancy 
concluded that these signals could not be differentiated in their cohort when rigorous 
contamination controls were used (Lauder et al., 2016). Furthermore, it remains 
impossible to assert from our data whether those organisms identified from placental 
samples functioned as mutualists that directly promoted the health of the developing 
fetus, or were commensal, and essentially neutral in their role. Metagenomic analyses, 
in which gene level information is retrieved, will serve to enlighten the functional role 
of this community in the future, in a way that 16S analyses cannot.  
To summarise, these data show that sPTB is associated with the placental presence of 
some well-known and some novel genera of interest. Some of these sPTB cases appear 
to have involved infectious triggers originating from the overgrowth of a single, or 
small number of, organism(s), originating from the vaginal or oral cavities. This study 
gathered novel data from a tissue that remains largely unexplored from an unbiased 
microbiological perspective. The cohort consisted of a large number of spontaneous, 
early preterm births, for which a large number of biological replicates were also 
available. This improved the power of the study to detect colonisation patterns of 
interest. Furthermore, the use of a specifically defined ‘non-spontaneous’ preterm birth 
group was a novel addition to previous studies. These nsPTB placenta provided a 
comparison group that was essentially matched for GA with the sPTB cases, but very 
likely had different underlying aetiology. A number of interesting associations have 
been observed using this data. Replication of the more novel associations, such as the 
enrichment of the Erwinia genus in one of the sPTB placenta, is critical to elucidate 
their importance to this common and often debilitating pregnancy complication.  Such 
follow up work will serve to further elucidate the clinical significance of these specific 
organisms to sPTB initiation, and potentially lead to the development of more targeted 
strategies to mitigate their pathogenic effect.  
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: Maternal Systemic Cytokine Chapter 7
Profiles and Pregnancy Outcome 
The experimental laboratory work in this chapter was initiated during a two-month 
secondment within Professor Buck’s lab at Virginia Commonwealth University. This 
study was designed to investigate the association between maternal systemic cytokine 
profiles and sPTB within a subset of samples taken from the BBB cohort. The 
optimisation and initial experimental work were carried out personally during my visit 
to the United States in 2015. The remaining experimental work was completed after I 
left Virginia, with the generous assistance of Dr Ana Perez Miranda and Dr Anita 
Marinelli.  
7.1 Introduction 
The initiation, maintenance and completion of normal human pregnancy depend upon 
the successful integration of maternal endocrine and immune pathways. Traditional 
models of parturition, and evidence from non-human mammals, previously supported 
the view that endocrine changes were primarily responsible for the induction of labour 
(Golightly et al., 2011). However, over the past decade, evidence has been growing that 
refutes this endocrine-centric model of human parturition. Such evidence supports the 
hypothesis that in late pregnancy, it is the maternal immune system that drives the 
physical and biochemical changes that precede spontaneous labour in humans (Gomez-
Lopez et al., 2014).   
Pregnancy has often been characterized as a period of maternal immune suppression 
and tolerance (Sykes et al., 2012). The innate and adaptive immune systems reach a 
delicate balance where mothers must tolerate the semi-allogeneic fetus, whilst 
maintaining the capacity to fight off infection, and even reject the fetus if necessary. A 
switch from a T helper 1 to T helper 2 cytokine profile is thought partly to facilitate this 
complex demand (Sykes et al., 2012). These changes facilitate maternal acceptance of 
the foreign fetus, by suppressing the cell-mediated immune responses that normally 
detect foreign antigens. At the same time they serve to augment the antibody-mediated 
response to pathogens (Jamieson et al., 2006). However, as pregnancies progress into 
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their final weeks, this balance shifts. The culmination of normal pregnancy is labour 
and delivery. These events are characterised by an influx of immune cells into the 
uterine cavity, and a significant increase in the expression of pro-inflammatory 
proteins (Gomez-Lopez et al., 2014). In addition, a systemic or functional withdrawal of 
certain hormones, particularly progesterone, has been noted. These endocrine changes 
are thought to activate myometrial tissue from the quiescent state it has occupied 
throughout most of pregnancy (Golightly et al., 2011).  
The following sections address specific evidence for the involvement of cytokines in 
spontaneous parturition: the main outcome of interest in the experiments reported in 
this chapter. Cytokines are small proteins that regulate the complex pathways of 
human immunity, inflammation, and haematopoesis. These readily measureable 
signalling molecules were the focus of the work in this part of my PhD. They have 
formed an important part of previous research into the role of inflammatory pathways 
in human labour. Systemic cytokine profiles have been investigated in a number of 
studies as potential biomarkers for intra-uterine infection and preterm birth risk. 
Cytokines are usually secreted by the cell in response to immunological stimuli. They 
generally act locally across both time and space. The majority of cytokines exhibit 
either autocrine (acting on themselves) or paracrine (acting on nearby cells) actions 
(Williams, 2012). However, some show endocrine activity and can function over long 
distances. Therefore, their presence in peripheral blood can reflect remote 
inflammatory events (Hebisch et al., 2004). By binding to specific membrane receptors, 
cytokines trigger a cascade of molecular and physical changes that can affect cell fate, 
function, and chemotaxis. Table 7.1 uses a common grouping structure to categorise 
those cytokines assayed in the proceeding experiments (Williams, 2012).  
Table 7.1 – Classification of 27 cytokines used in the multiplex Bio-Rad assay used in 
this study by five commonly used groupings (Williams, 2012). 
Cytokine 
family 
Cytokine in assay 
Interleukin IL-1β, IL-1Ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17 
Interferon IFN-γ 
TNF ligand TNF-α 
Growth 
factor 
G-CSF, GM-CSF, VEGF, FGF basic, PDGF-BB 
Chemokine CCL2, CCL3, CCL4, CCL11, CXCL10, RANTES (CCL5) 
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7.1.1 Parturition as an inflammatory process 
Spontaneous labour is a physiological event in which the fetus, membranes, umbilical 
cord, and placenta are expelled from the uterus. It involves an integrated and 
sequential set of biochemical and physical changes, within four key tissues: the 
myometrium, decidua, cervix, and fetal membranes. These changes occur over a period 
of days or weeks and, in the majority of cases, result in a live vaginal birth. In general, 
changes in the structural properties of the cervix precede uterine contractility and 
cervical dilation. Fetal membrane rupture typically follows. The exact genetic and 
physiological cascades precipitating human labour are not yet fully understood.  
Pro-inflammatory cytokines such as IL1, IL6, and TNF-α are secreted by peripheral 
leukocytes that infiltrate the uterus prior to delivery (Srikhajon et al., 2014). They are 
also expressed by intra-uterine cells making up decidua, amnion, and chorion tissues 
(Mitchell et al., 1993). Evidence for the direct involvement of these molecules in 
parturition comes from human, animal, and in-vitro work, from diverse tissues. A large 
body of research implicates their involvement to all stages of human labour. The role of 
pro-inflammatory cytokines at the culmination of both term and preterm pregnancies 
is particularly well supported (Tornblom et al., 2005, Hebisch et al., 2004).  
7.1.1.1 Uterine contractility 
Regular uterine contractions are a defining feature of the first stage of labour. They 
serve physically to aid the descent of the fetus through the birth canal, as well as 
contributing to the effacement and opening of the cervix. The process of uterine 
contractility itself is very well documented clinically. The molecular transition of 
myometrial tissue from months of muscular quiescence, to rapid and regular 
contractility is only partially understood.  
Both term and preterm deliveries have been associated with increases in local and 
systemic pro-inflammatory cytokines. Samples taken from cervical secretions, and 
maternal blood, have implicated molecules such as IL8, IL6, IL-1β, TNF-α and CC type 
chemokines (e.g. CCL3, CCL4) in both events (Tency, 2014, Arntzen et al., 1997, Hebisch 
et al., 2004, Shobokshi and Shaarawy, 2002). Expression of CCL2, an important 
monocyte chemoattractant, was markedly increased in myometrial tissue from 
labouring as opposed to quiescent samples (Esplin et al., 2005). Cytokines such as IL1β, 
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IL6 and IL8, all have known pro-inflammatory activity and are present in the 
myometrium in both term and preterm labour (Young et al., 2002, Elliott et al., 2000). 
Such cytokines are thought to be involved in the transcriptional activation of a cassette 
of so-called ‘contraction-associated proteins’ (CAPs), such as oxytocin receptors, 
connexin-43 (cx-43), and prostaglandins. Prostaglandins are some of the most well-
known initiators of uterine contractions. They are also involved in membrane 
degradation prior to rupture (Olson, 2003). Prostaglandins are used clinically to induce 
labour and cervical ripening in women.  In-vitro work has shown that both IL1β and 
TNF-α stimulate prostaglandin production (Molnár et al., 1993, Leighton and 
Pfeilschifter, 1990). This is likely facilitated via the prolific transcription factor, NFkB 
(Mohan et al., 2004, Christiaens et al., 2008). 
In-vitro stimulation with pro-inflammatory IL1β, enhanced Ca2+ presence in smooth 
muscle myometrial cell lines that were grown from mothers undergoing routine CS 
(Tribe et al., 2003).  The addition of IL1β to the cell populations both increased the 
uptake of calcium into the cells, as well as augmenting its release from the intracellular 
sarcoplasmic reticulum compartment. Given the central role of Ca2+ ions to smooth 
muscle activity, this evidence provides a potential mechanistic link between pro-
inflammatory cytokine presence and myometrial activity. 
7.1.1.2 Cervical ripening 
The softening and dilation of the cervix during labour involves extensive remodelling of 
the collagen in its extracellular matrix. Molecular evidence again highlights the 
involvement of inflammatory mechanisms and cytokines in the effacement of the cervix 
during labour. One of the first pieces of evidence supporting this association was the 
observation that leukocytes of various kinds infiltrate the cervix at both preterm and 
term delivery (Liggins, 1981). Immuno-active cells, such as macrophages and 
neutrophils, have been observed in cervical samples at concentrations 6 to 10 fold 
higher at delivery than during the first trimester (Bokstrom et al., 1997). Such cells 
both release, and are potently attracted by, pro-inflammatory cytokines a such as IL8 
(Ekman-Ordeberg and Dubicke, 2012). Leukocytes and cervical smooth muscle cells 
also express collagenolytic enzymes such as matrix metalloproteinases 1, 3, and 9, 
which can directly degrade the cervical extra-cellular matrix (Watari et al., 1999).  
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In addition to changes in the key cellular populations in the cervix during labour, the 
molecular profile of the labouring cervix is strongly pro-inflammatory. Dubicke et al. 
(2010) observed major changes in the concentrations of both pro and anti-
inflammatory mRNA and protein from labouring cervices. These changes were 
observed regardless of GA, indicating a common mechanism in both preterm and term 
cervical dilation. Compared to non-labouring tissue, mRNA concentrations of the pro-
inflammatory cytokines IL1α, IL1β, IL13, and IL10, were increased in tissue from 
labouring cervices. These results document a suite of changes that are indicative of an 
association between labour, cervical ripening, and a pro-inflammatory response.  
7.1.2 Cytokines and sPTB 
Many of the immunological changes associated with labour are thought to be common, 
regardless of GA (Dubicke et al., 2010). It is therefore reasonable to hypothesise that it 
is in the instigation of labour, rather than the actual process itself, that any preterm 
specific cytokine changes may be most prominent. An untimely disruption of maternal 
immune tolerance, and perhaps an activation of the Th1 response, could trigger the 
normal labour cascade by abnormal mechanisms (Sykes et al., 2012).  
A number of events known to have strong pro-inflammatory components, such as 
infection, stress, and obesity, are also well known risk factors for preterm birth 
(Seematter et al., 2004, Lyon et al., 2003). This supports the hypothesis that 
inflammatory pathways contribute to preterm birth risk. It would be valuable to 
identify any immunological signatures associated specifically with sPTB. These 
signatures may be the result of pro-inflammatory events, such as infection, that 
precede labour. By contrast, they may be the result of physiological differences that are 
intrinsic to the mother or fetus. At risk mothers may present with an overactive pro-
inflammatory immune response, driven by an inflammatory syndrome, infection 
and/or genetic variation. Alternatively, differences in maternal immunological 
physiology could serve to increase vulnerability to ascending infection. For example, it 
has been shown that compromised immune states at sites such as the cervix, which are 
critical to protecting the uterus from ascending infection, are associated with increased 
sPTB incidence (Hunter et al., 2016). 
The majority of studies investigating the involvement of cytokines in sPTB, including 
the present one, have used maternal blood samples (Menon et al., 2011). Blood 
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collection is an inexpensive and safe procedure to use in clinical research. Furthermore, 
the identification of peripheral blood biomarkers for risk profiling, has more direct 
clinical utility than those identified in tissues that rely on invasive procedures, such as 
amniocentesis, for sampling. Increased concentrations of serum IL1β have been 
associated with preterm compared to term labour (Torbe et al., 2007, Vitoratos et al., 
2007). Investigations using peripheral cytokine profiles and sPTB have also focused on 
the pro-inflammatory candidates IL6 and IL8. Although there is some evidence of a 
positive association between such systemic cytokines and sPTB risk, results in 
asymptomatic women have been mixed, and associations have been generally weak or 
absent (Chan, 2014). Furthermore, the large variation in study designs has made meta-
analyses challenging to conduct (Menon et al., 2011).  
Cases of PPROM with and without infection, have been associated with increased levels 
of the pro-inflammatory cytokines, IL-1β, IL6, TNF-α, IFN-γ, VEGF in maternal serum 
and amniotic fluid (Shobokshi and Shaarawy, 2002). Fukuda et al. (2002) recruited a 
cohort of women with PPROM. They used samples from cordocentises to demonstrate 
an inverse correlation between fetal plasma IL6 concentrations and time to 
spontaneous labour and delivery (Fukuda et al., 2002). In this same study, correlations 
were observed with fetal plasma and amniotic fluid IL6 concentrations. By contrast, no 
correlations were observed between fetal and maternal systemic IL6, or maternal 
systemic IL6 and time to delivery. The authors suggest that these local inflammatory 
responses occurred in response to the presence of microorganisms that were identified 
within the uterine compartment, such as Ureaplasma and Mycoplasma spp. This was 
one of the first studies to demonstrate an important, and often overlooked, 
contribution of the fetal immune system to cases of inflammation mediated sPTB. The 
authors propose that in such cases, the onset of sPTL may be as much a survival 
mechanism for the fetus as it is for the mother. In this context, a fetal inflammatory 
response serves to trigger the cascade of events that will enable it to exit an 
environment that has become hostile. Furthermore, this study provided rare access to 
the amniotic and fetal compartments prior to the initiation of labour. This provided 
strong evidence that an up-regulation of pro-inflammatory molecules precedes, rather 
than follows, the clinically observed initiation of sPTB.  
Differences in cytokine profiles between preterm and term pregnancies will not 
necessarily be detectable throughout pregnancy. A study investigating differences in 28 
cytokines in the sera of mothers who delivered before 28 weeks, or at term, found no 
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differences at 15-18 weeks gestation (Yang et al., 2010). This implies that differences 
may only be observable within certain time periods, most likely closer to delivery. 
Identifying this critical window in which local or systemic changes in maternal 
physiology predispose women to preterm delivery is essential. This will facilitate the 
administration of potential treatments at a time when they will be effective, but prior to 
the point at which labour associated changes begin and become irreversible.  
In other circumstances, longer-term differences in exposure and physiology may play a 
role in certain sPTB pathologies. In one study, early pregnancy levels of the pro-
inflammatory cytokine, TNF-α, were higher in women with prior preterm delivery. 
These women with higher TNF-α concentrations were additionally at higher risk of a 
preterm birth in the current pregnancy (Curry et al., 2008). Indeed, a recent paper has 
called for a re-evaluation of concepts of immunology in pregnancy. It proposes that the 
mother’s long-term, prenatal exposure to paternal antigens, and environmental 
pathogens, may be involved in immunological pregnancy complications (Sisti et al., 
2016). 
Given the significant heritability of prematurity, it is unsurprising that the 
identification of susceptibility alleles associated with sPTB has been an important focus 
for researchers. Polymorphisms in a number of genes regulating immune responses 
have been associated with preterm birth risk (Crider et al., 2005). Both maternal and 
fetal TNF-α polymorphisms have been associated with sPTB (Crider et al., 2005). 
Polymorphisms associated with increased expression of the pro-inflammatory IL1β 
gene, and those associated with reduced expression of its receptor agonist, IL-1Ra, 
were enriched in sPTB groups (Crider et al., 2005). A polymorphism associated with 
reduced expression of the pro-inflammatory cytokine IL6 was investigated in a study 
by Simhan et al (2003). It was present at significantly lower frequencies in women who 
underwent labour before 34 weeks compared to term deliveries (Simhan et al., 2003).  
7.1.3 Animal models and infectious mediated PTB 
Whilst evidence from a variety of sources links intra-uterine infection, pro-
inflammatory pathways, and sPTB, it remains difficult to elucidate the direction of 
causality in this relationship. Do inflammatory signals serve to initiate labour? Or are 
these signals the result of the degradative changes associated with cervical 
remodelling, myometrial activity, and membrane rupture that lead to an inflammatory, 
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protective response from the mother? These questions are particularly relevant in 
human studies in which access to tissues of interest prior to delivery is almost entirely 
restricted. For this reason, animal studies have been an important experimental model 
for further understanding inflammation and labour. More specifically, it is important to 
consider how dysregulation of this axis is a causal mechanism in infectious and 
inflammation mediated preterm birth. 
Over the past 20 years, animal models, particularly murine, have been developed to 
study infection, inflammation, and sPTB in more detail. Intra-uterine or systemic 
injections of bacterial cells or their products, such as LPS, enable investigators to 
observe and manipulate underlying molecular mechanisms. Studies in mice have 
consistently shown that LPS or bacterial cell administration results in the induction of 
labour, and fetal death, prior to that observed in control groups. Evidence has shown 
that this pathway is mediated by intra-uterine pro-inflammatory cytokines (Kaga et al., 
1996, Hirsch and Muhle, 2002, Fidel et al., 1994). Similarly, the systemic administration 
of pro-inflammatory cytokines, such as IL1β, have been shown to induce preterm 
delivery in mice (Romero et al., 1991, Romero and Tartakovsky, 1992). These studies 
strongly support direct causal involvement of infection and maternal/fetal 
inflammatory responses in cases of human sPTB.  
IL10 knock-out (KO) mice have been used to demonstrate the centrality of the anti-
inflammatory cytokine, IL10, to susceptibility to LPS induced preterm labour and fetal 
loss (Robertson et al., 2006, Christiaens et al., 2008). In IL10 null mutant mice 
substantially elevated expression of inflammatory cytokines was recorded. 
Concentrations of TNF-α, IL1, IL6, and IFN-γ were higher following LPS administration 
in KO, compared to wildtypes (Robertson et al., 2006). The study demonstrated a direct 
correlation between this anti-inflammatory molecule, and the ability of the maternal 
immune system to respond to infection during pregnancy. 
Recent RNA-seq data from three different murine models of labour have been shown to 
support the hypothesis that there is a unique LPS induced path to parturition, which 
differs from normal parturition (Migale et al., 2016). A core set of genes were shown to 
be up-regulated in LPS induced labour compared to term. This was also shown when 
the core set was compared to a progesterone-blocking preterm model. About 80% of 
gene changes in the LPS model were unique and included genes belonging mainly to 
inflammatory pathways. Animal models from the same group have also enabled 
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investigations of how bacterial serotypes can have different effects on pregnancy 
outcome (Migale et al., 2015). Such observations highlight the importance of discerning 
the specific underlying infections precipitating sPTB in order to better target 
treatment. 
When the amniotic cavity of rhesus monkeys were injected with the pro-inflammatory 
IL1β cytokine, a concomitant increase in TNF-α, and then prostaglandin, was observed 
(Baggia et al., 1996). Furthermore, increases in uterine pressure, a measure used as a 
proxy for contractions, were documented. These changes indicate a directional link 
between inflammatory molecules and labour-associated chemical and physical 
changes. However, in these experiments frank labour, defined by cervical ripening and 
continued contractions, did not occur. This indicates that proteins and processes, 
beyond upregulation of a single inflammatory cytokine, are necessary for sustained and 
successful labour.  Interestingly, in a related study by the same group, inoculation of the 
intra-amniotic cavity with group B streptococci cells, resulted in similar changes such 
as an increase in TNF-α, IL6, and IL1β (Gravett et al., 1994). In this experiment, 
contractions and cervical changes did occur, resulting in the full ‘package’ of labour. 
These studies suggest that sustained infection will likely lead to the induction of 
molecular components beyond IL1β and TNF-α that were used in the previous study. 
Furthermore, these data demonstrate a cause-and-effect relationship between bacterial 
infection, inflammatory responses, and preterm labour. 
There is a high prevalence of fetal demise in animal models using LPS to induce 
preterm labour. This raises concerns over the impact of aberrant inflammation on fetal 
development in-utero. Are expectant management and the use of tocolytics to delay 
labour always desirable if the fetus will be exposed to continuing infectious insult and 
inflammatory responses for longer? Indeed, a meta-analysis provided no evidence for 
improved perinatal outcomes following the use of tocolysis to delay labour (Gyetvai et 
al., 1999). The consequences of intrauterine inflammation on fetal and neonatal 
cardiopulmonary, cerebral, and renal systems can be significant. However, they are 
beyond the scope of this thesis and are described in an excellent review by Galinsky et 
al. (2013).  
 
 
  200 
7.1.4 Hypotheses and aims 
A substantial body of work has attempted to elucidate the causal and mechanistic 
pathways involved in term and preterm labour over recent decades. It is now widely 
accepted that labour is, at least in part, an inflammatory event, and that sPTB 
represents an aberrant form of this process. However, reproducibly identifying those 
cytokines involved in pathological outcomes, which could be useful for clinical 
interventions and predictive testing, has been a challenge. In this study a nested case-
control design was used to attempt to identify cytokines associated with sPTB, when 
compared to term deliveries.  
The hypothesis behind this study was that in the weeks preceding delivery, maternal 
systemic cytokine profiles would vary between sPTB and term births. sPTB 
pregnancies were hypothesised to show a more consistently pro-inflammatory signal, 
particularly amongst cytokines known to be associated with immune responses to 
bacterial infection. Additionally, any cytokines specific to preterm, as opposed to term 
labour, would show uniform differences when compared to both term deliveries 
precipitated by a spontaneous event and those in which labour never occurred. The 
two central aims of this study were as follows: 
1) Investigate the link between maternal systemic cytokine concentrations and 
pregnancy outcome in the run up to delivery, using BBB samples. 
 
2) Identify cytokines associated with preterm labour that are distinct from those 
involved in normal term labour, and may reflect responses to intra-uterine infectious 
insults. 
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7.2 Materials and methods 
7.2.1 Cohort selection 
Sera from 126 pregnancies (44 sPTB, 39 spontaneous term, and 43 non-spontaneous 
term), collected up to 31 days before delivery, were selected from the BBB cohort for 
this nested case-control study (Figure 7.1). I chose to focus on those preterm births 
most likely to be linked to an infectious and inflammatory pathology. Therefore, the 
criterion for inclusion in the case group was any preterm delivery preceded by a 
spontaneous membrane rupture or labour event. The term control group consisted of 
both spontaneous and non-spontaneous births, from healthy pregnancies (no PE, IUGR, 
<42 weeks). In order to capture the immunological changes related to labour and 
delivery, I chose only samples taken within 31 days of birth. 65% of samples were 
taken in the final week of pregnancy. All samples available within the BBB that adhered 
to the criteria stated above and were available on the day of delivery were used (N=15).  
Baby Bio Bank 
Delivery at <37 weeks 
Spontaneous labour 
and/or spontaneous 
membrane rupture 
Maternal serum taken 
<32 days from 
delivery (N=44) 
Uncomplicatd term 
pregnancies 
Spontaneous labour 
and/or spontaneous 
membrane rupture 
Maternal serum taken 
<32 days from 
delivery (N=39) 
No labour and 
artificial/no 
membrane rupture 
Maternal serum taken 
<32 days from 
delivery (N=43) 
Figure 7.1 – Flow diagram documenting selection of cytokine case-control cohort 
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This study design facilitated the investigation of associations between cytokine profiles 
and pregnancy outcome. Any relationships identified could be the result of direct 
involvement in causal pathways, and thus hold potential for clinical developments. 
Alternatively, they may be the result of indirect physiological changes associated with 
sPTB. These could instead serve as potential late pregnancy biomarkers. Given the 
likelihood that the activity of some cytokines will change in the run up to delivery, 
samples in the three outcome groups of interest (sPTB, spontaneous term, and non-
spontaneous term) were distribution matched for days before delivery at sample 
collection. The preterm group served as the baseline for matching, as this was the most 
limited collection (Figure 7.2).  
 
 
Figure 7.2 – Figure showing distribution matched profiles of days before delivery in 
three study groups of interest. 
 
7.2.2 Sample collection 
See section 2.4.2. 
7.2.3 Multiplex ELISA assay 
See section 2.4 for general methods and section 3.4 for optimisation work. 
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7.2.4 Statistical analyses 
As discussed in section 2.5, normality of data was tested using the Shapiro-Wilcox test. 
Dependent on the nature of distributions, cytokine data were summarised using a 
number of parametric and non-parametric tests, prior to regression analyses. The lme4 
package (Bates et al., 2015) was used in R to perform a linear mixed effects analysis for 
the prediction of cytokine concentration, from pregnancy outcome. Models were run 
with a random intercept term for participant number, to account for the presence of 
technical replicates in the sample set. An additional, independent random intercept 
term for batch was included if its addition improved the model fit. Otherwise batch was 
included as a fixed effect. In all adjusted analyses, the fixed effects of maternal ethnicity, 
age at booking, smoking behaviour, BMI, parity, and days before delivery at sampling 
were added into the model. Visual inspection of residual plots and QQ-plots confirmed 
that models were conforming to the assumptions of homoscedasticity and normality. P-
values and degrees of freedom were estimated for the models using the Kenward-
Roger approximation in the pbkrtest R package (Halekoh and Højsgaard, 2014). 
Samples were considered to be potentially influential outliers if their Cook’s distance 
value was >0.1. Subsequently, such samples were removed from the dataset and 
models were rerun for sensitivity analyses until no further influential values were 
observed. Final models without any such influential values are also reported. 
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7.3 Results 
7.3.1 Clinical dataset 
Clinical data for all samples were available from the BBB clinical database. Key clinical 
and demographic characteristics of the cohort are summarised in Table 7.3. Diabetes 
data was available for less than half of the pregnancies in this group, in which only one 
case was observed. Therefore, this clinical category was omitted from models. 58% of 
deliveries were vaginal. A detailed breakdown of the labour and membrane rupture 
groupings in the three main clinical categories is given in Table 7.2. 
Table 7.2 – Labour onset and membrane rupture method in sPTB, term spontaneous 
and term non-spontaneous groups for which maternal serum cytokine profiles were 
assessed. 
Experimental 
grouping 
Labour onset (N) Membrane rupture method (N) 
None Spontaneous None Spontaneous 
sPTB 12 32 8 36 
Term 
spontaneous 
4 35 3 36 
Term non- 
spontaneous 
43 0 43 0 
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Table 7.3 – Summary of maternal and pregnancy clinical data for participants of cytokine study. 
Variable Category Sub-category N (%) 
Shapiro 
test (P) 
Median (IQR) Mean (SD) Range 
Total 
(N) 
Missing 
Wilcox or 
Fisher’s 
exact test 
GA at birth 
(weeks) 
All 
  
1.25E-9 38  (35-37) 37 (3.38) 23-41 126 0 
 
Preterm 
  
1.04E-6 35 (32.8-35) 33.4 (3.13) 23-36 44 0 
W=0 
P<2E-16 
Term 
  
1.66E-5 39 (38-40) 39 (1.19) 37-41 82 0 
Birthweight 
(grams) 
All 
  
3.00E-4 3180 (2540-3450) 2980 (799.1) 540-4500 125 1 
 
Preterm 
  
0.9 2260 (1620-2540) 2150 (699.18) 540-2540 43 1 
W=190.5 
P=3.08E-16 
Term 
  
7.00E-3 3310 (3150-3690) 3409.18 (419.63) 2580-4500 82 0 
Maternal 
age at 
booking 
All 
  
0.033 33 (29-37) 32.5 (5.77) 16-46 126 0 
 
Preterm 
  
0.44 32 (28-31.5) 31.5 (5.98) 20-42 44 0 
W=1553 
P=0.199 
Term 
  
0.034 33.5 (30-33.1) 33.1 (5.62) 16-46 82 0 
GA at blood 
draw 
(weeks) 
All 
  
7.41E-9 7 (1-14) 8.79 (8.47) 0-31 126 0 
 
Preterm 
  
4.1E-5 3.5 (1-13) 7.39 (7.92) 0-28 44 0 
W=1488 
P=0.105 
Term 
  
2.88E-6 7 (2-15.5) 9.55 (8.71) 0-31 82 0 
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Maternal 
BMI 
(weight/ 
height2) 
All 
Underweight 5 (3.97) 
    
126 0 
 
Normal 106 (84.13) 
     
Obese 15 (11.90) 
     
Preterm 
Underweight 3 (6.82) 
    
44 0 
Fisher's 
P=0.22 
Normal 38 (86.36) 
    
Obese 3 (6.82) 
    
Term 
Underweight 2 (2.44) 
    
82 0 Normal 68 (82.93) 
    
Obese 12 (14.63) 
    
Maternal 
parity 
All 
0 62 (49.20) 
    
126 0 
 
1 46 (36.51) 
    
2+ 18 (14.29) 
    
Preterm 
0 29 (65.91) 
    
44 0 
Fisher's 
P=0.0049 
1 8 (18.18) 
    
2+ 7 (15.91) 
    
Term 
0 33 (40.24) 
    
82 0 1 38 (46.34)     
2+ 11 (13.42) 
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Maternal 
smoking 
behaviour at 
booking 
All 
Non-smoker 119 (95.97) 
    124 2 
 Smoker 5 (4.03) 
    
Preterm 
Non-smoker 40 (90.91) 
    44 0 
Fisher's 
P=0.053 
Smoker 4 (9.09) 
    
Term 
Non-smoker 79 (98.75) 
    80 2 
Smoker 1 (1.25) 
    
Maternal 
ethnicity 
All 
Asian/Asian 
British 
9 (7.34) 
    
122 4 
 
Black/Black 
British 
13 (10.66) 
     
White/White 
British 
77 (63.11) 
     
All others 23 (18.85) 
     
Preterm 
Asian/Asian 
British 
2 (4.76) 
    
42 2 
Fisher's 
P=0.67 
Black/Black 
British 
3 (7.14) 
    
White/White 
British 
27 (64.29) 
    
All others 10 (23.81) 
    
Term 
Asian/Asian 
British 
7 (8.75) 
    
80 2 
Black/Black 
British 
10 (12.50) 
    
White/White 
British 
50 (62.50) 
    
All others 13 (16.25) 
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7.3.2 Missingness and batch effects 
This assay did not quantify all cytokines with equal efficiency, and some cytokines were 
more likely to have values that fell below the LOD, or outside of reliable ranges of the 
standard curve than others. It was important to explore the completeness of our 
experimental dataset, and adjust missingness appropriately, as outlined in section 
3.4.2.1, before proceeding with downstream analyses.  
Any fluorescence value that fell below the LOD, defined by the blank sample, was 
recoded as zero. A small number of cytokines accounted for the majority of zero values 
in the assay: IL2, IL15, CCL2, and GM-CSF. 17 observations had a high (>20%) 
coefficient of variation between repeat measures. These observations were deemed to 
be unreliable and were recoded as not available (NA).  
259 observations fell below the range of the reliable standard curve. These values were 
recoded as half the minimum observed reliable value per plate. There was one 
occurrence, IL8 on plate 6, in which no observed value fell within the reliable range of 
the standard curve, due to a particularly poorly run curve in which only 7 out of 9 
standards were within 70-130% efficiency. The assay had been reliable on all previous 
plates for IL8. Therefore, to minimise loss of data, the observed values, which fell 
outside of the reliable standard curve range, but were extrapolated by the software, 
were used. 44 total observations were above the reliable range of the standard curve. 
All of these values were from RANTES. These were recoded as the maximum observed 
reliable value for each plate. 
526 observations, 14% of the total, were adjusted for missingness. Per cent 
missingness per plate was distributed across the cytokines in a non-random manner. 
The majority was the result of observations below the LOD of the assay (see Appendix 
Table A 17, page 265 for batch by batch breakdown). Missingness was focused in 
results from a small number of cytokines: IL2, IL15, GM-CSF, and CCL2. 
Variation across batches had been approximated during optimisation (section 3.4.2.4). 
Correlations were high between replicates but batch effects were still clearly visible. 
The final two experimental batches were run with kits with a different batch of 
standards to the optimisation runs and the first four experimental plates. Although the 
manufacturers predict only minimal variation across such standard batches, it was 
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important to capture the nature of any differences between early and late batches. 12 
experimental replicates were run between the first four and final two plates. Case and 
control samples were present across all plates. The analysis showed that 
reproducibility of individual cytokines varied considerably between these two 
standard sets.  
The ICC values of repeats from the optimisation experiments and from the 
experimental replicates, were calculated and compared (Appendix Table A 18, page 
266). Based on these calculations, a number of cytokines were deemed to show poor 
reproducibility. This was defined as either a low ICC value in both optimisation and 
experimental analyses (e.g. IL4), or unacceptably low reproducibility in technical 
replicates from experimental samples, due to the change in standard batches (e.g. IL9). 
On this basis, cytokines IL4, IL7, IL9, IL13, IL15, CXCL10, IFN-γ, PDGFbb, RANTES, and 
G-CSF were not included in final models. 
For the 17 cytokines taken forward, models with and without batch as a random effect, 
were compared as discussed in section 7.2.4. Based on these comparisons, IL-1Ra, IL2, 
IL6, IL8, IL10, and CCL2 were run as models with only participant number as a random 
intercept, and batch as a fixed effect. IL1β, IL5, IL12, IL17A, CCL11, FGF-basic, GM-CSF, 
CCL3, CCL4, TNF-α, and VEGF were all run with the effects of participant identity and 
batch modelled as two independent random intercepts (see Appendix Table A 19, page 
266 for model comparisons). 
7.3.3 Summary of cytokine concentrations 
The general distributions and characteristics of all 17 reliably assayed cytokines are 
displayed in Table 7.4. The range in concentrations varies widely by cytokine. In certain 
cases, zeros dominated the distribution (e.g. IL2). Furthermore, many of the cytokines 
were highly skewed. Therefore, for all further analyses, cytokine concentrations were 
log+1 transformed. This served to improve the fit of downstream regression models 
(data not shown).  
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Table 7.4 – Summary of results from cytokine experiments for 17 assayed proteins 
for which reproducible data were available. Concentrations in pg/ml. 
Cytokine Total (N) Null values (N) Missing (N) Median (range) Mean (SD) 
IL1β 140 0 1 2.2 (0.69-33) 2.9 (3.5) 
IL-1Ra 140 1 1 100 (0-3900) 180 (400) 
IL2 140 80 1 0 (0-260) 8.3 (32) 
IL5 140 23 0 3.8 (0-130) 6.6 (12) 
IL6 140 0 3 9.1 (0.05-340) 18 (39) 
IL8 140 0 0 25 (9.9-38000) 440 (3600) 
IL10 140 7 0 8.8 (0-1500) 39 (150) 
IL12 140 1 1 16 (0-2900) 52 (250) 
IL17A 140 3 0 76 (0-430) 94 (71) 
CCL11 140 0 0 44 (18-140) 50 (25) 
FGF-basic 140 2 0 77 (0-300) 88 (54) 
GM-CSF 140 76 2 0 (0-530) 49 (100) 
CCL2 140 81 0 0 (0-5200) 81 (520) 
CCL3 140 2 1 4.6 (0-53) 6.2 (6.5) 
CCL4 140 0 0 110 (37-650) 120 (70) 
TNF-α 140 0 0 41 (18-990) 54 (84) 
VEGF 140 10 0 17 (0-1100) 38 (110) 
 
7.3.4 Cytokine profiles and pregnancy outcome 
Two categorisations of predictor variables were used when modelling the association 
between pregnancy outcome and the 17 cytokines that passed quality control. The first 
was a two-group test in which cytokine concentrations in all term samples were 
compared to those from sPTB deliveries. The second was a three-group model in which 
both term spontaneous and term non-spontaneous deliveries were compared to sPTB 
outcome. The latter model was used to investigate whether any observed differences 
between term and sPTB cytokine concentrations were a function of the non-
spontaneous nature of many of the term group samples, rather than specific molecular 
mechanisms involved in sPTB pathology.  
In unadjusted models, IL-1Ra, IL2, IL6, CCL11, GM-CSF, and CCL4 concentrations were 
all significantly associated with sPTB (see Appendix Table A 20 and Table A 21, pages 
267-269 for full tables). Following adjustment for days before birth at sampling, 
maternal BMI, maternal age at booking, maternal ethnicity, maternal smoking 
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behaviour, batch (fixed or random), and parity, associations with IL6 disappeared, and 
IL8, IL10, CCL2, and IL5 associations became significant. Associations were classified 
into one of three groups after adjustment for confounding: (1) cytokines increased in 
sPTB cases; (2) cytokines decreased in sPTB cases; and (3) cytokines not associated 
with pregnancy outcome in this cohort. A summary of these groupings from final 
adjusted models is provided in Figure 7.3. 
 
 
 
 
 
 
Figure 7.3 – Schematic showing those cytokines increased (green), decreased (red), and 
not associated with sPTB in adjusted linear regression models, before and after removal 
of potential influential samples. Arrow shows the three cytokines associated with sPTB that 
loose significance following influential sample removal. 
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 Table 7.5 – Results from adjusted linear regression analyses quantifying difference in concentrations (pg/ml) of IL2, IL8, and IL10, between sPTB 
(baseline) and term or term spontaneous/non-spontaneous using whole cohort. 
 
 
Table 7.6 - Results from adjusted linear regression analyses quantifying difference in concentrations (pg/ml) of IL2, IL8, and IL10, between sPTB 
(baseline) and term or term spontaneous/non-spontaneous following removal of influential samples. 
 
Cytokine 
Whole cohort 
Outcome β (95% CI), P Outcome β (95% CI), P 
IL2 Term -0.63 (-1.19--0.07), 0.041 
Term spontaneous -0.62 (-1.24-0.01), 0.074 
Term non-spontaneous -0.64 (-1.26--0.01), 0.064 
IL8 Term -0.52 (-0.91- -0.14), 0.014 
Term spontaneous -0.54 (-0.97- -0.11), 0.02 
Term non-spontaneous -0.50 (-0.94 - -0.061), 0.039 
IL10 Term -0.55 (-1.12-0.03), 0.083 
Term spontaneous -0.71 (-1.35--0.08), 0.043 
Term non-spontaneous -0.37 (-1.02-0.27), 0.29 
Cytokine 
Following removal of influential samples 
Outcome β (95% CI), P Outcome β (95% CI), P 
IL2 Term -0.3 (-0.78-0.19), P=0.25 
Term spontaneous -0.22 (-0.75-0.32), P=0.45 
Term non-spontaneous -0.38 (-0.92-0.17), P=0.20 
IL8 Term  -0.073 (-0.3- 0.041), P=0.45 
Term spontaneous  -0.024 (-0.19 -0.13), P=0.78 
Term non-spontaneous  -0.0065 (-0.18 0.16), P=0.94 
IL10 Term -0.46 (-0.99-0.09), P=0.11 
Term spontaneous -0.58 (-1.17-0.03), P=0.074 
Term non-spontaneous -0.33 (-0.93-0.29), P=0.32 
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Cytokines IL2, IL8, and IL10 were associated with pregnancy outcome in the 
preliminary adjusted models. However, after models were checked for assumptions 
and potential influential values removed, the associations disappeared and were no 
longer significant (Table 7.5 and Table 7.6). Table 7.7 summarises those cytokines in 
which associations persisted through sensitivity analyses. See Appendix Table A 22-
Table A 33, pages 271-282, for full tables of all significant models pre and post 
influential sample removal model. 
Concentrations of IL-1Ra were significantly increased in sPTB cases, both in two and 
three group comparisons. In sample 336, no detectable protein was observed. This was 
identified using Cook’s Test as an influential value, along with samples 1226 and 2388. 
These latter two samples came from women with sPTBs and the two highest 
concentrations of IL-1Ra. Following the removal of these three potential influential 
values, the significant association between IL-1Ra concentration and sPTB persisted in 
both models, but the effect size almost halved in both cases (Table 7.7).  
CCL2 was also present at significantly higher concentrations in sPTB cases. No 
influential values were identified via diagnostic analyses. However, a large proportion 
of women had either no CCL2 in their sera at the time of sampling, or levels below the 
LOD of the assay, represented by zeros in the assay. This large proportion of zeros 
influenced the fit of regression analyses. Therefore, an alternative model was run to try 
to improve this fit by more appropriately modelling these zero values. Using an 
adjusted, binomial multi-level regression model, the relationship between pregnancy 
outcome and presence (>0 pg/ml) or absence (0 pg/ml) of CCL2 was investigated. In 
line with the linear model, women with detectable CCL2 protein in their serum samples 
had significantly lower odds of having a term birth. This relationship was significant 
when term births were grouped as one outcome (OR sPTB/term = 0.1 P=0.0015), or as 
two (OR sPTB/term spontaneous = 0.13, P=0.007, OR sPTB/non-spontaneous term = 
0.081, P=0.001). The comparison of sPTB with non-spontaneous term births showed 
the largest difference in odds. CCL2 was associated with sPTB in this cohort in a dose 
dependent manner. In addition, the mere presence of CCL2 in maternal sera appears to 
be a biomarker for sPTB in these women. 
CCL11 was higher in sera from sPTB pregnancies than term births, when considered 
both together and separately by spontaneous/non-spontaneous outcome. This 
relationship was attenuated, but persisted, after the removal of one significant outlier. 
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CCL4 concentration was also associated with sPTB outcome in the two-group model. 
However, this relationship was one of the weakest of all significant associations. When 
the three-group model was run, both term groups still had, on average, a reduced CCL4 
concentration compared to sPTB cases. However, this effect was only significant for the 
comparison with non-spontaneous term births.  
GM-CSF was higher in sPTB cases than term births. When investigated further using the 
three-group model, the relationship was only significant for spontaneous term 
compared to sPTB births. However, the effect sizes of both groups were similar, 
suggesting this may have been an issue of power. GM-CSF was also a cytokine that had 
a substantial number of zero values. However, when these results were split by 
spontaneous/non-spontaneous outcomes, no significant association was observed. A 
non-significant trend of lower odds of a term birth when GM-CSF was detectable was 
observed (data not shown). No influential values were identified for analyses involving 
GM-CSF. 
IL5 was the only cytokine that was significantly increased in term compared to sPTB 
cases. However, when the three-group model was run, it was clear that the majority of 
this association was accounted for by differences between sPTB and non-spontaneous 
term births. With the removal of potentially influential samples, these relationships 
persisted. As this pattern was strongly indicative of an association with spontaneous 
events rather than outcomes by GA, this was also investigated. When IL5 concentration 
was compared between pregnancies culminating in a non-spontaneous outcome and a 
spontaneous outcome, it was significantly reduced in the spontaneous group (Beta=-
0.51 95% CI=-0.84- -0.19, P=0.0022). This association supports the hypothesis that IL5 
is related to pregnancy maintenance, and its reduction may be a hallmark of 
spontaneous parturition.   
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Table 7.7 - Summary table of significant associations between cytokine concentrations (pg/ml) and pregnancy outcome for two and three group 
models using a linear regression model adjusted for confounders. 
 
Cytokine 
Predictor 
(baseline
=sPTB) 
2 group model (β (95% CI), P) Predictor 
(baseline=sPTB) 
3 group model (β (95% CI) and P) 
Adjusted model After removal of outliers Adjusted model After removal of outliers 
IL-1Ra Term -0.73 (-1.09--0.37), 0.00024 
-0.38 (-0.63--0.13), 
0.0054 
Term spontaneous -0.8 (-1.2--0.39), 0.00033 -0.41 (-0.69--0.14), 0.0066 
Term not spontaneous -0.66 (-1.07--0.26), 0.0027 -0.35 (-0.62--0.07), 0.022 
CCL2 Term -1.66 (-2.47--0.86), 0.00019 - 
Term spontaneous -1.63 (-2.53--0.74), 0.0010 - 
Term not spontaneous -1.69 (-2.59--0.8), 0.0006 - 
IL5 Term 0.27 (-0.1-0.64), 0.15 
0.43 (0.07-0.78), 
0.019 
Term spontaneous 0.01 (-0.4-0.41), 0.969 0.15 (-0.24-0.54), 0.44 
Term not spontaneous 0.52 (0.11-0.92), 0.012 0.61 (0.23-1), 0.0021 
CCL11 Term -0.32 (-0.47--0.16), 0.000056 
-0.24 (-0.41--0.07), 
0.0049 
Term spontaneous -0.34 (-0.51--0.15), 0.00015 -0.24 (-0.44--0.05), 0.011 
Term not spontaneous -0.3 (-0.48--0.12), 0.0013 -0.24 (-0.43--0.05), 0.014 
GM-CSF Term -1.06 (-2.01--0.09), 0.020 - 
Term spontaneous -1.27 (-2.33--0.19), 0.013 - 
Term not spontaneous -0.87 (-1.91-0.21), 0.091 - 
CCL4 Term -0.18 (-0.35--0.01), 0.034 - 
Term spontaneous -0.13 (-0.32-0.06), 0.16 -0.1 (-0.29-0.09), 0.30 
Term not spontaneous -0.23 (-0.42--0.04), 0.016 -0.22 (-0.41--0.03), 0.022 
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7.4 Discussion  
This study has shown that the late pregnancy maternal systemic profiles of a number of 
cytokines are associated with sPTB. To differing degrees, IL-1Ra, CCL2, CCL4, CCL11, 
and GM-CSF were all up-regulated in maternal serum taken from mothers who had a 
sPTB, compared to those who had a term birth. By contrast, concentrations of IL5 
tended to be lower among maternal serum collected from sPTB pregnancies, and in 
women with any spontaneous event. The remaining 21 cytokines in the assay were 
either omitted due to poor performance in assay optimisation, or showed no 
statistically significant association with outcome in this cohort. 
There are two plausible interpretations for these observations. The first is that the 
differences between the two, or three, case groups of interest were a reflection of 
differences directly involved in the initiation, or the progression of parturition. In other 
words they are on the causal pathway. An alternative explanation is that these 
differences were not directly involved in the processes of interest, but instead reflected 
physiological responses to alternative events that precipitated these outcomes. For 
example, the up-regulation of the anti-inflammatory IL-1Ra cytokine in the sPTB group 
is unexpected if we interpret this change to reflect changes on the causal pathway to 
preterm labour. Instead, it is perhaps more plausible to interpret this specific 
association as a homeostatic mechanism evoked in response to the pro-inflammatory 
triggers hypothesised to underlie sPTB. Whilst reports of causal relationships are more 
useful for the development of clinical interventions, secondary associations are still of 
significant interest. Such indirect associations, provided they are reproducible, can still 
be powerfully utilised in the development of predictive screening programmes for 
women at risk of, or threatening, sPTB. From these data, it is only possible to 
hypothesise the nature of the observed associations based on prior knowledge. Future 
functional work is required to explore further these associations and their direct or 
indirect link to sPTB in this cohort. 
IL-1Ra, CCL2, and CCL11 are the most promising candidates for cytokines involved in 
the molecular basis of sPTB in this cohort. These associations with sPTB, appear to be 
distinct from mechanisms involved in normal labour and membrane rupture. All three 
cytokines were consistently higher in sPTB deliveries when compared to the term 
group as a whole, as well as to either term group separately. The robustness of these 
associations makes it unlikely that the differences in cytokine concentration can be 
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explained by the fact that half of the term cohort was made up of pregnancies ending in 
non-spontaneous events. Instead, it is hypothesised that these cytokines may be 
directly or indirectly involved in the specific molecular mechanisms underlying sPTB. 
Such mechanisms may be activated following an infectious insult or some other 
inflammation-inducing event, such as stress. These changes could subsequently serve 
to increase the chances of premature activation of the normal labour cascade. 
Alternatively, these associations may be a consequence, rather than a cause, of the 
underlying molecular mechanisms of sPTB.  
The picture is less clear for the two other cytokines, which were initially shown to be 
up-regulated in sPTB cases, compared to term births: CCL4 and GM-CSF. Whilst the 
direction of change is the same in both term groups, there was a loss of significance for 
CCL4 when compared to the term spontaneous group, and also a loss of significance 
with GM-CSF, when compared to term non-spontaneous. Whilst this difference may be 
an issue of power reduction, due to smaller samples sizes of the sub-groups, it may also 
be representative of true underlying physiology. The discordance implies that at least 
some of the observed association between sPTB and CCL4 may be on account of the 
type of labour and/or membrane rupture method that occurred in these groups.  
The upregulation of IL-1Ra in sera from sPTB pregnancies in both regression models is 
a somewhat unexpected observation based on its known functional role. This cytokine 
is produced by macrophages, monocytes and neutrophils, and acts as the agonist for 
the IL1 receptor, functionally blocking the pro-inflammatory activity of IL1. IL1 has 
been shown across numerous independent studies to be up-regulated during 
spontaneous labour (Dubicke et al., 2010, Romero et al., 1992). Such observations serve 
to support the hypothesis that the antagonistic, and thus anti-inflammatory, effects of 
IL-1Ra may be protective of sPTB. The association of IL-1Ra with preterm birth is not 
limited to this study. Fukuda et al. (2002) observed elevated IL-1Ra expression in 
amniotic fluid and umbilical venous blood from PPROM cases. The authors 
hypothesised that this association reflected the maternal and fetal attempts to prevent 
overt and damaging (infectious mediated) inflammation. IL-1Ra has also been reported 
to be associated with labouring, compared to non-labouring, human myometrial tissue. 
This is again hypothesised to be involved in the resolution of labour associated 
inflammation (Srikhajon et al., 2014). This up-regulation of IL-1Ra, a cytokine central to 
homeostasis of inflammatory pathways, may be a direct response to a concomitant 
increase in IL1β following events such as infection. An up-regulation in sera prior to 
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preterm, as opposed to term delivery, may reflect the more extreme inflammatory 
events that precede preterm labour. This association may reflect an unsuccessful 
attempt by the immune system to suppress pro-inflammatory pathways and prevent 
sPTB, in the face of an infectious challenge. Given this observation, it is notable that we 
did not see any observable change in IL1β profiles in this study. It is possible that such 
changes were more localised to the site of infection. To our knowledge, only one other 
study has reported an association between peripheral IL-1Ra in maternal plasma and 
preterm birth (Brou et al., 2012). In a similarly sized study, women in preterm labour 
had a significantly higher concentration of Il1Ra than women in term labour in both 
maternal and fetal cord plasma. 
In this study, three functionally and structurally related proteins, CCL2, CCL4, and 
CCL11, which are all located on chromosome 17, were up-regulated in sPTB. CCL11 and 
CCL2 showed more consistent associations with the sPTB phenotype. The CC-type 
chemokines are a class of small cytokines that act primarily as chemo-attractants 
within immune-modulatory pathways. Some are considered homeostatic and key to 
cell migration and normal tissue development and maintenance. Others are pro-
inflammatory and are key to the direction of leukocytes, primarily macrophages, to 
sites of infection. These molecules exert their functionality through a large family of G-
protein coupled receptors.  
Both CCL2 and CCL4 can mediate inflammatory responses to bacterial infection 
(Williams, 2012). Mestan et al. (2009) showed that these two molecules, as well as 
CCL3, were raised in the cord blood of preterm versus term infants. By contrast, CCL2 
was shown to be down regulated in cervical secretions from preterm compared to term 
mothers (Hunter et al., 2016). However, this observation is not necessarily inconsistent 
with a systemic or intra-uterine increase in this pro-inflammatory molecule. These 
authors hypothesise that it is precisely a lack of CCL2 at the cervices of these women, 
and thus a reduction in leukocyte recruiting capacity, that makes them vulnerable to 
infection by ascending microorganisms. By contrast, a systemic or intra-uterine 
increase in CCL2 may reflect response to an already present infection, as opposed to 
defensive mechanisms in place at the cervix. The chemo-attractant properties of these 
cytokines may be involved in the recruitment of leukocytes into the chorio-decidual 
space in those sPTBs precipitated by infectious events. 
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IL5 is a Th2 cytokine. These cytokines are hypothesised to predominate the maternal 
inflammatory profile during pregnancy (Sykes et al., 2012). IL5 is key to eosinophil 
activation and has long been shown to be involved in allergic diseases such as asthma. 
The results from the present study support the idea that IL5 may be a ‘pregnancy’ 
molecule. In both term and preterm groups in which a spontaneous event had 
occurred, there was a reduction in average IL5 concentration. This implies that 
reductions in IL5 may be part of the physiological changes that occur during, or prior 
to, both term and preterm spontaneous parturition. 
There are a number of limitations to this study. In the first instance the scope of 
molecules investigated was limited by the design of a pre-defined assay. Furthermore, 
of those cytokines that were included, a large number were omitted from downstream 
analyses due to their poor performance in optimization tests. Another limitation of this 
study was sample size. The assay was expensive and the available samples within the 
timeframe outlined in the study design were limited. This may have limited the power 
of the study to detect smaller effect sizes. Furthermore, associations with additional 
outcomes of interest, for example very early preterm births or pregnancies associated 
with cervical suture, were not possible given the number of samples available. More 
complex models involving interactions of cytokines themselves were also not 
investigated here. It is likely that such network analyses will be important if 
understanding of the complex interplay of immune molecules is to be improved.  
Given the nature of the BBB resource, longitudinal data was not available for 
individuals included within this study. As data was only available at a single time point 
this precluded temporal interpretation of cytokine associations with sPTB.  Increased 
variation was also potentially introduced into the dataset by the fact that cytokines 
were assayed within a window of time prior to delivery rather than one static time 
point. Although this may have reduced the power to detect some associations, the 
majority of cytokines were assayed within 7 days of delivery.  
Finally, it was unfortunate that there was not a larger overlap between the infection 
based assays of this thesis and this immunologically focused study. This would have 
provided an exciting opportunity to test the underlying assumption that any aberrant 
inflammation observed in the sPTB group was the result of an intra-uterine infectious 
insult. However, the samples were not available within the cohort to carry out such 
comparisons with any power. 
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Results from this study support the hypothesis that aberrant inflammation, distinct 
from the normal processes involved in term labour, is involved in the period preceding 
and during spontaneous preterm parturition. The work described in this chapter used a 
previously unexplored cohort to investigate how variation in concentrations of 
commonly occurring cytokines, in the days and hours before delivery, associate with 
sPTB. Most notably, there was a consistent upregulation of the three chemokines, CCL2, 
CCL4, and CCL11, in women who experienced a sPTB event. It is plausible that these 
patterns are representative of underlying aetiologies involved in preterm birth. It is 
reasonable to hypothesise that at least some of the observed increase in these 
molecules associated with leukocyte activity was a response to underlying maternal 
infection. This hypothesis is supported by the associations between placental infection 
and sPTB described in the previous chapters of this thesis, as well as evidence from 
independent studies linking infection with sPTB. Further work is required to determine 
whether the patterns discussed above are part of the causal pathway in preterm birth, 
or are instead biomarkers of underlying inflammatory events. Studies such as this help 
to elucidate which molecules are involved in inflammation and infectious mediated 
sPTB that may be viable candidates for future clinical developments in the field. 
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: Conclusion Chapter 8
The overarching objective of this thesis was to contribute to the improvement of the 
prediction, prevention, and management of preterm birth, and ultimately, to the health 
of infants born to such pregnancies. Four key objectives were set out at the start of this 
work. Taken together, these aimed to characterise the association between placental 
infection and maternal systemic inflammation, and preterm birth, in a large UK cohort. 
Specifically, the first aim was to collate and characterise the clinical data and biological 
samples held within the BBB. The outcome of this is described in Chapter 4 and is 
reviewed in a recent publication (Leon et al, 2016), which is available as a useful 
resource for future BBB based research. Next, a case control cohort of preterm and 
healthy term pregnancies was compiled. Samples from these pregnancies were 
investigated, for both quantitative and qualitative differences in the placental bacterial 
DNA composition of preterm and term pregnancies. In recognition of recently 
published, novel observations describing an apparently unique and universal ‘placental 
microbiome’, we investigated the existence of such a signature in our own placental 
samples. The final aim of this PhD was to examine maternal systemic cytokine profiles 
in the run up to delivery, with the intention of improving understanding of maternal 
inflammatory responses associated with preterm birth. This was conducted in a 
separate BBB cohort of spontaneous preterm, and term births.  
The research described within this thesis, has demonstrated that certain placental 
microbial signatures, and maternal immunological states, associate with gestational 
length and pregnancy outcome. The studies that have been described were conducted 
on a unique and previously unexplored cohort of pregnancies, a significant number of 
which were born preterm with unknown aetiology. The examination of the broad range 
placental microbiome reported here, represents one of the largest studies to date 
carried out in this area. Our cohort contained a particularly large and valuable group of 
spontaneous, early, preterm births, taken from a multi-ethnic, UK population.  
The link between infection and sPTB is well established and has been discussed at 
length in this thesis (Goldenberg et al., 2000). However, the specific role of the placenta 
in this relationship, as a site potentially harbouring both protective and pathogenic 
organisms during gestation, remains a topic of debate. Well-established qPCR and 
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protein assays, as well as state-of-the-science NGS techniques, with analytical strategies 
developed specifically for this cohort, were used to explore this theme further. The key 
findings in this thesis demonstrated that sPTB occurrence was indeed associated with 
both a quantitative and qualitative enrichment of certain 16S placental transcripts. 
These observations serve to support previous research that has reported an 
enrichment of bacterial DNA, and cells, in placental tissue collected from preterm 
pregnancies (Onderdonk et al., 2008a, Onderdonk et al., 2008b, Prince et al., 2016, 
Rours et al., 2011, Stout et al., 2013). 
A higher 16S load was observed in placental tissue from sPTB deliveries, when 
compared to both nsPTB and term births, at both the maternal and fetal sides of the 
placenta. Not all of these associations remained significant after adjustment for 
confounders, although the direction of change was always the same, implying that 
some of this loss of significance may be attributable to issues of power. These 
observations imply that there may be a, largely overlooked, quantitative component to 
bacterial intra-uterine infection and preterm birth risk. Although these patterns were 
relatively robust, there was a large overlap in distributions of loads observed across all 
three groups: not all sPTB placenta had high 16S loads. Based on the detection of signal 
from negative extraction controls, it was not possible to conclusively assign all 
observed fluorescence from these samples to endogenous, placental bacterial DNA. 
This makes it difficult to use our qPCR data as evidence for a universal placental 
microbiome. If this entire signal was indeed ‘real’, and not from contaminants in 
reagents, the idea of a threshold quantity of bacterial DNA is a viable hypothesis for 
underlying sPTB aetiology in this cohort. However, an alternative hypothesis is that 
only the highest quantities of DNA observed in our experiments, were truly 
representative of bacterial infection during pregnancy. This latter scenario supports a 
more traditional concept of bacterial infection of the placenta as rare, largely 
pathogenic, and certainly not universal (Goldenberg et al., 2000). This distinction 
requires further investigation in future cohorts with a wider range of contamination 
controls available for analysis. 
Qualitative summaries of the placental microbiome, in both preterm and term 
delivered placenta, were produced by sequencing the V5-V7 region of the 16S gene. 
The key observation from these experiments was that a number of extreme, single 
organism infections were reproducibly present within replicate placental samples, 
from a small number of individual sPTB cases. Mycoplasma hominis, Erwinia spp., and 
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Fusobacteria spp. were some of the most notable associated organisms. These 
individual, extreme cases likely underlie the majority of differential abundance 
observations identified using the Limma statistical model. This implies that it is a sub-
section of extreme sPTB cases that account for differences in microbial signatures 
observed in this cohort, rather than a general difference in microbiome structure and 
composition between the two groups. This was supported by data from beta diversity 
analyses. There remained significant overlap between the OTUs observed within 
placenta from other sPTB cases, and the control groups used for comparison. sPTB is a 
diverse syndrome, precipitated by an array of underlying physiological and 
environmental states, with infection being just one of a number of important causes. 
This is supported by our data where only a subset of sPTB cases provided evidence for 
underlying, potentially causal, infection. However, it could also be argued that since 
only a very small section of placenta was examined from each pregnancy, a number of 
infectious cases may well have been missed if an infected part of the placenta was, by 
chance, not analysed.  
The data from these experiments provide further evidence that both vaginal and oral 
bacteria are present in placental tissue, and may contribute to adverse outcomes. 
Importantly, these associations were observed independently of mode of delivery and 
other potential confounders. Capnocytophaga and Fusobacteria spp. are two such 
examples of organisms recovered from our placental tissue. These are both genera 
largely confined to the oral cavity that have, to differing degrees, been previously 
associated with adverse pregnancy outcomes (DiGiulio, 2012, Doyle et al., 2014, Lopez 
et al., 2010a). The observations by Aagard et al. (2014) that placental bacteria more 
closely resemble the oral, rather than vaginal, cavity could not be explicitly addressed 
here. However, it was certainly not the case that oral organisms made up the largest 
proportion of transcripts recovered.  
In this study the most abundant genera present in placental tissue, whether term or 
preterm, tended to be vaginal and skin associated organisms, such as Lactobacillus spp. 
and Streptococcus spp.. Statistical analyses showed that abundances of these vaginal 
and skin organisms were strongly associated with delivery method. This demonstrated 
that this was an important determinant of colonisation patterns within this study. 
However, such genera were never exclusive to either method. This implies that not all 
of these vaginal and skin commensals were picked up during delivery, and that the 
concept of a low-level endogenous, healthy placental microbiome cannot be totally 
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rejected. Evidence from this data is inconclusive and must be further investigated, 
using cohorts with a more rigorously designed contamination protocol. Without such 
extra data, and further exploration of the involvement of delivery contaminants of 
placental samples, evidence for the universality of a placental microbiome remains 
mixed. Molecular evidence for such a phenomenon is, in light of these data, less 
conclusive than has perhaps been suggested by previous studies (Aagaard et al., 2014, 
Prince et al., 2016).  
The work in this PhD has also demonstrated that variations in certain cytokines, 
present in maternal serum, correlate with pregnancy outcome. In line with previous 
work that has demonstrated an association between inflammatory phenotypes and 
sPTB, a number of cytokines, particularly those involved in the chemotaxis of 
leukocytes, such as CCL2 and CCL4, were up-regulated in maternal blood. However, this 
pattern was not exclusively observed in pro-inflammatory proteins. The upregulation 
of IL-1Ra, a cytokine that acts to suppress the pro-inflammatory actions of IL1, 
demonstrates that certain signatures will represent responses to adverse physiological 
events, rather than being directly on the causal pathway of preterm labour. The ability 
to identify associations within peripheral blood, whether variation is directly or 
indirectly involved in sPTB mechanisms, is encouraging for future clinical 
developments. Such work may in the future help to identify those women who are most 
likely to give birth early, and those who will carry to term. Such risk assessments have 
remained a significant clinical challenge within obstetrics to date. 
This thesis has also identified, and presented strategies to mitigate, methodological 
challenges, specific to microbiome research in tissues of low biomass, such as the 
placenta. Interest in studying the human microbiome in health and disease is 
continuing to grow. Whilst the majority of early studies in this area have focused on 
well-established microbial communities in sites such as the vagina, gut, or oral cavity, 
there is increasing interest in documenting colonisation within tissues traditionally 
labelled as ‘sterile’ (Segal et al., 2013, Bassis et al., 2015). Such sites have often been 
overlooked in traditional microbiological work. Developing experimental, 
computational, and statistical approaches that have the sensitivity to identify low 
biomass communities, in mixed clinical samples, is an ongoing task. OTU picking 
algorithms, whilst constantly improving in efficiency and accuracy, remain imperfect. 
Reference databases are incomplete and of varying quality. Additionally, there remains 
a degree of inherent error within reads generated by NGS techniques. Although this is 
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relatively low, it contributes to phantom diversity and inaccurate OTU clustering, and 
thus potential misinterpretation of data. Nevertheless, in the context of such challenges, 
the work carried out in this thesis provides a proof of principle that signals of interest 
are discernible, from real patient populations and at low biomass sites.  
Future studies investigating microbial presence in the placenta would benefit for the 
inclusion of a large and diverse range of contamination controls, against which 
experimental samples can be compared. It would be ideal to have as many rigorously 
collected controls, from all stages of sample collection and experimental work, as in the 
recent study by Lauder et al. (2016). However, this paper was based on experiments 
from samples of only 12 healthy pregnancies. The feasibility of carrying out such 
stringent contamination controls in large scale, real patient populations, such as the 
BBB, is limited. A balance between the requirements of sample size and control 
collection must be met by future studies. 
Establishing causality between microbial states within the uterine cavity, systemic 
inflammatory markers, and adverse pregnancy outcomes, is complex. This endeavour is 
aided by both observational studies, such as the research outlined in this PhD, as well 
as functional in-vitro, and animal studies. Strengthening evidence for the long-standing 
associations between infection and PTB, serves to improve clinical options available to 
treat women at risk of, or threatening sPTB. The work in this thesis supports a model of 
infectious mediated sPTB in which specific organisms, rather than a complex ‘preterm 
microbiome’, elicit pathogenic outcomes. This implies that targeted antibiotic 
treatment of known pathogens could help improve PTB incidence and outcome. 
Identifying the specific contribution of vaginal versus oral species to these pathogenic 
outcomes, is also an important future aim that will further inform PTB prophylaxis, and 
therefore contribute to the improvement of maternal and infant health worldwide. 
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Appendix 
Table A 1 - Primers tested for use in qPCR analyses. Tests carried out at 20pmol/μl 
concentration. Sequences run within RDP probe match to identify number of potential 
matches to curated species within RDP database. 
 
 
 
 
 
 
Primer 
pair 
Primer Sequence 
(position on 16S rRNA E. coli 
sequence) 
Length 
(bp) 
N RDP 
matches 
PCR 
efficie
ncy 
Reference 
785F-
1175R 
GGATTAGATACCCBRGTAGTC - 
ACGTCRTCCCCDCCTTCCTC 
390 1326070 53% 
Doyle et al. 
(2014) 
785F-
907R 
GGATTAGATACCCBRGTAGTC - 
CCGTCAATTCMTTTRAGTTT  
122 1547022 140% 
Morales and 
Holben (2009) 
U337F-
U518R 
GACTCCTACGGGAGGCWGCAG 
- 
GTATTACCGCGGCTGCTGG  
181 1464742 115% Jaric et al. (2013) 
785F-
984R 
GGATTAGATACCCBRGTAGTC - 
GTAAGGTTCYTCGCGT 
199 1266536 81% 
Wang and Qian 
(2009) 
785F-
939R 
GGATTAGATACCCBRGTAGTC - 
CTTGTGCGGGYCCCCGTCAAT 
154 1473011 84% 
Wang and Qian 
(2009) 
785F-
926R 
GGATTAGATACCCBRGTAGTC - 
CCGTCAATTCMTTTGAGT 
141 1550814 81% 
Wang and Qian 
(2009) 
785F-
E939R 
GGATTAGATACCCBRGTAGTC - 
CTTGTGCGGGCCCCCGTCAATT
C 
154 1024705 86% 
Wang and Qian 
(2009) 
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Table A 2 – Summary characteristics of qPCR plates run for analysis of bacterial load 
in placental tissue. Concentrations quantified using PCR, slope R2 and efficiency refer to 
plate specific standard curves. Three negative controls were run per plate to check for 
bacterial contamination in PCR reagents. 
 
Plate 
Concentration 
of standard 
(pg/ul) 
Slope R2 
Efficiency 
(%) 
Negative 
control 1 
(CT) 
Negative 
control 2 
(CT) 
Negative 
control 3 
(CT) 
1 810 -3.90 0.99 80.16 33.10 31.47 NA 
2 810 -3.66 0.99 87.51 32.48 32.64 33.72 
3 810 -3.57 0.99 90.54 33.36 35.53 32.13 
4 810 -3.57 0.99 90.71 32.61 31.93 31.62 
5 810 -3.30 0.99 100.83 30.81 29.85 31.83 
6 550 -3.57 0.96 90.75 33.01 32.46 32.85 
7 550 -3.51 0.99 92.87 32.91 32.69 33.55 
8 550 -3.58 0.96 90.36 31.95 33.34 33.00 
9 550 -3.76 0.98 84.52 33.46 32.44 33.45 
10 550 -3.53 0.97 92.06 32.84 33.59 32.42 
11 550 -3.58 0.98 90.42 31.95 32.13 32.30 
12 550 -3.49 0.98 93.60 32.18 32.99 32.74 
13 376 -3.53 0.97 92.08 34.69 33.51 33.31 
14 376 -3.31 0.97 100.50 34.32 35.01 34.59 
15 376 -3.48 0.99 93.70 32.57 32.93 32.78 
16 376 -3.52 0.99 92.24 32.92 33.01 NA 
17 376 -3.33 0.99 99.52 30.81 31.34 31.10 
18 376 -3.40 0.96 96.80 32.36 34.97 33.21 
19 376 -3.58 0.97 90.42 32.72 32.83 34.52 
20 376 -3.44 0.96 95.33 30.60 33.27 33.45 
21 412 -3.34 0.96 99.25 31.77 32.91 32.77 
22 412 -3.31 0.96 100.41 32.10 31.97 29.94 
23 412 -3.24 0.97 103.34 31.25 31.34 31.65 
24 412 -3.43 0.98 95.86 29.89 32.86 32.62 
25 412 -3.66 1.00 87.51 32.72 31.85 29.96 
26 412 -3.69 0.98 86.63 31.36 31.60 28.42 
27 412 -3.32 0.98 100.16 29.97 32.67 32.10 
28 412 -3.37 0.99 98.15 32.54 31.94 32.66 
29 412 -3.31 0.97 100.66 32.35 32.77 32.99 
30 412 -3.59 0.99 89.79 31.39 31.87 27.60 
31 412 -3.40 0.99 96.74 32.78 33.16 28.35 
32 628 -3.48 0.99 93.84 34.37 34.56 33.46 
33 628 -3.62 0.99 89.01 32.68 35.18 31.64 
34 628 -3.50 0.98 93.12 32.38 34.51 31.68 
35 628 -3.20 0.97 105.47 32.73 32.89 32.46 
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Table A 3 – List of potential contaminating genera present in extraction reagents. 
Contaminants defined as any OTUs with at least two reads in at least two of negative extraction 
samples. Red = all OTUs mapping to genus removed from experimental samples; Orange = 
OTUs present in negative extracts removed from samples; Green = not removed from samples. 
Genus 
N OTUs in 
negative 
extractions 
N OTUs in 
placental 
samples 
Mean % 
abundance 
negative 
extractions 
Mean % 
abundance 
placental 
samples 
Listed in 
Glassing 
et al. 
(2016)? 
Acidovorax 2 2 1.67 0.06 Yes 
Aeromonas 1 1 0.05 0.04 No 
Afipia 1 1 0.09 0.04 Yes 
Arabidopsis 2 2 0.41 0.08 No 
Aureimonas 1 1 0.22 0 No 
Brevibacterium 3 21 0.23 0.05 Yes 
Chryseobacterium 1 56 0.45 0.05 Yes 
Cloacibacterium 1 9 0.03 0.38 Yes 
Enhydrobacter 3 15 5.39 0.89 Yes 
Janibacter 1 7 0.05 0.12 Yes 
Klebsiella 1 1 0.11 0.02 Yes 
Massilia 6 6 11.68 0.8 Yes 
Paracoccus 1 17 0.02 0.01 Yes 
Polynucleobacter 1 2 0.05 0 No 
Ralstonia 2 3 0.26 0.03 Yes 
Rheinheimera 1 6 0.02 0 No 
Variovorax 2 2 0.65 0.05 Yes 
Acinetobacter 25 78 20.44 4.54 Yes 
Bacillus 1 85 0 0 Yes 
Corynebacterium 4 117 0.93 0.58 Yes 
Delftia 2 11 1.12 0.19 Yes 
Dermacoccus 1 7 0.88 0.01 No 
Enterococcus 1 89 0.24 0.17 Yes 
Escherichia 6 39 4.7 1.5 Yes 
Finegoldia 1 6 0.08 0.06 No 
Granulicatella 1 9 0.09 0.07 Yes 
Haemophilus 1 20 0.04 0.02 Yes 
Kocuria 7 17 1.7 0.12 Yes 
Lactococcus 1 6 2.3 0.06 No 
Micrococcus 1 9 1.55 0.58 Yes 
Mycoplana 1 13 0.07 0.3 No 
Neisseria 2 18 0.96 0.05 Yes 
Peptoniphilus 1 20 0.19 0.1 Yes 
Peptostreptococcus 1 89 0.01 0.05 No 
Propionibacterium 6 47 4.28 1.34 Yes 
Pseudomonas 4 75 4.04 1.3 Yes 
Rothia 3 28 0.74 0.14 Yes 
Sphingomonas 3 25 1.31 0.63 Yes 
Staphylococcus 15 205 8.14 3.5 Yes 
Streptococcus 7 390 2.63 2.53 Yes 
Unassigned 5 2813 2.25 0.7 No 
Lactobacillus 2 120 0.27 17.89 Yes 
Mycoplasma 1 19 0.01 1.66 No 
Veillonella 1 22 0.22 8.18 Yes 
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Table A 4 – Distributions of types of missingness in optimisation experiments by cytokine and batch. 
 
Cytokine IL-1β IL1ra IL2 IL4 IL5 IL6 IL7 IL8 IL9 
Batch 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
Below blank 0 0 0 3 16 18 0 0 6 5 0 0 0 0 0 0 1 0 
OOR below 0 0 3 6 7 7 3 0 8 4 0 0 4 6 0 0 13 2 
OOR above 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Extrapolated 
beyond curve 
5 3 0 0 0 1 0 0 3 9 0 0 0 0 0 0 0 0 
%CV >20 0 1 0 1 0 1 0 1 0 1 0 1 3 3 0 1 4 3 
Total N (%) 
5  
(13) 
3  
(8) 
3  
(8) 
9  
(25) 
23 
(63) 
26 
(72) 
3  
(8) 
0  
(0) 
17 
(47) 
18 
(50) 
0  
(0) 
0  
(0) 
4  
(11) 
6  
(16) 
0  
(0) 
0  
(0) 
14 
(38) 
2  
(5) 
                   Cytokine IL10 IL12 IL13 IL15 IL17A CCL11 FGF basic G-CSF GM-CSF 
Batch 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
Below blank 8 3 8 9 3 6 17 25 10 12 0 0 9 7 0 0 33 28 
OOR below 0 0 0 0 7 2 6 5 4 0 0 0 5 1 9 0 1 2 
OOR above 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Extrapolated 
beyond curve 
0 6 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
%CV >20 0 1 0 1 3 4 0 1 0 1 0 1 0 1 2 1 1 0 
Total N (%) 
8  
(22) 
9  
(19) 
8  
(22) 
10 
(27) 
10 
(27) 
8  
(22) 
23 
(63) 
30 
(83) 
14 
(38) 
12 
(33) 
0  
(0) 
0  
(0) 
14 
(38) 
8  
(22) 
9  
(25) 
0  
(0) 
34 
(94) 
30 
(83) 
                   Cytokine IFN-γ CXCL10 CCL2 CCL3 PDGFbb CCL4 RANTES TNF-α VEGF 
Batch 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
Below blank 0 0 0 0 14 2 3 0 0 0 0 0 0 0 8 3 18 14 
OOR below 36 19 0 0 5 10 0 0 0 0 0 0 0 0 0 0 7 0 
OOR above 0 0 0 0 0 0 0 0 0 0 0 0 31 0 0 0 0 0 
Extrapolated 
beyond curve 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 1 3 
%CV >20 0 1 0 0 0 3 0 1 2 2 0 0 0 0 0 1 0 1 
Total N (%) 
36 
(100) 
19  
(52) 
0  
(0) 
0  
(0) 
19 
(52) 
12 
(33) 
3  
(8) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
31 
(86) 
0  
(0) 
9  
(25) 
7  
(19) 
26 
(72) 
17 
(47) 
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Table A 5 – Summary of cytokine concentration distributions when samples are diluted 1:2 or 1:4. Comparisons of medians conducted using Wilcox 
test. 
 
Cytokine 
1:2 Dilution 1:4 Dilution Difference 
between 
medians 
Difference 
between 
ranges 
W P 
Median Min-Max (Range) Median Min-Max (Range) 
IL-1β 2.52 0.34-6.44 (6.1) 3.99 0.19-8.21 (8.02) 1 1.92 527 0.175 
IL-1Ra 146.24 0-399.77 (399.77) 223.17 0-517.87 (517.87) 77 118.1 519 0.148 
IL2 2.60 0.125-26.39 (26.27) 2.60 0.125-38.62 (38.50) 0 12.23 627 0.806 
IL4 5.54 0.64-15.33 (14.69) 8.03 0.15-25.6 (25.45) 2 10.76 458 0.033 
IL5 4.20 0.03-16.49 (16.46) 5.08 0.03-23.77 (23.74) 1 7.28 570 0.489 
IL6 17.10 0-27.27 (27.27) 23.36 3.07-36.56 (33.49) 6 6.22 327 0.00031 
IL7 6.75 0-13.71 (13.71) 7.33 0-34.65 (34.65) 1 20.94 486 0.353 
IL8 21.51 0-53.14 (53.14) 37.73 0-83.83 (83.83) 16 30.69 424 0.012 
IL9 11.15 0-31.89 (31.89) 26.90 0-47.32 (47.32) 16 15.43 341 0.004 
IL10 0.62 0-21.38 (21.38) 0.00 0-32.49 (32.49) -1 11.11 462 0.053 
IL12 11.57 0-34.88 (34.88) 28.36 0-73.58 (73.58) 17 38.7 444 0.021 
IL13 5.05 0.225-13.12 (12.90) 5.49 0.225-12.4 (12.175) 0 -0.72 502 0.594 
IL15 3.33 0-24.09 (24.09) 0.68 0-33.58 (33.58) -3 9.49 706 0.469 
IL17A 33.12 0.85-124.14 (123.29) 99.50 0.85-309.61 (308.76) 66 185.47 464 0.036 
CCL11 0.00 0-49.74 (49.74) 0.00 0-70.08 (70.08) 0 20.34 354 0.0010 
FGF basic 15.07 0.465-98.17 (97.71) 46.92 0.465-236 (235.54) 32 137.83 467 0.059 
G-CSF 60.31 6.13-158.52 (152.39) 99.75 6.13-233.61 (227.48) 39 75.09 407 0.016 
GM-CSF 1.55 0-5.96 (5.96) 1.55 0-71.88 (71.88) 0 65.92 501 0.006 
IFN-γ 66.05 43.865-178.65 (134.79) 66.05 0-250.55 (250.55) 0 115.765 610 0.64 
CXCL10 280.37 90.24-562.73 (472.49) 353.00 191.35-710.74 (519.39) 73 46.9 427 0.012 
CCL2 17.91 3.61-55.18 (51.57) 28.98 3.61-105.28 (101.67) 11 50.1 550 0.457 
CCL3 2.63 0.42-5.7 (5.28) 7.59 0.085-13.91 (13.83) 5 8.545 354 0.0010 
PDGF bb 495.58 0-2688.37 (2688.37) 788.54 0-3548.13 (3548.13) 293 859.76 445 0.11 
CCL4 0.00 0-54.03 (54.03) 37.67 0-96.19 (96.19) 38 42.16 201 9.9E-08 
RANTES 1323.94 1064.36-6263.08 (5198.72) 2873.28 1323.94-15485.9 (14161.96) 1549 8963.24 421 0.0080 
TNF-α 25.27 0.415-84.68 (84.27) 42.52 0.42-120.41 (119.99) 17 35.725 498 0.092 
VEGF 0.31 0.27-27.17 (26.9) 1.26 0.27-53.66 (53.39) 1 26.49 465 0.031 
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Table A 6 – Adjusted and unadjusted regression models for impact of maternal BMI on GA at birth (weeks). 
 
 
Table A 7 – Adjusted and unadjusted regression models for impact of maternal BMI on odds of having a term versus preterm birth.  
 
 
 
Predictors 
Unadjusted Adjusted 
β (95% CI) β SE P β (95% CI) β SE P 
Intercept 38.45 (38.32-38.59) 0.069 <2E-16 38.72 (38.56-38.88) 0.08 < 2E-16 
Maternal BMI (baseline = Normal)    
   
 Obese -0.32 (-0.67-0.04) 0.18 0.080 -0.16 (-0.54-0.21) 0.19 3.83E-01 
 Underweight -0.25 (-0.98-0.48) 0.37 0.50 -0.27 (-1.03-0.49) 0.39 4.84E-01 
Maternal ethnicity (baseline =White, white British)      
 Asian, Asian British    -1.36 (-1.96--0.75) 0.31 1.30E-05 
 Black, Black British    -1.22 (-1.66--0.79) 0.22 5.44E-08 
 All others    -0.57 (-0.9--0.23) 0.17 1.11E-03 
Predictors 
Unadjusted Adjusted 
OR (95% CI) β SE P OR (95% CI) β SE P 
Intercept 6.03 (5.26-6.95) 0.071 <2E-16 7.64 (6.4-9.2) 0.092 < 2E-16 
Maternal BMI (baseline=Normal)       
 Obese 0.78 (0.56-1.1) 0.17 0.15 0.86 (0.61-1.25) 0.18 0.43 
 Underweight 0.69 (0.37-1.43) 0.34 0.29 0.63 (0.33-1.31) 0.35 0.19 
Maternal ethnicity (baseline = White, white British)      
 Asian, Asian British    0.47 (0.28-0.83) 0.28 0.0063 
 Black, Black British    0.39 (0.27-0.58) 0.20 2.08E-06 
 All others    0.66 (0.47-0.93) 0.17 0.017 
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Table A 8 – Adjusted and unadjusted regression models for impact of maternal diabetes status on GA at birth (weeks). 
 
 
Table A 9 – Adjusted and unadjusted regression models for showing impact of maternal diabetes status on odds of having a term over preterm 
birth. The odds of having a preterm birth in mothers with gestational or established diabetes are higher than those of having a term birth. This remains 
significant for gestational but not established diabetes status, when adjusted for the confounding effects of maternal ethnicity. 
 
 
Predictors 
Unadjusted Adjusted 
β  (95% CI) β SE P β  (95% CI) β SE P 
Intercept 38.29 (38.14-38.44) 0.08 < 2E-16 38.59 (38.39-38.78) 0.10 < 2E-16 
Maternal diabetes (baseline=None)       
 Gestational -0.87 (-1.62--0.12) 0.38 0.023 -0.75 (-1.53-0.03) 0.40 0.061 
 Established -1.38 (-2.36--0.39) 0.50 0.0063 -1.16 (-2.17--0.14) 0.52 0.025 
Maternal ethnicity (baseline= White, white British)      
 Asian, Asian British    -1.86 (-2.61--1.11) 0.38 1.27E-06 
 Black, Black British    -1.21 (-1.69--0.73) 0.25 9.35E-07 
 All others    -0.52 (-0.93--0.11) 0.21 0.013 
Predictors 
Unadjusted Adjusted 
OR (95% CI) β SE P OR (95% CI) β SE P 
(Intercept) 5.27 (4.58-6.09) 0.07 <2E-16 6.6 (5.46-8.06) 0.10 < 2E-16 
Maternal diabetes (baseline=None)       
 Gestational 0.44 (0.25-0.8) 0.29 0.0051 0.45 (0.25-0.84) 0.31 0.01 
 Established 0.46 (0.22-1.01) 0.38 0.0402 0.61 (0.28-1.48) 0.42 0.24 
Maternal ethnicity (baseline= White, white British)      
 Asian, Asian British    0.38 (0.21-0.69) 0.30 0.00103 
 Black, Black British    0.43 (0.29-0.64) 0.20 2.63E-05 
 All others    0.71 (0.49-1.05) 0.19 0.08 
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Table A 10 - Adjusted and unadjusted models for effect of a one-week increase in GA at birth on the odds of having a vaginal over a CS delivery. 
The odds of having a vaginal rather than a CS delivery increase with every one-week increase in GA at birth. This relationship remains significant with 
adjustment for potential confounders. 
 
 
 
Predictor 
 Unadjusted  Adjusted 
OR (95% CI) β SE P OR (95% CI) β  SE P 
Intercept 0.0016 (0.00030-0.0077) 0.83 6.06E-15 0.0081 (0.0013-0.048) 0.92 1.76E-07 
GA at birth 1.20 (1.15-1.25) 0.022 <2e-16 1.21 (1.16-1.26) 0.022 <2E-16 
Parity (baseline=0)      
 
1  
 
0.95 (0.74-1.21) 0.12 0.68 
2 or 3  1.36 (0.97-1.92) 0.17 0.074 
4 or more  1.91 (0.77-5.08) 0.48 0.17 
Maternal age at booking  0.94 (0.92-0.96) 0.011 3.87E-08 
Maternal diabetes (baseline=No)     
 
Established  0.31 (0.58-1.73) 0.28 0.0294 
Gestational  1.00 (0.09-0.81) 0.54 0.99 
Maternal BMI  
 
 0.025 
 Obese   0.68 (0.49-0.93) 0.16 0.015 
 Underweight   1.18 (0.65-2.26) 0.32 0.596 
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Table A 11 – Summary table showing comparison in distributions of key clinical characteristics between preterm pregnancies within the BBB 
taken forward for qPCR analyses of placental tissue, compared to those without available placental tissue. 
Clinical 
characteristic 
Sub-group 
qPCR preterm cohort 
(N=146) 
BBB preterm samples without placental tissue 
(N=145) 
Wilcox or X2 
GA at birth  
Mean = 33.5 SD = 3.01 
Median = 35 IQR = 33-36 
Mean = 32.8 SD = 3.8 
Median = 34 IQR = 31-36 
W=11354 
P=0.27 
Birthweight  
Mean = 2122 SD =745 
Median = 2230 IQR = 1605-2600 
Mean = 2012 SD = 798.2 
Median = 2080 IQR = 1510-2540 
W=10755 
P=0.23 
Delivery method    
 Vaginal 54 (37%) 47 (32.4%) X2 = 0.00026 
P=0.99  CS 87 (59.6%) 73 (50.3%) 
Labour onset     
 No labour 88 (60.3%) 74 (51.0%) X2 = 0.90 
P=0.34  Spontaneous 44 (30.1%) 49 (34.0%) 
Membrane rupture    
 None 81 (55.5%) 68 (46.9%) X2 = 0.73  
P = 0.39  Spontaneous 51 (34.9%) 55 (37.9%) 
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Table A 12 - Adjusted multi-level linear regression model for association between 
bacterial load (log 16S copy number) and pregnancy outcome in whole cohort. 
Predictor β (95% CI) β SE P 
Intercept 4.67 (4.25-5.09) 0.21 <2.2E-16 
Outcome 
(baseline=sPTB) 
nsPTB -0.29 (-0.5--0.08) 0.11 0.0064 
Term -0.13 (-0.3-0.04) 0.09 0.13 
Delivery method Vaginal -0.02 (-0.15-0.12) 0.07 0.79 
Maternal ethnicity 
Asian 0.05 (-0.22-0.31) 0.14 0.73 
Black 0.29 (0.09-0.48) 0.10 0.0047 
All others -0.05 (-0.22-0.12) 0.09 0.58 
Plate 
2 1.33 (0.93-1.73) 0.20 4.3E-10 
3 0.09 (-0.36-0.55) 0.23 0.69 
4 0.63 (0.21-1.05) 0.21 3.4E-03 
5 0.17 (-0.44-0.77) 0.31 0.59 
6 0.47 (0.03-0.91) 0.22 0.037 
7 0.03 (-0.36-0.43) 0.20 0.87 
8 0.5 (0.07-0.93) 0.22 0.024 
9 1.48 (1.06-1.91) 0.21 4.2E-11 
10 0.72 (0.29-1.14) 0.21 9.8E-04 
11 1.19 (0.81-1.57) 0.19 2.6E-09 
12 0.93 (0.53-1.32) 0.20 5.5E-06 
13 0.55 (0.17-0.94) 0.20 0.0054 
14 0.15 (-0.24-0.54) 0.20 0.46 
15 -0.09 (-0.52-0.33) 0.22 0.67 
16 -0.01 (-0.44-0.41) 0.22 0.95 
17 0.04 (-0.45-0.52) 0.25 0.88 
18 0.1 (-0.36-0.57) 0.24 0.66 
19 0.44 (0.03-0.86) 0.21 0.035 
20 0.7 (0.22-1.19) 0.25 0.0046 
21 -0.35 (-0.76-0.06) 0.21 0.097 
22 -0.39 (-0.81-0.03) 0.21 0.071 
23 0.15 (-0.24-0.55) 0.20 0.44 
24 0.35 (-0.07-0.76) 0.21 0.10 
25 0.85 (0.44-1.27) 0.21 6.60E-05 
26 0.65 (0.03-1.26) 0.31 0.039 
27 0.28 (-0.15-0.72) 0.22 0.20 
28 0.05 (-0.39-0.48) 0.22 0.84 
29 -0.54 (-0.98--0.09) 0.22 0.018 
30 0.38 (-0.06-0.82) 0.22 0.089 
31 -0.31 (-0.76-0.13) 0.23 0.17 
32 0.49 (0.03-0.95) 0.23 0.037 
33 0.68 (0.27-1.09) 0.21 1.20E-03 
34 0.33 (-0.05-0.71) 0.19 0.084 
35 -0.43 (-0.85-0) 0.22 0.048 
Smoking No -0.09 (-0.33-0.15) 0.12 0.46 
Maternal BMI Obese -0.02 (-0.18-0.15) 0.08 0.86 
 
Underweight -0.14 (-0.44-0.16) 0.15 0.36 
Recruitment centre QCCH -0.05 (-0.31-0.2) 0.13 0.69 
 
SMH -0.01 (-0.14-0.12) 0.07 0.86 
Tissue type Villous 0.07 (-0.11-0.25) 0.09 0.43 
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Table A 13 - Adjusted multi-level linear regression model for association between 
bacterial load (log 16S copy number) and pregnancy outcome in parenchyma tissue. 
Predictor β (95% CI) β SE P 
Intercept 
 
4.74 (4.32-5.16) 0.21 <2.2E-16 
Outcome 
(baseline=sPTB) 
nsPTB -0.33 (-0.53--0.12) 0.11 0.0022 
Term -0.15 (-0.32-0.02) 0.09 0.076 
Delivery method Vaginal -0.05 (-0.19-0.08) 0.07 0.43 
Ethnicity 
Asian 0.07 (-0.2-0.33) 0.13 0.63 
Black 0.25 (0.05-0.44) 0.10 0.013 
All others -0.02 (-0.2-0.15) 0.09 0.79 
Plate 
2 1.31 (0.92-1.7) 0.20 4.93E-10 
3 0.14 (-0.3-0.58) 0.22 0.53 
4 0.64 (0.23-1.05) 0.21 0.0025 
5 0.06 (-0.53-0.66) 0.30 0.84 
6 0.46 (0.02-0.89) 0.22 0.039 
7 0.04 (-0.34-0.43) 0.19 0.82 
8 0.53 (0.11-0.95) 0.21 0.015 
9 1.49 (1.08-1.91) 0.21 3.27E-11 
10 0.73 (0.32-1.14) 0.21 0.00057 
11 1.19 (0.82-1.56) 0.19 1.9E-09 
12 0.92 (0.54-1.3) 0.19 4.3E-06 
13 0.55 (0.17-0.93) 0.19 0.0046 
14 0.17 (-0.21-0.55) 0.19 0.38 
15 -0.12 (-0.53-0.3) 0.21 0.58 
16 -0.02 (-0.43-0.4) 0.21 0.94 
17 0.05 (-0.47-0.56) 0.26 0.86 
19 0.28 (-0.19-0.75) 0.24 0.25 
20 0.69 (-0.17-1.54) 0.43 0.12 
21 -0.31 (-0.71-0.09) 0.20 0.13 
22 -0.35 (-0.78-0.07) 0.22 0.10 
23 0.16 (-0.23-0.55) 0.20 0.41 
24 0.23 (-0.19-0.65) 0.21 0.28 
25 0.77 (0.36-1.18) 0.21 0.00030 
26 0.67 (0.08-1.27) 0.30 0.027 
27 0.39 (-0.09-0.87) 0.24 0.12 
28 0.1 (-0.34-0.55) 0.23 0.64 
29 -0.58 (-1.08--0.07) 0.26 0.025 
30 0.45 (-0.03-0.93) 0.24 0.065 
31 -0.24 (-0.71-0.22) 0.23 0.30 
32 0.54 (0.08-1) 0.23 0.022 
33 0.8 (0.36-1.23) 0.22 0.00037 
34 0.34 (-0.05-0.72) 0.20 0.090 
35 -0.29 (-0.73-0.15) 0.22 0.20 
Smoking No -0.15 (-0.4-0.1) 0.13 0.24 
Maternal BMI Obese 0 (-0.16-0.16) 0.08 0.98 
 
Underweight -0.11 (-0.42-0.19) 0.16 0.47 
Recruitment 
hospital 
QCCH -0.01 (-0.28-0.25) 0.14 0.93 
SMH 0 (-0.12-0.13) 0.06 0.98 
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Table A 14 - Adjusted multi-level linear regression model for association between 
bacterial load (log 16S copy number) and pregnancy outcome in villous tissue. 
Predictor β (95% CI) β SE P 
Intercept 5.25 (3.72-6.78) 0.76 7.04E-09 
Outcome 
(baseline=sPTB)  
nsPTB -0.59 (-1.43-0.26) 0.42 0.17 
Term -0.32 (-1.01-0.36) 0.34 0.35 
Delivery method Vaginal 0.09 (-0.4-0.57) 0.24 0.72 
Maternal ethnicity 
Asian, Asian British 0.46 (-0.6-1.52) 0.53 0.39 
Black, Black British 0.71 (-0.15-1.57) 0.43 0.10 
All others -0.26 (-0.82-0.31) 0.28 0.37 
Plate 
18 -0.07 (-1.43-1.29) 0.68 0.92 
19 0.35 (-1.04-1.73) 0.69 0.62 
20 0.41 (-0.95-1.76) 0.68 0.55 
22 -0.72 (-2.51-1.07) 0.89 0.42 
23 -0.19 (-1.99-1.62) 0.90 0.84 
24 0.78 (-0.89-2.46) 0.84 0.35 
25 1.17 (-0.64-2.99) 0.91 0.20 
27 -0.46 (-1.96-1.04) 0.75 0.54 
28 -0.92 (-2.62-0.77) 0.85 0.28 
29 -0.95 (-2.38-0.48) 0.71 0.19 
30 0.21 (-1.26-1.69) 0.73 0.77 
31 -0.76 (-2.33-0.8) 0.78 0.33 
32 -0.67 (-2.83-1.48) 1.08 0.53 
33 0.03 (-1.44-1.5) 0.73 0.96 
34 -0.03 (-1.55-1.5) 0.76 0.97 
35 -1.02 (-2.52-0.48) 0.75 0.18 
Smoking No -0.07 (-0.75-0.6) 0.34 0.83 
Maternal BMI 
Obese -0.17 (-0.91-0.58) 0.37 0.66 
Underweight -0.68 (-1.66-0.3) 0.49 0.17 
Recruitment 
hospital 
QCCH -0.15 (-0.85-0.56) 0.35 0.68 
SMH -0.72 (-1.69-0.25) 0.48 0.14 
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Table A 15 - Adjusted regression model for association between placental bacterial 
load (log 16S copy number) and cervical suture in current pregnancy 
Predictor β (95% CI) β SE P 
Intercept 4.65 (4.21-5.09) 0.22 6.94E-58 
Suture No -0.31 (-0.64-0.02) 0.17 0.068 
Delivery Vaginal 0.01 (-0.13-0.16) 0.07 0.84 
Plate 
2 1.53 (1.12-1.94) 0.21 4.9E-12 
3 0.19 (-0.28-0.66) 0.24 0.43 
4 0.86 (0.43-1.29) 0.22 0.00012 
5 0.39 (-0.27-1.05) 0.33 0.24 
6 0.74 (0.24-1.23) 0.25 0.0038 
7 0.28 (-0.13-0.7) 0.21 0.18 
8 0.53 (0.1-0.97) 0.22 0.016 
9 1.69 (1.24-2.13) 0.23 3.5E-12 
10 0.87 (0.43-1.31) 0.22 0.00014 
11 1.42 (1.05-1.8) 0.19 3.7E-12 
12 1.11 (0.71-1.51) 0.20 1.3E-07 
13 0.73 (0.33-1.12) 0.20 0.00036 
14 0.26 (-0.15-0.66) 0.21 0.21 
15 0.14 (-0.31-0.58) 0.23 0.54 
16 0.25 (-0.25-0.76) 0.26 0.33 
17 -0.24 (-1.49-1.01) 0.63 0.71 
18 0.18 (-0.32-0.68) 0.25 0.48 
19 0.55 (0.11-0.98) 0.22 0.014 
20 0.89 (0.37-1.41) 0.26 0.00082 
21 -0.14 (-0.56-0.27) 0.21 0.50 
22 -0.17 (-0.62-0.27) 0.22 0.44 
23 0.36 (-0.04-0.77) 0.21 0.078 
24 0.55 (0.13-0.98) 0.21 0.011 
25 1.06 (0.63-1.49) 0.22 2.5E-06 
26 0.85 (0.24-1.46) 0.31 0.0069 
27 0.52 (0.07-0.96) 0.23 0.023 
28 0.2 (-0.25-0.65) 0.23 0.39 
29 -0.3 (-0.8-0.2) 0.25 0.24 
30 0.55 (0.06-1.03) 0.25 0.028 
31 -0.2 (-0.67-0.28) 0.24 0.42 
32 0.66 (0.19-1.14) 0.24 0.0063 
33 0.89 (0.47-1.31) 0.21 4.12E-05 
34 0.59 (0.19-0.98) 0.20 0.0039 
35 -0.29 (-0.72-0.14) 0.22 0.18 
Outcome 
nsPTB -0.19 (-0.41-0.03) 0.11 0.098 
Term -0.11 (-0.28-0.07) 0.09 0.24 
Tissue Villous 0.05 (-0.14-0.25) 0.10 0.59 
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Table A 16 – Log2 fold change of differentially abundant OTUs between vaginally and 
CS delivered placenta. Q values are Benjamini-Hochberg adjusted P values. 
OTU Genus Log2 fold change P Q 
519673 Lactobacillus -3.15 (-4.16--2.14) 2.96E-09 3.65E-06 
823803 Lactobacillus -1.15 (-1.57--0.72) 2.18E-07 1.35E-04 
820367 Lactobacillus -0.68 (-0.94--0.41) 1.03E-06 3.39E-04 
593376 Lactobacillus -0.79 (-1.1--0.48) 1.10E-06 3.39E-04 
888575 Lactobacillus -1.36 (-1.94--0.79) 5.28E-06 1.22E-03 
813785 Lactobacillus -1.15 (-1.64--0.66) 5.92E-06 1.22E-03 
553352 Lactobacillus -0.51 (-0.74--0.28) 2.05E-05 3.62E-03 
NROTU60 Lactobacillus -0.93 (-1.36--0.5) 2.95E-05 4.56E-03 
815380 Lactobacillus -0.51 (-0.75--0.27) 3.56E-05 4.88E-03 
806179 Lactobacillus -0.44 (-0.66--0.23) 6.45E-05 7.97E-03 
4447432 Lactobacillus -0.82 (-1.23--0.41) 1.00E-04 1.12E-02 
817903 Lactobacillus -0.55 (-0.83--0.26) 1.92E-04 1.92E-02 
498355 Lactobacillus -0.55 (-0.83--0.26) 2.01E-04 1.92E-02 
354225 Lactobacillus -0.58 (-0.89--0.27) 2.63E-04 2.32E-02 
316515 Lactobacillus -0.3 (-0.47--0.13) 5.41E-04 4.18E-02 
335967 Lactobacillus -0.26 (-0.4--0.11) 5.41E-04 4.18E-02 
255367 Lactobacillus -0.35 (-0.55--0.14) 9.02E-04 6.56E-02 
308463 Lactobacillus -0.26 (-0.41--0.1) 1.20E-03 8.22E-02 
350349 Lactobacillus -0.32 (-0.52--0.13) 1.26E-03 8.22E-02 
NROTU138 Lactobacillus -0.65 (-1.05--0.26) 1.35E-03 8.32E-02 
840914 Prevotella -0.62 (-1--0.24) 1.47E-03 8.59E-02 
956654 Lactobacillus -1.62 (-2.61--0.62) 1.53E-03 8.59E-02 
366068 Faecalibacterium -0.47 (-0.77--0.18) 1.63E-03 8.75E-02 
132873 Lactobacillus -0.35 (-0.57--0.13) 2.26E-03 1.16E-01 
365717 Faecalibacterium -0.38 (-0.63--0.13) 3.05E-03 1.49E-01 
622256 Ruminococcus -0.49 (-0.82--0.17) 3.12E-03 1.49E-01 
697479 Tepidimonas 1.1 (0.35-1.86) 4.19E-03 1.89E-01 
4200918 Lactobacillus -0.3 (-0.5--0.09) 4.27E-03 1.89E-01 
4348210 Lactobacillus -0.23 (-0.38--0.07) 4.44E-03 1.89E-01 
583656 Bacteroides -0.38 (-0.64--0.12) 4.72E-03 1.94E-01 
818672 Lactobacillus -0.22 (-0.38--0.07) 5.18E-03 2.07E-01 
936190 Streptococcus 0.14 (0.04-0.23) 5.65E-03 2.18E-01 
344154 Bacteroides -0.49 (-0.83--0.14) 5.82E-03 2.18E-01 
244464 Lactobacillus -0.2 (-0.34--0.06) 6.07E-03 2.20E-01 
804653 Lactobacillus -0.19 (-0.32--0.05) 6.22E-03 2.20E-01 
1015143 Streptococcus 0.18 (0.05-0.32) 6.63E-03 2.28E-01 
944266 Staphylococcus 0.3 (0.08-0.51) 7.22E-03 2.41E-01 
NROTU158 Streptococcus 0.5 (0.14-0.87) 7.52E-03 2.45E-01 
958496 Lactobacillus -0.15 (-0.26--0.04) 8.09E-03 2.56E-01 
766571 Staphylococcus 0.16 (0.04-0.27) 8.27E-03 2.56E-01 
813944 Lactobacillus -0.2 (-0.34--0.05) 8.50E-03 2.56E-01 
560336 Bacteroides -0.34 (-0.6--0.09) 8.84E-03 2.56E-01 
359650 Faecalibacterium -0.18 (-0.31--0.05) 9.05E-03 2.56E-01 
525215 Faecalibacterium -0.3 (-0.53--0.08) 9.13E-03 2.56E-01 
132829 Lactobacillus -0.15 (-0.27--0.04) 9.59E-03 2.60E-01 
1028283 Prevotella -0.53 (-0.94--0.13) 9.66E-03 2.60E-01 
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Figure A 1 - Abundance (%) of total reads in placentas from individual pregnancies by individual genera 1. A) sPTB placenta B) Term delivered 
placenta C) nsPTB placenta. 
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Figure A 2 - Abundance (%) of total reads in placentas from individual pregnancies by individual genera 2. A) sPTB placenta B) Term delivered 
placenta C) nsPTB placenta. 
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Figure A 3 - Abundance (%) of total reads in placentas from individual pregnancies by individual genera 3. A) sPTB placenta B) Term delivered 
placenta C) nsPTB placenta. 
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Table A 17 – Distribution of missingness (%) by cytokine and batch in 6 ELISA assays. 
Batch 
Type of 
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Batch 1 
(%) 
LOD 0 0 47 0 0 0 0 0 0 12 0 0 82 0 0 0 0 65 0 0 65 0 0 0 0 0 12 
OOR 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 65 0 0 
Total 0 0 47 0 0 0 0 0 0 12 6 0 82 0 0 0 0 65 0 0 65 0 0 0 65 0 12 
Batch 2 
(%) 
LOD 0 0 64 0 0 0 0 0 0 7 0 0 100 7 0 7 0 93 0 0 64 7 0 0 0 0 7 
OOR 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 71 0 0 
Total 0 0 64 0 7 0 0 0 0 7 0 0 100 7 0 7 0 93 0 0 64 7 0 0 71 0 7 
Batch 3 
(%) 
LOD 0 0 25 0 0 0 0 0 0 6 0 0 75 0 0 0 0 62 0 0 56 0 0 0 0 0 6 
OOR 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 6 0 0 62 0 0 
Total 0 0 25 0 0 6 0 0 0 6 0 0 75 0 0 0 0 62 6 0 56 6 0 0 62 0 6 
Batch 4 
(%) 
LOD 0 0 65 0 41 0 0 0 0 18 0 0 88 12 0 6 0 88 0 0 76 6 0 0 0 0 29 
OOR 6 6 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Total 6 6 65 0 41 6 0 0 0 18 0 0 88 12 0 6 0 88 0 0 76 6 0 0 0 0 29 
Batch 5 
(%) 
LOD 0 0 74 0 34 0 0 0 0 0 3 47 76 0 0 0 0 42 0 0 39 0 0 0 0 0 3 
OOR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 0 0 
Total 0 0 74 0 34 0 0 0 0 0 3 47 76 0 0 0 0 53 0 0 39 0 0 0 0 0 3 
Batch 6 
(%) 
LOD 0 3 53 0 8 0 0 0 0 0 0 0 82 0 0 0 0 29 0 0 63 0 0 0 0 0 0 
OOR 0 36 0 0 0 0 0 100 0 0 0 0 13 3 0 0 0 16 0 0 0 0 0 0 0 0 0 
Total 0 39 53 0 8 0 0 100 0 0 0 0 95 3 0 0 0 45 0 0 63 0 0 0 0 0 0 
All 
plates 
(%) 
LOD 0 1 57 0 16 0 0 0 0 5 1 13 82 2 0 1 0 54 0 0 58 1 0 0 0 0 7 
OOR 1 10 0 0 1 1 0 27 0 0 0 0 4 1 0 0 0 7 1 0 0 1 0 0 22 0 0 
Total 1 11 57 0 17 1 0 27 0 5 1 13 86 3 0 1 0 61 1 0 58 2 0 0 22 0 7 
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Table A 18 – Intraclass correlation coefficients between concentrations individual 
cytokines of technical replicates in optimisation and experimental datasets. Grey=not 
taken forward to final analyses due to poor reproducibility. 
Cytokine 
ICC (95% CI) 
Optimisation data (N=36) Experimental data (N=14) 
IL-1β 0.96 (0.92-0.98) 0.85 (0.6-0.95) 
IL-1Ra 0.85 (0.72-0.92) 0.51 (0.02-0.82) 
IL2 0.73 (0.53-0.85) 0.5 (0-0.81) 
IL4 0.25 (-0.07-0.53) -0.33 (-0.65-0.21) 
IL5 0.88 (0.79-0.94) 0.42 (-0.09-0.78) 
IL6 0.95 (0.91-0.98) 0.67 (0.26-0.89) 
IL7 0.49 (0.2-0.7) -0.2 (-0.58-0.35) 
IL8 0.51 (0.23-0.72) 0.93 (0.81-0.98) 
IL9 0.75 (0.57-0.87) -0.15 (-0.55-0.39) 
IL10 0.9 (0.81-0.95) 0.52 (0.04-0.83) 
IL12 0.88 (0.78-0.94) 0.69 (0.29-0.9) 
IL13 0.7 (0.48-0.83) -0.07 (-0.5-0.46) 
IL15 0.26 (-0.07-0.54) 0.33 (-0.18-0.73) 
IL17A 0.93 (0.86-0.96) 0.63 (0.19-0.87) 
CCL11 0.83 (0.7-0.91) 0.5 (0-0.81) 
FGF-basic 0.84 (0.72-0.92) 0.39 (-0.12-0.76) 
G-CSF 0.77 (0.6-0.88) 0.16 (-0.33-0.64) 
GM-CSF 0.77 (0.6-0.88) 0.39 (-0.12-0.76) 
IFN-γ 0.03 (-0.3-0.35) 0.12 (-0.37-0.61) 
CXCL10 0.76 (0.59-0.87) 0.15 (-0.34-0.63) 
CCL2 0.52 (0.24-0.72) 0.71 (0.31-0.9) 
CCL3 0.85 (0.73-0.92) 0.79 (0.47-0.93) 
PDGF-BB 0.72 (0.52-0.85) 0.02 (-0.44-0.54) 
CCL4 0.88 (0.78-0.94) 0.83 (0.56-0.95) 
RANTES -0.52 (-0.72--0.24) -0.06 (-0.5-0.47) 
TNF-α 0.85 (0.72-0.92) 0.48 (-0.02-0.81) 
VEGF 0.78 (0.62-0.88) 0.7 (0.3-0.9) 
 
Table A 19 – Comparison of AIC values when one (participant Trio number) or two 
(Trio and Batch) random intercepts are used to predict cytokine concentration from 
pregnancy outcome using ANOVA. 
Cytokine Trio AIC Trio and batch AIC ANOVA P Include batch as a level? 
IL1β 145.75 113.96 6.16E-09 Yes 
IL-1Ra 335.04 337.04 0.99 No 
IL2 467.76 469.71 0.83 No 
IL5 381.36 361.37 2.75E-06 Yes 
IL6 332.22 334.06 0.68 No 
IL8 357.55 357.23 0.13 No 
IL10 477.68 477.18 0.11 No 
IL12 394.94 377.66 1.13E-05 Yes 
IL17A 388.19 365.11 5.54E-07 Yes 
CCL11 161.87 159.27 0.032 Yes 
FGF-basic 340.80 298.84 3.50E-11 Yes 
GM-CSF 606.40 601.53 0.0088 Yes 
CCL2 578.23 579.45 0.38 No 
CCL3 253.87 234.00 2.93E-06 Yes 
CCL4 142.67 135.02 0.0019 Yes 
TNF-α 195.27 164.45 1.01E-08 Yes 
VEGF 461.69 421.60 8.70E-11 Yes 
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Table A 20 – Unadjusted, fixed effects linear regression models predicting effect on cytokine concentration (pg/ml) from 2 or 3 group models of 
pregnancy outcome.  
Cytokine Model Term Estimate SE P 
IL1ra 
2 group model 
Intercept 4.87 (4.65-5.08) 0.11 <2E-16 
Term -0.3 (-0.58--0.02) 0.14 0.034* 
3 group model 
Intercept 4.87 (4.65-5.08) 0.11 <2E-16 
Spontaneous term -0.35 (-0.68--0.02) 0.17 0.039* 
Non spontaneous term -0.26 (-0.58-0.06) 0.16 0.116 
IL2 
2 group model 
Intercept 1.24 (0.88-1.61) 0.18 5.85E-10 
Term -0.52 (-0.98--0.07) 0.23 0.026* 
3 group model 
Intercept 1.24 (0.88-1.61) 0.18 5.16E-10 
Spontaneous term -0.45 (-0.99-0.09) 0.27 0.102 
Non spontaneous term -0.59 (-1.12--0.06) 0.27 0.030* 
IL6 
2 group model 
Intercept 2.6 (2.38-2.83) 0.11 <2E-16 
Term -0.34 (-0.62--0.05) 0.14 0.022* 
3 group model 
Intercept 2.6 (2.38-2.83) 0.11 <2E-16 
Spontaneous term -0.33 (-0.67-0) 0.17 0.054 
Non spontaneous term -0.34 (-0.67--0.01) 0.17 0.047* 
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IL8 
2 group model 
Intercept 3.54 (3.29-3.8) 0.13 <2E-16 
Term -0.29 (-0.61-0.03) 0.16 0.075 
3 group model 
Intercept 3.54 (3.29-3.8) 0.13 <2E-16 
Spontaneous term -0.26 (-0.64-0.12) 0.19 0.180 
Non spontaneous term -0.32 (-0.69-0.05) 0.19 0.088 
IL10 
2 group model 
Intercept 2.28 (1.89-2.66) 0.19 <2E-16 
Term 0.08 (-0.41-0.56) 0.24 0.757 
3 group model 
Intercept 2.28 (1.9-2.66) 0.19 <2E-16 
Spontaneous term -0.07 (-0.64-0.5) 0.29 0.799 
Non spontaneous term 0.21 (-0.34-0.77) 0.28 0.453 
CCL2 
2 group model 
Intercept 1.8 (1.26-2.33) 0.27 1.33E-09 
Term -0.66 (-1.34-0.01) 0.34 0.055 
3 group model 
Intercept 1.8 (1.26-2.33) 0.27 1.22E-09 
Spontaneous term -0.58 (-1.38-0.22) 0.40 0.154 
Non spontaneous term -0.74 (-1.51-0.04) 0.39 0.065 
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Table A 21 - Unadjusted linear regression models with batch as random intercept predicting effect on cytokine concentration (pg/ml) from 2 or 3 
group models of pregnancy outcome. 
Cytokine 
  
Estimate SE P 
Il1b 
2 group model 
Intercept 1.17 (0.97-1.37) 0.09 1.43E-11 
Term -0.06 (-0.21-0.09) 0.07 0.42 
3 group model 
Intercept 1.17 (0.97-1.38) 0.09 6.37E-12 
Spont term -0.11 (-0.28-0.06) 0.09 0.21 
Not spont term -0.02 (-0.19-0.14) 0.08 0.79 
Il5 
2 group model 
Intercept 1.41 (0.98-1.86) 0.20 4.13E-05 
Term 0.19 (-0.16-0.54) 0.18 0.31 
3 group model 
Intercept 1.42 (0.98-1.87) 0.20 6.54E-05 
Spont term 0 (-0.41-0.41) 0.20 0.99 
Not spont term 0.32 (-0.06-0.7) 0.19 0.13 
Il12 
2 group model 
Intercept 3.08 (2.64-3.52) 0.20 7.14E-12 
Term -0.07 (-0.45-0.31) 0.19 0.72 
3 group model 
Intercept 3.09 (2.65-3.51) 0.20 1.52E-12 
Spont term -0.22 (-0.67-0.22) 0.22 0.33 
Not spont term 0.04 (-0.38-0.46) 0.21 0.84 
Il17A 
2 group model 
Intercept 4.08 (3.62-4.56) 0.21 6.96E-10 
Term 0.13 (-0.23-0.49) 0.18 0.47 
3 group model 
Intercept 4.08 (3.62-4.56) 0.21 1.27E-09 
Spont term 0.12 (-0.3-0.54) 0.21 0.59 
Not spont term 0.15 (-0.24-0.54) 0.20 0.47 
CCL11 
2 group model 
Intercept 4.01 (3.89-4.13) 0.06 <2E-16 
Term -0.32 (-0.46--0.16) 0.07 0.00016 
3 group model 
Intercept 4.01 (3.89-4.13) 0.06 <2E-16 
Spont term -0.35 (-0.52--0.16) 0.09 0.00027 
Not spont term -0.29 (-0.46--0.12) 0.08 0.0014 
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FGF basic 
2 group model 
Intercept 4.15 (3.69-4.62) 0.21 3.77E-09 
Term -0.05 (-0.34-0.23) 0.14 0.72 
3 group model 
Intercept 4.15 (3.69-4.62) 0.21 3.14E-09 
Spont term -0.05 (-0.38-0.29) 0.17 0.78 
Not spont term -0.06 (-0.36-0.25) 0.15 0.72 
GM-CSF 
2 group model 
Intercept 2 (1-3.07) 0.47 2.14E-04 
Term -0.96 (-1.84--0.05) 0.42 0.032 
3 group model 
Intercept 2.01 (0.99-3.09) 0.47 9.11E-05 
Spont term -1.15 (-2.19--0.1) 0.50 0.024 
Not spont term -0.83 (-1.78-0.14) 0.46 0.077 
CCL3 
2 group model 
Intercept 1.72 (1.44-2.01) 0.13 5.08E-10 
Term -0.05 (-0.28-0.19) 0.11 0.69 
3 group model 
Intercept 1.72 (1.44-2.01) 0.13 2.93E-10 
Spont term -0.07 (-0.34-0.21) 0.13 0.63 
Not spont term -0.03 (-0.29-0.22) 0.13 0.79 
CCL4 
2 group model 
Intercept 4.77 (4.61-4.94) 0.08 <2E-16 
Term -0.18 (-0.34--0.02) 0.08 0.029* 
3 group model 
Intercept 4.77 (4.61-4.94) 0.08 <2E-16 
Spont term -0.13 (-0.31-0.06) 0.09 0.18 
Not spont term -0.22 (-0.4--0.05) 0.09 0.015* 
TNF-α 
2 group model 
Intercept 3.74 (3.51-3.97) 0.11 <2E-16 
Term 0 (-0.18-0.18) 0.09 0.99 
3 group model 
Intercept 3.74 (3.51-3.97) 0.11 <2E-16 
Spont term -0.05 (-0.26-0.15) 0.10 0.61 
Not spont term 0.04 (-0.15-0.24) 0.10 0.67 
VEGF 
2 group model 
Intercept 2.64 (1.95-3.35) 0.32 2.89E-07 
Term -0.19 (-0.64-0.25) 0.22 0.39 
3 group model 
Intercept 2.64 (1.95-3.36) 0.32 1.56E-07 
Spont term -0.27 (-0.79-0.24) 0.26 0.30 
Not spont term -0.14 (-0.62-0.35) 0.24 0.58 
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Table A 22 – Change in IL-1Ra concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders, before and after removal 
of influential samples using a linear regression model. 
*Participants 336, 2388, 1226 
 All samples After removal of influential values* 
IL-1Ra Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 4.64 (3.77-5.51) 0.47 <2E-16 5.38 (4.79-5.98) 0.33 <2E-16 
Pregnancy outcome (sPTB)       
 
Term -0.73 (-1.09--0.37) 0.19 0.00024 -0.38 (-0.63--0.13) 0.13 0.0054 
Batch (1)       
 
2 -0.1 (-0.66-0.43) 0.28 0.72 -0.12 (-0.51-0.26) 0.20 0.56 
3 -0.1 (-0.64-0.44) 0.29 0.73 0.12 (-0.24-0.5) 0.20 0.54 
4 -0.19 (-0.69-0.32) 0.27 0.50 -0.32 (-0.67-0.03) 0.19 0.095 
5 0.57 (0.1-1.03) 0.25 0.021 0.36 (0.03-0.68) 0.17 0.041 
6 0.33 (-0.13-0.76) 0.23 0.16 0.28 (-0.03-0.59) 0.17 0.092 
Days before delivery at sampling 0.01 (-0.01-0.03) 0.01 0.22 0.01 (0-0.02) 0.01 0.26 
Maternal BMI (normal)       
 
Obese 0 (-0.43-0.43) 0.23 0.99 -0.04 (-0.33-0.24) 0.16 0.79 
Underweight -0.19 (-0.91-0.53) 0.39 0.63 -0.38 (-0.86-0.1) 0.26 0.15 
Smoker (No)       
 Yes -0.38 (-1.06-0.31) 0.37 0.31 -0.41 (-0.87-0.04) 0.25 0.10 
Maternal ethnicity (white, white British)      
 
Asian, Asian 
British 
-0.18 (-0.72-0.37) 0.29 0.55 -0.28 (-0.64-0.09) 0.20 0.16 
Black, black 
British 
-0.01 (-0.48-0.47) 0.26 0.98 -0.07 (-0.39-0.25) 0.17 0.68 
All others -0.15 (-0.5-0.2) 0.19 0.42 -0.13 (-0.36-0.1) 0.13 0.30 
Maternal age at booking 0.01 (-0.02-0.03) 0.01 0.65 -0.02 (-0.04-0.01) 0.01 0.05 
Maternal parity (0)       
 
1 0.15 (-0.18-0.48) 0.18 0.41 0.01 (-0.21-0.23) 0.12 0.91 
>1 -0.03 (-0.46-0.4) 0.23 0.90 -0.01 (-0.3-0.28) 0.16 0.96 
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Table A 23 - Change in IL-1Ra concentration (pg/ml) by pregnancy outcome (3 group model) adjusted for confounders, before and after removal 
of influential samples using a linear regression model. 
*Participants 336, 2388, 1226 
 All samples After removal of influential values* 
IL-1Ra Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 4.66 (3.79-5.54) 0.47 <2E-16 5.39 (4.8-5.99) 0.33 <2E-16 
Pregnancy outcome (sPTB)       
 
Term spontaneous -0.8 (-1.2--0.39) 0.21 0.00033 -0.41 (-0.69--0.14) 0.15 0.0066 
Term non-spontaneous -0.66 (-1.07--0.26) 0.22 0.0027 -0.35 (-0.62--0.07) 0.15 0.022 
Batch (1)       
 
2 -0.09 (-0.65-0.43) 0.28 0.75 -0.11 (-0.5-0.26) 0.20 0.58 
3 -0.09 (-0.62-0.46) 0.29 0.77 0.13 (-0.24-0.5) 0.20 0.51 
4 -0.17 (-0.67-0.33) 0.27 0.53 -0.32 (-0.67-0.04) 0.19 0.10 
5 0.59 (0.12-1.05) 0.25 0.018 0.37 (0.04-0.69) 0.17 0.037 
6 0.35 (-0.11-0.79) 0.24 0.14 0.3 (-0.02-0.61) 0.17 0.081 
Days before delivery at sampling 0.01 (-0.01-0.03) 0.01 0.23 0.01 (0-0.02) 0.01 0.27 
Maternal BMI (normal)       
 
Obese -0.02 (-0.46-0.41) 0.24 0.92 -0.05 (-0.34-0.24) 0.16 0.74 
Underweight -0.21 (-0.92-0.51) 0.39 0.60 -0.39 (-0.87-0.1) 0.26 0.15 
Smoker (No)       
 Yes -0.36 (-1.05-0.32) 0.37 0.34 -0.41 (-0.86-0.05) 0.25 0.10 
Maternal ethnicity (white, white British)      
 
Asian, Asian British -0.2 (-0.75-0.35) 0.30 0.50 -0.29 (-0.66-0.08) 0.20 0.15 
Black, black British 0.02 (-0.46-0.5) 0.26 0.95 -0.06 (-0.38-0.26) 0.17 0.74 
All others -0.16 (-0.51-0.19) 0.19 0.41 -0.13 (-0.37-0.1) 0.13 0.30 
Maternal age at booking 0.01 (-0.02-0.03) 0.01 0.72 -0.02 (-0.04-0) 0.01 0.050 
Maternal parity (0)       
 
1 0.14 (-0.19-0.47) 0.18 0.44 0.01 (-0.21-0.23) 0.12 0.94 
>1 -0.01 (-0.44-0.43) 0.24 0.97 0 (-0.29-0.29) 0.16 0.98 
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Table A 24 - Change in CCL2 concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders using a linear regression 
model. 
 
 All samples After removal of influential values 
CCL2 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 2.43 (0.5-4.37) 1.05 0.022 - - - 
Pregnancy outcome (sPTB) 
   
   
 
Term -1.66 (-2.47--0.86) 0.43 0.00019 - - - 
Batch (1) 
   
   
 
2 -1.27 (-2.51--0.05) 0.66 0.057 - - - 
3 0.16 (-1.05-1.38) 0.66 0.80 - - - 
4 -1.33 (-2.48--0.19) 0.62 0.034 - - - 
5 0.79 (-0.25-1.85) 0.56 0.16 - - - 
6 -0.26 (-1.26-0.75) 0.54 0.63 - - - 
Days before delivery at sampling 0.01 (-0.03-0.04) 0.02 0.70 - - - 
Maternal BMI (normal) 
   
   
 
Obese -0.15 (-1.1-0.79) 0.51 0.76 - - - 
Underweight -2.19 (-3.79--0.6) 0.86 0.013 - - - 
Smoker (No) 
   
   
 
Yes -0.61 (-2.12-0.9) 0.82 0.46 - - - 
Maternal ethnicity (white, white British) 
  
   
 
Asian, Asian British -0.69 (-1.9-0.52) 0.66 0.29 - - - 
Black, black British 1.15 (0.14-2.17) 0.55 0.039 - - - 
All others -0.51 (-1.28-0.26) 0.42 0.23 - - - 
Maternal age at booking 0.01 (-0.05-0.06) 0.03 0.84 - - - 
Maternal parity (0) 
   
   
 
1 -0.18 (-0.9-0.54) 0.39 0.65 - - - 
>1 0.34 (-0.61-1.3) 0.52 0.51 - - - 
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Table A 25 - Change in CCL2 concentration (pg/ml) by pregnancy outcome (3 group model) adjusted for confounders using a linear regression 
model. 
 All samples After removal of influential values 
CLL2 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 2.42 (0.49-4.36) 1.05 0.024 - - - 
Pregnancy outcome (sPTB) 
   
   
 
Term spontaneous -1.63 (-2.53--0.74) 0.48 0.0010 - - - 
 
Term non-spontaneous -1.69 (-2.59--0.8) 0.48 0.0006 - - - 
Batch (1) 
   
   
 
2 -1.27 (-2.51--0.06) 0.66 0.057 - - - 
3 0.16 (-1.06-1.38) 0.66 0.82 - - - 
4 -1.34 (-2.49--0.19) 0.62 0.034 - - - 
5 0.78 (-0.27-1.84) 0.57 0.17 - - - 
6 -0.27 (-1.29-0.75) 0.55 0.62 - - - 
Days before delivery at sampling 0.01 (-0.03-0.04) 0.02 0.70 - - - 
Maternal BMI (normal) 
   
   
 
Obese -0.15 (-1.1-0.81) 0.52 0.78 - - - 
Underweight -2.19 (-3.78--0.59) 0.87 0.013 - - - 
Smoker (No) 
   
   
 
Yes -0.62 (-2.13-0.89) 0.82 0.46 - - - 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British -0.68 (-1.9-0.54) 0.66 0.31 - - - 
Black, black British 1.14 (0.12-2.16) 0.56 0.042 - - - 
All others -0.51 (-1.28-0.26) 0.42 0.23 - - - 
Maternal age at booking 0.01 (-0.05-0.06) 0.03 0.83 - - - 
Maternal parity (0) 
   
   
 
1 -0.17 (-0.9-0.55) 0.40 0.66 - - - 
>1 0.33 (-0.63-1.29) 0.53 0.53 - - - 
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Table A 26 - Change in IL5 concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders, before and after removal of 
influential samples.  
 All samples After removal of influential values* 
IL5 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 1.42 (0.47-2.37) 0.48 0.0035 1.25 (0.36-2.14) 0.45 0.0061 
Pregnancy outcome (sPTB) 
   
   
 
Term 0.27 (-0.1-0.64) 0.19 0.15 0.43 (0.07-0.78) 0.18 0.019 
Days before delivery at sampling -0.01 (-0.03-0.01) 0.01 0.39 -0.01 (-0.03-0.01) 0.01 0.19 
Maternal BMI (normal) 
   
   
 
Obese -0.07 (-0.52-0.38) 0.23 0.75 -0.01 (-0.44-0.42) 0.22 0.96 
Underweight -0.37 (-1.13-0.39) 0.39 0.33 0.02 (-0.79-0.84) 0.41 0.95 
Smoker (No) 
   
   
 
Yes 0.04 (-0.67-0.76) 0.36 0.90 0.15 (-0.54-0.83) 0.34 0.67 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British 0.17 (-0.41-0.75) 0.29 0.56 0.18 (-0.36-0.73) 0.28 0.51 
Black, black British 0.2 (-0.29-0.68) 0.24 0.42 0.16 (-0.33-0.65) 0.25 0.53 
All others 0.1 (-0.27-0.47) 0.19 0.59 0.12 (-0.23-0.47) 0.18 0.51 
Maternal age at booking 0 (-0.03-0.03) 0.01 0.93 -0.023 (-0.02-0.03) 0.17 0.87 
Maternal parity (0) 
   
   
 
1 -0.1 (-0.45-0.24) 0.17 0.56 -0.13 (-0.46-0.2) 0.01 0.44 
>1 0.34 (-0.11-0.8) 0.23 0.14 0.29 (-0.15-0.73) 0.22 0.20 
*Participants 813, 1785 
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Table A 27 - Change in IL5 concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders, before and after removal of 
influential samples using a linear regression model. 
*Participant 1785 
 
 All samples After removal of influential values* 
IL5 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 1.58 (0.64-2.51) 0.47 0.0010 1.4 (0.51-2.28) 0.45 0.0022 
Pregnancy outcome (sPTB) 
   
   
 
Term spontaneous 0.01 (-0.4-0.41) 0.2 0.969 0.15 (-0.24-0.54) 0.20 0.44 
 
Term non-spontaneous 0.52 (0.11-0.92) 0.2 0.012 0.61 (0.23-1) 0.20 0.0021 
Days before delivery at sampling -0.01 (-0.02-0.01) 0.01 0.34 -0.01 (-0.03-0.01) 0.01 0.19 
Maternal BMI (normal) 
   
   
 
Obese -0.15 (-0.59-0.29) 0.22 0.51 -0.08 (-0.5-0.34) 0.21 0.70 
Underweight -0.43 (-1.17-0.31) 0.37 0.25 -0.39 (-1.1-0.32) 0.36 0.28 
Smoker (No) 
   
   
 
Yes 0.09 (-0.61-0.78) 0.35 0.81 0.13 (-0.54-0.79) 0.33 0.70 
Maternal ethnicity (white, white British) 
  
   
 
Asian, Asian British -0.01 (-0.03-0.02) 0.01 0.67 0.06 (-0.48-0.59) 0.27 0.84 
Black, black British 0.08 (-0.49-0.64) 0.29 0.79 0.08 (-0.38-0.54) 0.23 0.73 
All others 0.26 (-0.21-0.74) 0.24 0.27 0.1 (-0.24-0.45) 0.17 0.55 
Maternal age at booking 0.09 (-0.26-0.45) 0.18 0.62 
-0.0016 (-0.03-
0.02) 0.01 0.90 
Maternal parity (0) 
   
   
 
1 -0.14 (-0.48-0.19) 0.17 0.40 -0.12 (-0.44-0.2) 0.16 0.46 
>1 0.44 (-0.01-0.88) 0.23 0.056 0.45 (0.02-0.88) 0.22 0.038 
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Table A 28 - Change in CCL11 concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders, before and after removal 
of influential samples using a linear regression model. 
 
 All samples After removal of influential values* 
CCL11 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 3.83 (3.41-4.25) 0.21 <2E-16 3.85 (3.42-4.27) 0.21 <2E-16 
Pregnancy outcome (sPTB) 
  
   
 
Term -0.32 (-0.47--0.16) 0.08 0.000056 -0.24 (-0.41--0.07) 0.084 0.0049 
Days before delivery at sampling 0.0018 (-0.01-0.01) 0 0.67 0 (-0.01-0.01) 0.0042 0.97 
Maternal BMI (normal) 
   
   
 
Obese 0.03 (-0.19-0.24) 0.11 0.81 0.04 (-0.18-0.25) 0.11 0.73 
Underweight 0.03 (-0.33-0.4) 0.18 0.85 -0.01 (-0.36-0.34) 0.18 0.96 
Smoker (No) 
   
   
 
Yes -0.04 (-0.39-0.3) 0.17 0.80 -0.03 (-0.38-0.31) 0.17 0.85 
Maternal ethnicity (white, white British) 
  
   
 
Asian, Asian British -0.15 (-0.42-0.12) 0.14 0.28 -0.15 (-0.42-0.12) 0.14 0.26 
Black, black British 0 (-0.24-0.23) 0.12 0.97 0.03 (-0.2-0.26) 0.12 0.79 
All others -0.12 (-0.3-0.05) 0.09 0.17 -0.14 (-0.32-0.03) 0.089 0.11 
Maternal age at booking 0.01 (-0.01-0.02) 0.01 0.38 0.0043 (-0.01-0.02) 0.0064 0.50 
Maternal parity (0) 
   
   
 
1 -0.03 (-0.2-0.14) 0.08 0.73 -0.02 (-0.18-0.15) 0.083 0.82 
>1 0.03 (-0.19-0.25) 0.11 0.79 0.04 (-0.17-0.25) 0.11 0.71 
*Participant 1375 
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Table A 29 - Change in CCL11 concentration (pg/ml) by pregnancy outcome (3 group model) adjusted for confounders, before and after removal 
of influential samples using a linear regression model. 
 
 All samples After removal of influential values* 
CCL11 Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 3.84 (3.42-4.26) 0.21 <2E-16 3.85 (3.42-4.28) 0.22 <2E-16 
Pregnancy outcome (sPTB) 
   
   
 
Term spontaneous -0.34 (-0.51--0.15) 0.09 0.00015 -0.24 (-0.44--0.05) 0.094 0.011 
 
Term non-spontaneous -0.3 (-0.48--0.12) 0.09 0.0013 -0.24 (-0.43--0.05) 0.10 0.014 
Days before delivery at sampling 0 (-0.01-0.01) 0.00 0.68    
Maternal BMI (normal) 
   
0 (-0.01-0.01) 0.0042 0.97 
 
Obese 0.02 (-0.2-0.24) 0.11 0.85 0.04 (-0.18-0.25) 0.11 0.74 
Underweight 0.03 (-0.33-0.39) 0.18 0.86 -0.01 (-0.36-0.34) 0.18 0.95 
Smoker (No) 
   
   
 
Yes -0.04 (-0.38-0.3) 0.17 0.81 -0.03 (-0.38-0.31) 0.18 0.85 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British 0.01 (-0.01-0.02) 0.01 0.40 -0.15 (-0.42-0.12) 0.14 0.26 
Black, black British -0.16 (-0.43-0.12) 0.14 0.26 0.03 (-0.2-0.26) 0.12 0.79 
All others 0 (-0.23-0.23) 0.12 1.00 -0.14 (-0.32-0.03) 0.089 0.11 
Maternal age at booking -0.12 (-0.3-0.05) 0.09 0.17 0 (-0.01-0.02) 0.0064 0.50 
Maternal parity (0) 
   
   
 
1 -0.03 (-0.2-0.13) 0.08 0.70 -0.02 (-0.18-0.15) 0.083 0.82 
>1 0.04 (-0.19-0.26) 0.11 0.75 0.04 (-0.18-0.26) 0.11 0.71 
* Participant 1375 
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Table A 30 - Change in GM-CSF concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders using a linear regression 
model. 
 
 
 All samples After removal of influential values 
GM-CSF Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 2.98 (0.69-5.28) 1.16 0.011 - - - 
Pregnancy outcome (sPTB) 
   
   
 
Term -1.06 (-2.01--0.09) 0.45 0.020 - - - 
Days before delivery at sampling 0.02 (-0.03-0.06) 0.02 0.46 - - - 
Maternal BMI (normal) 
   
   
 
Obese 0.32 (-0.81-1.45) 0.57 0.57 - - - 
Underweight -2.01 (-3.86--0.16) 0.94 0.034 - - - 
Smoker (No) 
   
   
 
Yes 1.18 (-0.55-2.92) 0.88 0.18 - - - 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British 0.02 (-1.38-1.42) 0.71 0.98 - - - 
Black, black British 0.09 (-1.11-1.3) 0.60 0.88 - - - 
All others -0.24 (-1.15-0.67) 0.46 0.60 - - - 
Maternal age at booking -0.03 (-0.1-0.03) 0.03 0.32 - - - 
Maternal parity (0) 
   
   
 
1 -0.17 (-1.01-0.67) 0.42 0.69 - - - 
>1 0.87 (-0.31-2.04) 0.59 0.15 - - - 
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Table A 31 - Change in GM-CSF concentration (pg/ml) by pregnancy outcome (3 group model) adjusted for confounders using a linear regression 
model. 
 
 
 
 All samples After removal of influential values 
GM-CSF Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 3.08 (0.78-5.39) 1.17 0.0092 - - - 
Pregnancy outcome (sPTB) 
  
   
 
Term spontaneous -1.27 (-2.33--0.19) 0.50 0.013 - - - 
 
Term non-spontaneous -0.87 (-1.91-0.21) 0.51 0.091 - - - 
Days before delivery at sampling 0.02 (-0.03-0.06) 0.02 0.48 - - - 
Maternal BMI (normal) 
   
   
 
Obese 0.24 (-0.9-1.38) 0.57 0.67 - - - 
Underweight -2.06 (-3.9--0.21) 0.94 0.030 - - - 
Smoker (No) 
   
   
 
Yes 1.21 (-0.51-2.95) 0.87 0.17 - - - 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British -0.04 (-0.1-0.03) 0.03 0.28 - - - 
Black, black British -0.05 (-1.46-1.36) 0.71 0.94 - - - 
All others 0.14 (-1.06-1.36) 0.60 0.81 - - - 
Maternal age at booking -0.23 (-1.14-0.68) 0.46 0.61 - - - 
Maternal parity (0) 
   
   
 
1 -0.21 (-1.04-0.63) 0.42 0.63 - - - 
>1 0.95 (-0.24-2.13) 0.60 0.11 - - - 
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Table A 32 - Change in CCL4 concentration (pg/ml) by pregnancy outcome (2 group model) adjusted for confounders using a linear regression 
model 
 
 All samples After removal of influential values 
CCL4 - Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 4.87 (4.44-5.3) 0.22 <2E-16 - - - 
Pregnancy outcome (sPTB) 
   
   
 
Term -0.18 (-0.35--0.01) 0.08 0.034 - - - 
Days before delivery at sampling 0 (-0.01-0.01) 0 0.82 - - - 
Maternal BMI (normal) 
   
   
 
Obese -0.01 (-0.23-0.2) 0.11 0.92 - - - 
Underweight -0.25 (-0.6-0.1) 0.18 0.17 - - - 
Smoker (No) 
   
   
 
Yes -0.04 (-0.38-0.31) 0.17 0.83 - - - 
Maternal ethnicity (white, white British) 
   
   
 
Asian, Asian British -0.15 (-0.42-0.12) 0.14 0.27 - - - 
Black, black British 0.2 (-0.03-0.43) 0.12 0.083 - - - 
All others 0.17 (0-0.35) 0.09 0.052 - - - 
Maternal age at booking 0 (-0.02-0.01) 0.01 0.69 - - - 
Maternal parity (0) 
   
   
 
1 -0.08 (-0.24-0.08) 0.08 0.34 - - - 
>1 -0.08 (-0.3-0.13) 0.11 0.43 - - - 
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Table A 33 - Change in CCL4 concentration (pg/ml) by pregnancy outcome (3 group model) adjusted for confounders using a linear regression 
model. 
 All samples After removal of influential values* 
CCL4 - Predictor (baseline) β (95% CI) β SE P β (95% CI) β SE P 
Intercept 4.84 (4.41-5.27) 0.22 <2E-16 4.83 (4.41-5.26) 0.21 <2E-16 
Pregnancy outcome (sPTB) 
   
   
 
Term spontaneous -0.13 (-0.32-0.06) 0.09 0.16 -0.1 (-0.29-0.09) 0.093 0.30 
 
Term non-spontaneous -0.23 (-0.42--0.04) 0.10 0.016 -0.22 (-0.41--0.03) 0.095 0.022 
Days before delivery at sampling 0.00081 (-0.01-0.01) 0.00 0.85 0 (-0.01-0.01) 0.0041 0.78 
Maternal BMI (normal) 
   
   
 
Obese 0.0033 (-0.21-0.22) 0.11 0.98 0 (-0.21-0.22) 0.11 0.97 
Underweight -0.24 (-0.59-0.12) 0.18 0.19 -0.04 (-0.43-0.36) 0.20 0.85 
Smoker (No) 
   
   
 
Yes -0.05 (-0.39-0.3) 0.17 0.79 -0.02 (-0.36-0.32) 0.17 0.91 
Maternal ethnicity (white, white British) 
  
   
 
Asian, Asian British -0.13 (-0.4-0.14) 0.14 0.34 0.26 (0.03-0.5) 0.12 0.030 
Black, black British 0.19 (-0.04-0.42) 0.12 0.11 0.18 (0.01-0.35) 0.087 0.042 
All others 0.18 (0-0.35) 0.09 0.048 0 (-0.01-0.01) 0.0063 0.79 
Maternal age at booking -0.0016 (-0.01-0.01) 0.01 0.80 -0.11 (-0.37-0.16) 0.13 0.42 
Maternal parity (0)       
 
1 -0.07 (-0.23-0.09) 0.08 0.40 -0.1 (-0.26-0.07) 0.082 0.24 
>1 -0.1 (-0.32-0.11) 0.11 0.35 -0.15 (-0.37-0.07) 0.11 0.17 
* Participant 813 
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About 20% of pregnancies are affected by some form of complication. Research has shown that anomalies
in implantation, development, and growth of the fetus; ineffective nutrient exchange between mother
and fetus due to placental dysfunction; and maternal problems such as hypertension or infection during
pregnancy can all lead to adverse pregnancy outcomes. However, the molecular aetiology of such events
remains poorly understood. Fetal growth restriction (FGR), recurrent miscarriage (RM), preterm birth
(PTB), and pre-eclampsia (PE) are the most common pregnancy complications encountered in the UK and
these outcomes can result in an array of morbidities in both mother and baby, and in the most severe
cases in mortality. We need to know more about normal pregnancy and where the important triggers are
for failure. This prompted us to collect a large set of biological samples with matching clinical data from
over 2500 normal and abnormal pregnancies, for use in research into these conditions. This paper
outlines the nature of these sample sets and their availability to academia and industry, with the
intention that their widespread use in research will make signiﬁcant contributions to the improvement
of maternal and fetal health worldwide (http://www.ucl.ac.uk/tapb/sample-and-data-collections-at-ucl/
biobanks-ucl/baby-biobank).
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Each year, tens of thousands of women in the UK, and millions
across the world, encounter mild to life-threatening pregnancy
complications. Despite substantial developments in the clinical
management and biological understanding of such cases, many
questions regarding the molecular aetiology of common compli-
cations in pregnancy remain unanswered. A key challenge often
associated with research into pregnancy is obtaining sufﬁcient
numbers of biological samples to conduct well-powered studies.
The Baby Bio Bank (BBB) is a large, UK based biobank that was set
up to remove the obstacle of recruitment and to support research
into the environmental and genetic mechanisms underlying com-
mon complications of pregnancy. The BBB provides ethically
approved, high-quality biological samples and clinical data to ac-
ademic and industrial partners, both nationally and internationally.
Funded primarily through the UK based charity, Wellbeing of
Women, the BBB began recruiting pregnant mothers from three
hospitals across London in 2009. The project's recruitment phase
has now reached completion, amassing over 54,000 biological
samples from 2515 healthy and complicated pregnancies.
Recruitment and sample collection was based at three London
hospitals: Queen Charlotte and Chelsea (QC), Chelsea and West-
minster (CW), and St Mary's (SM). Together these London mater-
nity services deliver around 13,000 infants a year. The BBB received
ethical approval for collection from these hospitals from Trent
Derby Research Ethics Committee [1]. Ethical consent for biological
sample collection from the proband (fetus/infant), mother, and
father, as well as access to participating patient records was ob-
tained in advance of the birth. All samples are stored at the UCL
Institute of Child Health, with a duplicate of the entire biobank
located at SM, Imperial College London. Semi-anonymised patient
data, downloaded directly from electronic clinical records and
supplemented by data gathered by the BBB recruitment team (see
S6 for questionnaire format used), is stored in a secure, custom* Corresponding author.
E-mail address: lydia.leon.11@ucl.ac.uk (L.J. Leon).
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designed online database that links directly to matching sample
information.
Fetal growth restriction (FGR), pre-eclampsia (PE), preterm birth
(PTB) and recurrent miscarriage (RM) were chosen as the primary
foci for the BBB on account of their prevalence within the UK, but
also because they capture a physiological spectrum of pregnancy
disorders. These disorders are all considered multifactorial, caused
by the combined and varying effects of the maternal and fetal ge-
notype, the intrauterine environment, and many other clinical and
environmental factors. It is thought likely that many issues
covering abnormal implantation to preterm membrane rupture
and delivery may share similar or overlapping aetiologies,
including physiological mechanisms, pathways and even speciﬁc
genetic predisposition variants.
The BBB contains data and paired biological samples from 236
FGR, 133 PE, 373 PTB, and 232 RM pregnancies. Over 1500 ‘normal’
pregnancies with none of the above complications were also
collected for use as control samples, and 636 of these are classiﬁed
as ‘perfect’ controls with no recorded problems associated with the
mothers' health, pregnancy, or delivery.
A unique and valuable aspect of this dataset is the compre-
hensiveness of the paternal samples and clinical data that has been
amassed, accompanying 68% of the participating pregnancies.
Availability of these samples enables investigators interested in
genetic contributions to common pregnancy complications to
conduct powerful genetic studies using traditional trio designs, or
to study in isolation the paternal contribution to pregnancy and
fetal outcome.
This paper summarises the design, recruitment, and main de-
mographic and clinical characteristics of the BBB cohort, and pro-
vides researchers with contact details to enquire about availability
for sample groups of interest. Detailed information regarding
sample collection, preparation, and storage are available in
Supplementary Information.
2. Recruitment design
On account of the expertise of the BBB's founders and the likely
high contribution of genetic factors to the phenotypes of interest,
the BBB was principally conceptualised as a genetic and epigenetic
resource. However, additional opportunities for biomarker research
are available due to the parallel collection of plasma/sera from
mothers, fathers and infants, in addition to urine from the mother.
Recruitment for the BBB was carried out over a four-year period
at three hospitals (SM, CW, QC), following a targeted prospective
cohort design (Fig. 1). Where possible, recruitment occurred at the
antenatal clinic or at follow-up appointments when conditions of
interest ﬁrst presented. This normally gave participants at least
several days to ask questions about the consent form and infor-
mation leaﬂets. Some women were also recruited on antenatal and
labour wards. Any consenting family having a baby at one of the
participating units was able to contribute.
Given the ambitious size of the project, a variety of strategies
were employed to ensure that recruitment to each complication
was as high as possible, whilst still ensuring that they were
recruited prior to delivery. Many women were targeted for
recruitment if deemed to be at risk for a particular complication.
For example, women belonging to certain risk groups (e.g. with a
hypertensive disorder, or complicated pregnancy history) were
approached by recruiters. Nurses and clinicians would also notify
recruiters when women began presenting with clinical symptoms
of a complication, regardless of prior risk status (e.g. at the onset of
pre-eclampsia or following preterm membrane rupture). In addi-
tion, a large number of normal, uncomplicated pregnancies were
also recruited for comparative purposes, with some of these
pregnancies ultimately contributing to the complications groups
(e.g. a woman with no known complication at the time of recruit-
ment could end up delivering preterm).
This process was designed to be feasible within a routine clinical
setting. Whereas a simple randomised or stratiﬁed randomised
design would have been theoretically preferable in minimising
selection bias, this was not possible given the context and the re-
sources at hand.
The BBB recruitment team consisted of three full-time re-
cruiters: two research associates with international experience in
recruitment and research, and one research nurse with substantial
experience of recruitment to large cohort collections, all of whom
were trained phlebotomists and had expertise in the necessary
sample preparation techniques. Each recruiter was based at one of
the three hospitals taking part in the project. The recruiters were
responsible for counselling and obtaining consent from the parents,
as well as collecting and preparing samples around the clock.
Recruitment numbers for each hospital are listed in Table 1.
Recruitment was initiated at SM, before recruitment commenced at
CW, followed by QC.
3. Sample collection and storage
The variety of samples (and relevant accompanying informa-
tion) that were intended for collection from each pregnancy are
presented in Table 2. Recruiters focused on securing the collection
of ‘Trio’ sample sets, inwhich tissue, DNA, and RNA are available for
mother, father, and baby. This aim was achieved for 1328 preg-
nancies in total, across all of the complications and control preg-
nancies. If we assume a dominant model of inheritance for a
potential genetic trait of interest, and a signiﬁcance threshold of 5%,
these trio numbers within the BBB would have reasonable power
(>0.7) to detect risk variants with relative risks above 1.5, if all cases
are combined into one larger ‘complications group’ (under the
hypothesis that certain variants may affect all complications), or
2e2.5 if case groups are considered individually (see S5 for further
details).
Each recruitment centre took responsibility for sample receipt
and storage. Samples received were matched with the clinical
phenotype data and barcoded at point of entry. All tissue and blood
samples are stored at 80 C until requested, with tissue stored in
RNAlater. DNA and RNA are stored at80 C and are available for all
samples in which the relevant primary tissue is available.
Each placenta was collected at birth and processed as quickly as
possible (normally within one hour). Four 1 cm3 sections were
excised from beneath the placental membrane, equidistant from
the umbilical cord and washed in PBS to remove excess maternal
blood. Collecting multiple samples from each placenta increased
the total amount of tissue available, as well as facilitating in-
vestigations into variation in gene/protein expression in different
parts of placenta. By taking samples from four distinct sites,
mosaicism can be detected by standard karyotyping. Placental
mosaicism is present in approximately 2% of chorionic villous
samples [2] and it is likely that a number of such samples will be
present in our collection. In addition to sampling from the chorionic
plate, villous tissue from the maternal side of the placenta, as well
as umbilical cord, cord blood, and fetal membrane tissue were also
collected where possible. All tissue was immediately transferred to
a vile containing RNAlater to minimise degradation of nucleic acids.
Occasionally the placenta, cord or cord blood were not available
(e.g. a baby was delivered at home, in an emergency, or another
hospital). In such instances a buccal swab from the baby was
requested and DNA extracted from this specimen. Buccal swabs for
DNA extraction were also taken from fathers where blood was
unavailable.
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For ease of collection and to encourage participation by mini-
mising the number of blood draws/hospital visits for mothers,
maternal blood and urine samples were collected once during
pregnancy, at a time that was convenient to the mother, and were
not restricted to a certain time point in gestation. This usually
coincidedwith hospital appointments and blood draws being taken
for clinical purposes. Plasma and serum were extracted immedi-
ately from such samples (see S2 for detailed protocol). Where
possible, approximately 20 ml of blood was collected from each of
the parents. Whole blood, serum and plasma were aliquoted into
maximum volumes of 2 ml to minimise exposure of samples to
freeze-thaw cycles. Urine was collected in standard specimen
containers by the donor and aliquoted into 2ml volumeswithin 1 h,
for long-term storage at 80 C. Given the expected high yields of
DNA from the protocols used for extraction, and the volume of
samples collected, tens of thousands of standard molecular ana-
lyses will be possible using the amount of DNA and RNA available
within the bank.
Maternal blood collection ranged from 7 weeks gestation until
delivery, with the mean gestational age for collection being 25
weeks. Bloods are available for points collected throughout preg-
nancy, with peaks at certain times, such as week 12which coincides
with a key antenatal hospital visit for mothers in the UK (Fig. 2).
20% of blood samples were collected within the 1st trimester, 38%
in the 2nd, and 42% in the 3rd. BBB sample requests can be speciﬁed
by gestational age. As maternal samples were collected once from
each pregnancy, consecutive samples are not available. We recog-
nise that this, and the variation in time points of blood collection,
would be a limitation for certain biomarker studies, however this
maximised the number of participants within the study.
To ensure biological samples were processed and maintained to
the highest possible standards necessary for use across all common
molecular applications, detailed quality control audits using PCR,
sequencing, and nucleic acid integrity assessment with the Agilent
2200 TapeStation System, have been conducted on a random se-
lection of at least 15% of the whole cohort. These tests have assured
high purity and integrity of DNA and RNA extracted from BBB
samples, supporting their use in standard molecular biology assays
including Sanger sequencing, qPCR and end-point PCR in which all
samples tested positive for housekeeping genes used as standards.
A number of samples have also been used successfully for exome
analyses and genome-wide methylation assays, in which high DNA
quality and integrity is essential.
Both informal and formal audits of the BBB were conducted.
Informal audits were conducted by the BBB manager. Formal audits
were carried out annually by both the UCL and Imperial Human
Tissue Authority committees respectively. On all audits there was
100% concordance with samples in the electronic database and the
physical location of samples. This was seen in both directions (from
database to sample and sample to database). Retrieval of consent
forms for all samples was also 100%.
4. Clinical and demographic characteristics
Pregnancy related morbidity and mortality are known to be
associated with various neonatal and maternal characteristics that
are well documented in the BBB, and may be of interest either as
the central phenotype under investigation or in downstream
multivariable analyses. To ensure the BBB clinical database was as
comprehensive as possible, data were collected by recruiters using
standardised forms in addition to detailed clinical downloads from
electronic maternity records at each hospital. The two collections
were subsequently merged by the BBB data manager into a format
that is available to BBB users. This design enabled the collection of
certain additional maternal data (e.g. occupation) as well as
paternal data, which were not available on clinical records. This
strategy also allowed for discrepancies in data entry to be identiﬁed
and corrected via comparison of any duplicate categories. A
Fig. 1. Flow-diagram outlining BBB recruitment and sample collection process.
Table 1
Hospital recruitment rates.
Hospital N (%)
St Mary's 1107 (44)
Chelsea and Westminster 880 (35)
Queens Charlotte's and Chelsea 528 (21)
Table 2
Variety of samples collected from participating trios.
Sample type
Maternal whole blood/serum/plasma
Paternal whole blood/serum/plasma
Maternal urine
Maternal DNA and RNA (from blood/buccal swab)
Paternal DNA and RNA (from blood/buccal swab)
Placental parenchyma, villous, and membrane
Cord blood
Umbilical cord tissue
Baby DNA and RNA (from placenta/buccal swab)
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selection of the key recorded information and their provenances
are listed in Table 3. A full list of clinical data categories is available
on request.
The original project aimed to collect only pregnancies from
white European mothers and as can be seen (Table 4) this remains
the largest group within the BBB. However, due to the multina-
tional population in London it proved difﬁcult to identify and
consent a strictly white European cohort. Many clinics were
attended by individuals of Asian and African origin expressing an
interest in participating in the BBB. We were aware that such a
valuable resourcewould be of greater value if it were inclusive of all
ethnic backgrounds and ultimately included such individuals in the
hope that funding would one day be available to cover a similarly
sized cohort collection for these ethnic groups too.
Ethnicity can be grouped in numerous ways and there is often a
lack of consensus within clinical and research communities on
precisely how to do this. The BBB electronic database contains two
separate data columns on maternal ethnicity, that are used widely
throughout the NHS and are based on those used in the national
census. Ethnicity data is summarized into four broad categories to
give the reader an idea of the ethnic distribution within the BBB
cohort. The main demographic characteristics of currently available
clinical data of the cohort are outlined in Table 4. Some categories,
e.g. delivery method, have larger amounts of missing data than
others. The further population of these missing ﬁelds is ongoing,
requiring the interrogation of paper rather than electronic notes.
5. Deﬁnitions and veriﬁcation of outcome data.
Clinical diagnosis of FGR, PE, RM and PTB is recorded for all our
samples, the deﬁnitions for each of these complications were
consistent across the three NHS hospitals from which our samples
were collected and are outlined below. However, we recognise that
researchers may have speciﬁc deﬁnitions to categorise clinical
complications. To address this, each BBB sample is linked to, and
can be searched by more than 200 ﬁelds of data that we hold,
enabling bespoke categorisation of sample sets, as well as a deeper
analysis of data by the creation of sub-categories as required.
Whilst this potential for sub-categorisation is a valuable feature of
the Bank, we recognise that any such manipulation of the cohort is
limited by the original clinical deﬁnitions used during recruitment,
as stipulated in the following sections.
6. Preterm birth
Prematurity affects between 5 and 18% of births worldwide and
is the leading cause of neonatal death globally [3]. In the UK, around
7% of births are preterm [4]. Prematurity is associated with a
complex array of morbidities from neurodevelopmental issues, to
gastrointestinal complications that often extend beyond the
neonatal period, through childhood and into adulthood [5]. Pre-
term births in the BBB were deﬁned as any delivery occurring
before 37 weeks gestation.
Biological samples were collected from the 373 preterm preg-
nancies within the BBB, 122 of which were trios. To achieve this
sizeable collection, recruiters actively targeted mothers with a
history of preterm birth, women presenting with spontaneous
Fig. 2. Graph showing distribution of gestational ages at maternal blood sampling within the BBB.
Table 3
Selection of clinical information available.
Maternal Paternal Fetal
Agea,b Agea Genderb
BMIb Heighta,c Gestationb
Height b,c Weighta,c Birthweightb
Weight b,c BMIc Placental Weightc
Ethnicityb Ethnicitya Head Circumferenceb
Pre-Pregnancy Weighta Diabetesa Birth Lengthb
Paritya,b Hypertensiona Apgar Scoreb
Diabetesa,b Smokinga Mode Of Deliveryb
Hypertensiona,b Medicationa Congenital abnormalitiesb
Smokinga,b Occupationa
Medicationa,b
Occupationa,b
Pregnancy historya,b
Age at menarchea,b
Marital statusa,b
Infectious diseaseb
a Information volunteered from patient to recruitment staff.
b Information gathered from clinical records.
c Measured by recruiting staff.
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pretermmembrane rupture or threatening preterm labour, women
with shortened cervices, or those with a positive fetal ﬁbronectin
result. Research into the underlying aetiology of preterm birth
often focuses on the most extreme ‘very early preterm’ cases in
order to best elucidate underlyingmechanisms. Generally classiﬁed
as those born at less than 33 weeks gestation, these births are also
the hardest to collect biological material from, given the compli-
cated nature of such deliveries. The BBB has managed to secure
biological and clinical data from 96 such valuable cases.
The mean gestational age at birth for this group (Table 5) is 33
weeks and the youngest delivery was at just 20 weeks gestation, 3
weeks below the current ‘limit of viability’ upheld by obstetricians
[6]. PTB is often split into three main phenotypic categories for
research: spontaneous, indicated and preterm premature rupture
of membranes (PPROM). The numbers of pregnancies within each
of these sub-categories are also displayed in Table 5. This sub-
categorisation was carried out with reference to data from clinical
records that provided labour, membrane rupture and delivery in-
formation. Deﬁnitions used for categorisation are listed below
Table 5. The BBB preterm deliveries were fairly evenly distributed
between the three main modes of delivery: emergency caesarean
section (CS), elective CS, and vaginal.
7. Pre-eclampsia
PE is a multisystem disorder that affects around 2e8% of preg-
nancies globally [7e9]. Patients typically present with hyperten-
sion during pregnancy in conjunction with proteinuria. The
condition tends to affect women in the latter half of pregnancy and
is associated with both FGR and PTB. PE is estimated to account for
10e15% of all global maternal mortality, with women in developing
countries bearing the vast majority of this burden [10].
In our cohort, pre-eclampsia was diagnosed as new hyperten-
sion, i.e. at least two consecutive blood pressure (BP) readings
above 140/90 mmHg or an increase in systolic BP of at least
30 mmHg or diastolic BP of at least 15 mmHg above booking,
combined with new proteinuria deﬁned as a protein creatinine
ratio (PCR) of greater than 50, or 24 h quantitation with a level of
greater than 300 mg. These diagnoses were recorded in the clinical
notes and available to BBB recruiters and data managers for sub-
sequent categorisation. Womenwho had personal or family history
of PE, displayed one or more of the symptoms of the disorder, or
were being actively monitored or treated for it were targeted by the
recruitment team.
The BBB recruited 133 women who went on to have a pre-
eclamptic pregnancy, from which over 700 biological samples
were accrued. 41 of these pregnancies were collected as trios. 45 of
these women also delivered preterm, representing an important
sub-phenotype of the syndrome. As well as women with clinically
diagnosed PE, the BBB also contains a substantial number of
women with PE associated symptoms such as pregnancy induced
hypertension (PIH) or renal complications (as identiﬁed from
maternal clinical records). The number of pregnancies associated
with these morbidities within the BBB are summarized in Table 6.
8. Fetal growth restriction
FGR describes the condition of a fetus unable to reach its growth
potential [11,12], which often results in a small for gestational age
(SGA) baby. SGA is deﬁned as a birthweight for gestational age
below the 10th centile and is often used as a proxy for FGR during
pregnancy. In high-income countries, FGR affects about 5e6% of
pregnancies [13e16]. FGR is associated with perinatal morbidity
and mortality. Furthermore, survivors are at risk for adult-onset
Table 4
Demographic characteristics of the BBB cohort.
Variable Category N (%) Range (SD) Mean
Maternal ethnicity White 1565 (68.2)
Black 229 (10.0)
Asian 99 (4.3)
Otherb 401 (17.5)
Maternal smoking Non-smoker 2074 (87.7)
Smoker 100 (4.2)
Quit within last 12 months 190 (8.1)
Maternal age at booking <20 25 (1.3) 14e55 (5.48) 32.83
20e25 187 (9.6)
26e30 372 (19.1)
31e35 741 (38.0)
36e40 478 (24.5)
41e45 140 (7.2)
>46 6 (0.3)
Maternal BMI at booking <18.5 (Underweight) 71 (3.0) 14e66 (5.27) 24.87
18.5e24.9 (Normal weight) 1304 (55.3)
25.0e29.9 (Pre-obesity) 630 (26.7)
30.0e34.9 (Obesity Class 1) 217 (9.2)
35e39.9 (Obesity Class 2) 94 (4.0)
Above 40 (Obesity Class 3) 42 (1.8)
Maternal parity Nulliparous 1324 (53.5) 0e12 (0.95) 0.67
Primiparous 797 (32.2)
Multiparous 354 (14.3)
Neonate gender Male 1182 (52.0)
Female 1092 (48.0)
Number of infants Singletons 2445 (97.2)
Twins 70 (2.7)
Delivery method CS 716 (42.2)
Vaginal 980 (57.8)
Birthweight (g) 295e5470 (728.92) 3164
GA at birth (weeks)a 20e43 (2.81) 38.32
a Assessed from ultra-sound scanning.
b Chinese, other Asian, other black, other, and all mixed groups.
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diseases, such as type 2 diabetes, obesity and cardiovascular disease
[17e20].
Although the original intention was to establish a pure FGR
cohort, we have chosen to use a broader deﬁnition of growth re-
striction in this summary paper, and report here the characteristics
of SGA infants within the BBB, whose birthweight for age centile (as
deﬁned by the 1996 gender speciﬁc four-in-one growth charts
produced by the Child Growth Foundation, London) fell below the
10th centile. Whilst we are aware of the limitations that this deﬁ-
nition holds as a proxy for all FGR pregnancies, with the current
debate surrounding deﬁnitions of FGR and variations in clinical
diagnoses we decided to use this looser deﬁnition under the
assumption that a large number of these SGA babies would indeed
be true cases of FGR. Furthermore, more detailed clinical data from
the pregnancy, including from ultra-sound scans that enable the
mapping of growth trajectories, can be retrieved if a more conser-
vative and strict deﬁnition of FGR is required by BBB users.
The BBB recruited 234 women with babies that fell below the
10th birthweight for gestational age centile. 82 of these deliveries
were successfully recruited as trios. Within this group, 112 babies
were below the 5th birthweight centile and 50% delivered preterm.
The mean birthweight for this SGA cohort was 1880g. The distri-
bution of birthweight for age centiles within the BBB, alongside the
mean birthweight for each centile grouping are summarized in
Table 7.
Alongside interest in the physiological, genetic and environ-
mental underpinnings of FGR, there is now a growing interest in
deliveries at the other end of the spectrum in which neonates are
large for gestational age, known as macrosomia. Over 200 babies in
the BBB were born above the 95th birthweight for age centile and
over 300 were above the 90th centile. This group poses particular
risks to mothers during delivery and is an important phenotype to
study in attempts to minimise maternal morbidity and mortality
related to childbirth.
9. Recurrent miscarriage
Miscarriage is the commonest complication of pregnancy and is
deﬁned as the spontaneous loss of a fetus before it has reached
viability. Hence, the term miscarriage includes all the losses from
conception up to the 24th week of gestation. Recurrent miscarriage
affects about 1.5% of couples trying to conceive [21]. Studies have
shown that the risk of miscarriage increases after each successive
pregnancy loss and it can reach 45% after three consecutive losses
[22]. Recurrent miscarriage (RM) was deﬁned as three or more
consecutive pregnancy losses, data that was collected from the
clinical records.
The BBB contains samples and clinical data for 232 women who
have a clinical diagnosis of RM, as well as many who have experi-
enced one or two previous miscarriages (Table 8). A large number
of these cases were recruited from the internationally recognized
centre for mothers' suffering from recurrent miscarriage based at
SM and run in part by the BBB principal investigator, LR. 97 of the
RM pregnancies belong to a BBB trio. In total over 1500 mis-
carriages were experienced by women in the cohort, and 770
Table 5
Number of preterm pregnancies according to gestational age and mode of delivery.
Preterm birth data (cumulative N)
Gestational age at birth
(weeks)
Total Spontaneous
PTBa
Spontaneous onset of
labourb
PPROMc Indicated
PTB
Missing data on labour/
membrane
Caesarean section
deliveryd
Vaginal
delivery
Induced
labour
20 1 1 0 1 0 0 0 0 1
21 1 0 0 1 0 1 0 0 1
22 2 0 0 1 0 2 0 0 1
23 4 0 3 4 0 4 0 3 1
24 6 0 4 5 1 5 0 5 2
25 16 8 6 8 2 6 2 7 2
26 15 11 9 10 4 0 6 8 2
27 30 17 16 15 6 7 9 12 3
28 33 22 19 20 11 0 17 14 3
29 41 24 21 21 17 0 24 15 3
30 61 30 27 25 21 10 31 17 3
31 80 37 33 31 32 11 40 20 3
32 96 44 39 36 40 12 49 25 3
33 132 58 51 47 60 14 73 32 3
34 186 80 70 64 86 20 94 43 6
35 252 102 87 85 124 26 121 68 21
36 373 145 113 123 186 42 172 105 48
a Spontaneous labour and/or membrane rupture and delivery before 37 weeks.
b Labour is spontaneous and delivery occurs before 37 weeks.
c Membrane rupture is spontaneous and resultant delivery occurs before 37 weeks.
d Emergency and elective.
Table 6
Number of pregnancies associated with a pre-eclamptic phenotype.
Pre-eclampsia phenotype BBB N
Pre-eclampsia 133
PIH 57
PIH in previous pregnancy/ies 76
Essential hypertension 98
Cardiac complications 15
Renal complications 16
Thrombosis 8
Table 7
Distribution of centiles and mean birthweight across the BBB.
Centile BBB N Mean birthweight (g)
<5th 112 1555
5th-<10th 122 2179
10th -< 25th 576 2614
25th-<50th 410 2876
50th-<75th 401 3273
75th-<90th 273 3590
90th-<95th 143 3913
>95th 206 4122
Data not available 272 NA
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women had had at least one previous miscarriage prior to their BBB
pregnancy. 20 women were receiving treatment with aspirin dur-
ing their pregnancy.
10. Other complications
Alongside the four main complications in pregnancy, the size of
the BBB means that a substantial number of other maternal com-
plications were also recorded, as detailed in Table 9.
11. Using the BBB
Interested parties are encouraged to contact the BBB manage-
ment team with any questions or requests they may have relating
to the bank. Procurement of samples is subject to review by the BBB
Research Management Board (who have so far approved all 14
initial applications), as well as written evidence from the applicant
of an ethically approved project for which the samples will be used.
Enquiries should be directed to the BBB Manager, Dr Nita Solanky
(nita.solanky@ucl.ac.uk). Further information on the BBB including
our SOPs, contact details and application form are available at
http://www.ucl.ac.uk/tapb/sample-and-data-collections-at-ucl/
biobanks-ucl/baby-biobank.
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Distribution of number of previous miscarriages within BBB.
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Data not available 79
Table 9
Summary of extra clinical categories of interest.
Maternal clinical category BBB N
Diabetes 23
Gestational Diabetes 31
Pregnancy from In vitro Fertilization 22
Placenta previa 11
Placental abruption 26
Urinary tract infection 36
Thyroid complications 27
Cardiac complications 29
Epilepsy 48
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Identifying the genetic input for fetal growth will help to understand common,
serious complications of pregnancy such as fetal growth restriction. Genomic
imprinting is an epigenetic process that silences one parental allele, resulting
in monoallelic expression. Imprinted genes are important in mammalian fetal
growth and development. Evidence has emerged showing that genes that are
paternally expressed promote fetal growth, whereas maternally expressed
genes suppress growth. We have assessed whether the expression levels of
key imprinted genes correlate with fetal growth parameters during pregnancy,
either early in gestation, using chorionic villus samples (CVS), or in term
placenta. We have found that the expression of paternally expressing insulin-
like growth factor 2 (IGF2), its receptor IGF2R, and the IGF2/IGF1R ratio in
CVS tissues significantly correlate with crown–rump length and birthweight,
whereas term placenta expression shows no correlation. For the maternally
expressing pleckstrin homology-like domain family A, member 2 (PHLDA2),
there is no correlation early in pregnancy in CVS but a highly significant nega-
tive relationship in term placenta. Analysis of the control of imprinted
expression of PHLDA2 gave rise to a maternally and compounded grand-
maternally controlled genetic effect with a birthweight increase of 93/155 g,
respectively, when one copy of the PHLDA2 promoter variant is inherited.
Expression of the growth factor receptor-bound protein 10 (GRB10) in term pla-
centa is significantly negatively correlated with head circumference. Analysis of
the paternally expressing delta-like 1 homologue (DLK1) shows that the paternal
transmission of type 1 diabetes protective G allele of rs941576 single nucleotide
polymorphism (SNP) results in significantly reduced birth weight (2132 g). In
conclusion, we have found that the expression of key imprinted genes show a
strong correlation with fetal growth and that for both genetic and genomics
data analyses, it is important not to overlook parent-of-origin effects.
1. Background and results
(a) Fetal growth
Birthweight and its relationship to mortality show one of the strongest links
observed in epidemiology, illustrated by a reverse-J-shaped curve with the
highest mortality observed in the lightest and heaviest groups [1]. Growing
appropriately in utero is essential for a long and healthy life. Fetal growth
& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
restriction (FGR) affects approximately 6% of pregnancies,
and is identified in approximately half of stillborn fetuseswith-
out malformations [2,3]. While the majority of FGR babies
demonstrate catch-up growth, the combination of suboptimal
intrauterine growth followed by accelerated childhood
growth can increase their susceptibility to adult-onset diseases,
including type 2 diabetes, hypertension and coronary artery
disease [4]. Each baby’s unique growth potential in utero is
determined by the successful nutritional and respiratory sup-
port from the mother to the fetus via a placenta, and
disturbing this balance could lead to FGR [5]. Fetal growth is
influenced by both genetic and environmental factors,
although the relevant molecular pathways are still poorly
defined. Identifying key genes and pathways that regulate
fetal growth will allow for better monitoring of intrauterine
growth, maximizing healthy outcomes.
(b) Genomic imprinting
Genomic imprinting is a process of epigenetic modification on
the genome that causes silencing of one allele according to its
parental origin, resulting in monoallelic expression, without
changing the DNA sequence [6–8]. Sex-specific imprint
marks are heritable to daughter cells, but are erased and re-
established in the germline during gametogenesis [9]. Evidence
from mouse models and rare human imprinting disorders
suggests that genes that are paternally expressed tend to
increase fetal growth, whereas maternally expressed genes
restrict fetal growth. For example, mice knockouts for pater-
nally expressed genes Igf2, mesoderm-specific transcript
(Mest) and paternally expressed gene 3 (Peg3) result in FGR,
whereas mice deficient for maternally expressed genes insu-
lin-like growth factor 2 receptor (Igf2r), H19 and Grb10 show
an overgrowth phenotype [10–14] (table 1). Rare imprinting
disorders such as the growth-restricted phenotype of Silver–
Russell syndrome (SRS)may implicate complex roles involving
both absence of growth promoters such as IGF2 and potential
increase of growth restrictors such asGBR10 (reviewed in [26]).
The kinship theory or parental ‘conflict theory’ predicts
that imprinting may have evolved as a result of competition
between the paternal and maternal genome for maternal
nutrient provision. The paternal genome encourages fetal
growth by extracting nutrients from the mother, whereas
the maternal genome counterbalances this by limiting
resources to the offspring to ensure not only her survival,
but also the equal provision of nutrients among her offspring
[41]. Genomic imprinting is observed predominantly in pla-
cental mammals, and it is, indeed, the placenta which
serves as the key regulatory site for this genomic conflict.
More than 100 imprinted genes have been identified in
mice and approximately half of them are conserved in
humans. In addition to this, many more tissue-specific
human-imprinted loci are being discovered (http://igc.otago.
ac.nz/; http://www.har.mrc.ac.uk/) [42]. In the current pro-
ject, we have studied 13 imprinted genes that are highly
expressed in human term placenta and are known to lead to
growth phenotypes when deficient in mice (table 1). In
addition, we included three non-imprinted genes that were
critical to the action of IGF2, which is a key paternally
expressed imprinted growth promoter (table 2).We have inves-
tigated the expression of these genes in both early and late
gestation using the King’s College London (KCL) CVS cohort
(11–13 weeks of gestation) and the Moore term placenta
cohort, respectively, and correlated these data with important
growth parameters such as birthweight, placental weight and
head circumference.
Also, in a separate analysis reported here, thepotential influ-
ence of other variables such as the baby’s sex, gestational age,
parity, maternal weight/body mass index (BMI) and maternal
smoking were tested against gene expression. In some situ-
ations, loss of imprinting (LOI) can occur, leading to biallelic
expression of the gene. Because this could potentially influence
the overall genedosage, termplacenta andCVS samples used in
these expression studies were also investigated to see whether
they retained a normal imprinting pattern, or showed monoal-
lelic expression. In this hybrid review/research article, we
summarize our previous findings together with new data.
(c) Insulin-like growth factor axis and IGF2/H19 locus
The insulin/IGF growth factor ‘axis’ constitutes key regulat-
ory endocrine factors of pre- and postnatal growth. These
include insulin (INS), IGF1, IGF2 and their corresponding
receptors (IR, IGF1R and IGF2R), and six binding proteins
(IGFBP1–6) [48]. INS and IGF1 exclusively bind to IR and
IGF1R, respectively, whereas IGF2 can bind to IGF1R,
IGF2R and IR 11-isoform [49]. IGF2R is located on human
chromosome 6q25.3 and shows maternal expression in only
10% of term placentas and CVS [17,50]. One of its major func-
tions is the lysosomal targeting and degradation of IGF2, thus
acting as a growth suppressor [51]. IGF2 and H19 map to one
of the most intensely studied imprinted gene clusters on
human chromosome 11p15. Their reciprocal imprinting is con-
trolled by differential methylation of imprinting control region
1 (ICR1) which is normally only methylated on the paternal
allele [52]. The unmethylatedmaternal ICR1 allows the binding
of the CTCF transcription factor, blocking the access of IGF2
promoters to the H19 downstream enhancers, resulting in the
activation of H19 expression. Conversely, the CTCF protein is
prevented from binding to the paternal methylated ICR1,
resulting in monoallelic paternal IGF2 expression owing to
IGF2 promoter interaction with the enhancers. Approximately
50%of the growth-restricted SRS cases show loss ofmethylation
at ICR1,which could lead to decreased IGF2 expression [24] and
that may well contribute to SRS growth restriction.
In our previous studies, we have shown that IGF2 and
IGF2R expression in term placenta has no correlation with
baby’s birth size parameters. However, their expression
levels in CVS tissues showed a strong positive correlation
with birthweight [17,33], indicating their role as ‘early
growth effectors’. In addition to this study, the expression
levels of H19 (n ¼ 104) relative to the ribosomal protein L19
(L19) endogenous control gene in CVS tissues was measured
by RT-quantitative polymerase chain reaction (qPCR). The
relative expression levels of H19 were correlated to birth
weight in a regression model adjusted for baby’s sex, parity,
gestational age at birth, maternal BMI and smoking habits.
The CVS expression data for IGF2, IGF2R, H19, PHLDA2,
IGF1 and IGF1Rwere also correlated to CRL at the gestational
age of 12 weeks, using the same regression model, except this
time the gestational age at CRLmeasurement was used instead
of gestational age at birth. Correlation betweenH19 expression
and birthweight was not statistically significant (p ¼ 0.07).
However, there was significant evidence for positive associ-
ation between CRL at 12 weeks and IGF2 expression ( p ¼
0.004; figure 1a), IGF2R expression (p ¼ 0.03; figure 1b),
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IGF2/IGF1R ratio ( p ¼ 0.03; figure 1c) and H19 expression
( p ¼ 0.04; figure 1d and table 3). These results suggest that
the many members of the IGF axis (IGF2, IGF2R and IGF1R),
and the closely associated H19, shape the growth trajectory
early in pregnancy.
There was no correlation between maternal smoking and
the expression in CVS of the genes tested (those listed above)
in our samples. Nevertheless, we observed an association
between IGF2 expression and parity, whereby IGF2 expres-
sion is higher in the ‘parity greater than one’ group of babies
( p ¼ 0.03; electronic supplementary material, figure S1a); this
is consistent with the role of IGF2 as a positive growth regula-
tor. This observation is interesting as the majority of second
born babies are bigger [36]. We also found evidence that
the maternal BMI was positively correlated with IGF2R
expression (p ¼ 0.03; electronic supplementary material,
Table 1. Imprinted genes highly expressed in the placenta. Origin, parental origin of the expressed allele; M, maternally expressed; P, paternally expressed;
ncRNA, non-coding RNA; FGR, fetal growth restriction; Dup, duplication; UPD, uniparental disomy; ICR, imprinting control region; LBW, low birthweight; BW,
birthweight; HC, head circumference; CVS, chorionic villus sampling tissues; CRL, crown–rump length; PIP, phosphatidylinositol phosphate lipid; mat del,
maternally inherited deletion; pat del, paternally inherited deletion; T1D, type 1 diabetes; TNDM, transient neonatal diabetes mellitus; BWS, Beckwith–
Wiedemann syndrome; SRS, Silver–Russell syndrome; CNV, copy number variation; asterisk, ﬁndings from this study.
locus gene origin description mouse KO phenotypes human growth phenotypes
6q24 PLAGL1 P zinc ﬁnger protein FGR, bone malformation, high
neonatal lethality [15]
TNDM (pUPD6, pDup6q24, ICR
hypomethylation) [16]
6q25 IGF2R M/biallelic clearance of IGF2 fetal and placental overgrowth,
organ and skeletal abnormalities
[11]
CVS expression positively correlated to
BW [17] and CRL*
7p12 GRB10 M/P GF receptor-bound
protein
fetal and placental overgrowth [10] implicated in SRS (mDup7p11.2–13)
[18]; term placenta expression
negatively associates with HC*
7q21.3 PEG10 P retrotransposon
derived
embryonic lethal due to placental
malformation [19]
hypermethylation at ICR and reduced
expression in LBW cord blood [20];
upregulated in FGR placenta [21]
7q32.2 MEST P/biallelic a/b hydrolase
fold family
fetal and placental growth
restriction, high postnatal
lethality, abnormal maternal
behaviour [12]
implicated in SRS (mUPD 7q31-qter)
[22]
11p15 H19 M long ncRNA fetal and placental overgrowth
[13,23]
ICR1 hypomethylation [24] and CNV
[25] in SRS
IGF2 P growth factor fetal and placental growth restriction CVS expression positively correlated to
BW [17] and CRL*; implicated in
BWS and Wilm’s tumour [26]
CDKN1C M tumour suppressor gestational fetal and placental
overgrowth [27]
mutated in IMAGe [28], BWS [29] and
SRS [30] patients
SLC22A18 M organic cation
transporter
not reported term placenta expression associated
with HC [31]
PHLDA2 M PH domain, PIP
binding
placental overgrowth [32] highly expressed in lower BW and FGR
placenta [21,33–35]; promoter
variant associated with BW [36]
14q32 DLK1 P transmembrane
glycoprotein
pre- and postnatal growth
restriction, high perinatal
lethality, obese postnatally [37]
associated with T1D [38], UPD14
syndromes [26], T1D SNP correlated
to BW*
MEG3 M ncRNA postnatal lethal (mat del), pre- and
postnatal growth restriction, high
perinatal lethality (pat del) [39]
associated with T1D [38], reduced
expression in FGR placenta [35]
19q13.4 PEG3 P zinc ﬁnger protein placental and fetal growth
restriction, abnormal maternal
behaviour [14]
tumour suppressor [40]
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figure S1b) and negatively correlated with IGF1 ( p ¼ 0.046;
electronic supplementary material, figure S1c). This suggests
that it is important to allow for correction for maternal BMI/
weight when investigating the gene expression in association
with fetal growth. Interestingly, H19 was expressed signifi-
cantly higher in males (p ¼ 0.006; electronic supplementary
material, figure S1e and table S2). The observed sex bias
cannot be explained by LOI (i.e. biallelic expression of H19 in
males only), because all of the CVS tissues tested retained
monoallelic expression (table 4), therefore it is likely to result
from upregulation of the active maternal copy. Males are
normally born bigger than females [36], and the sexual
dimorphism in antenatal biometry has been reported to be evi-
dent around 8–12 weeks of gestation [53]. AsH19 is a negative
growth regulator, the higher expressionmay help preventmale
babies from growing too large.
(d) GBR10
GRB10 is located in the human chromosome 7q12 imprinted
region. Chromosome7 is implicated in causality for SRS, because
10% of patients show maternal uniparental disomy of chromo-
some 7. FGR is a key feature of SRS, which has been suggested
to result either from the overexpression of amaternally expressed
gene or loss of a paternally expressed growth-promoting gene.
GRB10 encodes a growth factor receptor binding protein that
can interact with receptor tyrosine kinases and intracellular
proteins [54]. GRB10 is imprinted in an isoform- and a tissue-
specific manner [55]. In humans, GRB10 shows biallelic
expression in most tissues, while exhibiting isoform-specific
paternal expression in the brain but with maternal expression
confined to the placental villous trophoblast [56]. In mice,
Grb10 is paternally expressed in the brain, but shows ubiquitous
maternal expression in other tissues [55]. This pattern is roughly
Table 2. Non-imprinted genes highly expressed in the placenta.
locus gene description mouse KO phenotypes human growth phenotypes
7p12 IGFBP3 carrying protein for IGF1 and
IGF2
retinal vessel loss [43] implicated in common cancers [44]
12q23.2 IGF1 growth promoter pre- and postnatal growth restriction,
infertile [45]
pre- and postnatal growth
restriction [46]
15q26.3 IGF1R IGF1 and IGF2 receptor fetal growth restriction and perinatal lethal pre- and postnatal growth
restriction [47]
p = 0.004** p = 0.03*
p = 0.04*p = 0.03*
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Figure 1. Correlation between imprinted gene expression in CVS and CRL. Expression levels of each gene relative to the L19 endogenous control gene were cor-
related to crown–rump length (CRL: mm) using a multiple linear regression model adjusted for maternal BMI, baby’s sex, parity, gestational age when CRL was
measured and maternal smoking habit. Positive correlations with CRL and (a) IGF2 expression (r ¼ 0.77; p ¼ 0.004), (b) IGF2R expression (r ¼ 0.76; p ¼ 0.03), (c)
IGF2/IGF1R ratio (r ¼ 0.74; p ¼ 0.03) and (d ) H19 expression (r ¼ 0.74; p ¼ 0.04) were observed. (Online version in colour.)
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the opposite of what is seen for Igf2, where it is preferentially
maternally expressed in the adult mouse brain but paternally
expressed in other tissues [57]. Inactivation of the maternal
copyofGrb10 results in fetal andplacental overgrowth, indicative
of its role as a potent growth suppressor [10]. In contrast, mice
with a disrupted paternal copy showed normal growth but
increased social dominance behaviour, illustrated by increased
facial barbering (whisker removal) on cage-mates [58].
Table 3. The association between mRNA levels and fetal growth in term placenta and CVS. Shading indicates previously published results [17,33].
The correlation signiﬁcance is indicated by p-values. Correlation coefﬁcient (r) is presented underneath the p-values for the associations reaching signiﬁcance.
n, number of samples; BW, birth weight; PW, placental weight; HC, head circumference; CRL, crown–rump length; NT, not tested.
gene
CVS term placenta
n BW CRL n BW PW HC
IGF2 260 0.009** 0.004** (r ¼ 0.77) 200 0.9 0.46 0.43
IGF2R 260 0.004** 0.03* (r ¼ 0.76) 200 0.86 0.56 0.7
IGF2/IGF2R 260 0.93 0.58 200 0.5 0.56 0.62
IGF1 200 0.48 0.07 NT NT NT NT
IGF1R 260 0.08 0.93 NT NT NT NT
IGF1/IGF1R 200 0.76 0.06 NT NT NT NT
IGF2/IGF1R 260 0.005** 0.03* (r ¼ 0.74) NT NT NT NT
PHLDA2 260 0.55 0.92 200 0.0001** 0.7 0.95
MEST NT NT NT 200 0.96 0.78 0.42
H19 104 0.07 0.04* (r ¼ 0.74) 86 0.28 0.42 0.51
DLK1 99 0.67 0.25 272 0.07 0.8 0.4
GRB10 NT NT NT 193 0.64 0.69 0.04* (r ¼20.35)
MEG3 NT NT NT 195 0.88 0.54 0.43
PEG10 NT NT NT 110 0.48 0.21 0.32
PEG3 NT NT NT 93 0.87 0.52 0.82
SLC22A18 NT NT NT 78 0.13 0.57 0.52
CDKN1C NT NT NT 81 0.82 0.6 0.98
PLAGL1 NT NT NT 102 0.77 0.91 0.61
PLAGL1imp NT NT NT 102 0.18 0.55 0.064
IGFBP3 NT NT NT 102 0.63 0.62 0.49
Table 4. Summary of imprinting analysis in CVS tissues and term placenta. M, maternal expression; P, paternal expression. %, percentage of samples with
monoallelic expression within informative samples; n.a., not available.
gene parental origin imprinting in term placenta imprinting in CVS polymorphic site
IGF2 P 67/67 (100%) 40/40 (100%) rs680
IGF2R M/biallelic n.a. 3/24 (12%) rs1805075
PHLDA2 M 11/11 (100%) 21/21 (100%) rs13390, rs1056819
MEST P/biallelic 34/42 (81%) n.a. rs10863
H19 M 19/19 (100%) 33/33 (100%) rs2067051
DLK1 P 30/30 (100%) n.a. rs1802710
MEG3 M 9/9 (100%) n.a. rs45617834, rs941575
PEG3 P 14/16 (88%) n.a. rs1055359
PEG10 P 42/42 (100%) n.a. rs13073, rs13226637
GRB10 M (placenta), P (brain) n.a. n.a. n.a.
SLC22A18 M 23/23 (100%) n.a. rs1048046, rs1048047
PLAGL1 P 11/11 (100%) n.a. rs2076684
CDKN1C M 24/24 (100%) n.a. PAPn repeat
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In this study, we have observed a significant negative
association between GRB10 expression (all isoforms) and
head circumference (figure 2, p ¼ 0.04), but no significant
correlation with birthweight ( p ¼ 0.64) or placental weight
( p ¼ 0.69; table 3). The direction of association is consistent
with the role of GRB10 as a negative growth regulator. It is
interesting that the observed association is specific to head
circumference, because it is oppositely imprinted in the
brain. There was no correlation between maternal smoking
and expression of the genes tested in term placenta samples
(electronic supplementary material, table S3). Interestingly,
GRB10 expression showed a positive association with increas-
ing gestational age ( p ¼ 0.03; electronic supplementary
material, figure S2a). This suggests that GRB10 is acting to
suppress the head circumference of the baby close to birth,
because a head size too large for the birth canal would be
detrimental for the mother.
(e) PHLDA2
PHLDA2 is a maternally expressed gene located on the centro-
meric domain of the Chr11p15 imprinting cluster, along with
other maternally expressed genes CDKN1C and SLC22A18.
PHLDA2 encodes a small (144 amino acid) protein with a
Pleckstrin-homology (PH) domain which has the capacity
to bind membrane phosphatidylinositol phosphate lipids
(PIPs) [59], suggesting a role for it as a cell signalling protein.
In line with the kinship theory, Phlda2-deficient mice have an
enlarged placenta, whereas overexpression of Phlda2 in trans-
genic mice results in placental stunting with a modest
reduction in fetal weight [60,61]. We have previously shown
that birth weight is not correlated with PHLDA2 expression
levels in CVS tissues, but has a significant negative correlation
in term placenta [17,33], indicative of a function as a ‘late
growth effector’. Other studies have observed upregulation
of PHLDA2 in FGR placentas [21,34,35], and in first and
second trimester miscarriage placentas [62]; these data all
support the hypothesis that PHLDA2 is an important negative
regulator of growth.
More recently, upregulation of placental PHLDA2 expres-
sion among mothers who smoke during pregnancy has been
reported [63]. Inour study, however,wedidnotobserve anycor-
relation between maternal smoking and CVS or term placental
expression of PHLDA2 (electronic supplementary material,
table S3). PHLDA2 expression in CVS and term placenta did
not show correlation with any of the confounding variables
used in the model, except for gestational age. We identified
that reduced PHLDA2 expression in CVS tissues was associated
with advancing gestational age at birth (p ¼ 0.0092; electronic
supplementarymaterial, figure S1e). Because a shorter gestation
results in smaller babies, its high expression inCVS fits its role as
a growth suppressor.
All the samples used in the analysis showed monoallelic
expression of PHLDA2, demonstrating that LOI cannot account
for the increased expression seen in the smaller birth weight
babies [33]. To further investigate this correlation, we succes-
sively interrogated the nearby region for potential genetic
variations that correlate with fetal growth. We identified a
rare 15 bp repeat sequence variant (RS1) in the PHLDA2 pro-
moter region, which has been shown to reduce the PHLDA2
promoter efficiency [36]. Maternal inheritance of RS1 resulted
in a 93 g increase in birthweight, and when the mother is
homozygous for RS1, the effect on birthweight is 155 g,
suggesting a grand-maternal influence. Paternal inheritance
of RS1 does not influence fetal growth as the variant lies on
the epigenetically silenced paternal allele, emphasizing the
importance of taking into account parent-of-origin effects
when analysing genetic variants. Taken together, these data
show that PHLDA2 is a strong negative growth suppressor
and provide a potential pre-pregnancy test, using the RS1
variant, to predict birthweight.
( f ) DLK1
DLK1 (PREF1 and FA1) is a paternally expressed gene located
in the human chromosome 14q32 imprinting cluster, approxi-
mately 90 kb away from the maternally expressed non-coding
RNA gene MEG3 (also called GTL2). DLK1 encodes a trans-
membrane glycoprotein with six epidermal growth factor-
like repeat motifs [64], known to be involved in adipogenesis
[65]. Dlk1-null mice show high perinatal lethality, pre- and
postnatal growth restriction followed by an obese phenotype
[37], suggesting that it acts as a growth promoter.
In this study, the expression levels of DLK1 (all isoforms) in
CVS (n ¼ 99) and term placenta (n ¼ 272) were correlated to
fetal growth parameters. For the CVS analysis, only the tissues
from extreme birthweight babies (less than 10th centile
and more than 90th centile) were used. Using the regression
model as described forH19, we did not observe any association
between DLK1 expression and birthweight (p¼ 0.23) or
with CRL (p¼ 0.16). However, term placental DLK1 expres-
sion did show a weak positive association with birthweight
(p ¼ 0.07; table 3). Although this trend did not reach statistical
significance, the direction of influence is consistent with its
role as a growth promoter. Interestingly, DLK1 expression
showed a positive correlation with increasing parity (p ¼ 0.05;
electronic supplementary material, figure S2b and table S3),
possibly increasing the size of the later parity babies.
p = 0.04*
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Figure 2. Negative correlation between GRB10 term placental expression and
head circumference. The expression level of GRB10 relative to the L19 house-
keeping gene was correlated to head circumference (cm) using a multiple
linear regression model adjusted for baby’s sex, parity, gestational age at
birth, maternal weight and smoking habits. GRB10 expression values in log-
arithmic scale was used. Significant negative association was observed for
GRB10 term placenta expression and head circumference (r ¼20.35;
p ¼ 0.04). (Online version in colour.)
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The rs941576 (G/A) SNP of the DLK1-MEG3 gene region
on human chromosome 14 has previously been identified as
a type 1 diabetes (T1D) susceptibility locus [38]. A reduced
paternal, but not maternal, transmission of the protective G
allele was observed in the T1D-affected individuals, showing
a clear parent-of-origin effect. It was suggested that the
rs941576 variant may affect nearby paternally expressed
genes, including DLK1. Notably, higher birthweight has
been linked to increased T1D risk [66–68]. This prompted
us to test whether paternal transmission of the protective G
allele is associated with (i) lower DLK1 expression and/or
with (ii) reduced birthweight using the DNA samples from
the Moore cohort. Because this is located within intron 6
of MEG3 and 105 kb downstream of DLK1, its potential
influence on MEG3 expression was also tested.
In this study, 295 trio DNA samples from the Moore cohort
were used for genotyping the rs941576 SNP. The resulting
frequencies of the three genotypes were GG: 24%, AG: 45%
and AA: 31%. 112 and 141 babies inherited paternal G and
Abases, respectively, and 119 and132 babies inheritedmaternal
G and A, respectively. Using multiple linear regression analy-
sis, we found that paternal or maternal transmission of the
G allele is not correlated with DLK1 expression (p ¼ 0.47 and
p ¼ 0.63, respectively) or with MEG3 expression (p ¼ 0.7
and p ¼ 0.085, respectively).
Next, the association between the inheritance of a paternal
G allele with fetal growth was investigated, using a multiple
linear regression model, adjusted for sex of the baby, parity,
gestational age and maternal weight and smoking habit.
Paternal transmission of the G allele was significantly
associated with an average decrease of birthweight by 132 g
(p ¼ 0.01, 95% CI2 232 to 232; figure 3a), and a 0.5 cm
reduction in head circumference of the baby (p ¼ 0.01, 95%
CI 20.85 to 20.11; figure 3b), but not with placental weight
(20.45 g; p ¼ 0.98, 95% CI 235 to 35; figure 3c). Importantly,
the scale of birthweight reduction (2132 g) associated with
paternal G transmission is similar to that of the maternal smok-
ing (2152 g). Maternal inheritance of the G or A allele was not
associated with birthweight (p¼ 0.8), head circumference
(p ¼ 0.62) or placental weight (p ¼ 0.86), consistent with
the observed paternal effect of the protective G allele in
T1D susceptibility.
(g) Other imprinted genes studied
No evidence of correlation betweenH19,MEG3, PEG10, PEG3,
SLC22A18, CDKN1C, PLAGL1_imp (imprinted transcript),
PLAGL1_all (all transcripts) or IGFBP3 expression, in term pla-
centa, with fetal growthwas observed (summarized in table 3).
In addition, we were unable to corroborate a previously
reported association between SLC22A18 expression and head
circumference [31].We did not observe anyLOI in our samples,
except for PEG3, where 2/16 (12%) samples showed biallelic
expression in term placenta. Table 4 details the polymorphic
variants used for each gene and imprinting analysis results.
It was not possible to test all the candidate genes in both
term placenta and for CVS tissues, owing to the limited avail-
ability of material for the latter, whereas some candidates
also showed a level of expression undetected by quantitative
PCR. Therefore, the candidate genes have been prioritized
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Figure 3. The association between paternal A/G SNP rs941576 at the DLK1 locus and fetal growth. Partial residual plots illustrating the correlation between paternal
inheritance of the A or G allele and (a) birthweight (g), (b) head circumference (cm) and (c) placental weight (g), corrected for baby’s sex, parity, gestational age,
maternal weight and smoking habit in the multiple regression model. In comparison to the A allele, paternal G allele inheritance is associated with significantly
reduced birthweight ( p ¼ 0.01, 95% CI2232 to 232) and head circumference ( p ¼ 0.01, 95% CI 20.85 to 20.11) but not with placental weight ( p ¼ 0.98,
95% CI 235 to 35). Paternal A/G, paternal transmission of A/G SNP rs941576; A, paternal transmission of the A allele; G, paternal transmission of the G allele; BW,
birthweight; HC, head circumference; PW, placental weight. (Online version in colour.)
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according to their functional relevance. Although it would
have been interesting to test GRB10 expression in CVS,
head circumference measurements were not available for
the KCL CVS cohort.
2. Discussion
Suboptimal or excessive intrauterine growth leads to perinatal
morbidity and mortality, as well as an increased risk for adult-
hood diseases [4]. Finding genetic factors that regulate normal
fetal growth will potentially provide more precise monitoring
of intrauterine growth. Genomic imprinting epigenetically
silences one parental allele resulting in monoallelic expression.
It is now accepted that paternally expressed genes tend to
encourage fetal growth, whereas maternally expressed genes
restrict this. In this paper, the role of imprinted genes on fetal
growth was explored by summarizing and connecting our
previous and current findings. Although DNA methylation
plays a key regulatory role in imprinted gene expression,
their methylation statuses were not assessed in our samples
as CVS is a limited resource. RNA expression variation is
downstream of DNAmethylation or other possible DNA regu-
latory factors, and therefore potentially more functionally
relevant. An additional DNA methylation status assessment
would be an interesting aspect for the future study.
(a) The early and late effectors of fetal growth
Combining past and present studies, we have investigated
the correlation between fetal growth measurements and
expression levels of 13 imprinted and three non-imprinted
genes highly expressed in CVS tissues and term placenta
(tables 1 and 2). Our candidate gene approach has identified
some early and late effectors of fetal growth. We have shown
that the CVS expression of IGF2 and IGF2R is positively cor-
related to birthweight, whereas this correlation disappears in
term placenta (table 3). Conversely, PHLDA2 expression in
CVS is not correlated to birthweight, whereas PHLDA2
expression at term is strongly negatively correlated to birth-
weight. Although GRB10 expression in CVS was not tested,
its expression in term placenta showed a strong negative
association with head circumference. These observations
suggest that IGF2 and IGF2R can act to set the growth poten-
tial of the baby early in the pregnancy, and two maternally
expressed growth suppressing genes, PHLDA2 and GRB10,
act to fine tune growth in late pregnancy, potentially to
avoid the risk of giving birth to a macrosomic baby. Impor-
tantly, mouse studies indicate that both Phlda2 and Grb10
control placental growth by mechanisms independent of
Igf2 [10,32], implying the evolution of separate pathways to
control overall fetal size, possibly reflected by the difference
in timing of their functional action.
The first half of placental development is characterized by a
series of important trophoblast proliferation and differentiation
processes, forming mature villous and extravillous structures.
The second half of gestation results in an extensive vasculariza-
tion and placentalmass expansion [69]. Early gestational insults
such as maternal diabetes have been associated with long-
term effects on the fetus, owing to their influence on the initial
structural formation of the placenta. It is possible that IGF2
and IGF2R are key regulators of early formation of the placenta,
which then sets the growth capacityof the fetus andplacenta for
the rest of gestation. Interestingly, overexpression of mouse
Phlda2 results in placental size reduction, with decreased glyco-
gen storage and failed mobilization, accompanied by
progressive fetal weight loss in late gestation [61]. It has been
suggested that halving Phlda2 expression by silencing the
paternal allele later in gestation may promote energy provision
for the fetus at this time, by increasing the glycogen stores that
will be used in late gestation when there is a particularly high
nutrient demand from the fetus [61].
(b) Environment and other physiological effectors on
gene expression
Although placenta is fetal in origin, it is under the influence
of both maternal and fetal circulation. The placental villi con-
sist of syncytiotrophoblasts facing the maternal blood, with
cytotrophoblasts in the middle and endothelial cells facing
the fetal circulation [69]. Therefore, the mRNA measured in
the placenta could be a result of response to the hormones
and growth factors present in both maternal and fetal circula-
tion. In this study, potential influences of environmental
variations (maternal weight/BMI and maternal smoking)
and physiological variation (baby’s gender, gestational age
and parity) on gene expression were tested.
We did not observe a correlation between maternal smok-
ing and gene expression levels with all genes tested in both
CVS and term placenta (electronic supplementary material,
table S2). This result contradicts the previous report where
the upregulation of placental PHLDA2 in smokers (n ¼ 12)
compared with non-smokers (n ¼ 64) was observed in a
microarray experiment [63]. This could be due to different
sensitivities between the two techniques. However, our cohorts
contained more smokers (n ¼ 27, Moore cohort and n ¼ 33,
CVS cohort; electronic supplementary material, table S1),
which allows for more accurate measure of expression. IGF2R
expression in CVS showed a positive association with mater-
nal BMI (electronic supplementary material, figure S1b and
table S2). This is interesting, because IGF2R has been found
in the syncytiotrophoblast, which is in direct contact with the
maternal blood circulation, and therefore possibly regulating
the effect of fetal IGF2 levels on the mother [70].
Notably, we have found a sex-biased expression of H19
in CVS tissues,where it is expressedmore highly inmales (elec-
tronic supplementarymaterial, figure S1d).H19 has previously
been reported to show female-biased expression in mouse eyes
[71]. Therefore, H19 expression could be dually regulated
according to the sexes of the parent (imprinting) and also the
baby (sexual dimorphism), in a tissue- and time-specific
manner. Moreover, downregulation of PLAGL1 in FGR pla-
centa of females, but not males, has been reported [72]. This
was not evident in our normal term placenta samples, imply-
ing FGR-specific effects. Insight into the effect of sexual
dimorphism is important for understanding both normal
molecular mechanisms and sex-biased disease conditions.
(c) DLK1, type 1 diabetes and parent-of-origin effect on
fetal growth
Type 1 diabetes (T1D) is caused by autoimmune destruction of
pancreatic beta cells, resulting in insulin deficiency, although
its aetiology is not fully understood [68]. The DLK1-MEG3
imprinting locus has recently been identified as a T1D suscep-
tibility region, marked by the rs941576 SNP in which paternal
inheritance of a G allele was associated with reduced risk [38].
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DLK1 is highly expressed in pancreatic islet cells and is
involved in differentiation of pancreatic beta cells, suggesting
its strong functional candidacy [73].
In this study, we found that paternal transmission of the
protective G allele results in a significant decrease of birth-
weight, by 132 g (figure 3a), and head circumference, by
0.5 cm (figure 3b). Of note, higher birthweight has been
linked to increased T1D risk [66–68]. Therefore, paternal
inheritance of the G allele may give protective effect from
T1D via its association with reduced birthweight. This could
also be associatedwith a decrease inDLK1 expression although
this association did not reach statistical significance. Impor-
tantly, the magnitude of birthweight reduction (2132 g) and
head circumference (20.5 cm) related to the paternal G allele
inheritance was similar to that observed for the increase in
birthweight (þ155 g) and in head circumference (þ0.23 cm)
caused by inheriting a PHLDA2 promoter RS1 allele from a
RS1homozygousmother [36]. Our currentworking hypothesis
regarding the relationship between the role of DLK1 in fetal
growth and T1D is described in figure 4 [37,64,65].
3. Conclusion
We have identified that expression of IGF2 and IGF2R in
early placenta (CVS) are positively correlated to CRL and
birthweight, but not in term placenta when the oppositely
maternally expressed genes PHLDA2 and GRB10 act to
negatively regulate growth. We have also identified that the
paternal transmission of the T1D protective G allele of
rs941576 SNP results in a significant reduction in birthweight
(p ¼ 0.01, 95% CI2232 to 232), emphasizing the importance
of accounting for parent-of-origin effects when analysing geno-
mic data. Characterization of genes important in intrauterine
growth will allow a more accurate surveillance of fetal growth
and help identify targets for clinical intervention in suboptimal
pregnancies. During pregnancy, a combination of different
levels of imprinted genes or genetic predispositions will affect
the baby’s birthweight. An additional environmental layer is
added by maternal smoking. Further investigation of all these
candidates is warranted in larger cohorts to identify further
genetic variants that exhibit parent-of-origin associated
growth regulation and to find gene expression variations.
Together with previously known genetic variants associated
with fetal growth (reviewed in [26]), and expression studies,
these may be used as an effective, combined diagnostic tool
to identify and predict growth-restricted and macrosomic
babies, which would provide huge benefits for the short- and
long-term health of both mother and baby.
4. Materials
(a) King’s College London chorionic villus sample cohort
CVS was carried out between 11 and 13 weeks of gestation in
355 singleton pregnancies that were followed by normal live
birth at term. Participants were undergoing CVS for prenatal
diagnosis for chromosomal abnormality at King’s College
Hospital London. The samples used in this study were
obtained from excess CVS tissues from fully ethically con-
sented women, and the research was approved by the King’s
College Hospital Ethics Committee. The medical records of
this cohort are summarized in the electronic supplementary
material, table S1 [17].
(b) Moore cohort
TheMoore cohort consists of 302 consentedwhiteEuropean trios
recruited at Queen Charlotte’s and Chelsea Hospital between
2003 and 2004 [33]. The placental samples were collected from
ultrasound dated, live birth singleton pregnancies. Each placen-
tal samplewas dissected into four pieces near the umbilical cord
insertion point, washed in phosphate-buffered saline, snap-
frozen in liquid nitrogen and stored at 2808C. Parental blood
samples (10 ml) were collected in EDTA tubes. The medical
records and characteristics of the Moore cohort are summarized
in the electronic supplementary, table S1.
5. Methods
(a) DNA and RNA extraction
Total RNA from term placental tissue was extracted using Trizol
reagent (Life Technologies), and treated with TURBO DNase
(Ambion) according to the manufacturers guidelines. Fetal
DNA from 1 g of term placental tissue and parental DNA from
2 ml of whole blood were isolated using a standard phenol–
chloroform protocol. RNA and DNA from CVS tissues were
extracted by the iPrep PureLink total RNA and TrizolPlus
RNA kit, including the DNase treatment and iPrep Charge-
Switch gDNA tissue kit using the iPrep purification instrument
(Life Technologies) following the manufacturer’s instructions.
The quantity and purity of nucleic acid was measured by Nano-
Drop ND-1000 spectrophotometer (Thermo Scientific). Only
RNA samples with the 260/260 ratio in the range of 2+0.2
were used for further study.
(b) Reverse transcription
A first strand of complementary DNA (cDNA) was synthesized
from 1 mg (term placenta) and 100 ng (CVS) of RNA with Molo-
ney murine leukemia virus reverse transcriptase (M-MLV RT)
according to the manufacturer’s instructions (Promega). Dupli-
cate sets of samples without reverse transcriptase were made
as negative controls to detect any genomic contamination in
RNA samples. The conversion of RNA to cDNA was confirmed
by polymerase chain reaction (PCR) with Taq DNA polymerase
paternal G type I diabetes
DLK1 expression birthweight
protective
positive
correlation
paternal G
associated with
reduced BW
positive trend
slight decrease
but not significant
Figure 4. Current hypothesis on the association between paternal G SNP
rs941576 and fetal growth. Solid lines indicate results from this study and
dotted lines indicate published data [41–43]. Paternal inheritance of the
G allele is associated with an average reduction in birthweight by 132 g
( p ¼ 0.01). The paternal G allele is also correlated with reduction in
DLK1 expression although not significantly ( p ¼ 0.47). There was a trend
of positive association between DLK1 expression in term placenta and
birthweight ( p ¼ 0.07). Our hypothesis suggests that the paternal G
allele reduces DLK1 expression which causes reduction in birthweight and
risk of type 1 diabetes. (Online version in colour.)
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(Bioline) beta-actin (ACTB) primers (electronic supplementary
material table S5).
(c) Quantitative polymerase chain reaction
qPCR was performed using the Power SYBRGreen PCR master
mix (Life Technologies). Each sample was tested in triplicate,
and each plate contained a no-template-control and a cDNA
pool as a reference sample to control for interplate variations.
The reaction plate was placed on the StepOne plus real-time
PCR systems, analysed in the comparative Ct mode. Ribosomal
protein L19 (L19) housekeeping gene was used as an endogenous
control throughout the experiments. Thermal cycle conditions
consist of initial incubation at 508C for 2 min for one cycle, poly-
merase activation at 958C for 10 min for one cycle and 40 cycles
of denaturation at 958C for 15 s, and annealing and extension at
608C for 1 min. The efficiency of the primers was determined by
running a standard curve and calculated by 10(1=slope)  1: The
qPCR primer sequences are provided in the electronic sup-
plementary material, table S4. The resulting data were analysed
with the STEPONE v. 2.1 software to obtain relative quantification
(RQ) values, using the formula RQ5 22DDCt.
(d) Imprinting analysis
Monoallelic expression of genes was investigated by sequencing
gene-specific amplicons from cDNA samples that corresponded
to genomic DNA heterozygous for selected SNPs. Parental DNA
was available for termplacental samples, andwas used for sequen-
cing to check the parental origin of the expressed allele. SNPs with
relatively high average heterozygosity were chosen for each gene
within the exon covering all isoforms. PCR primer sequences are
summarized in the electronic supplementary material, table S5,
and the list of selected SNPs is found in table 4. Sequencing was
carried out using the BigDye terminator v. 1.1 cycle sequencing
kit (Life Technologies), and the read-out was analysed with
SEQUENCHER v. 4.8 (Gene Codes Corporation).
(e) Statistical analysis
All statistical analyses were performed using the R software (R
Foundation for Statistical Computing). The relative expression
of the candidate genes in term placenta was correlated to the
baby’s birth weight, placental weight and head circumference
using a multiple linear regression model adjusted for baby’s
sex, gestational age, parity, maternal weight/BMI and smoking
habits. These variables used in the model have previously been
established as confounding factors in our previous studies in
the same cohort [33,36]. A logarithmic scale was used for the
expression values when appropriate, and BIC test was performed
to check the fit of the models. A significance threshold of 5% was
used in the analysis.
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Abstract
Two London Universities, University College London and Imperial College London, have established a biobank as
a resource for investigating the four main complications of pregnancy (recurrent miscarriage, preterm birth, fetal
growth restriction (FGR) and pre-eclampsia), that collectively affect about 20% of families trying to conceive.
Samples are being taken from the three key members of the family, mother, father and baby, allowing hereditary
factors from both parents to be tracked. Additional samples are being stored to allow parallel analysis of the
functional mechanisms of pregnancy including the epigenetic, anatomical, physiological and even metabolic causes
for the high loss of fecundity in man. http://www.ucl.ac.uk/babybiobank
Introduction
Collections of human biological samples from large cohorts of
families with carefully collected phenotypic and clinical data allows
detailed study of the mechanisms behind many diseases. For many
years researchers have used animal models to understand the effects of
genetic mutations on phenotype, but have often acknowledged that to
translate knowledge fully to human disorders they must have access to
corresponding matched human samples. There are some ethical
barriers to overcome with humans but access to tissue samples post-
surgery, a small extra blood sample during routine procedures and
buccal/saliva swabs have provided invaluable material for human
research. The Baby Bio Bank is focussing on the four main
complications of pregnancy, recurrent miscarriage, preterm birth,
FGR and pre-eclampsia.
The genetic and environmental mechanisms of growth and
development in utero are complex as both genes and the environment
have interacting effects. There have been many studies showing gene
associations with complications of pregnancy, but due to small
numbers of samples it is often difficult to draw definitive conclusions.
The Baby Bio Bank (BBB) will provide the necessary number of
samples for scientific research into complications of pregnancy in
order to identify the genes and biological mechanisms involved. By
creating a bioresource for national and international research, the BBB
aims to provide samples of high quality so that data can be universally
compared. It will also foster collaborative research to ensure the best
use is made of the samples. By providing these samples as a biobank,
the burden in terms of ethics applications, staff costs and recruitment
for individual projects can be minimised.
Biobanking
Biobanking is defined as the collection and storage of samples and
can vary from the collection of a single sample to millions, for
individual use to global use and from simple generic to highly
specialized collections. In most cases biobanks are established for the
purpose of health research and translational medicine. This is the only
sensible way forward for the study of complex, multifactorial diseases
in humans where hundreds of samples are needed to elucidate
function.
The UK hosts several large biobanks. The UK Biobank (http://
www.ukbiobank.ac.uk) is perhaps best known, and its purpose is for
specific research into diseases occurring in mid- to late life such as
cancer, heart disease, diabetes, dementia, depression, osteoporosis,
arthritis, Parkinson’s disease and lung and kidney disorders. It has
now recruited 500,000 individuals since its beginning in 2006, with 22
assessment centres around the country The UK Biobank collects and
stores blood, urine and saliva with an extensive set of medical data on
blood pressure, lung function and grip strength, height, weight and
body mass, arterial stiffness, vision, hearing, family history of common
diseases, bone density, diet and fitness.
Biobanks can also complement one another, such as the The
Confederation of Cancer Biobanks (CCB-http://www.oncoreuk.org)
which is a consortium of UK based organisations involved in the
development, management and use of biobank resources for cancer
research. The CCB also promotes the transfer of knowledge and
experience amongst smaller biobanks to promote collaboration rather
than competition. Other biobanks are more specialised, for example
the Oxford Pregnancy Biobank, which collects maternal blood and
urine, as well as clinical data such as scans, specifically for research
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into micro- and nanoparticle biology in the search for new biomarkers
in pre-eclampsia (http://www.obs-gyn.ox.ac.uk/research/ian-sargent).
The Baby Bio Bank
The BBB is directed by Professors Gudrun Moore (Institute of
Child Health) and Lesley Regan (St Mary’s Hospital, Paddington)
supported by two clinical collaborators, Professors Catherine
Williamson (Queen Charlotte’s and Chelsea Hospital), Mark Johnson
(Chelsea and Westminster Hospital), The BBB manager, Dr Sayeda
Abu-Amero is responsible for all administrative aspects including
HTA compliance, ethics application, annual reports, website
management, biannual newsletter and management of the recruitment
and sample management team. There are three recruiters (Ms
Katherine Rogers, Drs Ana Maria Perez Miranda and Nita Solanky)
working at the different hospital sites and they provide 24 hour cover
to ensure as many samples are collected to complete trios as well as
two sample management personnel (Drs Shawnelle White and Anna
Thomas) responsible for sample barcoding, processing, quality
control, storage as well as database entry.
The BBB has its own Research Management Board (RMB) currently
chaired by Dame Joan Higgins which is responsible for ensuring all
protocols are carried out according to national tissue bank ethics and
the HTA and will also be responsible for determining which projects
are successful at obtaining samples for future research.
Recurrent miscarriage is the loss of 3 or more consecutive
pregnancies, and affects 1-2% of couples trying to have a successful
pregnancy outcome [1]. While the actual number is difficult to
quantify because of the nature of this complication, experts estimate
there are at least 6,000 couples newly affected every year in the UK
(according to the American College of Obstetrician and
Gynaecologists) and miscarriages are the most common type of
pregnancy loss (http://www.nhs.uk/conditions/miscarriage/Pages/
Introduction.aspx).
One in every 13 babies is born before 37 weeks and is classed as a
preterm birth. Prematurity is responsible for 80% of all neonatal
deaths, and affects 30,000 babies in the UK annually. The rate of
cerebral palsy in preterm babies is up to 30 times higher than in babies
born at term. This incidence has not changed significantly in recent
years, and prematurity represents a major health issue and challenge
for modern obstetric care (http://www.nhs.uk/planners/
pregnancycareplanner/pages/prematurelabour.aspx) [2].
Fetal Growth Restriction (FGR previously referred to as IUGR
(intra-uterine growth restriction)) refers to a condition in which a
fetus is unable to achieve its genetically determined potential size and
affects 20,000 babies in the UK every year and this condition accounts
for 50% of all stillbirths. Defining true fetal growth restriction (for
example, by identifying falling intrauterine growth profiles) is difficult
and defining a group of babies at or below the 10th percentile is often
used as a proxy. Although 60% of these will turn out to be normal
small babies, the remainder are at an increased risk of potentially
preventable perinatal death. (http://www.patient.co.uk/doctor/
Intrauterine-Growth-Retardation.htm) [3].
Pre-eclampsia is a multisystem disorder that typically presents with
high blood pressure and proteinuria in the second half of pregnancy
and is a leading cause of maternal death. Mild pre-eclampsia affects
4-6% of first time pregnancies with 1% of pregnant women
experiencing severe pre-eclampsia [4]. Women who have pre-
eclampsia in one pregnancy are at a higher risk of developing the
condition in subsequent pregnancies. It is responsible for a
considerable proportion of the 500,000 infant deaths per year
worldwide and around six women in the UK die annually as a result of
complications associated with pre-eclampsia (http://www.nhs.uk/
Conditions/Pre-eclampsia/Pages/Introduction.aspx).
There is evidence that the four complications of pregnancy are part
of a biological continuum which originates at the time of embryonic
implantation with interrelated genetic and environmental factors
influencing the final outcome of the pregnancy (Figure 1). Using
samples collected by the BBB and advanced scientific technology
capable of analysing many samples in parallel we can begin to dissect
the biological, physiological, genetic and even epigenetic causes of
these complications. The results should give rise to predictive
biomarkers that might identify those most at risk prior to disease
onset. This should offer the opportunity to design therapies to prevent
disease or reduce the severity of adverse maternal and fetal outcomes
associated with recurrent miscarriage, preterm birth, FGR and pre-
eclampsia.
Figure 1: The four complications of pregnancy targeted by the BBB
are a continuum.
The BBB collection will provide the biological materials for research
into the causes of these and related pregnancy complications. The
target of the BBB is to recruit 500 white European trios (mother, father
and baby) from pregnancies affected by each complication plus 500
normal trios for comparative purposes giving a total of 2500 trios over
the course of five years. Mothers and their partners are recruited in a
variety of clinics but most often at their first booking in the antenatal
clinic. Blood samples for DNA, serum and plasma, are collected from
all consenting participants, plus urine from the mother. Where father
is reluctant to give blood we the option of a saliva samples which
provides high yields of excellent quality DNA [5]. The families are
tracked throughout their pregnancy, and at the birth of the baby, we
are notified and collect pieces of placenta, umbilical cord and cord
blood. Where the baby is missed because delivery is at another hospital
or any other reason, recruiters aim to get a buccal swab. Where no
fetal sample is available-we are still able to use the maternal and/or
paternal samples with available clinical information for other studies
not looking at inherited genetic markers.
Ethical approval for the BBB was a straight forward process using
the National Research Ethics Service (NRES) via the online Integrated
Research Application System (IRAS-https://
www.myresearchproject.org.uk/) and communications with Trent
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Research Ethics Committee (REC) (new NRES committee name is
East Midlands Derby 1 REC) have been efficient. We applied for
Research Tissue Bank (RTB-https://www.myresearchproject.org.uk/
help/ResearchTissueBanks.aspx) ethics which is voluntary and has the
benefit that ‘favourable ethical opinion applies to all research projects
conducted in the UK using tissue or data supplied by the tissue bank,
provided that the release of tissue or data complies with the attached
conditions’ (see https://www.myresearchproject.org.uk/help/Help
%20Documents/PdfDocuments/researchtissuebank.pdf). This means
that the BBB RMG are able to apply ethical approval to peer reviewed
projects which relieves the potential research groups from the time
consuming process of ethics application for their studies. Interested
researchers are able to apply via the WoW BBB website (http://
www.wellbeingofwomen.org.uk/research/baby-bio-bank/?menu=3c)
where they submit a brief description of the proposal, type, number
and amount of samples required, proof of funding and local R&D peer
review. Applicants are also able to apply at the same time as applying
for grants to help speed the research process. Applications are
acknowledged by the BBB Manager and submitted to the BBB RMB
for consideration every 4 months. Applicants are informed within 1
month of the BBB RMB meeting if their application is successful and
samples dispatched within 3 months of approval. All applicants will
have to submit an annual progress report and any unused samples
must be returned to the BBB. The WoW BBB RMB recently met in
March 2014 and approved the first three projects from within the UK-
one with funding and two pending funding.
The hospitals in the BBB portfolio were selected as representing
clinics with high proportions of pregnancies with complications. In
addition, many research projects and clinical trials are also conducted
in these (and other) hospitals for the ultimate benefit of the
participant. The BBB recruiting staff put the wellbeing and satisfaction
of the participant at the top of their list when considering recruitment
as this is fundamental to the success of any biobank or research project
involving patients [6].
BBB recruiters spending some time discussing the patient
information sheet with the couple, giving the couple time to go home
and discuss any issues if necessary before consenting and arranging for
the bloods to be taken at the participant’s convenience.
As all the samples are intended for DNA, RNA and protein
isolation, they are being collected, processed and stored to the highest
possible scientific standards. Quality control audits followed by
downstream applications such as PCR, real-time PCR and sequencing
has shown clearly that the samples are of high quality and can be used
with confidence by researchers. The biological specimens have
restricted value without the relevant clinical information for the
pregnancy under investigation. We have ethical approval to include
clinical information from the hospital databases relating to factors
affecting pregnancy such as parental height, weight and relevant
medical history such as diabetes, hypertension, and smoking.
Importantly, we also collect fetal outcome data such as gestational age,
birth weight, placental weight and mode of delivery. Consent is
obtained from parents for access to their notes and information stored
in the hospital database and also for any relevant queries which may be
missing/unavailable to be followed up with the participants
themselves. Currently, the BBB database stores detailed sample
information (type of sample, amount or volumes available, date
collected, time to process sample) in APOnline database, which is
custom designed for the BBB (Assettrac-http://www.assettrac.co.uk/).
We have nearly reached our 2500 recruitment target (2448 mothers
at the end of February 2014) with nearly 1,500 trios completed and
available to researchers making it a unique resource as it stands today.
We have >280 complete trios from recurrent miscarriage, preterm and
pre-eclampsia and >200 from FGR. We will finish recruitment and
collection by June 2014 and at that time will be able to publish a
detailed breakdown of the BBB cohort. To date, only six participants
from the 2500 who have participated have withdrawn indicating
committed interest from the participants and public and satisfaction
with BBB protocol, staff and information sheets.
The BBB is a unique collection of biological samples and medical
data available for national and international researchers interested in
understanding pregnancy complications. We opened on the 1st
November 2013 and have approved the first three applications from
interested researchers and have already received preliminary enquiries
from a further ten. More information on the BBB is available at http://
www.ucl.ac.uk/babybiobank including the BBB protocol and biannual
newsletters. We welcome your applications.
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Abstract
Context: Fetal growth involves highly complex molecular pathways. IGF2 is a key paternally expressed growth hormone
that is critical for in utero growth in mice. Its role in human fetal growth has remained ambiguous, as it has only been
studied in term tissues. Conversely the maternally expressed growth suppressor, PHLDA2, has a significant negative
correlation between its term placental expression and birth weight.
Objective: The aim of this study is to address the role in early gestation of expression of IGF1, IGF2, their receptors IGF1R and
IGF2R, and PHLDA2 on term birth weight.
Design: Real-time quantitative PCR was used to investigate mRNA expression of IGF1, IGF2, IGF1R, IGF2R and PHLDA2 in
chorionic villus samples (CVS) (n = 260) collected at 11–13 weeks’ gestation. Expression was correlated with term birth
weight using statistical package R including correction for several confounding factors.
Results: Transcript levels of IGF2 and IGF2R revealed a significant positive correlation with birth weight (0.009 and 0.04,
respectively). No effect was observed for IGF1, IGF1R or PHLDA2 and birth weight. Critically, small for gestational age (SGA)
neonates had significantly lower IGF2 levels than appropriate for gestational age neonates (p = 3?661027).
Interpretation: Our findings show that IGF2 mRNA levels at 12 weeks gestation could provide a useful predictor of future
fetal growth to term, potentially predicting SGA babies. SGA babies are known to be at a higher risk for type 2 diabetes. This
research reveals an imprinted, parentally driven rheostat for in utero growth.
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Introduction
Fetal growth involves a complex interaction between genes and
the environment, with such significant complexity that many of the
molecular pathways remain to be elucidated. Normal fetal growth
depends on the successful nutrient exchange between the mother
and the fetus via the placenta. When this critical balance is
impaired it can result in a small for gestational age (SGA) baby [1].
SGA neonates have a reported incidence of ,6% of pregnancies
in developed countries and as high as 40% in some developing
countries [2,3]. SGA is also associated with an increased risk of
neonatal death. Although the survivors do exhibit catch up
growth, it is important to note that they remain at a higher risk for
common, late onset chronic diseases such as type 2 diabetes (T2D)
and cardiovascular disease [4]. Hales et al., (1991) reported a
graded inverse association between birth weight and T2D risk with
the highest risks of T2D occurring at the lowest levels of birth
weight [5]. In a more recent meta-analysis, an increased risk for
T2D (OR=1.47) is seen for SGA versus appropriate for
gestational age (AGA) neonates [6].
One group of growth genes of particular interest are the
imprinted genes that are found almost exclusively in Eutherian
(placental) mammals. Genomic imprinting defines allele-specific,
differential expression of a gene, according to its parent of origin.
If the paternal allele is expressed, the maternal allele is imprinted
(silenced) and vice versa. The ‘‘parental conflict hypothesis’’ is still
the most widely accepted explanation for the evolution of genomic
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85454
imprinting [7]. It has been suggested that expression of the father’s
genes enhance fetal growth improving the success of the paternal
genome to be passed on. In contrast, the mother’s genome limits
fetal growth, distributing equal resources to each of her offspring,
whilst ensuring her own survival post birth allowing her to
reproduce again. Studies of imprinted genes generally support this
model, with one of the most striking examples being the reciprocal
imprinting effects and associated growth patterns for mouse
insulin-like growth factor 2 (Igf2) and its chelating receptor Igf2r
[8]. In transgenic mice, loss of function of the paternally-expressed
Igf2 results in a 40% reduction in birth weight which contrasts with
loss of the maternally-expressed Igf2r, resulting in a 30% increase
in birth weight [9,10]. In addition, IGF2 has been implicated in
two imprinted human growth disorders, the overgrowth, Beck-
with-Wiedemann syndrome (BWS) [11] and the growth restricting
Silver-Russell syndrome (SRS) [12].
Pleckstrin homology-like domain family A member 2 (PHLDA2)
is maternally expressed, paternally imprinted, in both humans and
mice [13]. Involvement of Phlda2 in growth and development of
the placenta was demonstrated by knockout mouse models that
were associated with a significant increase in placental size during
mid to late gestation [14]. Studies that have investigated the
human placental expression of PHLDA2 report increased expres-
sion in SGA pregnancies and a negative association with birth
weight [15,16,17].
Insulin-like growth factor 1 (IGF1) and its primary binding
receptor IGF1R are not imprinted. IGF1 exerts its growth
properties on almost every cell in the body. A homozygous partial
deletion of Igf1r in mice stunted height and weight, as well as
disrupted the pubertal growth spurt. A complete inactivation of
Igf1r is lethal in the neonatal period [18]. In contrast to Igf2
deficient mice, restriction of growth was seen to continue into the
postnatal period in the Igf1 mutants [19].
The analyses of human placental expression of IGF1, IGF2,
IG1R and IGF2R have previously been confined to samples
obtained at the time of birth. IGF1 under-expression was observed
in term placental samples from SGA pregnancies [20], while
mutations in the IGF1R gene led to abnormalities in the function
of IGF1 receptors that may also slow down intrauterine and
subsequent growth in humans [21].
Studies on IGF2 have reported conflicting results. Some
demonstrate no correlation between IGF2 expression and birth
weight [16] whereas others have variably shown that in SGA
pregnancies compared to controls, IGF2 expression is either
increased [22], decreased [15,23,24], or similar [25], including at
the protein level [26]. Moreover, studies have either shown no
significant relationship between IGF2 cord serum levels and size at
birth [27], or a positive effect on birth weight [28]. In others, IGF2
cord blood levels were significantly correlated with birth weight
only when its interaction with IGF2R was taken into account [29].
The profound role of the IGF1 and IGF2 pathways in the
regulation of fetal growth have been established largely based on
experiments using the mouse as a model [9,10,18]. Analysis in
humans has been hampered by the lack of available tissue to study
during the course of pregnancy and has therefore relied on the use
of term placenta, at a time when this tissue has become redundant
and therefore the levels of gene expression may no longer reliably
reflect the needs of the growing baby. To fully assess the role of
these growth factors and their receptors, we have focused on an
earlier developmental time point when these genes are much more
likely to measure functionally relevant expression levels.
Methods
Study population
Chorionic villus sampling (CVS) was performed at 11–13 weeks
of gestation in 260 singleton pregnancies that subsequently
resulted in normal live births at term. The samples were collected
from women undergoing CVS for prenatal diagnosis of chromo-
somal defects at King’s College Hospital London. The excess
tissue samples used for this study were obtained from women
agreeing to participate in research, which was approved by the
King’s College Hospital Ethics Committee.
Demographic characteristics were recorded including maternal
age, racial origin, smoking status, parity and body mass index as
well as pregnancy outcomes such as gestational age at delivery, sex
and birth weight. Other birth parameters such as placental weight
were not available, nor were blood or tissue samples from the
newborn baby. The pregnancies were subdivided according to the
birth weight of neonates into small for gestational age (SGA) with
birth weight ,10th percentile, large (LGA) with birth weight
.90th percentile and appropriate (AGA).
Preparation of DNA and RNA from chorionic villus
samples
DNA and RNA were extracted using the iPrep Purification
Instrument (Invitrogen), either by use of the iPrepTM ChargeS-
witchH gDNA Tissue Kit, or iPrepTM PureLinkTM Total RNA
and TrizolH Plus RNA kit including DNAse treatment, according
to the manufacturer’s instructions.
Reverse transcription
Reverse transcriptase (RT) methodology was based on a
standard protocol using M-MLV reverse transcriptase and
random primer hexamers (Promega). Primers for the housekeep-
ing gene b-actin (ACTB) were used to check the integrity of the
cDNA and ensure no DNA contamination. The forward (F) and
reverse (R) primers spanned an intron and the sequences are: b-
actin.F- gtcttcccctccatcgtg and b-actin.R- ggtcatcttctcgcggttg.
Polymerase Chain Reaction (PCR)
Genomic DNA and cDNA from CVS were amplified by PCR
before sequencing. Primers (59 to 39 sequence) used for genomic
DNA are IGF2.F- aacaccccacaaaagctcag; IGF2.R- tgcatg-
gattttggttttca; IGF2R.F- gaaacacaaaacctacgacc; IGF2R.R-
agaacccaaaagagccaacc; PHLDA2.F- caaaccccgcacgccatgag and
PHLDA2.R- ctgtgcccattgcaaataaatc. The same primers were used
for cDNA with the exception of IGF2R.R- cctttggagtacgtgacaac.
20 ul reactions were set up and thermal cycling conditions were
94uC for 5 min, 94uC for 30 sec, 60uC for 30 sec, 72uC for 30 sec
for 35 cycles, and 72uC for 2 min.
Imprinting analysis
Imprinting analysis of IGF2, IGF2R and PHLDA2 in CVS was
carried out by DNA sequence analysis of expressed single
nucleotide polymorphisms (SNP) in CVS gDNA after amplifica-
tion using specific primers (IGF2.F- aacaccccacaaaagctcag;
IGF2R.R- cctttggagtacgtgacaac and PHLDA2.F- caaaccccgcacgc-
catgag). Corresponding cDNA samples were screened in patients
heterozygous for the IGF2 A/G (rs680), IGF2R A/G (rs1805075)
and PHLDA2 A/G (rs1056819) SNPs (http://www.ncbi.nlm.nih.
gov/projects /SNP/). Sequencing reactions were prepared
according to the manufacturer’s instructions (Applied Biosystems)
using the ABI Prism Big Dye terminator cycle sequencing ready
reaction kit (BDT v1.1). Sequencing products were run on an ABI
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Prism 3730 DNA analyzer, and the read-out was analysed with
SequencherTM v4.8 (Gene Codes Corporation).
Real-time quantitative PCR
The quantitative expression analysis of the genes of interest,
IGF1, IGF2, IGF1R, IGF2R and PHLDA2 as well as the
endogenous control gene L19 (a housekeeping gene ubiquitously
expressed in the placenta) [16] was determined by real-time
quantitative PCR (RTqPCR) with SYBR Green (ABI) using the
StepOnePlus Real-Time PCR System (ABI). Primers (59 to 39
sequence) used for quantitative analysis are IGF1.F- ggaggctgga-
gatgtattgc; IGF1.R- acttgcttctgtcccctcct; IGF2.F- cgagagggacgtgtc-
gacc; IGF2.R- ggactgcttccaggtgtcata; IGF2R.F- ccggcgtgctctgga;
IGF2R.R- ccagagggtcacagtggaaga; IGF1R.F- ccaagggtgtggtgaaa-
gat; IGF1R.R- tccatgatgaccagtgttgg; PHLDA2.F- ccatccccgcagcc-
caaacc; PHLDA2.R- ccacgtcctagcctgggtcc; L19.F- gcggaagggta-
cagccaat and L19.R- caggctgtgatacatgtggcg. All primer sets were
free of primer-dimer products. The RTqPCR assays were run in
triplicate for each sample, with the gene of interest and
housekeeping gene run on the same 96-well plates. A control
pool of CVS cDNA was also included on each plate. Amplification
conditions include initial incubation at 95uC for 10 min and
repetitive denaturation at 95uC for 15 sec and annealing at 60uC
for 1 min for 40 cycles.
After amplification, quantitative expression levels were obtained
using the StepOne software (version 2.1). All triplicate cycle
threshold (CT) values were within 1 CT of each other. The
quantitative values for each triplicate were averaged and the
Figure 1. mRNA expression levels of IGF2, IGF2R, PHLDA2, IGF1 and IGF1R in chorionic villi. The expression levels of IGF2, IGF2R, PHLDA2,
IGF1 and IGF1R after standardization to the endogenous control gene L19, in relation to birth weight corrected for parity, sex, GA at term, maternal
BMI and smoking status. Significant associations were observed for CVS expression of A) IGF2 (p = 0.009) and B) IGF2R (p = 0.04). No significant
association was found for C) PHLDA2 (p = 0.73), for D) IGF1 (p = 0.48) or for E) IGF1R (p = 0.08).
doi:10.1371/journal.pone.0085454.g001
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relative expression of the genes of interest was determined by a
ratio of their expression to that of the L19 housekeeping gene for
the same sample.
Statistical analysis
Standard multiple linear regression models were used to
examine the correlation of IGF1, IGF2, IGF2R, IGF1R and
PHLDA2 relative expression values to birth weight after adjust-
ment for gestational age at delivery, sex, parity, maternal age,
smoking status and maternal body mass index. Any outliers more
than 2 standard deviations from the mean were removed. The
analysis of variance (one-way ANOVA) was used to compare the
gene expression means between the three different categorical
birth weight groups (SGA, AGA, LGA) taking into consideration
any confounding factors. Statistical package ‘‘R’’ (version 2.13.0)
was used for the analyses and for calculating adjusted R-squared
(R2) values. Significance was defined as p,0.05.
Results
In this study, we have investigated the relationship between
IGF1, IGF2, IGF2R, IGF1R and PHLDA2 mRNA levels in first-
trimester placental tissue with the birth weight of the resultant
term new born babies. We correlate this data taking into account
the carefully recorded birth parameters that may have a
confounding effect (gestational age, sex, parity, maternal BMI
and smoking status; figure S1). Regression analysis was performed
after standardization to the endogenous control gene L19, in
relation to birth weight corrected for confounding factors.
Significant associations were observed for expression of IGF2
(p = 0.009) and IGF2R (p = 0.04) between CVS tissue and birth
weight (figure 1A–B). Importantly the range of IGF2 in relative
expression units was from 1.5–12 with one relative expression unit
being equivalent to a change in birth weight of 63 g. No
association was found for PHLDA2 (p = 0.73), IGF1 (p = 0.48) or
IGF1R (p = 0.08) between CVS tissue and birth weight (figure 1C–
E).
As both IGF1 and IGF2 bind to the IGF1R and only IGF2
binds to the IGF2R we decided to look at this relationship between
the ligands and their receptors and any correlation they might
have with birth weight. The ratio of IGF2 to IGF1R (p = 0.005) was
significantly associated with birth weight but no association was
found for the ratio of IGF1 to IGF1R (p = 0.76) or the ratio of IGF2
to IGF2R (p = 0.93) between CVS tissue and birth weight (figure 2).
To investigate the whole growth spectrum we subdivided the
pregnancies into small for gestational age (SGA; n= 50) with birth
weight ,10th percentile, large (LGA; n= 65) with birth weight
.90th percentile and appropriate (AGA; n= 145). In the SGA
group compared to the AGA group, IGF2 expression was reduced
by statistically significant amounts (p = 3.661027), despite no
significant differences in the expression levels of individual
receptors (IGF2R, p = 0.76 or IGF1R, p = 0.15). In the LGA group
IGF2R expression was found to be higher than in the AGA group
(p = 0.02) and IGF1R expression was lower than in the SGA group
(p = 0.05) (figure 3).
Given that IGF2 and PHLDA2 are both known to be imprinted
in mouse and human [8,13,30], we wanted to confirm that
monoallelic expression was maintained in CVS material, since
reversion to biallelic expression may impact on mRNA levels.
Furthermore, IGF2R in the human population is reported to be
monoallelically expressed (i.e. imprinted) in only 10% of individ-
uals, which is in contrast to the mouse, where it is fully imprinted
[31]. We therefore wished to confirm its imprinting status in CVS
material and to investigate for any potential skewing. The
transcribed SNPs rs680 (IGF2), rs1805075 (IGF2R) and
rs1056819 (PHLDA2) were used to report on allele-specific
expression and thus determine imprinting status of IGF2, IGF2R
and PHLDA2. Genomic DNA extracted from the CVS from 200
patients were tested for heterozygosity at these SNPs, with 40
samples found to be informative at rs680 for IGF2, 24 samples at
rs1805075 for IGF2R and 21 samples at rs1056819 for PHLDA2.
The 40 informative IGF2 individuals and the 21 informative
PHLDA2 individuals were all found to be monoallelically
expressed. For the 24 samples informative for IGF2R, 21 (88%)
Figure 2. mRNA expression levels of IGF1/IGF1R, IGF2/IGF2R and IGF2/IGF1R in chorionic villi. The expression levels of IGF1/IGF1R, IGF2/
IGF2R and IGF2/IGF1R after standardization to the endogenous control gene L19, in relation to birth weight corrected for parity, sex, GA at term,
maternal BMI and smoking status. No significant association was found for A) the ratio of IGF1 to IGF1R (p = 0.76), or for B) the ratio of IGF2 to IGF2R
(p = 0.93). Significant association was observed for CVS expression of C) the ratio of IGF2 to IGF1R (p = 0.005) and birth weight.
doi:10.1371/journal.pone.0085454.g002
IGF2 Expression Correlates with Birth Weight
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e85454
were biallellically expressed for IGF2R and 3 (12%) were
monoallelic, which is similar to the expected population frequency
(figure 4). Thus, skewed monoallelic/biallelic expression was
unlikely to be a factor reflected in the relative expression levels
associated with birth weight.
Discussion
Previous studies have linked IGF2 expression to birth weight, by
showing that IGF2 in term placenta is decreased in SGA
pregnancies compared to controls [23,24]. However, the first
trimester IGF2 expression data reported in this study, provides the
first evidence for the role of this paternally expressed imprinted
gene as an in utero fetal growth enhancer this early in human
pregnancy. This is compatible with results previously described in
animal studies [9,32]. For example, in mouse experiments,
paternally expressed Igf2 was reported to control 40% of fetal
growth, with the maternally expressed gene Igf2r limiting fetal
growth [10,33]. In humans, IGF2 is consistently maternally
imprinted and therefore a paternal-expression driven growth
promoter. However, in humans, IGF2R is polymorphic for its
imprinting status with 90% of individuals showing biallelic
expression [31]. This indicates a possible shift in the mechanism
of its regulation of expression away from that used in the mouse.
Interestingly, here, the samples showing monallelic expression of
IGF2R had similar levels to those showing biallelic expression.
As fetal size is subject to both positive and negative regulation,
IGF2 and IGF2R genes can exert opposite forces on the fetus,
achieving a fine degree of control over the growth process. As
levels of IGF2 increase in the fetus, the levels of IGF2R can also
increase, resulting in clearance of IGF2 from plasma and tissue
fluids, correcting and maintaining levels of IGF2 in the circulation.
This acts as a fine-tuning rheostat designed to prevent babies from
overgrowth in order to maintain a normal growth trajectory. This
is also supported by the fact that no association was observed
between the IGF2/IGF2R expression levels and birth weight, as the
ligand and the receptor work tightly together to regulate growth.
The same applies for IGF1 and its regulating receptor IGF1R.
In this study, expression of IGF1 in chorionic villi was not
associated with birth weight outcome. These results directly
Figure 3. mRNA expression levels of IGF2, IGF2R, and IGF1R in chorionic villi according to BW centile. Relative IGF2, IGF2R, and IGF1R
expression levels in the pregnancies with small (SGA), appropriate (AGA) and large (LGA) neonates. In the SGA group, compared to the AGA group, A)
IGF2 expression was lower (p = 3?661027), but there was no significant difference in the expression levels of B) IGF2R (p = 0?76) or C) IGF1R (p = 0?15).
In the LGA group B) IGF2R expression was higher than in the AGA group (p = 0?02) and C) IGF1R expression was lower than in the SGA group
(p = 0?05).
doi:10.1371/journal.pone.0085454.g003
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contradict findings from studies involving mouse models which
highlighted IGF1 role in the regulation of both pre- and postnatal
growth [34]. There also remains a strong possibility that IGF1 is
indeed relevant to intrauterine growth in the later stages of
pregnancy as it is preparing the baby for a postnatal life. While
fetal chorionic fetal samples in the present cohort proved an
opportunity to assess correlation between gene expression and fetal
growth in early gestation (11–13 weeks), this narrow window might
not be the best to investigate IGF1 expression, as IGF1 does not
appear in the fetal circulation until later [35].
Although previous studies have shown that placental PHLDA2
expression is negatively associated with birth weight [16,17], in our
study no statistically significant association was observed between
PHLDA2 expression levels in CVS and birth weight. This suggests
that maternally expressed PHLDA2 is suppressing the baby’s
growth later in pregnancy rather than early on. Previous studies
investigating term placental IGF2 expression have shown incon-
clusive results. However, in our study a statistically significant
association was observed between IGF2 expression levels in CVS
and birth weight, suggesting that the paternal genome is
promoting the baby’s growth earlier in pregnancy. Therefore,
the two parental genomes appear to be acting at different times
during pregnancy to control the fetal weight. This supports the
idea that whilst increased fetal growth is important early on, it
must still require careful regulation by the mother to ensure a
successful birth.
In our study, SGA neonates had significantly lower IGF2
expression levels compared to AGA neonates, but no differences
were observed between the levels of the receptors IGF2R and
IGF1R. This highlights the importance of the IGF2 ligand rather
than the receptor level in determining size of the neonate in SGA
pregnancies. This is in agreement with previous studies investi-
gating IGF2 mRNA levels in the placentas from growth-restricted
pregnancies [23,24].
Figure 4. Imprinting analysis of IGF2, PHLDA2 and IGF2R. Representative sequencing chromatograms are shown from one of the 40 informative
CVS samples for the IGF2 A/G polymorphism (rs680) (A, B), one (from 21) for the PHLDA2 A/G polymorphism (rs1056819) (C, D) and two (from 24) for
the IGF2R A/G polymorphism (rs1805075) (E, F, G, H). Heterozygous genomic CVS DNA sequence is shown in A), C), E) and G). While monoallelic
expression from the corresponding cDNA samples are shown in B), D) and H). Monoallelic expression in cDNA was found in all informative IGF2 and
PHLDA2 samples as well as 12% of IGF2R samples. Biallelic expression, as shown in F), was found in the majority (88%) of informative cDNA samples
for IGF2R.
doi:10.1371/journal.pone.0085454.g004
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To better understand the causes and consequences of fetal
growth restriction as a human pregnancy complication, we focused
on available tissue from the first trimester, as this time window is
more likely to accurately reflect the in utero growth potential. We
used a larger sample size and we investigated the whole growth
spectrum including not only SGA but also LGA neonates. We
reasoned that extending the investigation of these genes to samples
displaying macrosomic birth weight would also reveal further
correlations between growth parameters and gene expression. In
this study, LGA neonates had higher IGF2R expression levels
compared to AGA neonates and lower IGF1R levels compared to
SGA babies. Similar results have been reported in placenta tissue
for IGF1R mRNA levels alone [36], and this suggests that fetuses
with high birth weight are producing more IGF2R and
correspondingly less IGF1R, which could remove IGF2. This
balance may represent another important compensatory mecha-
nism in response to fetal overgrowth. This is also supported by the
fact that a significant association was observed between the ratio of
IGF2 to IGF1R and birth weight, suggesting that the levels of
IGF1R in LGA neonates decrease as their IGF2 levels increase, to
avoid any further increase in size.
The ‘‘small baby syndrome hypothesis’’ proposed by Barker et
al., (1993) suggests that there is an inverse linear relation between
birth weight and T2D [37]. This is also supported by a large meta-
analysis [38]. The mechanisms by which birth weight is related to
T2D is still under debate, Barker et al. claim that this relationship
reflects long-term consequences of under-nutrition in utero [37],
whereas others do not see under-nutrition as playing a significant
role [39]. Interestingly, specific fetal IGF2 paternal haplotypes are
linked to higher maternal glucose levels that increase the risk of
gestational diabetes [40]. Nevertheless the amount of IGF2
available from the placenta early in the first trimester is likely to
be a major factor in promoting growth.
An important aim for antenatal care is the prediction, detection
and treatment of anomalous fetal growth. We know that variation
in size at birth results from interaction between fetal genetic factors
and the maternal genetic and uterine environment. In this study
we also implicate the important role of the father’s genes in fetal
growth in utero. Understanding the developmental role, function
and parent-of-origin effect of critical imprinted genes during
human fetal growth will make an important contribution to
effective clinical evaluation of growth disorders and their
association with longer term, metabolically related, health risks
such as T2D. Determination of paternal IGF2 expression in the
first trimester, potentially in maternal blood, may act as a
predictor of fetal growth trajectory for later in the pregnancy.
An early growth biomarker could be invaluable to alert
Obstetricians and Neonatologists towards closer ‘at risk’ pregnan-
cy surveillance.
Supporting Information
Figure S1 Confounding factors. Correlation of birth weight
with gestational age at term (p= 4.8610215; Fig. S1A), with
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Fig. S1C), with parity (p = 7.561025; Fig. S1D), and maternal
smoking status (p = 0.33; Fig S1E).
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within gestational tissues.  
•  Explore variation in bacterial load between control and preterm group, but also within 
preterm group (e.g. spontaneous vs. indicated vs. pPROM preterms). 
•  Investigate the relationship between bacterial abundance and diversity profiles, and the 
maternal immune response. 
 
Aims 
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Around 70,000 babies are born preterm (before 37 completed weeks gestation) in the UK 
annually. Numerous morbidities are associated with preterm birth in the neonatal period 
and beyond, and it is the leading cause of neonatal death globally. 
	

A large proportion of preterm births are characterised by signs of infection and/or 
inflammation in the uterus, the vagina and at the maternal-fetal interface, with increased 
prevalence and diversity of bacteria often observed in preterm versus term gestational 
tissues (e.g. fetal membrane, amniotic fluid, placenta, umbilical cord). Up-regulation of 
several proteins involved in inflammatory pathways have also been observed in pre-term 
versus term placenta e.g. IL-1ᵝ, TNFα, IL-8. 
 
	

Background 
 
DNA extraction from tissue 
 
•  3 x 50mg tissue excised from two points on fetal side of placenta and a mixture of sites 
from maternal villous tissue. 
•  Care taken to avoid possible events of contamination at all stages of collection and 
extraction. 
•  Qiagen mini-prep for blood and tissue used according to manufacturers protocol with 
additional bead-beating step added to ensure sufficient lysis of bacterial cell walls. 
 
Real time PCR absolute quantification using SYBR-Green 
•  Broad range primers anneal to highly conserved regions of bacterial specific 16s rRNA 
gene to enable cross-species amplification of any bacterial DNA present in placental 
samples. 
•  E-coli standard curve run on each real time plate to enable relative quantification of 
sample bacterial population against this standard of known bacterial DNA 
concentration. 
 
Materials and Methods 
 
This inhibitory effect of higher template concentration is observed in samples of human 
DNA spiked with known quantities of E. coli DNA but not when only E. coli standards are 
used (figure 2). As a result of this methodological work, it was decided that all subsequent 
work would be normalised to 25ng/ul to minimise this inhibitory effect but maximise 
sensitivity to any endogenous bacterial DNA in sample. 
 
 
 
 
 
 
 
 
 
From figure 3 it is clear that as gestational age increases in the cohort, the proportion of 
vaginal births compared to caesarean sections (CS) increases.  Despite concerns over 
variation in levels of bacterial contamination depending on mode of delivery (i.e. higher 
exposure in vaginal births), there is no evidence so far of an effect of delivery method on 
absolute bacterial prevalence in placental tissues in this cohort (figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
At present, there is no evidence of a difference in the absolute quantity of bacterial DNA 
between control and preterm placentas. However, when preterms are further divided into 
spontaneous preterm births (sPTB) and non-spontaneous (non-sPTB), sPTB placentas 
appear to have a higher bacterial load than both controls and nsPTBs – the biggest 
difference is between the two preterm groups (figure 5). This highlights the need to 
consider carefully the categorization of this cohort – sPTB will likely have a different 
aetiology than non- sPTB. This is in line with evidence from independent studies that 
bacterial infection is more likely to be a causal factor in spontaneous as opposed to 
indicated preterm births. 
 
 
 
  
 
 
 
 
Preliminary Results 
Ongoing and Future Work 
 
16s rRNA gene sequencing for species specific identification 
 
•  Library preparation for next generation sequencing of regions V5-V7 of bacterial 16s 
rRNA gene underway. 
•  Fetal placental and maternal villous samples will all be run on MiSeq sequencer by 
year end. 
•  Plan to sequence bacterial 16s DNA from cord blood and maternal blood, which will 
provide information relating to possible routes of bacterial colonization. 
•  Compare bacterial profiles of cohort placental tissues to those from Human Microbiome 
Project (HMP) – particularly vaginal and oral – to identify similarities and differences. 
 
High throughput cytokine assay to identify maternal immune response 
 
•  Collaboration established with group at Virginia Commonwealth University who have 
recently received funding from HMP to conduct a pregnancy microbiome project 
(MOMS-PI).  
•  Plan to travel to lab in spring/summer next year to conduct high-throughput cytokine 
panel on maternal serum (and possibly cord blood) from preterms and controls to 
examine relationship between bacterial profiles observed through  
    sequencing and maternal/fetal immune response. 
 
 
 
 
  
	

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Population 
Total BBB 
cohort	

(n=2264)	

Samples with 
GA at birth 
information	

(n=1878)	

	

GA at birth ≥ 40 
weeks	

(n=701)	

	

Complications 
and twins 
removed	

(n~23)	

Uncomplicated 
singletons	

(n=677)  	

Random 
selection of 
control group	

(n=350)	

Fetal placental 
tissue 	

(n=159 x 4)	

Maternal villous 
tissue	

(n=83 x 2)	

GA at birth ≤ 36 
weeks 6 days	

(n~270)	

Twin preterms	

(n~10)	

Singletons	

(n~260)	

Singleton 
preterms with 
placenta	

(n=146)	

Fetal placental 
tissue	

(n=140 x 4)	

Maternal villous 
tissue	

(n=84 x 2)	

The Baby Bio Bank (BBB):  
A resource that contains clinical data 
and biological samples from nearly 
3000 pregnancies at 3 hospitals 
across London. 
 
The BBB is a cohort of mainly white 
Caucasian mothers experiencing both 
normal and complicated pregnancies 
(growth restriction, pre-eclampsia, 
multiple miscarriage, preterm birth). 
 
For the preterm cohort, cases 
delivered before 37 completed weeks 
gestation. Controls were randomly 
selected from deliveries at or after 40 
weeks, following an uncomplicated 
pregnancy. Cases can be further 
divided according to nature of labour 
(spontaneous or non-spontaneous) 
and membrane rupture method. 
 
At present, only a third of placental samples have been analysed and the following data is 
therefore preliminary. 
 
Initial real time experiments were complicated by need to limit inhibitory effect of human 
DNA (~99% of sample)  
whilst maximising sensitivity 
of assay to small amount  
of target bacterial 16s  
sequence (figure 1). 
 
 
 
 
Preliminary Results 
Figure 1- As 
concentration of starting 
template increases, 
sensitivity of assay 
decreases – shown by 
increase in average CT 
of same samples 
Figure 2 – Inhibitory 
effect of mixed sample 
human DNA on bacterial 
16s target amplification 
Microbiome analysis of human gestational tissues 
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Figure 3 – Delivery Method by GA Figure 4 – Delivery method and bacterial load 
Figure 5 – Mean bacterial 
load in spontaneous, non-
spontaneous PTB and 
control placentas 
(with 95% CIs) 
